Human mirnas for use in diagnosis, prognosis, and therapy of human conditions and diseases

ABSTRACT

Disclosed herein are novel compositions, methods, and systems for determining whether a subject has, or is at risk of developing, or is at a given stage of a condition afflicting a tissue of interest, or determining the tissue or cell provenance of a biological sample, based on expression level of one or more of the novel miRNA and isomiR sequences disclosed herein. The compositions, methods, and systems described herein can be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder, or determine the identity of the tissue or cell in a sample. In some embodiments, the compositions, methods, and systems described herein can be used to develop a treatment for the disease or disorder. For example, in some embodiments, the novel miRNAs can be used as therapeutics for treatment of a disease or disorder.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit under 35 U.S.C. § 119(e) of the U.S. Provisional Application Nos. 61/818,777 filed May 2, 2013, 61/870,898 filed Aug. 28, 2013, 61/901,989 filed Nov. 08, 2013, the contents each of which are incorporated herein by reference in their entireties.

GOVERNMENT SUPPORT

This invention was made with government support under grant No. 2U19-AI056363-06/2030984, awarded by the National Institutes of Health. The U.S. government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 2, 2014, is named 77983PCT.txt and is 8,071,491 bytes in size.

TECHNICAL FIELD

Provided herein relates to methods and compositions for determining a cellular state or a tissue state of a biological sample, or the tissue or cell provenance of a biological sample. Specifically, some embodiments of the methods described herein can be used to diagnose or prognose for a given stage of a disease, e.g., cancer, or disorder, in a subject. Other embodiments can be used to determine the tissue or cell type from which a biological sample was obtained.

BACKGROUND

MicroRNAs (miRNAs) are an abundant class of short non-coding RNAs (ncRNAs), ˜22 nucleotides (nts) in length, which play a significant role in the regulation of gene expression. Bartel, D. P., Cell, 2004, 116(2): 281-97; Bartel, D. P., Cell, 2009, 136(2): 215-33. The first animal miRNA, lin-4, was discovered accidentally during a genetic screen in Caenorhanditis elegans (C. elegans) where it was previously reported to repress the expression of a protein-coding gene lin-14. Ambros, V., Cell, 1989, 57(1): 49-57; Ruvkun, a and J. Giusto, Nature, 1989, 338(6213): 313-19. Down-regulation of lin-14 led to a change in pattern formation in C. elegans larvae. In 2000, a second miRNA, let-7, was reported to be an important miRNA in C. elegans development. Reinhart, B. J., et al., Nature, 2000, 403(6772): 901-6. Other miRNAs have been previously reported in various species, including worms, flies, and mammals. See, e.g., Chang, S., et al., Nature, 2004, 430(7001): 785-89; Johnston, R. J. and O. Hobert, Nature, 2003, 426(6968): p. 845-49; Brennecke, J. and S. M. Cohen, Genome Biol, 2003, 4(9): 228. See also the miRNA database accessible online at www.mirbase.org. Currently, more than two thousand miRNAs are known for the human genome and contained in rniRBase Release 19. Griffiths-Jones, S., Nucleic Acids Research, 2006, 34(90001): D140-D144.

MiRNAs interact with their target RNAs in a sequence-dependent manner. Miranda, K. C., et al., Cell, 2006, 126(6): 1203-1217; Bartel, D. P., Cell, 2004, 116(2): 281-297; Bartel, D. P., Cell, 2009, 136(2): 215-233; Rigoutsos, I., Cancer Research, 2009, 69(8): 3245-3248. MiRNAs can function as post-transcriptional regulators of gene expression. In mammals, over 90% of all protein-coding genes are generally believed to be regulated by miRNAs. Miranda, K. C., et al., Cell, 2006, 126(6): 1203-1217. Even though the entire miRNA sequence can bind to the mRNA target, the sequence spanning positions 2-7 inclusive from the 5′ end of a miRNA, known as the “seed,” is previously reported to be important for target determination and coupling. Bartel, D. P., Cell, 2004, 116(2): 281-97; Reinhart, B. J., et al., Nature, 2000, 403(6772): 901-06; Lee, R. C. et al., Cell, 1993, 75(5): 843-854; Wightman, B., et al., Cell, 1993, 75(5): 855-862; Tay, Y., et al., Nature, 2008, 455(7216): 1124-1128; Brodersen, P., Nat Rev Mol Cell Biol, 2009. 10(2): 141-48; Lal, A., et al, Mol Cell, 2009, 35(5): 610-25; Rigoutsos, I. and Tsirigos, A., in MicroRNAs in Development and Cancer Molecular Medicine and Medicinal Chemistry Ch.10, ed. F. J. Slack. Vol. 1, 2010: Imperial College Press; Xia, Z., et al., Sci Rep, 2012, 2: 569. Originally it was assumed that the presence of the reverse complement of the seed in mRNAs was both a sufficient and necessary condition for targeting. Bartel, D. P., Cell, 2009, 136(2): 215-233. However, genetic studies and numerous subsequent efforts showed miRNA functionality in the presence of inexact matches and/or bulges in the seed region. Wightman, B., et al. Cell, 1993, 75(5): 855-862; Tay, Y., et al., Nature, 2008, 455(7216): 1124-1128; Lal, A., et al., Mol Cell, 2009, 35(5): 610-25; Ha, I. et al., Genes Dev, 1996. 10(23): p. 3041-50; Vella, M. C., et al., Genes Dev, 2004. 18(2): 132-37; Farh, K. K., et al., Science, 2005, 310(5755): 1817-21; Stark, A., et al., Cell, 2005, 123(6): 1133-46; Didiano, D. and Hobert O., Nat Struct Mol Biol, 2006. 13(9): 849-51; Easow, G. et al., RNA, 2007, 13(8): 1198-204; Back, D., et al., Nature, 2008, 455(7209): 64-71; Selbach, M., et al., Nature, 2008. 455(7209): 58-63; Chi, S. W., et al., Nature, 2009, 460(7254): 479-86; Fabian, M. R. et al., Annu Rev Biochem, 2010, 79: 351-79; Hafner, M., et al., Cell, 2010, 141(1): 129-41; Thomas, M., Nat Struct Mol Biol, 2010, 17(10): 1169-74; Zisoulis, D. G., et al., Nat Struct Mol Biol, 2010. 17(2): 173-79; Chi, S. W. et al., Nat Struct Mol Biol, 2012. 19(3): 321-27; Skalsky, R. L., et al., PLoS Pathog, 2012. 8(1): e1002484. The importance of such inexact matches has been previously reported to have direct relevance to answering the question of how many targets a miRNA can have.

The role of microRNAs was shown in previous reports where miR-15a and miR-16 are down-regulated or deleted in most patients with chronic lymphocytic leukemia (CLL). Calin, G. A., et al., Proc Natl Acad Sci USA, 2002, 99(24): 15524-9; Cahn, G. A. and Croce, C. M., Blood, 2009, 114(23): 4761-4770. MiRNAs have also been reported to be involved in many fundamental biological processes. Lee, R. C. et al., Cell, 1993, 75(5): 843-854; Wightman, B. et al., Cell, 1993, 75(5): 855-862; Tay, Y., et al., Nature, 2008, 455(7216): 1124-1128; Ha, I. et al., Genes & Development, 1996, 10(23): 3041-3050; Ruvkun, G., et al., Nature, 2000. 403(6772): 901-906; Didiano, D. and Hobert, O., RNA, 2008. 14(7): 1297-1317. Previous reports have also showed miRNA connections to cardiovascular disease (Small, E. M. et al., Circulation, 2010. 121(8): 1022-1032; Small, E. M. and Olson, E. N. Nature, 2011. 469(7330): 336-342), immunity (Taganov, K. D. et al., Immunity, 2007. 26(2): 133-137), schizophrenia (Perkins, D. O., et al., microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biology, 2007. 8(2): R27), brain processes (Liu, X., et al., Brain Pathol, 2008. 18(1): 113-21; Wang, Y., et al., Front Biosci, 2007. 12: 2316-29), neurodegeneration (Wang, W.-X., et al., Journal of Neuroscience, 2008. 28(5): 1213-1223; Wang, W.-X., et al., The American journal of pathology, 2010. 177(1): 334-345; Abelson, J. F., et al., Science, 2005. 310(5746): 317-320), Alzheimer's and brain aging (Nelson, P. T. et al., Brain Pathol, 2008, 18(1): p. 130-8; Hebert, S. S. and De Strooper, B., Trends Neurosci, 2009. 32(4): 199-206; Ibanez-Ventoso, C. and Driscoll, M. Curr Genomics, 2009. 10(3): 144-53; Sorrel, M., et al., Genorne Res, 2010. 20(9): 1207-18), and other conditions (Small, E. M. and Olson, E. N., Nature, 2011, 469(7330): 336-342; Mendell, J. T., Cell, 2008. 133(2): 217-222; Vasilescu, C., et al., PLoS ONE, 2009. 4(10): e7405; Williams, A. H., et al., Science, 2009. 326(5959): 1549-1554. Further, many miRNAs are also linked to cancers (Calin, G. A., et al., Proc Natl Acad Sci USA, 2002, 99(24): 15524-9; Calin, G. A. and Croce, C. M. Blood, 2009. 114(23): 4761-4770; Esquela-Kerscher, A. and Slack, F. J., Nature Reviews Cancer, 2006. 6(4): 259-269; Hammond, S. M., Nature Genetics. 2007, 39: 582-583; Poliseno, L., et al., Supplement. Nature, 2010. 465(7301): p. 1-19), invasion and metastasis (Ma, L., et al., Nature, 2007. 449(7163): 682-688), and exhibit tissue- and cell-state-dependent profiles (Calin, G. A. and Croce, C. M., Cancer Research, 2006. 66(15): 7390-7394; Lu, M., et al., PLoS ONE, 2008. 3(10): e3420; Godshalk, S. E., et al., Oncogene, 2011, 30: 1542-50; Ryan, B. M. et al., Nature Reviews Cancer, 2010, 10(6): 389-402; Saey, T., Science News, 2010, “Cancer's little helpers: Tiny pieces of RNA may turn cells to the dark side”; Spizzo, R, et al., Cell, 2009, 137(3): 586-586.el; Ventura, A. and Jacks, T., Cell, 2009. 136(4): 586-591; Voorhoeve, P. M. and Agami, R., Cancer, 2007, 1775(2): 274-282). The prevalence of miRNA-driven regulatory interactions across a very wide spectrum of human conditions and diseases makes the question of how many miRNAs existing a very important one.

Recent advances in next generation sequencing have further complicated the picture by revealing that multiple distinct mature miRNA species can arise from the same miRNA precursor arm: these mature miRNAs are termed “isomiRs.” These isomiRs typically differ from the mature miRNA sequences currently in public databases such as miRBase (Griffiths-Jones S. 2006. Nucleic Acids Res 34(90001): D140-D144) on either their 5′ or 3′ ends thereby increasing the diversity and complexity of the miRNA-ome. While the biological relevance of isomiRs is not fully understood, they have been shown to associate with the Argonaute complex (Ameres S L, Zamore P D. 2013. Nat Rev Mol Cell Biol: 1-14) which in turn suggests a functional role. Recent studies of isomiR expression have either focused on isomiRs of a single miRNA or on the isomiR expression patterns within a specific tissue. For example, a 5′-isomiR of miR-101 was observed to be ubiquitously expressed in several human tissues and cell lines (Llorens et al., 2013. BMC Genomics 14: 104). There is a continuous demand for more accurate diagnostic and prognostic tools and improved therapies. As such, there is still a need to identify novel miRNA and isomiR sequences that can be used for diagnosis, prognosis, and therapy of human conditions or diseases or to identify the provenance (tissue or cell) of a biological sample.

SUMMARY

There is a need to identify novel miRNA sequences that provide more accurate or reliable diagnostic and/or prognostic tools and/or improved therapies or can be used to determine the origin of a biological sample. To this end, inventors analyzed about 1,367 next generation sequencing datasets (RNA-sequencing and Argonaute cross-linking and immunoprecipitation (CLIP)-sequencing) corresponding to human normal and disease states from 13 distinct tissue types (from a total of approximately 200 human tissue types) and discovered at least tens of thousands of novel miRNAs as disclosed herein: each of the novel miRNAs has an associated false discovery rate (FDR) of 0.05 or lower.

By analyzing a large collection of next generation sequencing datasets, the inventors have discovered numerous novel human miRNAs and variants thereof. For a large fraction of these novel miRNAs, the inventors have additional corroborating evidence, through the analysis of CLIP-sequencing datasets, that they are loaded on Argonaute, which provides further credence to their bona fide miRNA nature.

In addition, by analyzing short RNA sequence profiles of deep sequenced biological samples of various human tissues and/or cell types, the inventors have discovered that the actual instance of the mature miRNA product that arises from a given miRNA locus and is detected in a given cell or tissue context can be different from the instance of the mature miRNA product that arises from the same miRNA locus in a different cell or tissue context, and this finding has been observed for many of the miRNAs currently in miRBase, which is a public repository of miRNA sequences for vertebrates, invertebrates, viruses, and plants. Accordingly, these tissue and/or cell-type dependence correlation of the novel miRNAs described herein can be used to determine tissue of origin in samples of interest. Additionally or alternatively, the tissue/cell-type dependence of the novel miRNAs described herein can also be used to determine cell state, disease type, disease stage, etc.

Accordingly, these novel miRNAs described herein can be used in various applications, e.g., to generate novel molecular signatures for cell types, cell states, disease, disease stage, disease progression, etc. They can also be used to identify novel and unexpected molecular players in cellular contexts of interest and also to reveal unexpected molecular interplays that underlie the onset and progression of diseases. Further, the novel miRNAs described herein can provide novel and improved means for therapeutic interventions. Accordingly, provided herein relates to methods, compositions, assays and systems for determining a given state of a cell and/or a tissue, which can be used for diagnosing a disease or disorder, and/or prognosing a given stage and/or progression of a disease or disorder, and/or treating a disease or disorder.

In one aspect, provided herein relates to methods or assays of determining a given state of a cell and/or a tissue. The method or assay comprises detecting in a biological sample the presence or absence of one or more miRNAs described herein. In some embodiments, the biological sample can be derived from a subject suspected of being at risk of or having a given stage of a disease or disorder. Accordingly, methods or assays described herein can also be used to determine whether a subject has, or is at risk of developing, or is at a given stage of a disease or disorder, e.g., a condition afflicting a tissue of interest. In one embodiment, the condition afflicting a tissue of interest includes cancer.

In some embodiments, the method or assay described herein can comprise detecting in the biological sample the presence or absence of a plurality of the miRNAs described herein.

In some embodiments of the methods or assays described herein, detection of the presence or absence of at least one of the novel miRNAs described herein can include measuring an expression level of the miRNA of interest in the biological sample. The expression level of the miRNA of interest can be detected by any methods known in the art, including, but not limited to, sequencing, next-generation sequencing (e.g., deep sequencing), polymerase chain reaction (PCR), and real-time quantitative PCR, northern blot, microarray, in situ hybridization, serial analysis of gene expression (SAGE), cap analysis gene expression (CAGE), massively parallel signature sequencing (MPSS), direct multiplexed measurements of the type employed in the Nanostring platform, and any combinations thereof In such embodiments, the methods or assays can further comprise comparing with a reference sample the determined expression level of the miRNA of interest in the biological sample. When there is a discrepancy in the expression level or amount of at least one miRNA molecule between the biological sample and the reference sample, the discrepancy can be indicative of the cell or the tissue in a state different from the reference sample. For example, in some embodiments, the discrepancy can be indicative of a subject either having, or being at risk of developing, or being at a given stage of a disease or disorder, e.g., a condition afflicting the tissue. In alternative embodiments, the discrepancy can be indicative of a subject lacking of a disease or disorder to be evaluated.

The reference sample used in the methods, assays and systems described herein can be a sample derived from the same type of cell or tissue with a known condition. For example, the reference sample can represent a normal condition of a cell or tissue to be detected. The normal reference sample can be obtained from the test subject or a different subject. Alternatively, the reference sample can represent a recognizable stage of a possibly abnormal condition of a cell or a tissue to be detected.

A biological sample for evaluation in the methods, assays, and systems described herein can include one or more cells derived from any tissue or fluid in a subject. In one embodiment, the biological sample can be a tissue suspected of being at risk of, or being afflicted with a given stage of a disease or a disorder. Non-limiting examples of sample origins can include, but are not limited to, breast, pancreas, blood, prostate, colon, lung, skin, brain, ovary, kidney, oral cavity, throat, cerebrospinal fluid, and liver.

Different embodiments of the methods, assays and systems described herein can be used for diagnosis and/or prognosis of a disease or disorder (including a given stage of a disease or disorder) in a subject, e.g., a disease or disorder afflicting a certain tissue in a subject. For example, the disease or disorder to be diagnosed and/or prognosed in a subject can be associated with breast, pancreas, blood, prostate, colon, lung, skin, brain, ovary, kidney, oral cavity, throat, cerebrospinal fluid, liver, and any combination thereof. In some embodiments, the disease or disorder to be diagnosed and/or prognosed with the methods, assays or systems described herein can be a blood disorder, e.g., associated with diseased or abnormal platelets. In other embodiments, the disease or disorder to be diagnosed and/or prognosed with the methods, assays or systems described herein can be any cancer, e.g., but not limited to breast cancer and pancreatic cancer.

For a subject who is determined to have, or is at risk of developing, or is at a given stage of the disease or disorder, the subject can be administered or prescribed with a specific treatment. For example, in some embodiments where the subject is diagnosed with cancer (e.g., breast carcinoma or pancreatic carcinoma) or progression thereof, the method can further comprise administering or prescribing the subject a treatment, e.g., chemotherapy, radiation therapy, surgery, engineered transcripts that can “sponge” various combinations of the novel miRNAs described herein, or any combinations thereof.

Another aspect provided herein relates to systems for analyzing a biological sample, e.g., to determine a given state of a cell or a tissue, and/or to diagnose and/or prognose a disease or disorder, or a given state of a disease or disorder in a subject. In one embodiment, the system comprises: (a) a determination module configured to receive a biological sample and to determine sequence information and, optionally quantity estimate information, wherein the sequence information comprises a sequence of one or more miRNAs described herein; and wherein the quantity estimate information comprises at least an estimate of the abundance of said sequence, with said abundance optionally scaled with regard to the abundance of a reference molecule; (b) a storage device configured to store sequence information and optionally the quantity estimate information from the determination module; (c) a comparison module adapted to compare the sequence information and optionally the quantity estimate information stored on the storage device with reference data, and to provide a comparison result, wherein the comparison result identifies the presence or absence of the miRNA molecule, and optionally how its quantity estimate is related to the reference data, wherein a discrepancy in a quantity estimate level is indicative of the biological sample having an increased likelihood of having, or being at a cellular or tissue state different from a state represented by the reference data; and (d) a display module for displaying a content based in part on the comparison result for the user, wherein the content is a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of lacking a disease or disorder.

A computer-readable physical medium for determination of a given state of a cell or a tissue, including diagnosis and/or prognosis of a disease or disorder, or a state of a disease or disorder in a subject, is also provided herein. The computer-readable physical medium having computer readable instructions recorded thereon to define software modules includes a comparison module and a display module for implementing a method on a computer, wherein the method comprises: (a) comparing with the comparison module the data stored on a storage device with reference data to provide a comparison result, wherein the comparison result captures the presence or absence of the miRNA molecule and/or the difference between its quantity estimate and the reference data, wherein a discrepancy in a quantity estimate level is indicative of a biological sample having an increased likelihood of having, or being at a cellular or tissue state different from a state represented by the reference data; and (b) a display module for displaying a content based in part on the comparison result for the user, wherein the content is a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of lack of a disease or disorder.

In some embodiments, kits and/or assays for expressing, silencing, and/or quantitating one or more of the novel miRNAs described herein from the model organism of choice (e.g., but not limited to, human, mouse, and rat) are also encompassed within the scope of various aspects described herein.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-1B are block diagrams showing an example of a system for determining a state of a cell or a tissue and/or for diagnosing or prognosing a disease or disorder, or a stage of a disease or disorder in a subject, based on expression level of one or more novel miRNAs described herein.

FIG. 2 is a block diagram showing exemplary instructions on a computer readable medium for determining a state of a cell or a tissue and/or for diagnosing or prognosing a disease or disorder, or a stage of a disease or disorder in a subject, based on expression level of one or more novel miRNAs described herein.

FIG. 3 is a heatmap showing that the two groups of individuals with platelet antigen hyper-reactivity or hypo-reactivity have distinct miRNA/isomiR expression profiles.

FIG. 4 is a heatmap showing differential expression of novel isomiRs across human populations by ethnicities.

FIGS. 5A-5B is a heatmap showing differential expression of novel isomiRs across human populations by ethnicities and gender. FIG. 5A is based on male samples only. FIG. 5B is based on female samples only.

DETAILED DESCRIPTION OF THE INVENTION

There is a need to identify novel miRNA sequences that provide more accurate or reliable diagnostic and/or prognostic tools and/or improved therapies or provide improved tissue of origin identification. To this end, inventors analyzed 1,367 next generation sequencing datasets (RNA-sequencing and Argonaute cross-linking and immunoprecipitation (CLIP)-sequencing) corresponding to human normal and disease states from 13 distinct tissue types (from a total of approximately 200 human tissue types)) and discovered at least tens of thousands of novel miRNAs as disclosed herein: each of the novel miRNAs has an associated FDR of 0.05 or lower.

By analyzing a large collection of next generation sequencing datasets, the inventors have discovered numerous novel human miRNAs and variants thereof For a large fraction of these novel miRNAs, the inventors have additional corroborating evidence, through the analysis of CLIP-sequencing datasets, that they are loaded on Argonaute, which provides further credence to their bona fide miRNA nature.

In addition, by analyzing short RNA sequence profiles of deep sequenced biological samples of various human tissues and/or cell types, the inventors have discovered that the actual instance of the mature miRNA product that arises from a given miRNA locus and is detected in a given cell or tissue context can be different from the instance of the mature miRNA product that arises from the same miRNA locus in a different cell or tissue context, and this finding has been observed for many of the miRNAs currently in miRBase, which is a public repository of miRNA sequences for vertebrates, invertebrates, viruses, and plants. Accordingly, these tissue and/or cell-type dependence correlation of the novel miRNAs described herein can be used to determine tissue of origin in samples of interest. Additionally or alternatively, the tissue/cell-type dependence of the novel miRNAs described herein can also be used to determine cell state, disease type, disease stage, etc.

Accordingly, these novel miRNAs described herein can be used in various applications, e.g., to generate novel molecular signatures for cell types, cell states, disease, disease stage, disease progression, etc. They can also be used to identify novel and unexpected molecular players in cellular contexts of interest and also to reveal unexpected molecular interplays that underlie the onset and progression of diseases. Further, the novel miRNAs described herein can provide novel and improved means for therapeutic interventions. Accordingly, provided herein relates to methods, compositions, assays and systems for determining a given state of a cell and/or a tissue, which can be used for diagnosing a disease or disorder, and/or prognosing a given stage and/or progression of a disease or disorder, and/or treating a disease or disorder.

Methods and Assays for Determining a Given State of a Cell or a Tissue, or for Determining Tissue of Origin

One aspect described herein provides methods and assays for determining a specific state or condition of a cell or a tissue. As the cell or tissue can be derived from a biological sample of a subject suspected of being at risk of or having a given stage of a disease or disorder, e.g., a condition afflicting a tissue, methods and assays for determining whether a subject has or is at risk of developing, or is at a given stage of a disease or disorder, e.g., a condition afflicting a tissue, are also provided herein. The methods or assays of any aspects described herein comprise measuring in a biological sample from a tissue of interest expression level of one or more miRNAs selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 disclosed in Tables 1-3. In some embodiments, the methods or assays of any aspects described herein comprise measuring in a biological sample from a tissue of interest expression level of one or more miRNAs selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 disclosed in Tables 1-3. An alteration of the level of one or more miRNAs as compared to the level of the same miRNA sequence(s) in a reference sample is indicative of the subject either having, or being at risk of developing, or being at a given stage of the condition.

As shown in the Examples, some of the novel miRNAs/isomiRs are preferentially present in some tissues but not in other tissues. This indicats that signatures of one or more miRNAs can be used to answer the question of tissue of origin. Thus, in some embodiments, the methods and/or assays described herein can also be used to determine tissue of origin by comparing the level(s) of one or more miRNAs in the biological sample to that of reference samples of different tissues.

As used herein, the term “alteration of the level of one or more miRNAs” refers to a change in the level of one or more miRNAs in a sample relative to the corresponding level(s) in a reference sample. In some embodiments, the alteration or change in the level of one or more miRNAs can refer to an increase in the level of one or more miRNAs in a sample relative to the corresponding level(s) in a reference sample. For example, in some embodiments where there is an alteration in the level of one or more miRNAs, the level of one or more miRNAs in a sample can be increased by at least about 10% or more, including, e.g., at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 99% or more, relative to the corresponding level(s) in a reference sample. In some embodiments where there is an alteration in the level of one or more miRNAs, the level of one or more miRNAs in a sample can be increased by at least about 1.1-fold or more, including, e.g., at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold or more, relative to the corresponding level(s) in a reference sample.

In some embodiments, the level(s) of one or more miRNAs are considered to be altered (or differentially expressed) relative to reference sample(s) if it has a mean expression of at least 25 or more sequenced reads, and a log2-change in expression relative to the reference sample(s) of at least 0.5 or higher, or no more than −0.5 or lower.

In other embodiments, the alteration or change in the level of one or more miRNAs can refer to a decrease in the level of one or more miRNAs in a sample relative to the corresponding level(s) in a reference sample. For example, in some embodiments where there is an alteration in the level of one or more miRNAs, the level of one or more miRNAs in a sample can be decreased by at least about 10% or more, including, e.g., at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 99% or more (including 100%), relative to the corresponding level(s) in a reference sample.

In some embodiments, the “alteration of the level of one or more miRNAs” can refer to the presence (e.g., a detectable level) of one or more miRNAs in a sample, as compared to the absence (e.g., no detectable level) of those miRNA(s) in a reference sample.

In alternative embodiments, the “alteration of the level of one or more miRNAs” can refer to the absence (e.g., no detectable level) of one or more miRNAs in a sample, as compared to the presence (e.g., a detectable level) of those miRNA(s) in a reference sample.

In some embodiments of any aspects described herein, the method or assay can comprise detecting in the biological sample the level of a plurality (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, or more) of the miRNAs selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 disclosed in Tables 1-3.

An amount of a miRNA sequence in the biological sample can be measured or quantified by any known RNA detection methods. By way of example only, the miRNA(s) in a biological sample can be detected or read by a sequencing method (including Sanger sequencing, next-generation sequencing or deep sequencing, direct multiplexing, and any art-recognized sequencing method) and a read count of each miRNA sequence can be generated to determine its amount present in the biological sample. Alternatively, where the miRNA sequence(s) in a biological sample are determined by PCR-based methods (e.g., real-time PCR), the amount of the miRNA sequence(s) present in the biological sample can be represented by a C_(t) number, which can be compared to that of a reference sample. As a person having ordinary skill in the art would appreciate, a larger C_(t) number generally indicates a lower amount of a nucleic acid sequence present in a sample. In some embodiments, the quantitative amount of the miRNA sequence(s) detected by PCR-based methods (e.g., real-time PCR) can also be determined from a calibration curve generated with known amounts of a nucleic acid sequence.

Any other art-recognized methods detecting or measuring the level of a miRNA sequence, e.g., but not limited to the methods and kits for miRNA isolation and quantitation as described in U.S. Pat. No. 8,574,838, can also be used herein. Additional information about measuring or quantifying one or more miRNA sequences is described in the section “Exemplary method's for detecting or measuring the level of a miRNA sequence” below.

As the amount of the miRNA sequence(s) is determined in the biological sample, in some embodiments, the methods or assays described herein can further comprise comparing with a reference sample the level of one or more miRNA sequences described herein in the biological sample. When there is a difference (e.g., at least about 10% difference or higher) or a statistically significant difference in an amount of at least one or more (e.g., at least 2 or more) or in the profile of miRNA sequences between the biological sample and the reference sample, the difference or significant difference can be indicative of the cell or the tissue in a state different from the reference sample. If the cell or the tissue is derived from a biological sample of a subject, the results of the comparison can be used for diagnosing or prognosing a disease or disorder, or a state of a disease or disorder. Depending on the choice of a reference sample, in some embodiments, the difference or significant difference can be indicative of a subject either having, or being at risk of developing, or being at a given stage of a disease or disorder, e.g., a condition afflicting the tissue; while in other embodiments, the difference or significant difference can be indicative of a subject free of a disease or disorder, e.g., a condition afflicting the tissue. For example, if a subject's miRNA sequence level or profile has no significant difference from that of a normal sample, it indicates that the subject is free of a condition or disease. Additionally or alternatively, if a subject's miRNA sequence level or profile is significantly different from that of a sample of a known disease or disorder to be diagnosed, it indicates that the subject does not likely have that disease or disorder.

If the miRNA sequence level or profile of a biological sample contain miRNA(s) that are preferentially present in a certain tissue but not in other tissues, the tissue origin of the biological sample can be determined based on the presence of those tissue-specific miRNA(s).

The threshold level selected to distinguish a given state of a cell or tissue from another, and/or to determine if a subject has, or is at risk of developing, or is at a given stage of a condition afflicting a tissue of interest can be determined experimentally. For example, by comparing the levels and/or profiles of one or more miRNA molecules detected in a number of references samples of known conditions in a specific tissue (e.g., a normal breast sample vs. a cancerous breast sample), e.g., by deep sequencing and/or quantitative RT-PCR, one of skill in the art can determine a threshold level for levels of one or more miRNA sequences required to distinguish one condition from another (e.g., to distinguish a normal breast sample from a cancerous breast sample).

In some embodiments, the threshold level needs not be pre-determined. For example, cluster analysis can be computationally performed to classify miRNA expression profiles of a biological sample and a set of reference samples into groups such that samples in the same group (called a cluster) have more similar miRNA expression profiling to each other than to those in other groups (clusters). Accordingly, when a biological sample is categorized into the same group with a subset of reference samples of similar miRNA expression profiles, the biological sample is considered to have similar properties (e.g., genotype or phenotype) as the subset of reference samples. For example, when a breast tissue sample from a subject is categorized into the same group representing cancerous breast tissue reference samples, or more specifically, into a sub-group representing invasive breast cancer, the subject is determined to likely to have breast cancer, or more specifically an invasive breast cancer. Various clustering algorithms for classification and clustering are known in the art and can be used for the purposes described herein. Examples of clustering algorithms and/or models include, but are not limited to connectivity-based clustering (e.g., hierarchical clustering), centroid-based clustering (e.g., k-means clustering), distribution-based clustering (e.g., multivariate normal distributions used by the expectation-maximization algorithm), density-based clustering (e.g., DBSCAN and OPTICS), subspace models (e.g., biclustering), and any combinations thereof.

The reference sample used in the methods and assays described herein can be a sample derived from the same type of cell or tissue as a biological sample, and with a known condition. For example, the reference sample can represent a normal condition of a cell or tissue in a biological sample to be analyzed. The normal reference sample can be collected from a subject whose biological sample is being analyzed or from a different subject. Alternatively, the reference sample can represent a recognizable stage of an abnormal condition of a cell or a tissue in a biological sample to be analyzed. By way of example only, if a disease or disorder to be diagnosed or prognosed in a subject is breast cancer, a reference sample can include a normal breast tissue, a ductal carcinoma in situ breast tissue sample, an invasive ductal carcinoma tissue sample or subtype, an invasive lobular carcinoma tissue sample, a lobular carcinoma in situ tissue sample, and any combinations thereof.

In some embodiments, the reference sample can present a known condition of a known tissue origin. Depending on applications, the reference sample can have the same or different tissue origin from the biological sample. For example, in order to determine the tissue origin of a biological sample, the level(s) and/or profile of one or more miRNAs described herein can be compared to reference samples of different tissues.

By way of example only, in some embodiments, the methods described herein can be used to determine a primary origin of an unknown tumor or cancer. Thus, in some embodiments, the methods described herein can be used to determine whether the tumor is a primary tumor or a secondary tumor (i.e., a metastasis). For example, a biopsy of an unknown tumor can be subjected to the methods or assays described herein to determine the tissue origin of the tumor, wherein if the tissue origin of the tumor is determined to be the same tissue type as from where the biopsy is collected, the tumor is diagnosed as a primary tumor, or if the tissue origin of the tumor is determined to be different from the type of the tissue from where the biopsy is collected, the tumor is diagnosed as a secondary tumor (i.e., a metastasis). Thus, the methods described herein can be used to fingerprint a biological sample, e.g., whether it is a normal sample or a diseased sample (e.g., a cancerous sample).

In some embodiments, more than one reference samples can be used, wherein the reference samples can represent a variety of different conditions (e.g., normal condition, different stages of a disease or disorder, different tissue origins). By way of example only, if a biological sample of a subject generates a similar or comparable miRNA expression profile (e.g., in terms of levels and/or locations of miRNA sequences) to that of a normal sample or a group of normal samples (reference samples), the subject can be considered normal with respect to the normal sample or the group normal samples. Similarly, if a biological sample of a subject generates a similar or comparable miRNA expression profile (e.g., in terms of levels and/or locations of miRNA sequences) to that of a sample or a group of samples derived from a given tissue (reference samples), the subject's biological sample can be considered to have the same tissue type as the reference samples.

The miRNA expression profile can be generated based on one or more genes. In some embodiments, the miRNA expression profile can be generated based on a specific gene, e.g., a gene that is associated with a condition or disorder. In some embodiments, miRNA sequences can be detected from at least two genes in a biological sample and compared to the corresponding reference sample to determine if similar conclusions are obtained.

For a subject who is determined to have, or is at risk of developing, or is at a given stage of the disease or disorder, the subject can be administered or prescribed with an appropriate treatment. For example, in some embodiments where the subject is diagnosed with cancer (e.g., breast carcinoma or pancreatic carcinoma) or progression thereof, the method can further comprise administering or prescribing the subject an anti-cancer treatment, e.g., chemotherapy, radiation therapy, surgery, immunotherapy, RNA therapeutics (e.g., siRNAs, miRNAs), or any combinations thereof.

In some embodiments, a subject in need thereof can be administered with an antagonist or a mimic of one or more (e.g., at least one, at least two, at least three, at least four, at least five, or more) of the miRNA sequences selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 in Tables 1-3, depending on whether the subject is diagnosed to have an overexpression or a deficiency of one or more miRNA sequences determined to be associated with a condition or disorder. For example, in some embodiments where the level(s) of one or more miRNAs described herein are determined to represent a “causal event” for the disease or disorder, the level(s) of the miRNAs can be controlled in order to return their levels to what would be considered “normal” levels and thus alleviate the impact that can result from the changes in their amount. Examples of the techniques that can be used to control the level(s) of one or more miRNAs described herein include, but are not limited to, antisensing or sponging (e.g., microRNA sponges as described in Ebert and Shape. “MicroRNA sponges: Progress and possibilities” RNA (2010) 16:2043-2050; and Ebert et al. “MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells” Nat. Methods (2007) 4: 721-726), decoying (e.g., as described in Swami M. “Small RNAs: Pseudogenes act as microRNA decoys.” Nature Reviews Genetics (2010) 11: 530-531), overexpression, and/or any art-recognized techniques.

Additional information about antagonists or mimics of miRNAs described herein is described in the section “Pharmaceutical compositions” below.

Novel miRNA Sequences or Molecules Described Herein

The inventors have discovered a collection of novel microRNAs (miRNAs) of SEQ ID NO: 1 to SEQ ID NO: 47,972 in Tables 1-3 in a human genome, based on deep sequencing data using different tools and/or design methodology. The cardinality of the class of non-coding RNAs (ncRNAs) known as microRNAs or miRNAs has been a controversial issue for more than a decade. It was previously estimated that the number of human miRNAs would not exceed 300 (Lim et al. Science. 2003 Mar. 7; 299(5612):1540). However, different methods that were used later provided higher, yet concordant, figures for the number of human miRNAs and their cardinality was estimated to be in the several tens of thousands. The miRBase repository has served as a widely-accepted public clearinghouse of miRNA sequences for vertebrates, invertebrates, viruses and plants. The database's latest release (Rel. 20) from 2013 contains ˜2,600 human miRNA entries produced from ˜1,800 miRNA precursors.

Tables 1-3 listing sequences of novel miRNAs of SEQ ID NO: 1 to SEQ ID NO: 47,972 are submitted and incorporated herein by reference in their entireties. Oligonucleotides comprising sequences complementary to the novel miRNAs listed in Tables 1-3 are also encompassed within the scope of the inventions described herein. By “complementary” is meant that an oligonucleotide can form hydrogen bond(s) with another oligonucleotide by either traditional Watson-Crick or other non-traditional types. The complementary oligonucleotides can be completely or partially complementary to the novel miRNA sequences listed in Tables 1-3. In some embodiments, partial complementarity is indicated by the percentage of contiguous residues in an oligonucleotide that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second oligonucleotide sequence (e.g., 5, 6, 7, 8, 9,10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). “Completely complementary” or 100% complementarity means that all the contiguous residues of an oligonucleotide sequence will form hydrogen bond with the same number of contiguous residues in a second oligonucleotide sequence. Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands can hydrogen bond with each other.

Table 1 shows a listing of novel miRNAs of SEQ ID NO: 1 to SEQ ID NO: 19,754 that the inventors identified using their own designed methodology as described in Example 1. In Table 1, SEQ ID NO: 1 to SEQ ID NO: 9,877 contain miRNA sequences of mature form, while SEQ ID NO: 9,878 to SEQ ID NO: 19,754 contain sequences each having a hairpin sequence and a mature miRNA sequence.

Table 2 shows a listing of novel miRNAs of SEQ ID NO: 19,755 to SEQ ID NO: 27,168 that the inventors identified using a public tool called miRDeep2. MiRDeep2 (see Friedlander, M. R., et al., Nature Biotechnology, 2008, 26, 407-415, for methods of discovering microRNAs from deep sequencing data using miRDeep) follows a slightly different approach to finding miRNAs that is based on a multi-faceted scoring system. In an effort to be comprehensive, miRDeep2 was also used to discover miRNAs to complement the inventor's methodology (as described in Example 1). In Table 2, SEQ ID NO: 19,755 to SEQ ID NO: 23,461 contain miRNA sequences of mature form, while SEQ 1D NO: 23,462 to SEQ ID NO: 27,168 contain sequences each having a hairpin sequence and a mature miRNA sequence.

Table 3 shows a listing of novel miRNAs of SEQ ID NO: 27,169 to SEQ ID NO: 47,972. These are variants or isomers of miRNAs, called isomiRs. The term “isomiR” generally refers to a miRNA who sequence is slightly different than the sequence of a known miRNA, e.g., a miRNA that is known in the public databases.” However, this apparent difference could simply be because the “miRNA” is found in tissue X whereas the “isomiR” is found in tissue Y and it so happened that the tissue X was first studied. If tissue Y was first studied then what is called “isomiR” might have been called “miRNA” and vice versa.

In some instances, both the “miRNA” and the “isomiR” can be found in the same tissue but the isomiR has a lower expression than the miRNA. In some instances, tissues where what is commonly called as “miRNA” has lower expression than an “isomiR” from the same locus: in such examples, the labels of miRNA and isomiR can be used interchangeably. Accordingly, as used herein, the terms “miRNA” and “isomiR” are used herein interchangeably and will be making a distinction only if necessary to remove any ambiguities.

While the novel miRNA sequences listed in Tables 1-3 are from human genomes, many of these sequences are conserved in other species, e.g., but not limited to other primates such as Chimpanzee, Gorilla, Orangutan, and Macaque. Some human miRNA sequences as described herein are also conserved in mice, fruit-fly, and worms. See Example 2.

MicroRNAs (miRNAs) are small, non-coding RNA molecules that generally function as regulators of a genome. The terms “microRNA” or “miR_NA” are used interchangeably herein, are generally endogenous RNAs, some of which are known to regulate the expression of protein-coding genes at the posttranscriptional level. As used herein, the term “microRNA” refers to any type of micro-interfering RNA, including but not limited to, endogenous microRNA and artificial or synthetic microRNA. Typically, endogenous microRNA are small RNAs encoded in the genome which are capable of modulating the productive utilization of mRNA. A mature miRNA is a single-stranded RNA molecule of about 21-23 nucleotides in length that is complementary to a target sequence and hybridizes to the target RNA sequence to inhibit expression of a (protein-coding or non-coding) gene which encodes a miRNA target sequence. miRNAs themselves are encoded by genes that are transcribed from DNA but not translated into protein (non-coding RNA); instead they are processed from primary transcripts known as pri-miRNA to short stem-loop structures called pre-miRNA and finally to functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression. MicroRNA sequences have been described in publications such as, Lim, et al., Genes & Development, 17, p. 991-1008 (2003), Lim et al Science 299, 1540 (2003), Lee and Ambros Science, 294, 862 (2001), Lau et al., Science 294, 858-861 (2001), Lagos-Quintana et al, Current Biology, 12, 735-739 (2002), Lagos Quintana et al, Science 294, 853-857 (2001), and Lagos-Quintana et al, RNA, 9, 175-179 (2003), which are incorporated by reference. Multiple microRNAs can also be incorporated into the precursor molecule.

A mature miRNA is produced as a result of a series of rniRNA maturation steps; first a gene encoding the rniRNA is transcribed. The gene encoding the miRNA is typically much longer than the processed mature miRNA molecule; miRNAs are first transcribed as primary transcripts or “pri-miRNA” with a cap and poly-A tail, which is subsequently processed to short, about 70-nucleotide “stern-loop structures” known as “pre-miRNA” in the cell nucleus. This processing is performed in animals by a protein complex known as the Microprocessor complex, consisting of the nuclease Drosha and the double-stranded RNA binding protein Pasha. These pre-miRNAs are then processed to mature miRNAs in the cytoplasm by interaction with the endonuclease Dicer, which also initiates the formation of the RNA-induced silencing complex (RISC). This complex is responsible for the gene silencing observed due to miRNA expression and RNA interference. The pathway is different for miRNAs derived from intronic stem-loops; these are processed by Drosha but not by Dicer. In some instances, a given region of DNA and its complementary strand can both function as templates to give rise to at least two miRNAs. Mature miRNAs can direct the cleavage of mRNA or they can interfere with translation of the mRNA, either of which results in reduced protein accumulation, rendering miRNAs capable of modulating gene expression and related cellular activities.

As discussed above, recent advances in next generation sequencing have complicated this picture by revealing that multiple distinct mature miRNA species, the isomiRs, can arise from the same miRNA precursor arm (“pre-miR”). The isomiRs typically differ from the mature miRNA sequences currently in public databases such as miRBase on either their 5′ or 3′ ends, thereby increasing the diversity and complexity of the miRNA-orae. IsomiRs, just like miRNAs, associate with the Argonaute complex. Accordingly, the terms “miRNA” and “isomiR” are used herein interchangeably and will be making a distinction only if necessary to remove any ambiguities.

The term “pri-miRNA” refers to a precursor to a mature miRNA molecule which comprises: (i) a microRNA sequence and (ii) stem-loop component which are both flanked (i.e. surrounded on each side) by “microRNA flanking sequences”, where each flanking sequence typically ends in either a cap or poly-A tail. A pri-microRNA, (also referred to as large RNA precursors), are composed of any type of nucleic acid based molecule capable of accommodating the microRNA flanking sequences and the microRNA sequence. Examples of pri-miRNAs and the individual components of such precursors (flanking sequences and microRNA sequence) are provided herein. The nucleotide sequence of the pri-miRNA precursor and its stem-loop components can vary widely. In one embodiment, a pre-miRNA molecule can be an isolated nucleic acid; including microRNA flanking sequences and comprising a stem-loop structure and a microRNA sequence incorporated therein. A pri-miRNA molecule can be processed in vivo or in vitro to an intermediate species caller “pre-miRNA”, which is further processed to produce a mature miRNA.

The term “pre-miRNA” refers to the intermediate miRNA species in the processing of a pri-miRNA to mature miRNA, where pri-miRNA is processed to pre-miRNA in the nucleus, whereupon pre-miRNA translocates to the cytoplasm where it undergoes additional processing in the cytoplasm to form mature miRNA. Pre-miRNAs are generally about 70 nucleotides long, but can be less than 70 nucleotides or more than 70 nucleotides.

The term “microRNA flanking sequence” as used herein refers to nucleotide sequences including microRNA processing elements. MicroRNA processing elements are the minimal nucleic acid sequences which contribute to the production of mature miRNA from precursor microRNA. Often these elements are located within a 40 nucleotide sequence that flanks a microRNA stem-loop structure. In some instances the microRNA processing elements are found within a stretch of nucleotide sequences of between 5 and 4,000 nucleotides in length that flank a microRNA stem-loop structure. Thus, in some embodiments the flanking sequences are 5-4,000 nucleotides in length. As a result, the length of the precursor molecule can be, in some instances at least about 150 nucleotides or 270 nucleotides in length. The total length of the precursor molecule, however, can be greater or less than these values. In other embodiments the minimal length of the microRNA flanking sequence is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200 and any integer there between. In other embodiments the maximal length of the microRNA flanking sequence is 2, 000, 2,100, 2, 200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3, 000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900 4,000 and any integer there between.

MicroRNA flanking sequences can be native microRNA flanking sequences or artificial microRNA flanking sequences. A native microRNA flanking sequence is a nucleotide sequence that is ordinarily associated in naturally existing systems with microRNA sequences, i.e., these sequences are found within the genomic sequences surrounding the minimal microRNA hairpin in vivo. Artificial microRNA flanking sequences are nucleotides sequences that are not found to be flanking to microRNA sequences in naturally existing systems. microRNA flanking sequences within the pri-miRNA molecule can flank one or both sides of the stem-loop structure encompassing the microRNA sequence. Thus, one end (i.e., 5′) of the stem-loop structure can be adjacent to a single flanking sequence and the other end (i.e., 3′) of the stem-loop structure cannot be adjacent to a flanking sequence. Preferred structures have flanking sequences on both ends of the stein-loop structure. The flanking sequences can be directly adjacent to one or both ends of the stem-loop structure or can be connected to the stem-loop structure through a linker, additional nucleotides or other molecules.

A “stem-loop structure” refers to a nucleic acid having a secondary structure that includes a region of nucleotides which are known or predicted to form a double strand (stern portion) that is linked on one side by a region of predominantly single-stranded nucleotides (loop portion). The terms “hairpin” and “fold-back” structures arc also used herein to refer to stem-loop structures. Such structures are well known in the art and the term is used consistently with its known meaning in the art. The actual primary sequence of nucleotides within the stem-loop structure is not critical to the practice of the invention as long as the secondary structure is present. As is known in the art, the secondary structure does not require exact base-pairing. Thus, the stem can include one or more base mismatches. Alternatively, the base-pairing can be exact, i.e. not include any mismatches. In some instances the precursor microRNA molecule can include more than one stem-loop structure. The multiple stem-loop structures can be linked to one another through a linker, such as, for example, a nucleic acid linker or by a microRNA flanking sequence or other molecule or some combination thereof

The hairpin sequences in Tables 1 and 2 can provide information about novel miRNAs and the pre-miRNA that are believed to be responsible for the miRNAs production. The hairpin sequences of Tables 1 and 2 can be used in the same manner that one would use a pre-miRNA (e.g., similar preparation methods, similar delivery methods, similar application settings, similar detection methods).

Furthermore, miRNA-like stem-loops can be expressed in cells as a vehicle to deliver artificial or synthetic miRNAs for the purpose of modulating the expression of endogenous genes through the miRNA and/or RNAi pathways.

In some embodiments, the miRNAs described herein are miRNA mimetic. As used herein, the term “miRNA mimetic” refers to an artificial miRNA which is flanked by the appropriate sequences that will allow it to form the stem-loop like structures that are typical of a pri-miRNA.

The term “artificial microRNA” includes any type of RNA sequence, other than endogenous microRNA, which is capable of modulating the productive utilization of mRNA. For instance, the term artificial microRNA also encompasses a nucleic acid sequence which would be previously identified as siRNA, where the siRNA is incorporated into a vector and surrounded by miRNA flanking sequences as described herein.

In some embodiments, the term “miRNA” as used herein can encompass an oligonucleotide having a hairpin sequence and a mature miRNA sequence. In some embodiments, the term “miRNA” can encompass isomiR.

In some embodiments, the novel miRNA sequences described herein can encompass at least one or more nucleotide modifications, e.g., addition, deletion and/or substitutions of nucleotides, and/or modifications to the side groups and/or backbone of the nucleotides. Unmodified miRNA sequences can be less than optimal in some applications, e.g., unmodified miRNA sequences can be prone to degradation by e.g., cellular nucleases. However, chemical modifications to one or more of the subunits of the miRNA sequences can confer improved properties, e.g., can render miRNA sequences more stable to nucleases. Typical miRNA sequence modifications can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens in the phosphodiester intersugar linkage; (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar; (iii) wholesale replacement of the phosphate moiety with “dephospho” linkers; (iv) modification or replacement of a naturally occurring base with a non-natural base; (v) replacement or modification of the ribose-phosphate backbone, e.g. peptide nucleic acid (PNA); (vi) modification of the 3′ end or 5′ end of the oligonucleotide, e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety, e.g., conjugation of a ligand, to either the 3′ or 5′ end of oligonucleotide; and (vii) modification of the sugar, e.g., six membered rings.

The terms replacement, modification, alteration, and the like, as used in this context, do not imply any process limitation, e.g., modification does not mean that one must start with a reference or naturally occurring ribonucleic acid and modify it to produce a modified ribonucleic acid bur rather modified simply indicates a difference from a naturally occurring molecule. As described below, modifications, e.g., those described herein, can be provided as asymmetrical modifications.

Diseases or Disorders that can be Diagnosed, Prognosed, and/or Treated Using one or More Novel miRNAs Described Herein or Complementary Sequences Thereof

In some aspects, different embodiments of the methods, assays, compositions, and systems described herein can be used for diagnosis and/or prognosis of a disease or disorder, and/or the state of the disease or disorder in a subject, e.g., a condition afflicting a certain tissue in a subject. In other aspects, different compositions described herein can be used for treatment of a disease or disorder in a subject. For example, the disease or disorder in a subject can be associated with breast, pancreas, blood, prostate, colon, lung, skin, brain, ovary, kidney, oral cavity, throat, cerebrospinal fluid, liver, or other tissues, and any combination thereof. Examples 7-8 shows differential expression of some of the novel miRNA sequences listed in Tables 1-3 in tissues of different states (e.g., disease states or cell states).

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include conditions that are not terminal but can cause an interruption, disturbance, or cessation of a bodily function, system, or organ. Such examples of diseases or disorders can include, e.g., but are not limited to developmental disorders (e.g., autism), brain disorders (e.g., epilepsy), mental disorders (e.g., depression), endocrine disorders (e.g., diabetes), heart diseases (e.g., cardiomyopathy), or skin disorders (e.g., skin inflammation).

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include breast diseases or disorders. Exemplary breast disease or disorder includes breast cancer.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include pancreatic diseases or disorders. Nonlimiting examples of pancreatic diseases or disorders include acute pancreatitis, chronic pancreatitis, hereditary pancreatitis, pancreatic cancer (e.g., endocrine or exocrine tumors), etc., and any combinations thereof.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include blood diseases or disorders. Examples of blood diseases or disorders include, but are not limited to, platelet disorders, von Willebrand diseases, deep vein thrombosis, pulmonary embolism, sickle cell anemia, thalassemia, anemia, aplastic anemia, fanconi anemia, hemochromatosis, hemolytic anemia, hemophilia, idiopathic thrombocytopenic purpura, iron deficiency anemia, pernicious anemia, polycythemia vera, thrombocythemia and thrombocytosis, thrombocytopenia, and any combinations thereof.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include prostate diseases or disorders. Non-limiting examples of prostate diseases or disorders can include prostatis, prostatic hyperplasia, prostate cancer, and any combinations thereof

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include colon diseases or disorders. Exemplary colon diseases or disorders can include, but are not limited to, colorectal cancer, colonic polyps, ulcerative colitis, diverticulitis, and any combinations thereof.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include lung diseases or disorders. Examples of lung diseases or disorders can include, but are not limited to, asthma, chronic obstructive pulmonary disease, infections, e.g., influenza, pneumonia and tuberculosis, and lung cancer.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include skin diseases or disorders, or skin conditions. An exemplary skin disease or disorder can include skin cancer, e.g., melanoma; and psoriasis.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include brain diseases or disorders. Examples of brain diseases or disorders can include, but are not limited to, brain infections (e.g., meningitis, encephalitis, brain abscess), brain tumor, glioblastoma, stroke, ischemic stroke, multiple sclerosis (MS), vasculitis, and neurodegenerative disorders (e.g., Parkinson's disease, Huntington's disease, Pick's disease, amyotrophic lateral sclerosis (ALS), dementia, and Alzheimer's disease), and any combinations thereof.

In some embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include liver diseases or disorders. Examples of liver diseases or disorders can include, but are not limited to, hepatitis, cirrhosis, liver cancer, billary cirrhosis, primary sclerosing cholangitis, Budd-Chiari syndrome, hemochromatosis, transthyretin-related hereditary amyloidosis, Gilbert's syndrome, and any combinations thereof.

In other embodiments, diseases or disorders that can be diagnosed, prognosed, and/or treated using one or more novel miRNAs described herein or complementary sequences thereof can include cancer. Examples of cancers can include, but are not limited to. bladder cancer; breast cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer including colorectal carcinomas; endometrial cancer; esophageal cancer; gastric cancer; head and neck cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia, multiple myeloma, AIDS associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease, liver cancer; lung cancer including small cell lung cancer and non-small cell lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; osteosarcomas; ovarian cancer including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, synovial sarcoma and osteosarcoma; skin cancer including melanomas, Kaposi's sarcoma, basocellular cancer, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma (teratomas, choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and medullar carcinoma; transitional cancer and renal cancer including adenocarcinoma and Wilm's tumor.

In some embodiments, the methods, assays, kits, and systems described herein can be used for determining a given stage of cancer in a subject. The stage of a cancer generally describes the extent the cancer has progressed and/or spread. The stage usually takes into account the size of a tumor, how deeply the tumor has penetrated, whether the tumor has invaded adjacent organs, how many lymph nodes the tumor has metastasized to (if any), and whether the tumor has spread to distant organs. Staging of cancer is generally used to assess prognosis of cancer as a predictor of survival, and cancer treatment is primarily determined by staging. Thus, methods, systems, kits, and assays for determining a given stage of cancer in a subject are also provided herein. For example, such methods and assays can comprise detecting in a biological sample (e.g., a biopsy) the presence, absence or level of one or more miRNA sequences described herein.

In some embodiments, the cancer to be diagnosed or prognosed can be breast carcinoma. In such embodiments, the methods or assays described herein can be used to distinguish a cancerous breast tissue from a normal breast tissue, or identify a given stage of a cancerous breast tissue, e.g., ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal carcinoma or a subtype, invasive lobular carcinoma, etc.

In some embodiments, the cancer to be diagnosed or prognosed can be pancreatic cancer. In such embodiments, the methods or assays described herein can be used to distinguish a cancerous pancreas tissue from a normal pancreas tissue, or identify a given state of a cancerous pancreas tissue, e.g., early-stage pancreatic cancer or late-stage pancreatic cancer.

In some embodiments, the methods, assays, kits, and systems described herein can be used for determining tissue origin of a biological sample from a subject. For example, the tissue origin of a biological sample from a subject can be determined based on comparison of the level(s) and/or profile of one or more miRNAs described herein in the biological sample with reference samples of different tissues. Example 3 shows tissue specificity of the novel miRNAs described herein that can be used to identify tissue origin of a biological sample.

By way of example only, in some embodiments, the methods, assays, kits, and systems described herein can be used to determine a primary origin of an unknown tumor or cancer. Thus, in some embodiments, the methods described herein can be used to determine whether the tumor is a primary tumor or a secondary tumor (i.e., a metastasis). For example, a biopsy of an unknown tumor can be subjected to the methods or assays described herein to determine the tissue origin of the tumor, wherein if the tissue origin of the tumor is determined to be the same tissue type as from where the biopsy is collected, the tumor is diagnosed as a primary tumor, or if the tissue origin of the tumor is determined to be different from the type of the tissue from where the biopsy is collected, the tumor is diagnosed as a secondary tumor (i.e., a metastasis). Thus, the methods described herein can be used to fingerprint a biological sample, e.g., whether it is a normal sample or a diseased sample (e.g., a cancerous sample).

For a subject who is determined to have, or is at risk of developing, or is at a given stage of cancer (e.g., breast carcinoma or pancreatic carcinoma), the subject can be administered or prescribed with an anti-cancer treatment, e.g., chemotherapy, radiation therapy, surgery, immunotherapy, RNA therapeutics (e.g., siRNAs, miRNAs), or any combinations thereof.

In some embodiments, a subject in need thereof can be administered with an antagonist or a mimic of one or more of the miRNA sequences selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 in Tables 1-3, depending on whether the subject is diagnosed to have an overexpression or a deficiency of one or more miRNA sequences determined to be associated with a condition or disorder. Additional information about antagonists or mimics of miRNAs described herein is described in the section “Pharmaceutical compositions” below.

Exemplary Methods for Detecting One or More miRNA Sequences Described Herein

One or more miRNA sequence(s) can be detected by any methods known in the art, including, but not limited to, Sanger sequencing, nucleic acid amplification (e.g., polymerase chain reaction (PCR), and real-time quantitative PCR), northern blot, nucleic acid hybridization (e.g., microarray), in situ hybridization, serial analysis of gene expression (SAGE), cap analysis gene expression (CAGE) and massively parallel signature sequencing (MPSS), next generation sequencing (including deep sequencing, e.g., sequencing with deep coverage), direct multiplexing, etc., and any combinations thereof.

Methods for performing SAGE to detect RNAs have been previously described in Velculeseu, V. E. et al. “Serial Analysis of Gene Expression.” Science (1995) 270: 484-487; and Saha S. et al. “Characterization of the yeast transcriptome” Cell (1997) 88: 243-251, and exemplary SAGE protocols can be accessed at sagenet.org/protocol/index.htm. Methods for performing CAGE to detect RNAs has been previously described, e.g., in Kodzius R. et al. “CAGE: cap analysis of gene expression” Nature Methods (2006) 3: 211-222. Methods for performing MPSS to detect RNAs can be found, e.g., in Brenner, S. et al. “Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays” Nature Biotechnology (2000) 18: 630-634.

In some embodiments, the INVADER® assay (Third Wave Technologies Inc., Madison, Wis.) can be modified and used to detect miRNA sequences in a biological sample. The INVADER® assay is generally a homogeneous, isothermal, signal amplification system for the quantitative detection of nucleic acids. The assay can directly detect either DNA or RNA without target amplification or reverse transcription. It is based on the ability of Cleavase® enzymes to recognize as a substrate and cleave a specific nucleic acid structure generated through the hybridization of two oligonucleotides to the target sequence. Modification of the INVADER® assay for miRNA sequence detection has been previously described, e.g., in de Arruda, M. et al. “Invader technology for DNA and RNA analysis: Principles and applications” Expert Rev. Mol. Diagn (2002) 2: 487-496; Eis, P. S. et al. “An invasive cleavage assay for direct quantitation of specific RNAs” Nat. Biotechnol. (2001)19: 673-676; and Allawi H. T. et al. “Quantitation of microRNAs using a modified Invader assay” RNA (2004) 10: 1153-1161.

Next-generation sequencing (NGS) is a novel approach for the detection and sequencing of DNA or RNA molecules as reviewed, e.g., in Voelkerding K. V. et al. “Next-Generation Sequencing: From Basic Research to Diagnostics” Clinical Chemistry (2009) 55: 641-658; Metzker M. L. “Sequencing technologies—the next generation” Nature Reviews (2010) 11: 31-46; Zhang J. et al. “The impact of next-generation sequencing on genomics” J. Genet Genomics (2011) 38: 95-109; and Pareek C. S. et al. “Sequencing technologies and genome sequencing” J. Appl Genetics (2011) 52: 413-435. Various commercial NGS instruments and reagent kits for high-throughput next-generation sequencing have been developed and used for RNA-sequencing. For example, exemplary NGS instruments that can be used for RNA-sequencing or deep sequencing of RNA can include, but are not limited to, the GS FLX sequencer (based on pyrosequencing) from 454 Life Sciences now part of ROCHE Diagnostics [http://www.454.com/], the Genome Analyzer (based on polymerase-based sequence-by-synthesis) from Illumina [http://www.illumina.com], the SOLiD™ System (based on ligation-based sequencing) from Applied Biosystems [http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/solid-next-generation-sequencing/next-generation-systems.html], and the HeliScope™ Single Molecule Sequencer from Helicos BioScience [http://www.helicosbio.com/].

Other NGS or higher-generation sequencing methods based on single-molecule sequencing (without PCR amplification) can also be used to detect miRNA sequences or molecules in some embodiments of the methods, assays, and systems described herein. Examples of single-molecule sequencing methods can include, but are not limited to, Ion Torrent (pH sensing). nanopore sequencing, and transmission electron microscope (TEM) for sequencing. See, e.g., Perkel, J. “Making contact with Sequencing's Fourth Generation” BioTechniques (2011): 50:93-95.

Systems and Computer Readable Media for Determination of a Given State of a Cell or Tissue

Another aspect provided herein relates to systems (and non-transitory computer readable media for causing computer systems), e.g., to perform a method for determining a given state and/or condition of a cell or a tissue sample, and/or to perform the methods of various aspects described herein, based on determining presence and/or absence and/or level(s) of one or more miRNA sequence described herein. In some embodiments, the systems and computer readable media described herein can be used to diagnose and/or prognose a condition or a stage of the condition in a subject.

FIG. 1A depicts a device or a computer system 10 comprising one or more processors 20 and a memory 50 storing one or more programs 70 for execution by the one or more processors 20.

In some embodiments, the device or computer system 10 can further comprise a non-transitory computer-readable storage medium 200 storing the one or more programs 70 for execution by the one or more processors 20 of the device or computer system 10.

In some embodiments, the device or computer system 10 can further comprise one or more input devices 90, which can be configured to send or receive information to or from any one from the group consisting of: an external device (not shown), the one or more processors 20, the memory 50, the non-transitory computer-readable storage medium 200, and one or more output devices 130.

In some embodiments, the device or computer system 10 can further comprise one or more output devices 130, which can be configured to send or receive information to or from any one From the group consisting of: an external device (not shown), the one or more processors 20, the memory 50, and the non-transitory computer-readable storage medium 200.

In some embodiments, the device or computer system 10 for determining a given state and/or condition of a cell or tissue sample (biological sample) comprises:

one or more processors; and

memory to store one or more programs, the one or more programs comprising instructions for:

(i) measuring in a biological sample the level(s) of one or more miRNA sequences selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 listed in Tables 1-3; and

(ii) comparing the measured level(s) of one or more miRNA sequences to that of at least one or more reference samples to determine any significant alteration or difference in the level(s) of the miRNAs between the biological sample and the reference sample(s); and

(iii) displaying a content based in part on the data output from (ii), wherein the content comprises a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of no sign of the disease or disorder.

FIG. 1B depicts a device or a system (e.g., a computer system) for obtaining data from at least one biological sample obtained from one or more subjects. Accordingly, a system for analyzing a biological sample is provided herein. The system can be used to diagnose or prognose a condition or state of a condition in a subject. The system 10 comprises: (a) a determination module 40 configured to receive a biological sample and to determine sequence information, wherein the sequence information comprises a sequence of at least one or more miRNA molecules from the biological sample; (b) a storage device 30 configured to store sequence information from the determination module 40; (c) a comparison module 80 adapted to compare the sequence information stored on the storage device with reference data, and to provide a comparison result, wherein the comparison result identifies the presence or absence or level(s) of the miRNA molecule(s), wherein a discrepancy in an expression level of the miRNA molecule(s) from the reference data is indicative of the biological sample having an increased likelihood of having or being at a cellular or tissue state different from a state represented by the reference data; and (d) a display module 110 for displaying a content based in part on the comparison result for the user, wherein the content is a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of lacking a disease or disorder.

A tangible and non-transitory (e.g., no transitory forms of signal transmission) computer readable medium 200 having computer readable instructions recorded thereon to define software modules for implementing a method on a computer is also provided herein. In some embodiments, the software modules can include a comparison module and a display module for implementing a method on a computer. In some embodiments, the computer-readable medium 200 stores one or more programs for determining a given state of a condition of a cell or tissue (a biological sample). In some embodiments, the computer-readable medium 200 stores one or more programs for determining a condition or state of a condition of a subject. The one or more programs for execution by one or more processors of a computer system comprises (a) instructions for comparing the measured miRNA data (from a biological sample) stored on a storage device with reference data to provide a comparison result, wherein the comparison result the comparison result identifies the presence or absence (or difference in levels) of the miRNA molecule(s), wherein a discrepancy in level(s) of the miRNA molecule(s) from the reference data is indicative of the biological sample having an increased likelihood of having or being at a cellular or tissue state different from a state represented by the reference data; and (b) instructions for displaying a content based in part on the comparison result for the user, wherein the content is a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of lacking a disease or disorder.

Embodiments provided herein have been described through functional modules, which are defined by computer executable instructions recorded on computer readable media and which cause a computer to perform method steps when executed. The modules have been segregated by function for the sake of clarity. However, it should be understood that the modules need not correspond to discrete blocks of code and the described functions can be carried out by the execution of various code portions stored on various media and executed at various times. Furthermore, it should be appreciated that the modules may perform other functions, thus the modules are not limited to having any particular functions or set of functions.

Computing devices typically include a variety of media, which can include computer-readable storage media and/or communications media, in which these two terms are used herein differently from one another as follows. Computer-readable storage media or computer readable media (e.g., 200) can be any available tangible media (e.g., tangible storage media) that can be accessed by the computer, is typically of a non-transitory nature, and can include both volatile and nonvolatile media, removable and non-removable media. By way of example, and not limitation, computer-readable storage media can be implemented in connection with any method or technology for storage of information such as computer-readable instructions, program modules, structured data, or unstructured data. Computer-readable storage media can include, but are not limited to, RAM (random access memory), ROM (read only memory), EEPROM (erasable programmable read only memory), flash memory or other memory technology, CD-ROM (compact disc read only memory), DVD (digital versatile disk) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or other tangible and/or non-transitory media which can be used to store desired information. Computer-readable storage media can be accessed by one or more local or remote computing devices, e.g., via access requests, queries or other data retrieval protocols, for a variety of operations with respect to the information stored by the medium.

On the other hand, communications media typically embody computer-readable instructions, data structures, program modules or other structured or unstructured data in a data signal that can be transitory such as a modulated data signal, e.g., a carrier wave or other transport mechanism, and includes any information delivery or transport media. The term “modulated data signal” or signals refers to a signal that has one or more of its characteristics set or changed in such a manner as to encode information in one or more signals. By way of example, and not limitation, communication media include wired media, such as a wired network or direct-wired connection, and wireless media such as acoustic, RF, infrared and other wireless media.

In some embodiments, the computer readable storage media 200 can include the “cloud” system, in which a user can store data on a remote server, and later access the data or perform further analysis of the data from the remote server.

Computer-readable data embodied on one or more computer-readable media, or computer readable medium 200, can define instructions, for example, as part of one or more programs, that, as a result of being executed by a computer, instruct the computer to perform one or more of the functions described herein (e.g., in relation to system 10, or computer readable medium 200), and/or various embodiments, variations and combinations thereof Such instructions may be written in any of a plurality of programming languages, for example, Java, J#, Visual Basic, C, C#, C++, Fortran, Pascal, Eiffel, Basic, COBOL assembly language, and the like, or any of a variety of combinations thereof. The computer-readable media on which such instructions are embodied may reside on one or more of the components of either of system 10, or computer readable medium 200 described herein, can be distributed across one or more of such components, and may be in transition there between.

The computer-readable media can be transportable such that the instructions stored thereon can be loaded onto any computer resource to implement the aspects provided herein. In addition, it should be appreciated that the instructions stored on the computer readable media, or computer-readable medium 200, described above, are not limited to instructions embodied as part of an application program running on a host computer. Rather, the instructions can be embodied as any type of computer code (e.g., software or microcode) that can be employed to program a computer to implement various aspects described herein. The computer executable instructions can be written in a suitable computer language or combination of several languages. Basic computational biology methods are known to those of ordinary skill in the art and are described in, for example, Setubal and Meidanis et al., Introduction to Computational Biology Methods (PWS Publishing Company, Boston, 1997); Salzberg, Searles, Kasif, (Ed.), Computational Methods in Molecular Biology, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, Bioinformatics Basics: Application in Biological Science and Medicine (CRC Press, London, 2000) and Ouelette and Baxevanis Bioinformatics: A Practical Guide for Analysis of Gene and Proteins (Wiley & Sons, Inc., 2nd ed., 2001).

The functional modules of certain embodiments provided herein include a determination module, a storage device, a comparison module and a display module. The functional modules can be executed on one, or multiple, computers, or by using one, or multiple, computer networks. The determination module 40 has computer executable instructions to provide sequence information in computer readable form. As used herein, “sequence information” refers to any nucleotide sequence, including but not limited to full-length sequence, partial sequence, or mutated sequences. Moreover, information “related to” the sequence information includes detection of the presence or absence of a miRNA sequence, determination of the expression level of a miRNA sequence in a biological sample, and the like. In some embodiments, the sequence information can include sequences of any miRNA molecules present in a biological sample. In some embodiments, the sequence information can include sequences of miRNA molecules. In other embodiments, the sequence information can include sequences of miRNA molecules described herein, miRNA molecules, piRNA molecules, mRNA molecules, or any combinations thereof In some embodiments, the sequence information can include sequences of miRNA molecules present in a biological sample, and a genomic sequence of one or more protein-coding genes.

As an example, determination modules 40 for determining sequence information can include known systems for automated sequence analysis, including but not limited to, Hitachi FMBIO® and Hitachi FMBIO® II Fluorescent Scanners (available from Hitachi Genetic Systems, Alameda, Calif.); Spectrumedix® SCE 9610 Fully Automated 96-Capillary Electrophoresis Genetic Analysis Systems (available from SpectruMedix LLC, State College, Pennsylvania); ABI PRISM® 377 DNA Sequencer, ABI® 373 DNA Sequencer, ABI PRISM® 310 Genetic Analyzer, ABI PRISM® 3100 Genetic Analyzer, and ABI PRISM® 3700 DNA Analyzer (available from Applied Biosystems, Foster City, California); Molecular Dynamics FluorImager™ 575, SI Fluorescent Scanners, and Molecular Dynamics FluorImager™ 595 Fluorescent Scanners (available from Amersham Biosciences UK Limited, Little Chalfont, Buckinghamshire, England); GenomyxSC™ DNA Sequencing System (available from Genomyx Corporation (Foster City, California); and Pharmacia ALF™ DNA Sequencer and Pharmacia ALFexpress™ (available from Amersham Biosciences UK Limited, Little Chalfont, Buckinghamshire, England); any next- or higher-generation sequencing instruments such as, but not limited to, GF GLX Titanium, GS Junior (available from 454 Life Sciences, part of Roche Diagnostic Corporation, Branford, Conn.); HiSeq 2000, Genome Analyzer IIX, Genome Analyzer IIE, iScan SQ (available from Illumina, San Diego, Calif.); ABI SOLiD™ system (e.g., SOLiD4 platform available from Life Technologies, Applied Biosystems, Carlsbad, Calif.); HeliScope™ Single Molecule Sequencer (available from Helicos Biosciences Corporation, Cambridge, Mass.); and PACBIO RS (available from Pacific Biosciences, Menlo Park, Calif.).

Alternative methods for determining sequence information, i.e., determination modules 40, include systems for nucleic acid analysis. For example, mass spectrometry systems including Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) systems and SELDI-TOF-MS ProteinChip array profiling systems; systems for analyzing gene expression data (see, for example, published U.S. Patent Application, Pub. No. U.S. 2003/0194711); systems for array based expression analysis: e.g., HT array systems and cartridge array systems such as GeneChip® AutoLoader, Complete GeneChip® Instrument System, GeneChip® Fluidics Station 450, GeneChip® Hybridization Oven 645, GeneChip® QC Toolbox Software Kit , GeneChip® Scanner 3000 7G plus Targeted Genotyping System, GeneChip® Scanner 3000 7G Whole-Genome Association System, GeneTitan™ Instrument , and GeneChip® Array Station (each available from Affymetrix, Santa Clara, Calif.); Densitometers (e.g. X-Rite-508-Spectro Densitometer® (available from RP Imaging™, Tucson, Ariz.), The HYRYS™ 2 HIT densitometer (available from Sebia Electrophoresis, Norcross, Georgia); automated Fluorescence in situ hybridization systems (see for example, U.S. Pat. No. 6,136,540); 2D gel imaging systems coupled with 2-D imaging software; microplate readers; Fluorescence activated cell sorters (FACS) (e.g. Flow Cytometer FACSVantage SE, (available from Becton Dickinson, Franklin Lakes, N.J.); and radio isotope analyzers (e.g. scintillation counters).

The sequence information determined in the determination module can be read by the storage device 30. As used herein the “storage device” 30 is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with various embodiments described herein can include stand-alone computing apparatus, data telecommunications networks, including local area networks (LAN), wide area networks (WAN), Internet, Intranet, and Extranet, and local and distributed computer processing systems. Storage devices 30 also include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage media, magnetic tape, optical storage media such as CD-ROM, DVD, electronic storage media such as RAM, ROM, EPROM, EEPROM and the like, general hard disks and hybrids of these categories such as magnetic/optical storage media. The storage device 30 is adapted or configured for having recorded thereon sequence information or expression level information. Such information may be provided in digital form that can be transmitted and read electronically, e.g., via the Internet, on diskette, via USB (universal serial bus) or via any other suitable mode of communication.

As used herein, “expression level information” refers to any nucleotide expression level information, including but not limited to full-length nucleotide sequences, partial nucleotide sequences, or mutated sequences. Moreover, information “related to” the expression level information includes detection of the presence or absence of a sequence (e.g., presence or absence of a nucleotide sequence), determination of the concentration of a sequence in the sample (e.g., nucleotide (RNA or DNA) expression levels), and the like.

As used herein, “stored” refers to a process for encoding information on the storage device 30. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising the sequence information or expression level information.

A variety of software programs and formats can be used to store the sequence information or expression level information on the storage device. Any number of data processor structuring formats (e.g., text file or database) can be employed to obtain or create a medium having recorded thereon the sequence information or expression level information.

By providing sequence information or expression level information in computer-readable form, one can use the sequence information or expression level information in readable form in the comparison module 80 to compare a specific sequence or expression profile with the reference data within the storage device 30. In some embodiments, the comparison module 80 can also include bioinformatics analysis tools for next-generation sequencing data (e.g., short-read sequence data). Examples of bioinformatics analysis tools for next-generation sequencing (NGS) data can include any commercial NGS analysis packages that are compatible with the sequenced reads obtained from the NGS instrument. The NGS analysis package can include a sequence mapping tool for mapping sequences (e.g., short-read sequences) to a reference genome, sequence assembly tool for de nova assembly of overlapping reads to form contiguous nucleic acid sequence, a genome browser, and any combinations thereof Examples of short-read alignment tools for mapping miRNA sequences to a reference genome can include, without limitations, Bfast, BioScope, Bowtie, Burrows-Wheeler Aligner (BWA), CLC bio, CloudBurst, Eland/Eland2, Exonerate, GenomeMapper, GnuMap, Karma, MAQ, MOM, Mosaik, MrFAST/MrsFAST, NovoAlign, PASS, PerM, RazerS, RMAP, SSAHA2, Segemehl, SeqMap, SHRiMP, Slider/SliderII, SOAP/SOAP2, Srprism, Stampy, vmatch, ZOOM and any art-recognized alignment tools that can be used to align short-read sequences to a reference genome. In one embodiment, Burrows-Wheeler Aligner (BWA) can be used to map miRNA sequences to a reference genome (e.g., a human genome). Examples of sequence assembly tools include, but are not limited to, ABySS, ALLPATHS, Edena, Euler-SR, SHARCGS, SHARP, SSAKE, Velvet and any other art-recognized assembly tools. Different genome browsers can be used to visualize genomic maps, e.g., generated after sequence alignment to a reference genome.

In one embodiment, the comparison module 80 uses sequence information alignment programs such as BLAST (Basic Local Alignment Search Tool) or FAST (using the Smith-Waterman algorithm) that may be employed individually or in combination. These algorithms determine the alignment between similar regions of sequences and a percent identity between sequences.

In some embodiments, the comparison module can include a pattern recognition pattern that can be pre-trained with different reference data sets such as data sets comprising profiles of miRNA sequences obtained from different state of a tissue (e.g., normal data set vs. diseased or abnormal data set; or data sets corresponding to different stages of a disease or disorder and a normal data set).

Accordingly, in some embodiments, the comparison module can compare a profile of miRNA sequences of a biological sample determined by the determination module 40 to reference data stored on the storage device 30, and classify the biological sample into a specific state (e.g., normal, diseased or abnormal, and/or a given stage of a disease or disorder). For example, comparison programs can be used to compare an expression level of a miRNA sequence in a biological sample to a reference data expression level (e.g., sequence data from a control/ reference sample described herein) and/or profiles of miRNA sequences in a biological sample to reference data expression profiles (e.g., sequence data from a control/ reference sample described herein). The comparison made in computer-readable form provides a computer readable comparison result, which can be processed by a variety of means. Content 140 based on the comparison result can be retrieved from the comparison module 80 to indicate a given state of a cell or a tissue, and/or whether a subject has, or is at risk of developing of a disease or disorder, or a given state of the disease or disorder.

In one embodiment, the reference data stored in the storage device 30 to be read by the comparison module 80 is sequence information data obtained from a reference sample described herein or a control biological sample of the same type as the biological sample to be tested. Alternatively, the reference data are a database, e.g., a collection of sequence information data obtained from a plurality of reference samples described herein and control biological samples of the same type as the biological sample to be tested. For example, reference data can include profiles of miRNA sequences that arc indicative of a given state of a cell or tissue and/or a disease or disorder of interest or a given state of the disease or disorder. In one embodiment, the reference data can include sequence information of miRNA sequences and/or profiles of miRNA sequences that are indicative of a disease or disorder of interest, e.g., a disease or disorder afflicting a tissue, and or different stages of a disease or disorder of interest, e.g., different stages of cancer. By way of example only, reference data stored in a system for diagnosing and/or prognosing breast cancer can include, but not limited to, (a) profile(s) of miRNA sequences obtained from one or a group of normal subjects, (b) profile(s) of miRNA sequences obtained from one or a group of subjects having a given stage of breast cancer (e.g., DCIS, lobular carcinoma in situ, INV, etc.); (c) profile(s) of miRNA obtained from a normal tissue of the test subject, profile(s) of miRNA sequences obtained from a diseased or abnormal tissue of the test subject that was previously diagnosed, and any combinations thereof.

In one embodiment, the reference data are electronically or digitally recorded and annotated from databases including, but not limited to GenBank (NCBI) protein and DNA databases such as genome, ESTs, SNPS, Traces, Celara, Ventor Reads, Watson reads, HGTS, and the like; Swiss Institute of Bioinformatics databases, such as ENZYME, PROSITE, SWISS-2DPAGE, Swiss-Prot and TrEMBL databases; the Melanie software package or the ExPASy WWW server, and the like; the SWISS-MODEL, Swiss-Shop and other network-based computational tools; the Comprehensive Microbial Resource database (available from The Institute of Genomic Research). The resulting information can be stored in a relational database that may be employed to determine homologies between the reference data or genes or proteins within and among genomes.

The “comparison module” 80 can use a variety of available software programs and formats for the comparison operative to compare sequence information determined in the determination module 40 to reference data. In one embodiment, the comparison module 80 is configured to use pattern recognition techniques to compare sequence information from one or more entries to one or more reference data patterns. The comparison module 80 can be configured using existing commercially-available or freely-available software for comparing patterns, and may be optimized for particular data comparisons that are conducted. The comparison module 80 provides computer readable information related to the sequence information that can include, for example, detection of the presence or absence of a miRNA sequence; determination of the concentration of a miRNA sequence in the sample, or determination of an expression profile.

The comparison module 80, or any other module described herein, may include an operating system (e.g., UNIX) on which runs a relational database management system, a World Wide Web application, and a World Wide Web server. World Wide Web application includes the executable code necessary for generation of database language statements (e.g., Structured Query Language (SQL) statements). Generally, the executables will include embedded SQL statements. In addition, the World Wide Web application may include a configuration file, which contains pointers and addresses to the various software entities that comprise the server as well as the various external and internal databases which must be accessed to service user requests. The Configuration file also directs requests for server resources to the appropriate hardware--as may be necessary should the server be distributed over two or more separate computers. In one embodiment, the World Wide Web server supports a TCP/IP protocol. Local networks such as this are sometimes referred to as “Intranets.” An advantage of such Intranets is that they allow easy communication with public domain databases residing on the World Wide Web (e.g., the GenBank or Swiss Pro World Wide Web site). Thus, in a particular preferred embodiment provided herein, users can directly access data (via Hypertext links for example) residing on Internet databases using a HTML interface provided by Web browsers and Web servers. In one embodiment, users can access data residing on Cloud storage.

Various algorithms or software packages are available which are useful for comparing and analyzing sequence information and/or expression data determined in the determination module 40. For example, various software packages for next-generation sequencing (NGS) analysis are available in the commercial and/or public domains. Exemplary software packages for NGS analysis can include, without limitations, sequence alignment tools as discussed above; de novo alignment and/or assembly tools as discussed above; integrated solutions, such as CLCbio Genomics Workbench, Galaxy, Genomatix, JMP Genomics, NExtGENE, SeqMan Genome Analyzer, SHORE, SlimSearch; genome browser (including alignment viewer and/or assembly database) such as EagleView, LookSeq, MapView, Sequence Assembly Manager, STADEN, XMatchView; software packages for transciptomics such as ERANGE, S-Mo.R-Se, MapNext, QPalma, RSAT, TopHat; or any combinations thereof.

In some embodiments, when the sequence information is detennined by microarray-based methods, various software packages for microarray analysis can be used, e.g., but not limited to, GeneChip® Sequence Analysis Software (GSEQ), GeneChip® Targeted Genotyping Analysis Software (GTGS) and Expression Console™ Software. Accordingly, depending on methods used to produce sequence information in the determination module 40, various sequence analysis software can be used.

In one embodiment described herein, pattern comparison software is used to compare an expression profile of miRNA sequences to a reference data for determining a given state of a cell or tissue, or whether the expression profiled obtained from a test subject is indicative of a disease or disorder, or a given state of a disease or disorder.

The comparison module 80 provides computer readable comparison result that can be processed in computer readable form by predefined criteria, or criteria defined by a user, to provide a content based in part on the comparison result that may be stored and output as requested by a user using a display module 110. The display module 110 enables display of a content 140 based in part on the comparison result for the user, wherein the content 140 is a signal indicative of a subject having, or being at risk of developing or being at a given stage of a disease or disorder, or a signal indicative of the subject having no risk of the disease or disorder. Such signal, can be for example, a display of content 140 indicative of the presence or absence of increased risk for a disease or disorder, or a given state of a disease or disorder on a computer monitor, a printed page of content 140 indicating the presence or absence of increased risk for a given state of a disease or disorder from a printer, or a light or sound indicative of the presence or absence of increased risk for a given state of a disease or disorder.

The content 140 based on the comparison result can include an expression profile of one or more miRNA sequences determined from the test subject. In one embodiment, the content 140 based on the comparison result can include a comparison of the miRNA expression profile between the test subject and one or more reference samples described herein. In one embodiment, the content 140 based on the comparison result is merely a signal indicative of the presence or absence of an increased risk of a given state of a disease or disorder.

In one embodiment provided herein, the content 140 based on the comparison result is displayed a on a computer monitor. In one embodiment, the content 140 based on the comparison result is displayed through printable media. The display module 110 can be any suitable device configured to receive from a computer and display computer readable information to a user. Non-limiting examples include, for example, general-purpose computers such as those based on INTEL® processor, QUALCOMM® processors, Sun Microsystems processors, Hewlett-Packard processors, any of a variety of processors available from Advanced Micro Devices (AMD) of Sunnyvale, Calif., or any other type of processors (including mobile processors), visual display devices such as tablet computers, flat panel displays, cathode ray tubes and the like, as well as computer printers of various types.

In one embodiment, a World Wide Web browser is used for providing a user interface for display of the content 140 based on the comparison result. It should be understood that other modules described herein can be adapted to have a web browser interface. Through the Web browser, a user may construct requests for retrieving data from the comparison module. Thus, the user will typically point and click to user interface elements such as buttons, pull down menus, scroll bars and the like conventionally employed in graphical user interfaces. The requests formulated with the user's Web browser are transmitted to a Web application which formats them to produce a query that can be employed to extract the pertinent information related to the sequence information, e.g., but not limited to, display of nucleotide (RNA or DNA) expression levels; or display of information based thereon. In one embodiment, the sequence information of the reference sample data is also displayed.

In one embodiment, the display module 110 displays the comparison result based on sequence information and whether the comparison result is indicative of a disease or disorder, or a given stage of a disease or disorder. For example, in the ease of diagnosis of breast cancer, the display module 110 can display the comparison result based on determined sequence information and whether the comparison results is indicative of breast cancer, or a particular stage of breast cancer (e.g., duct carcinoma in situ, lobular carcinoma in situ, invasive, etc.).

In one embodiment, the content 140 based on the comparison result that is displayed is a signal (e.g. positive or negative signal) indicative of the presence or absence of an increased risk for a disease or disorder, or a given stage of the disease or disorder, thus only a positive or negative indication may be displayed.

In any embodiments, the comparison module can be executed by a computer implemented software as discussed earlier. In such embodiments, a result from the comparison module can be displayed on an electronic display. The result can be displayed by graphs, numbers, characters or words. In additional embodiments, the results from the comparison module can be transmitted from one location to at least one other location. For example, the comparison results can be transmitted via any electronic media, e.g., internet, fax, phone, a “cloud” system, and any combinations thereof. Using the “cloud” system, users can store and access personal files and data or perform further analysis on a remote server rather than physically carrying around a storage medium such as a DVD or thumb drive.

Each of the above identified modules or programs corresponds to a set of instructions for performing a function described above. These modules and programs (i.e., sets of instructions) need not be implemented as separate software programs, procedures or modules, and thus various subsets of these modules may be combined or otherwise re-arranged in various embodiments. In some embodiments, memory may store a subset of the modules and data structures identified above. Furthermore, memory may store additional modules and data structures not described above.

The illustrated aspects of the disclosure may also be practiced in distributed computing environments where certain tasks are performed by remote processing devices that are linked through a communications network. In a distributed computing environment, program modules can be located in both local and remote memory storage devices.

Moreover, it is to be appreciated that various components described herein can include electrical circuit(s) that can include components and circuitry elements of suitable value in order to implement the embodiments of the subject innovation(s). Furthermore, it can he appreciated that many of the various components can be implemented on one or more integrated circuit (IC) chips. For example, in one embodiment, a set of components can be implemented in a single IC chip. In other embodiments, one or more of respective components are fabricated or implemented on separate IC chips.

What has been described above includes examples of the embodiments of the present invention. It is, of course, not possible to describe every conceivable combination of components or methodologies for purposes of describing the claimed subject matter, but it is to be appreciated that many further combinations and permutations of the subject innovation are possible. Accordingly, the claimed subject matter is intended to embrace all such alterations, modifications, and variations that fall within the spirit and scope of the appended claims. Moreover, the above description of illustrated embodiments of the subject disclosure, including what is described in the Abstract, is not intended to be exhaustive or to limit the disclosed embodiments to the precise forms disclosed. While specific embodiments and examples are described herein for illustrative purposes, various modifications are possible that are considered within the scope of such embodiments and examples, as those skilled in the relevant art can recognize.

In particular and in regard to the various functions performed by the above described components, devices, circuits, systems and the like, the terms used to describe such components are intended to correspond, unless otherwise indicated, to any component which performs the specified function of the described component (e.g., a functional equivalent), even though not structurally equivalent to the disclosed structure, which performs the function in the herein illustrated exemplary aspects of the claimed subject matter. In this regard, it will also be recognized that the innovation includes a system as well as a computer-readable storage medium having computer-executable instructions for performing the acts and/or events of the various methods of the claimed subject matter.

The aforementioned systems/circuits/modules have been described with respect to interaction between several components/blocks. It can be appreciated that such systems/circuits and components/blocks can include those components or specified sub-components, some of the specified components or sub-components, and/or additional components, and according to various permutations and combinations of the foregoing. Sub-components can also be implemented as components communicatively coupled to other components rather than included within parent components (hierarchical). Additionally, it should be noted that one or more components may be combined into a single component providing aggregate functionality or divided into several separate sub-components, and any one or more middle layers, such as a management layer, may be provided to communicatively couple to such sub-components in order to provide integrated functionality. Any components described herein may also interact with one or more other components not specifically described herein but known by those of skill in the art.

In addition, while a particular feature of the subject innovation may have been disclosed with respect to only one of several implementations, such feature may be combined with one or more other features of the other implementations as may be desired and advantageous for any given or particular application. Furthermore, to the extent that the terms “includes,” “including,” “has,” “contains,” variants thereof, and other similar words are used in either the detailed description or the claims, these terms are intended to be inclusive in a manner similar to the term “comprising” as an open transition word without precluding any additional or other elements.

As used in this application, the terms “component,” “module,” “system,” or the like are generally intended to refer to a computer-related entity, either hardware (e.g., a circuit), a combination of hardware and software, software, or an entity related to an operational machine with one or more specific functionalities. For example, a component may be, but is not limited to being, a process running on a processor (e.g., digital signal processor), a processor, an object, an executable, a thread of execution, a program, and/or a computer. By way of illustration, both an application running on a controller and the controller can be a component. One or more components may reside within a process and/or thread of execution and a component may be localized on one computer and/or distributed between two or more computers. Further, a “device” can come in the form of specially designed hardware; generalized hardware made specialized by the execution of software thereon that enables the hardware to perform specific function; software stored on a computer-readable medium; or a combination thereof.

In view of the exemplary systems described above, methodologies that may be implemented in accordance with the described subject matter will be better appreciated with reference to the flowcharts of the various figures. For simplicity of explanation, the methodologies are depicted and described as a series of acts. However, acts in accordance with this disclosure can occur in various orders and/or concurrently, and with other acts not presented and described herein. Furthermore, not all illustrated acts may be required to implement the methodologies in accordance with the disclosed subject matter. In addition, those skilled in the art will understand and appreciate that the methodologies could alternatively he represented as a series of interrelated states via a state diagram or events. Additionally, it should be appreciated that the methodologies disclosed in this specification are capable of being stored on an article of manufacture to facilitate transporting and transferring such methodologies to computing devices. The term article of manufacture, as used herein, is intended to encompass a computer program accessible from any computer-readable device or storage media.

Provided herein therefore relates to systems 10 (and computer readable medium 200 for causing computer systems) to perform methods for determining a given stage of a cell or a tissue, and/or whether a subject has, or is at risk of developing, or is at a given stage of a disease, e.g., cancer, or disorder, based on expression profiles of miRNA sequences.

System 10, and computer readable medium 200, are merely an illustrative embodiments provided herein for performing methods of determining whether an individual has a specific disease or disorder or a pre-disposition, for a specific disease or disorder based on expression profiles or sequence information, and are not intended to limit the scope described herein. Variations of system 10, and computer readable medium 200, are possible and are intended to fall within the scope described herein.

The modules of the machine, or used in the computer readable medium, may assume numerous configurations. For example, function may be provided on a single machine or distributed over multiple machines.

Reference Sample(s) or Reference Data

As used herein, a reference sample can include a normal or negative control, alternatively a disease (or disorder) or positive control, against which biological samples can be compared. Therefore, it can be determined whether the biological sample to be evaluated for a specific disease or disorder, or a stage of a disease or disorder, has measurable difference or substantially no difference, as compared to a reference sample. A normal or healthy sample or tissue refers to a sample or tissue that does not have a disease or disorder to be evaluated.

The reference sample can be obtained from the patient to be diagnosed or prognosed, or from a different subject, who is preferably of same age and/or race.

In one embodiment, the reference sample can be obtained from the same patient at the same time that the biological sample is taken. In one embodiment, the reference sample can be taken from a normal and/or healthy tissue of the same patient. In one embodiment, the reference sample can be taken from a normal and/or healthy tissue, for example tissue taken adjacent to the cancer, such as within 1 or 2 cm diameter from the leading front of the tumor. Alternatively, the reference sample can be taken from an equivalent position in the subject's body, for example in the case of breast cancer, a reference sample can be taken from any area of the breast which is not cancerous. In another embodiment, the reference sample can be a disease or abnormal sample taken previously from the same patient, against which a new biological sample can be compared to provide an evaluation of the therapeutic treatment efficacy.

In one embodiment, the reference sample can be a sample taken previously, e.g., a sample of the same or a different cancer/tumor, the comparison of which can, for example, provide characterization of the source of the new tumor, and/or progression or development of an existing cancer, such as before, during or after therapeutic treatment. For example, the reference sample can be obtained from a different patient, e.g., it can be a control sample, or a collection of control samples, representing different stages or different types of diseases or disorders. In one embodiment, the reference sample can be a control sample or a collection of control samples, representing different stages of a specific cancer (e.g., cancer staging samples) or different types of cancer, for example those listed herein (i.e., cancer reference samples). Comparison of the biological sample data with data obtained from such cancer staging or cancer reference samples can, for example, allow for the characterization of the assessed cancer to a specific stage and/or type of cancer.

Depending on various applications, the reference sample can comprise a sample derived from a tissue type that is same as or different from the tissue type of a biological sample. In some embodiments wherein the tissue origin of a biological sample is unknown, the level(s) and/or profile of the miRNA present in the biological sample can be compared to a set of reference samples of different tissue origins in order to identify the tissue origin of the biological sample. In some embodiments where the tissue origin of a biological sample is known or believed to be known (e.g., while a tissue biopsy is known to be collected from a lung tissue, the sample can comprise cells originated from breast due to metastasis), the reference sample(s) can comprise a sample of the same tissue type as the biological sample, and/or a sample of a different tissue type from the biological sample. By comparison between the biological sample and reference sample(s), tissue origin of the biological sample can be validated and/or identified.

As used herein, the term “reference data” refers to data obtained from a reference sample as described herein, or a collection of reference samples as described herein.

Biological Sample of a Subject and Preparation Thereof

A “biological sample” subjected to analysis using the methods, assays and systems described herein generally refers to a sample taken or isolated from a subject or a biological organism. In some embodiments, the biological sample contains one or more cells, e.g., tissue culture mammalian cells, cell lysate, a tissue sample from a subject, a homogenate of a tissue sample from a subject or a fluid sample from a subject. Exemplary biological samples include, but are not limited to, blood (including whole blood, senim, cord blood, and plasma), sputum, urine, spinal fluid, pleural fluid, nipple aspirates, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, feces, sperm, cells or cell cultures, serum, leukocyte fractions, smears, tissue samples of all kinds, embryos, etc. The term also includes both a mixture of the above-mentioned samples such as whole human blood containing a cell. The term “biological sample” also includes untreated or pretreated (or pre-processed) biological samples.

A “biological sample” can contain at least one cell or a plurality of cells from a subject. In some embodiments, the biological sample can contain one or more somatic cells from a subject. In other embodiments, the biological sample can contain one or more germ cells from a subject. In other embodiments, the biological sample can contain one or more stem cells from a subject.

In one embodiment, the biological sample can contain one or more cells from a subject's biological fluid sample. Examples of biological fluids include, but are not limited to, saliva, bone marrow, blood, serum, plasma, urine, sputum, cerebrospinal fluid, an aspirate, tears, and any combinations thereof.

For example, the biological sample can contain one or more circulating tumor cells from a subject's blood (including whole blood, serum, cord blood, and plasma). In some embodiments, the biological sample can contain at least one type of blood cells (e.g., red blood cells, white blood cells, platelets).

In one embodiment, the biological sample can contain one or more cells derived from any tissue of a subject, e.g., a tissue suspected of being at risk of, or being afflicted with a given stage of a disease or a disorder. Non-limiting examples of a tissue can include, but are not limited to, breast, pancreas, blood, prostate, colon, lung, skin, brain, ovary, kidney, oral cavity, throat, liver, and any combinations thereof. In some embodiments, the tissue can be obtained from a resection, biopsy, or core needle biopsy. In addition, fine needle aspirate samples can be used. Samples can be either paraffin-embedded or frozen tissue.

The biological sample can be obtained by removing a sample of cells from a subject, but can also be accomplished by using previously isolated cells (e.g. isolated by another person). In addition, the biological sample can be freshly collected or a previously collected sample.

In some embodiments, the biological sample is a frozen biological sample, e.g., a frozen tissue or fluid sample such as urine, blood, serum or plasma. The frozen sample can be thawed before employing methods, assays and systems described herein. After thawing, a frozen sample can be centrifuged before being subjected to methods, assays and systems described herein.

In some embodiments, a biological sample can be a nucleic acid product derived from a tissue (e.g., fresh/frozen and paraffin-embedded) or a fluid sample (e.g., blood) of a subject or cultured cells. The nucleic acid product can include DNA, RNA, mRNA, miRNA, piRNA, siRNA, snRNA, miRNA molecules described herein, and any combinations thereof In some embodiments, the nucleic acid product can comprise one or more miRNA molecules described herein.

In some embodiments, a biological sample can include RNA isolated from a tissue (e.g., fresh or frozen or paraffin-embedded) or a fluid sample (e.g., blood) of a subject or cultured cells. Nucleic acid and ribonucleic acid (RNA) molecules can be isolated from a particular biological sample using any of a number of procedures, which are well-known in the art, the particular isolation procedure chosen being appropriate for the particular biological sample. For example, freeze-thaw and alkaline lysis procedures can be useful for obtaining nucleic acid molecules from solid materials; heat and alkaline lysis procedures can be useful for obtaining nucleic acid molecules from urine; and proteinase K extraction can be used to obtain nucleic acid from blood (Roiff, A et al. PCR: Clinical Diagnostics and Research, Springer (1994)).

In one embodiment, a biological sample can include RNA isolated from a tissue (e.g., fresh or frozen or paraffin-embedded) by any known methods in the art. When the RNA sample is deemed to be of good quality (according to one of skill in the art), the sample can be subjected to further treatment, following recommended instructions as provided by various commercial RNA preparation kits available for RNA sequencing (e.g., the kits from Life Technologies). Depending on the length of RNA molecules of interest, in some embodiments, the RNA sample can be subjected to miRNA sequencing. In other embodiments, the RNA sample can be subjected to long RNA sequencing.

In some embodiments, a biological sample can be an enriched RNA fraction derived from a tissue (e.g., fresh/frozen and paraffin-embedded) or a fluid sample (e.g., blood) of a subject or cultured cells, e.g., an RNA fraction enriched for non-coding RNAs. This can be achieved, for example, by removing mRNAs by use of affinity purification, e.g., using an oligodT column or any other art-recognized methods such as using commercial small RNA isolation kits.

In some embodiments, a biological sample can be a nucleic acid product or an RNA fraction amplified after polymerase chain reaction (PCR) or after reverse transcription-PCR. The nucleic acid product can include DNA (e.g., cDNA), RNA and mRNA and can be isolated from a particular biological sample using any of a number of procedures, which are well known in the art, the particular isolation procedure chosen being appropriate for the particular biological sample. Methods of isolating and analyzing nucleic acid variants as described above are well known to one skilled in the art and can be found, for example in the Molecular Cloning: A Laboratory Manual, 3rd Ed., Sambrook and Russel, Cold Spring Harbor Laboratory Press, 2001.

In some embodiments, the biological sample can he treated with a chemical and/or biological reagent. Chemical and/or biological reagents can be employed to protect and/or maintain the stability of the sample, including biomolecules (e.g., nucleic acids) therein, during processing. One exemplary reagent is an RNase inhibitor or RNA stabilizer, which is generally used to protect or maintain the stability of RNA during processing. In addition, or alternatively, chemical and/or biological reagents can be employed to release nucleic acid (e.g., miRNA molecules) from the biological sample.

The skilled artisan is well aware of methods and processes appropriate for pre-processing of biological samples required for determination of nucleic acid including miRNA molecules as described herein.

In some embodiments, a biological sample used for determining the level of one or more miRNAs can be a sample containing circulating miRNAs, e.g., extracellular miRNAs. Extracellular miRNAs freely circulate in a wide range of biological material, including bodily fluids, such as fluids from the circulatory system, e.g., a blood sample or a lymph sample, or from another bodily fluid such as cerebrospinal fluid (CSF), urine or saliva. Accordingly, in some embodiments, the biological sample used for determining the level of one or more miRNAs can be a bodily fluid, for example, blood, fractions thereof, serum, plasma, urine, saliva, tears, sweat, semen, vaginal secretions, lymph, bronchial secretions, CSF, etc. In some embodiments, the sample is a sample that is obtained non-invasively.

Circulating miRNAs include miRNAs in cells (cellular miRNA), extracellular miRNAs in microvesicles (microvesicle-associated miRNA), and extracellular miRNAs that are not associated with cells or microvesicles (extracellular, non-vesicular miRNA).

The biological sample is generally obtained from a subject who has or is suspected of having a disease or disorder, e.g., a condition afflicting a tissue, or who is suspected of having a risk of developing a disease or disorder, e.g., a condition afflicting a tissue. In some embodiments, the biological sample can be obtained from a subject who has or is suspected of having cancer, or who is suspected of having a risk of developing cancer. By way of example only, in one embodiment, the biological sample can be obtained from a subject who has or is suspected of having breast cancer, or who is suspected of having a risk of breast cancer. In another embodiment, the biological sample can be obtained from a subject who has or is suspected of having pancreatic cancer, or who is suspected of having a risk of pancreatic cancer.

In some embodiments, the biological sample can be obtained from a subject who is being treated for the disease or disorder, e.g., but not limited to, cancer such as breast cancer or pancreatic cancer. In other embodiments, the biological sample can be obtained from a subject whose previously-treated disease or disorder, e.g., but not limited to, cancer such as breast cancer or pancreatic cancer, is in. remission. In other embodiments, the biological sample can be obtained from a subject who has a recurrence of a previously-treated disease or disorder, e.g., but not limited to, cancer such as breast cancer or pancreatic cancer.

As used herein, a “subject” can mean a human or an animal. Examples of subjects include primates (e.g., humans, and monkeys). Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, and avian species, e.g., chicken, emu, ostrich. A patient or a subject includes any subset of the foregoing, e.g., all of the above, or includes one or more groups or species such as humans, primates or rodents. In certain embodiments of the aspects described herein, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “patient” and “subject” are used interchangeably herein. A subject can be male or female. The term “patient” and “subject” does not denote a particular age. Thus, any mammalian subjects from adult to newborn subjects, as well as fetuses, are intended to be covered.

In one embodiment, the subject or patient is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. In one embodiment, the subject is a human being. In another embodiment, the subject can be a domesticated animal and/or pet. In some embodiments, the subject is a human.

Pharmaceutical Compositions and Administration Methods

In some embodiments, a subject in need thereof, e.g., whose level(s) of one or more miRNAs (as selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 in Tables 1-3) in a biological sample are determined to be over-expressed or under-expressed, can be administered with a miRNA-related therapeutic. In some embodiments, the miRNA-related therapeutic is an antagonist against a target miRNA that inhibit the function of the target miRNA. As used herein, the term “antagonist” is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a microRNA disclosed herein. Suitable antagonist molecules specifically include, but are not limited to antisense oligonucleotides, small organic molecules, aptamers, etc. Methods for identifying antagonists of a microRNA can comprise contacting a target microRNA with a candidate antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the microRNA. Accordingly, one aspect provides a pharmaceutical composition comprising an antagonist against one or more miRNAs selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 in Tables 1-3.

In some embodiments, the miRNA-related therapeutic is a mimic of a target miRNA that induces or restores the function of the target miRNA. As used herein, the term “mimic” refers to a molecule (e.g., an oligonucleotide) that is capable of mimicking the activity of a miRNA molecule. In some embodiments, a miRNA mimic is a molecule (e.g., an oligonucleotide) that is capable of mimicking at least about 30% or above (including, e.g., at least about 40%, at least about 50%, at least about 60%. at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 99%, or up to 100%) of the activity of a miRNA molecule. Accordingly, a pharmaceutical composition comprising a mimic of one or more miRNAs selected from SEQ ID NO: 1 to SEQ ID NO: 47,972 in Tables 1-3 is also provided herein. In some embodiments, the pharmaceutical composition can comprise engineered transcripts that can “sponge” various combinations of the miRNAs described herein, or any combinations thereof

In some embodiments, the miRNA mimics can be a double-stranded and/or blunt-ended oligonucleotide, which means the oligonucleotide is double-stranded throughout the molecule and/or blunt-ended on both ends. In some embodiments, the miRNA mimics can be a single-strand oligonucleotide. In some embodiments, the single-stranded oligonucleotide can comprise a hairpin structure. Methods of making miRNA mimics are known in the art, e.g., as described in the International Patent Publication No. WO 2012/106586, which is incorporated herein by reference.

In some embodiments where the miRNA antagonists or miRNA mimics comprise an oligonucleotide, the oligonucleotide can be modified. For example, in some embodiments, the backbone of the oligonucleotides described herein can be modified, e.g., to stabilize the oligonucleotides for in vivo delivery. For example, the modified backbone of the oligonucleotides can comprise morpholino subunits, phosphorothioate subunits, locked nucleic acid (LNA), peptide nucleic acid (PNC), hexitol nucleic acid (HNA), or any combinations thereof. See, e.g., Singh Y. et al. Chem. Soc. Rev., 2010, 39, 2054-2070 for additional information about various examples of oligonucleotide backbones.

Additionally or alternatively, the oligonucleotides can be modified for a desired property, e.g., improved cell delivery, cell-targeting delivery, and/or enhanced stability. By way of example only, the oligonucleotides can be modified by conjugating it to a delivery-targeting moiety. As used herein, the term “delivery-targeting moiety” refers to a moiety that can facilitate binding of an oligonucleotide to the outer surface of a cell and/or uptake or endocytosis of the oligonucleotide into the cell. Any art-recognized delivery-targeting moiety, e.g., but not limited to, antibodies, peptides, proteins, aptamers, dendrimers, and molecules, can be used. In some embodiments, the delivery-targeting moiety is a cell surface receptor ligand. As used herein, a “cell surface receptor ligand” refers to a molecule that can bind to the outer surface of a cell. Exemplary, cell surface receptor ligand includes, for example, a cell surface receptor binding peptide, a cell surface receptor binding glycopeptide, a cell surface receptor binding protein, a cell surface receptor binding glycoprotein, a cell surface receptor binding organic compound, and a cell surface receptor binding drug.

Cell surface receptor ligands include, but are not limited to, cytokines, growth factors, hormones, antibodies, and angiogenic factors.

In some embodiments, the delivery-targeting moiety can also refer to a molecule that binds to or interacts with a target molecule. Typically the nature of the interaction or binding is noncovalent, e.g., by hydrogen, electrostatic, or van der Waals interactions, however, binding may also be covalent.

In some embodiments, the delivery-targeting moiety can include an endosomolytic ligand. As used herein, the term “endosomolytic ligand” refers to molecules having endosomolytic properties. Endosomolytic ligands promote the lysis of and/or transport of the composition of the invention, or its components, from the cellular compartments such as the endosome, lysosome, endoplasmic reticulum (ER), Golgi apparatus, microtubule, peroxisome, or other vesicular bodies within the cell, to the cytoplasm of the cell. Some exemplary endosomolytic ligands include, but are not limited to, imidazoles, poly or oligoimidazoles, linear or branched polyethyleneimines (PEIs), linear and brached polyamines, e.g. spermine, cationic linear and branched polyamines, polycarboxylates, polycations, masked oligo or poly cations or anions, acetals, polyacetals, ketals/polyketals, orthoesters, linear or branched polymers with masked or unmasked cationic or anionic charges, dendrimers with masked or unmasked cationic or anionic charges, polyanionic peptides, polyanionic peptidomimetics, pH-sensitive peptides, natural and synthetic fusogenic lipids, natural and synthetic cationic lipids.

In some embodiments, the delivery-targeting moiety can include a PK modulating ligand and/or PK modulator. As used herein, the terms “PK modulating ligand” and “PK modulator” refers to molecules which can modulate the pharmacokinetics (PK) of the composition described herein. Some exemplary PK modulator include, but are not limited to, lipophilic molecules, bile acids, sterols, phospholipid analogues, peptides, protein binding agents, vitamins, fatty acids, phenoxazine, aspirin, naproxen, ibuprofen, suprofen, ketoprofen, (S)-(+)-pranoprofen, carprofen, PEGs, biotin, and transthyretia-binding ligands (e.g., tetraiidothyroacetic acid, 2,4,6-triiodophenol and flufenamic acid).

In some embodiments, the oligonucleotides described herein can be conjugated to a molecule in any methods known in the art. By way of example only, the oligonucleotides can be conjugated in the following methods: (i) peptide-oligonucleotide conjugates (POCs); (ii) carbohydrate-oligonucleotide conjugates (COCs); (iii) lipophilic oligonucleotide conjugates (LOCs); (iv) metal complex-oligonucleotide conjugates (MCOCs); (v) nanoparticle-oligonucleotide conjugates (NOCs); (vi) these can include bifunctional oligonucleotides, which have one domain that hybridizes to target RNA and a second domain that attracts activator proteins; (vii) peptide-conjugated oligonucleotides, which can be fused to a peptide domain consisting of cationic and hydrophobic residues that facilitates cell entry; (viii) cell penetrating peptide-oligonucleotide; and (ix) any combinations thereof. See, e.g., Singh Y. et al. Chem. Soc. Rev., 2010, 39, 2054-2070 for additional information about some conjugation methods of oligonucleotides to a molecule.

In some embodiments, the oligonucleotides can be conjugated to a carrier molecule. In some embodiments, a carrier molecule can be a natural or synthetic polymer. For example, a carrier molecule can be cholesterol or an RNA aptamer and the like. A carrier molecule can be conjugated to the oligonucleotides at the 5′ and/or 3′ end, or at the 5′ and/or 3′ end of one of the strands, or at an internal nucleotide position.

In some embodiments, one or two strands of the oligonucleotides can be encoded by or delivered with a viral vector. A variety of viral vectors know in the art can be modified to express or carry an oligonucleotide into a target cell, for example herpes simplex virus-1 or lentiviral vectors have been used to enhance the delivery of siRNA.

In some embodiments, an oligonucleotide can be associated with a non-viral vector. Non-viral vectors can be coupled to targeting and delivery enhancing moieties, such as antibodies, various polymers (e.g., PEG), fusogenic peptides, linkers, cell penetrating peptides and the like. Non-viral vectors include, but are not limited to liposomes and lipoplexes, polymers and peptides, synthetic particles and the like. In some embodiments, a liposome or lipoplex has a neutral, negative or positive charge and can comprise cardolipin, anisamide-conjugated polyethylene glycol, diolcoyl phosphatidylcholine, or a variety of other neutral, anionic, or cationic lipids or lipid conjugates. siRNAs can be complexcd to cationic polymers (e.g., polyethylenimine (PEI)), biodegradable cationic polysaccharide (e.g., chitosan), or cationic polypeptides (e.g., atelocollagen, poly lysine, and protamine).

In some embodiments, oligonucleotide delivery can be enhanced by targeting the oligonucleotide to a cell. Targeting moieties can be conjugated to a variety of delivery compositions and provide selective or specific binding to a target cell(s). Targeting moieties can include, but are not limited to moieties that bind to cell surface receptors, cell specific extracellular polypeptide, saccharides or lipids, and the like. For example, small molecules such as folate, peptides such as RGD containing peptides, and antibodies such as antibodies to epidermal growth factor receptor can be used to target specific cell types.

In some embodiments, oligonucleotide delivery can be enhanced by moieties that interact with cellular mechanisms and machinery, such as uptake and intracellular trafficking. In certain aspects cell penetrating peptides (CPPs) (e.g., TAT and MPG from HIV-1, penetratin, polyarginine can be coupled with an siRNA or a delivery vector to enhance delivery into a cell. Fusogenic peptides (e.g., endodomain derivatives of HIV-I envelope (HGP) or influenza fusogenic peptide (diINF-7)) can also be used to enhance cellular delivery.

A variety of delivery systems such as cholesterol-siRNA, RNA aptamers-siRNA, adenoviral vector, lentiviral vector, stable nucleic acid lipid particle (SNALP), cardiolipin analog-based liposome, DSPE-polyethylene glycol-DOTAP-cholesterol liposome, hyaluronan-DPPE liposome, neutral DOPC liposome, atelocollagen, chitosan, polyethylenimine, poly-lysine, protamine, RGD-polyethylene glycol-polyethylenimine, HER-2 liposome with histidine-lysine peptide, HIV antibody-protamine, arginine, oligoarginine(9R) conjugated water soluble lipopolymer (WSLP), oligoarginine (15R), TAT-PAMAM, cholesterol-MPG-8, DOPE-cationic liposome, GALA peptide-PEG-MMP-2 cleavable peptide-DOPE and the like have been used to enhance the delivery of siRNA.

As described in detail below, the pharmaceutical compositions described herein can be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), gavages, lozenges, dragees, capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8) transmucosally; (9) nasally; or (10) intrathecally. Additionally, one or more REST E2- and/or E3-skipping modulating agents can be implanted into a patient or injected using a drug delivery system. See, for example, Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. “Controlled Release of Pesticides and Pharmaceuticals” (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; and U.S. Pat. No. 35 3,270,960, content of all of which is herein incorporated by reference.

As used here, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used here, the term “pharmaceutically-acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alchols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. The terms such as “excipient”, “carrier”, “pharmaceutically acceptable carrier” or the like are used interchangeably herein.

The amount of oligonucleotide which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally out of one hundred percent, this amount will range from about 0.1% to 99% of oligonucleotide, preferably from about 5% to about 70%, most preferably from 10% to about 30%.

Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compositions that exhibit large therapeutic indices are preferred. As used herein, the term ED denotes effective dose and is used in connection with animal models. The term EC denotes effective concentration and is used in connection with in vitro models.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.

The therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the therapeutic which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Levels in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay.

The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. For example, a therapeutic dose range for the miRNA mimics can be 0.01-5.0 mg of miRNA per kg of patient body weight (mg/kg).

With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to the polypeptides. The desired dose can be administered everyday or every third, fourth, fifth, or sixth day. The desired dose can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms. In some embodiments of the aspects described herein, administration is chronic, e.g., one or more doses daily over a period of weeks or months. Examples of dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.

In some embodiments, the pharmaceutical composition further includes at least a second therapeutic agent (e.g., an agent other than a miRNA antagonist or mimic described herein). Exemplary therapeutic agents that can formulated with a miRNA antagonist or mimic described herein include, but are not limited to, those found in Harrison's Principles of Internal Medicine, 17th Edition, 2008, McGraw-Hill N.Y., N.Y.; Physicians Desk Reference, 63rd Edition, 2008, Thomson Reuters, N.Y., N.Y.; Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition, 2005, McGraw-Hill N.Y., NY; United States Pharmacopeia, The National Formulary, USP-32 NF-27, 2008, U.S. Pharmacopeia, Rockville, Md., the complete contents of all of which are incorporated herein by reference.

Kits

Based on the identification of novel miRNA sequences associated with a condition or disease, one aspect described herein also provides for the design and preparation of detection reagents needed to identify or detect one or more novel miRNAs disclosed herein in a biological sample of a subject. Examples of detection reagents that can be used to identify the disclosed miRNA sequences in a biological sample can include a primer and a probe, wherein the probe can selectively hybridize the miRNA of interest.

Accordingly, provided herein include kits for determining whether a subject has, or is at risk of developing, or is at a given stage of condition afflicting a tissue of interest. In some embodiments, the kits can be used for monitoring the response of a subject to a therapeutic treatment. The kits can include at least one reagent specific for detecting for the presence or absence of at least one novel miRNAs described herein, and instructions for use.

In one embodiment, a kit can comprise an oligonucleotide array affixed with a plurality of oligonucleotide probes that interrogate no more than 100 novel miRNAs described herein (including no more than 75 miRNAs, no more than 50 miRNAs, no more than 25 miRNAs, no more than 20 miRNAs, no more than 15 miRNAs, no more than 10 miRNAs, no more than 5 miRNAs or less), wherein the miRNAs comprise at least two or any combinations of the novel miRNAs disclosed in Tables 1-3 submitted herewith and incorporated herein by reference in their entireties, and an optional container containing a detectable label (e.g., comprising a fluorescent molecule) to be conjugated to a nucleotide molecule derived from a test sample of a human subject; and at least one reagent. Examples of a reagent that can be included in the kit can include, without limitations, a restriction enzyme, a universal adaptor to be conjugated to a nucleotide molecule, a primer complementary to the universal adaptor, a wash agent, and any combinations thereof.

In some embodiments, the plurality of oligonucleotide probes affixed to an oligonucleotide array can interrogate about 2-100 miRNAs, e.g., about 3-50 miRNAs, about 3-25 miRNAs, about 3-10 miRNAs, or about 3-5 miRNAs, wherein the miRNAs comprise at least two or any combinations of the novel miRNAs disclosed in Tables 1-3 submitted herewith and incorporated herein by reference in their entireties.

Additional reagents included in the kit can vary with the selection of a sequencing method described herein.

Embodiments of various aspects described herein can be defined in any of the following numbered paragraphs:

-   1. A method of determining whether a subject has, or is at risk of     developing, or is at a given stage of a condition afflicting a     tissue of interest, or a method of determining tissue origin     comprising measuring in a biological sample from the tissue of     interest expression level of one or more of the miRNAs, wherein the     miRNAs comprise a sequence selected from SEQ ID NO: 1 to SEQ ID NO:     47,972, wherein the alteration of the level of said one or more     miRNAs as compared to the level of the same one or more miRNA in a     reference sample is indicative of the subject either having, or     being at risk of developing, or is at a given stage of the     condition. -   2. The method of paragraph 1, wherein the reference sample     represents a normal condition of the tissue. -   3. The method of paragraph 1, wherein the reference sample     represents a recognizable stage of an abnormal condition of the     tissue. -   4. The method of any of paragraphs 1-3, wherein the tissue of     interest is breast. -   5. The method of any of paragraphs 1-3, wherein the tissue of     interest is pancreas. -   6. The method of any of paragraphs 1-3, wherein the tissue of     interest is blood. -   7. The method of any of paragraphs 1-3, wherein the tissue of     interest is prostate. -   8. The method of any of paragraphs 1-3, wherein the tissue of     interest is colon. -   9. The method of any of paragraphs 1-3, wherein the tissue of     interest is lung. -   10. The method of any of paragraphs 1-3, wherein the tissue of     interest is skin. -   11. The method of any of paragraphs 1-3, wherein the tissue of     interest is brain. -   12. The method of any of paragraphs 1-3, wherein the tissue of     interest is liver. -   13. The method of any of paragraphs 1-3, wherein the tissue of     interest is heart. -   14. The method of any of paragraphs 1-3, wherein the tissue of     interest is muscle. -   15. The method of any of paragraphs 1-3, wherein the tissue of     interest is ovary. -   16. The method of any of paragraphs 1-3, wherein the tissue of     interest is testicle. -   17. The method of any of paragraphs 1-3, wherein the tissue of     interest is bone marrow. -   18. The method of paragraph 4, wherein the condition of interest is     cancer of the breast. -   19. The method of paragraph 5, wherein the condition of interest is     cancer of the pancreas. -   20. The method of paragraph 6, wherein the condition of interest is     leukemia. -   21. The method of paragraph 7, wherein the condition of interest is     cancer of the prostate. -   22. The method of paragraph 8, wherein the condition of interest is     cancer of the colon. -   23. The method of paragraph 9, wherein the condition of interest is     cancer of the lung. -   24. The method of paragraph 10, wherein the condition of interest is     melanoma. -   25. The method of paragraph 10, wherein the condition of interest is     psoriasis. -   26. The method of paragraph 10, wherein the condition of interest is     scleroderma. -   27. The method of paragraph 11, wherein the condition of interest is     Alzheimer's disease. -   28. The method of paragraph 11, wherein the condition of interest is     Parkinson's disease. -   29. The method of paragraph 11, wherein the condition of interest is     Multiple Sclerosis. -   30. The method of paragraph 11, wherein the condition of interest is     cancer of the brain. -   31. The method of paragraph 12, wherein the condition of interest is     cancer of the liver. -   32. The method of paragraph 13, wherein the condition of interest is     cardiomyopathy. -   33. The method of paragraph 14, wherein the condition of interest is     a muscle disorder. -   34. The method of paragraph 15, wherein the condition of interest is     ovarian cancer. -   35. The method of paragraph 16, wherein the condition of interest is     testicular cancer. -   36. The method of paragraph 17, wherein the condition of interest is     myelodysplastic syndrome (MDS) or myeloproliferative disorders     (MPD). -   37. The method of any of paragraphs 1-36, wherein said one or more     miRNAs are measured by a method comprising Sanger sequencing,     polymerase chain reaction (PCR), and real-time quantitative PCR,     northern blot, microarray, in situ hybridization, serial analysis of     gene expression (SAGE), cap analysis gene expression (CAGE) and     massively parallel signature sequencing (MPSS), next generation     sequencing, deep sequencing, direct multiplexing, and any     combinations thereof. -   38. A computer implemented method for determining whether a subject     has, or is at risk of developing, or is at a given stage of a     condition afflicting a tissue of interest, comprising: on a device     having one or more processors and a memory storing one or more     programs for execution by one or more processors, the one or more     programs including instructions for:

measuring in a biological sample from the tissue of interest expression level of one or more of the miRNAs, wherein the miRNAs comprise a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 47,972;

comparing the measured level of one or more miRNAs to that of at least one or more reference samples to determine alteration in the level of the miRNAs between the biological sample and the reference samples, wherein the alteration in the level of said one or more miRNAs in the biological sample as compared to the level of the same one or more miRNAs in the reference samples is indicative of the subject either having, or being at risk of developing, or is at a given stage of the condition; and

displaying a content based in part on the data output from (ii), wherein the content comprises a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of no sign of the disease or disorder.

-   39. The computer implemented method of paragraph 38, wherein said     one or more miRNAs are measured by a method comprising Sanger     sequencing, polymerase chain reaction (PCR), and real-time     quantitative PCR, northern blot, microarray, in situ hybridization,     serial analysis of gene expression (SAGE), cap analysis gene     expression (CAGE) and massively parallel signature sequencing     (MPSS), next generation sequencing, deep sequencing, direct     multiplexing, and any combinations thereof. -   40. The computer implemented method of paragraph 38 or 39, wherein     the reference samples comprise a sample representing a normal     condition of the tissue. -   41. The computer implemented method of any of paragraphs 38-40,     wherein the reference samples comprise a sample representing a     recognizable stage of an abnormal condition of the tissue. -   42. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is breast. -   43. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is pancreas. -   44. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is blood. -   45. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is prostate. -   46. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is colon. -   47. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is lung. -   48. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is skin. -   49. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is brain. -   50. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is liver. -   51. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is heart. -   52. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is muscle. -   53. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is ovary. -   54. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is testicle. -   55. The computer implemented method of any of paragraphs 38-41,     wherein the tissue of interest is bone marrow. -   56. The computer implemented method of paragraph 42, wherein the     condition of interest is cancer of the breast. -   57. The computer implemented method of paragraph 43, wherein the     condition of interest is cancer of the pancreas. -   58. The computer implemented method of paragraph 44, wherein the     condition of interest is leukemia. -   59. The computer implemented method of paragraph 45, wherein the     condition of interest is cancer of the prostate. -   60. The computer implemented method of paragraph 46, wherein the     condition of interest is cancer of the colon. -   61. The computer implemented method of paragraph 47, wherein the     condition of interest is cancer of the lung. -   62. The computer implemented method of paragraph 48, wherein the     condition of interest is melanoma. -   63. The computer implemented method of paragraph 48, wherein the     condition of interest is psoriasis. -   64. The computer implemented method of paragraph 48, wherein the     condition of interest is scleroderma. -   65. The computer implemented method of paragraph 49, wherein the     condition of interest is Alzheimer's disease. -   66. The computer implemented method of paragraph 49, wherein the     condition of interest is Parkinson's disease. -   67. The computer implemented method of paragraph 49, wherein the     condition of interest is Multiple Sclerosis. -   68. The computer implemented method of paragraph 49, wherein the     condition of interest is cancer of the brain. -   69. The computer implemented method of paragraph 50, wherein the     condition of interest is cancer of the liver. -   70. The computer implemented method of paragraph 51, wherein the     condition of interest is cardiomyopathy. -   71. The computer implemented method of paragraph 52, wherein the     condition of interest is a muscle disorder. -   72. The computer implemented method of paragraph 53, wherein the     condition of interest is ovarian cancer. -   73. The computer implemented method of paragraph 54, wherein the     condition of interest is testicular cancer. -   74. The computer implemented method of paragraph 55, wherein the     condition of interest is myelodysplastic syndrome (MDS) or     myeloproliferative disorders (MPD). -   75. The computer implemented method of any of paragraphs 38-74,     wherein the content is displayed on a computer display, a screen, a     monitor, an email, a text message, a website, a physical printout     (e.g., paper) or provided as stored information in a storage device. -   76. A computer system for determining whether a subject has, or is     at risk of developing, or is at a given stage of a condition     afflicting a tissue of interest, comprising: -   one or more processors and a memory to store one or more programs,     the one or more programs comprising instructions for:

measuring in a biological sample from the tissue of interest expression level of one or more of the miRNAs, wherein the miRNAs comprise a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 47,972;

comparing the measured level of one or more miRNAs to that of at least one or more reference samples to determine alteration in the level of the miRNAs between the biological sample and the reference samples, wherein the alteration in the level of said one or more miRNAs in the biological sample as compared to the level of the same one or more miRNAs in the reference samples is indicative of the subject either having, or being at risk of developing, or is at a given stage of the condition; and

displaying a content based in part on the data output from (ii), wherein the content comprises a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of no sign of the disease or disorder.

-   77. The computer system of paragraph 76, wherein said one or more     miRNAs are measured by a method comprising Sanger sequencing,     polymerase chain reaction (PCR), and real-time quantitative PCR,     northern blot, microarray, in situ hybridization, serial analysis of     gene expression (SAGE), cap analysis gene expression (CAGE) and     massively parallel signature sequencing (MPSS), next generation     sequencing, deep sequencing, direct multiplexing, and any     combinations thereof. -   78. The computer system of paragraph 76 or 77, wherein the reference     samples comprise a sample representing a normal condition of the     tissue. -   79. The computer system of any of paragraphs 76-78, wherein the     reference samples comprise a sample representing a recognizable     stage of an abnormal condition of the tissue. -   80. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is breast. -   81. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is pancreas. -   82. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is blood. -   83. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is prostate. -   84. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is colon. -   85. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is lung. -   86. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is skin. -   87. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is brain. -   88. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is liver. -   89. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is heart. -   90. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is muscle. -   91. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is ovary. -   92. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is testicle. -   93. The computer system of any of paragraphs 76-79, wherein the     tissue of interest is bone marrow. -   94. The computer system of paragraph 80, wherein the condition of     interest is cancer of the breast. -   95. The computer system of paragraph 81, wherein the condition of     interest is cancer of the pancreas. -   96. The computer system of paragraph 82, wherein the condition of     interest is leukemia. -   97. The computer system of paragraph 83, wherein the condition of     interest is cancer of the prostate. -   98. The computer system of paragraph 84, wherein the condition of     interest is cancer of the colon. -   99. The computer system of paragraph 85, wherein the condition of     interest is cancer of the lung. -   100. The computer system of paragraph 86, wherein the condition of     interest is melanoma. -   101. The computer system of paragraph 86, wherein the condition of     interest is psoriasis. -   102. The computer system of paragraph 86, wherein the condition of     interest is scleroderma. -   103. The computer system of paragraph 87, wherein the condition of     interest is Alzheimer's disease. -   104. The computer system of paragraph 87, wherein the condition of     interest is Parkinson's disease. -   105. The computer system of paragraph 87, wherein the condition of     interest is Multiple Sclerosis. -   106. The computer system of paragraph 87, wherein the condition of     interest is cancer of the brain. -   107. The computer system of paragraph 88, wherein the condition of     interest is cancer of the liver. -   108. The computer system of paragraph 89, wherein the condition of     interest is cardiomyopathy. -   109. The computer system of paragraph 90, wherein the condition of     interest is a muscle disorder. -   110. The computer system of paragraph 91, wherein the condition of     interest is ovarian cancer. -   111. The computer system of paragraph 92, wherein the condition of     interest is testicular cancer. -   112. The computer system of paragraph 93, wherein the condition of     interest is myelodysplastic syndrome (MDS) or myeloproliferative     disorders (MPD). -   113. The computer system of any of paragraphs 76-112, wherein the     content is displayed on a computer display, a screen, a monitor, an     email, a text message, a website, a physical printout (e.g., paper)     or provided as stored information in a storage device. -   114. A non-transitory computer-readable storage medium storing one     or more programs for determining whether a subject has, or is at     risk of developing, or is at a given stage of a condition afflicting     a tissue of interest, the one or more programs for execution by one     or more processors of a non-transitory computer-readable storage     medium, the one or more programs comprising instructions for:

measuring in a biological sample from the tissue of interest expression level of one or more of the miRNAs, wherein the miRNAs comprise a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 47,972;

comparing the measured level of one or more miRNAs to that of at least one or more reference samples to determine alteration in the level of the miRNAs between the biological sample and the reference samples, wherein the alteration in the level of said one or more miRNAs in the biological sample as compared to the level of the same one or more miRNAs in the reference samples is indicative of the subject either having, or being at risk of developing, or is at a given stage of the condition; and

displaying a content based in part on the data output from (ii), wherein the content comprises a signal indicative of a subject having, or being at risk of developing, or being at a given stage of a disease or disorder, or a signal indicative of no sign of the disease or disorder.

-   115. The non-transitory computer-readable storage medium of     paragraph 114, wherein said one or more miRNAs are measured by a     method comprising Sanger sequencing, polymerase chain reaction     (PCR), and real-time quantitative PCR, northern blot, microarray, in     situ hybridization, serial analysis of gene expression (SAGE), cap     analysis gene expression (CAGE) and massively parallel signature     sequencing (MPSS), next generation sequencing, deep sequencing,     direct multiplexing, and any combinations thereof. -   116. The non-transitory computer-readable storage medium of     paragraph 114 or 115, wherein the reference samples comprise a     sample representing a normal condition of the tissue. -   117. The non-transitory computer-readable storage medium of any of     paragraphs 114-116, wherein the reference samples comprise a sample     representing a recognizable stage of an abnormal condition of the     tissue. -   118. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is breast. -   119. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is pancreas. -   120. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is blood. -   121. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is prostate. -   122. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is colon. -   123. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is lung. -   124. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is skin. -   125. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is brain. -   126. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is liver. -   127. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is heart -   128. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is muscle. -   129. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is ovary. -   130. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is testicle. -   131. The non-transitory computer-readable storage medium of any of     paragraphs 114-117, wherein the tissue of interest is bone marrow. -   132. The non-transitory computer-readable storage medium of     paragraph 118, wherein the condition of interest is cancer of the     breast. -   133. The non-transitory computer-readable storage medium of     paragraph 119, wherein the condition of interest is cancer of the     pancreas. -   134. The non-transitory computer-readable storage medium of     paragraph 120, wherein the condition of interest is leukemia. -   135. The non-transitory computer-readable storage medium of     paragraph 121, wherein the condition of interest is cancer of the     prostate. -   136. The non-transitory computer-readable storage medium of     paragraph 122, wherein the condition of interest is cancer of the     colon. -   137. The non-transitory computer-readable storage medium of     paragraph 123, wherein the condition of interest is cancer of the     lung. -   138. The non-transitory computer-readable storage medium of     paragraph 124, wherein the condition of interest is melanoma. -   139. The non-transitory computer-readable storage medium of     paragraph 124, wherein the condition of interest is psoriasis. -   140. The non-transitory computer-readable storage medium of     paragraph 124, wherein the condition of interest is scleroderma. -   141. The non-transitory computer-readable storage medium of     paragraph 125, wherein the condition of interest is Alzheimer's     disease. -   142. The non-transitory computer-readable storage medium of     paragraph 125, wherein the condition of interest is Parkinson's     disease. -   143. The non-transitory computer-readable storage medium of     paragraph 125, wherein the condition of interest is Multiple     Sclerosis. -   144. The non-transitory computer-readable storage medium of     paragraph 125, wherein the condition of interest is cancer of the     brain. -   145. The non-transitory computer-readable storage medium of     paragraph 126, wherein the condition of interest is cancer of the     liver. -   146. The non-transitory computer-readable storage medium of     paragraph 127, wherein the condition of interest is cardiomyopathy. -   147. The non-transitory computer-readable storage medium of     paragraph 128, wherein the condition of interest is a muscle     disorder. -   148. The non-transitory computer-readable storage medium of     paragraph 129, wherein the condition of interest is ovarian cancer. -   149. The non-transitory computer-readable storage medium of     paragraph 130, wherein the condition of interest is testicular     cancer. -   150. The non-transitory computer-readable storage medium of     paragraph 131, wherein the condition of interest is myelodysplastic     syndrome (MDS) or myeloproliferative disorders (MPD). -   151. The non-transitory computer-readable storage medium of any of     paragraphs 114-150, wherein the content is displayed on a computer     display, a screen, a monitor, an email, a text message, a website, a     physical printout (e.g., paper) or provided as stored information in     a storage device. -   152. The method, computer implemented method, computer system, or     non-transitory computer-readable storage medium of any of the     preceding claims, wherein isoforms of the miRNAs are used. -   153. The method, computer implemented method, computer system, or     non-transitory computer-readable storage medium of claim 152,     wherein the isoforms can correspond to novel miRNAs. -   154. The method, computer implemented method, computer system, or     non-transitory computer-readable storage medium of claim 152,     wherein the isoforms can correspond to known miRNAs.

Some Selected Definitions

For convenience, certain terms employed in the entire application (including the specification, examples, and appended claims) are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used to describe the present invention, in connection with percentages means +1%.

In one respect, the present invention relates to the herein described compositions, methods, and respective component(s) thereof, as essential to the invention, yet open to the inclusion of unspecified elements, essential or not (“comprising”). In some embodiments, other elements to be included in the description of the composition, method or respective component thereof are limited to those that do not materially affect the basic and novel characteristic(s) of the invention (“consisting essentially of”). This applies equally to steps within a described method as well as compositions and components therein. In other embodiments, the inventions, compositions, methods, and respective components thereof, described herein are intended to be exclusive of any element not deemed an essential element to the component, composition or method (“consisting of”).

All patents, patent applications, and publications identified are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventor is not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

The term “statistically significant” or “significantly” or “significant” refers to statistical significance and generally means a one standard deviation (1SD) above or below a reference level. Alternatively, statistical significance can be measured by means of a “false discovery rate” threshold, e.g. 0.05. The term refers to statistical evidence that there is a difference. It is defined as the probability of making a decision to reject the null hypothesis when the null hypothesis is actually true. The decision is often made using the p-value. Alternatively, the decision is made using the estimated false discovery rate.

The term “deep sequencing” as used herein generally refers to next- or higher-generation sequencing known to a skilled artisan.

The term “nucleic acid” is well known in the art. A “nucleic acid” as used herein will generally refer to a molecule (i.e., strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g. an adenine “A,” a guanine “G,” a thymine “T” or a cytosine “C”) or RNA (e.g. an A, a G, a uracil “U” or a C). The term “nucleic acid” encompasses the terms “oligonucleotide” and “polynucleotide,” each as a subgenus of the term “nucleic acid.” The term “oligonucleotide” refers to a molecule of between about 2 and about 100 nucleobases in length. The term “polynucleotide” refers to at least one molecule of greater than about 100 nucleobases in length.

The term “non-coding” refers to sequences of nucleic acid molecules that cannot be translated in a sequence-specific manner to produce into a particular polypeptide or peptide. In some embodiments, the term “non-coding” in reference to RNA can refer to a RNA sequence that is not translated in a sequence-specific manner to produce a particular polypeptide or peptide. In some embodiments, a non-coding RNA can comprise a sequence corresponding to a fragment of a protein-coding region, but which is not translated into a functional peptide or protein when it forms part of a non-coding RNA. Non-coding sequences include but are not limited to introns or parts thereof, promoter regions or parts thereof, 3′ untranslated regions (3′ UTR) or parts thereof, 5′ untranslated regions (5′ UTR) or parts thereof, as well as intergenic regions. In general, a 3′ or 5′ untranslated region is part of or spans one or more exons.

The term “coding region” or “protein-coding region” as used herein, refers to a portion of the nucleic acid sequence, which is transcribed and translated in a sequence-specific manner to produce a particular polypeptide or protein when placed under the control of appropriate regulatory sequences and appropriate molecular machinery. The coding region of a protein-coding gene is said to encode one, or more, such polypeptide or protein.

The term “oligonucleotide,” as used herein is defined as a nucleic acid molecule, or its sequence representation, comprised of at least two or more ribo- or deoxyribonucleotides. The exact size of the oligonucleotide will depend on various factors and on the particular application and use of the oligonucleotide.

The term “probe” as used herein refers to an oligonucleotide, polynucleotide or nucleic acid, either RNA or DNA, whether occurring naturally as in a purified restriction enzyme digest or produced synthetically, which is capable of annealing with or specifically hybridizing to a nucleic acid with sequences complementary to the probe. A probe may be either single-stranded or double-stranded. The exact length of the probe will depend upon many factors, including temperature, source of probe and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, an oligonucleotide probe typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. The probes as disclosed herein are selected to he “substantially complementary” to different strands of a particular target nucleic acid sequence. This means that the probes must be sufficiently complementary so as to be able to “specifically hybridize” or anneal with their respective target strands. Therefore, the probe sequence need not reflect the exact complementary sequence of the target. For example, a non-complementary nucleotide fragment may be attached to the 5′or 3′ end of the probe, with the remainder of the probe sequence being complementary to the target strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarily with the sequence of the target nucleic acid to anneal therewith specifically.

In the context of this disclosure, the term “probe” refers to a molecule that can detectably distinguish among target molecules differing in sequence composition and also in structure (e.g. nucleic acid or protein sequence). Detection can be accomplished in a variety of different ways depending on the type of probe used and the type of target molecule. Thus, for example, detection may be based on discrimination on detection of specific binding. Examples of such specific binding include antibody binding and nucleic acid, antibody binding to protein, nucleic acid binding to nucleic acid, or aptamer binding to protein or nucleic acid. Thus, for example, probes can include enzyme substrates, antibodies and antibody fragments, and preferably nucleic acid hybridization probes.

The term “specifically hybridize” refers to the association between two single-stranded nucleic acid molecules of sufficient complementary sequence to permit such hybridization under pre-determined conditions generally used in the art (sometimes the sequences are referred to as “substantially complementary”). In particular, the term specifically hybridize also refers to hybridization of an oligonucleotide with a substantially complementary sequence as compared to non-complementary sequence.

The term “specifically” as used herein with reference to a probe which is used to specifically detect a given sequence of contiguous nucleotides, refers to a probe that identifies the particular sequence based on preferential hybridization to the sequence under consideration stringent hybridization conditions and/or on exclusive amplification or replication of molecules of interest.

The term “specifically” as used herein with reference to a probe which is used to specifically detect a sequence difference, refers to a probe that identifies a particular sequence difference based on exclusive hybridization to the sequence difference under stringent hybridization conditions and/or on exclusive amplification or replication of the sequence difference.

In its broadest sense, the term “substantially” as used herein in respect to “substantially complementary”, or when used herein with respect to a nucleotide sequence in relation to a reference or a target nucleotide sequence, means a nucleotide sequence having a percentage of identity between the substantially complementary nucleotide sequence and the exact complementary sequence of said reference or target nucleotide sequence of at least 60%, at least 70%, at least 80% or 85%, at least 90%, at least 93%, at least 95% or 96%, at least 97% or 98%, at least 99% or 100% (the later being equivalent to the term “identical” in this context). For example, identity is assessed over a length of at least 10 nucleotides, or at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or up to 50 nucleotides of the entire length of the nucleic acid sequence to said reference sequence (if not specified otherwise below). Sequence comparisons can be carried out using default GAP analysis with the University of Wisconsin GCG, SEQWEB application of GAP, based on the algorithm of Needleman and Wunsch (Needleman and Wunsch (1970) J MoI. Biol. 48: 443-453; as defined above), or any of the tools that have been used for this purpose by the skilled artisan. A nucleotide sequence “substantially complementary” to a reference nucleotide sequence hybridizes to the reference nucleotide sequence under low stringency conditions, preferably medium stringency conditions, most preferably high stringency conditions.

In its broadest sense, the term “substantially identical,” when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference or target nucleotide sequence, wherein the percentage of identity between the substantially identical nucleotide sequence and the reference or target nucleotide sequence is at least 60%, at least 70%, at least 80% or 85%, at least 90%, at least 93%, at least 95% or 96%, at least 97% or 98%, at least 99% or 100% (the later being equivalent to the term “identical” in this context). For example, identity is assessed over a length of 10-40 nucleotides, such as at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or up to 50 nucleotides of a nucleic acid sequence to said reference sequence (if not specified otherwise below). Sequence comparisons are carried out using default GAP analysis with the University of Wisconsin GCG, SEQWEB application of GAP, based on the algorithm of Needleman and Wunsch (Needleman and Wunsch (1970) J MoI. Biol. 48: 443-453; as defined above), or similar tools, as mentioned above. A nucleotide sequence “substantially identical” to a reference nucleotide sequence hybridizes to the exact complementary sequence of the reference nucleotide sequence (i.e. its corresponding strand in a double-stranded molecule) under low stringency conditions, preferably medium stringency conditions, most preferably high stringency conditions (as defined above). Homologues of a specific nucleotide sequence include nucleotide sequences that is at least 24% identical, at least 35% identical, at least 50% identical, at least 65% identical to the reference sequence, as measured using the parameters described above, wherein the molecule represented by the homologous sequence is considered to have the same biological activity as the molecule encoded by the specific nucleotide sequence. The term “substantially non-identical” refers to a nucleotide sequence that does not hybridize to the nucleic acid sequence under stringent conditions.

The term “primer” as used herein refers to an oligonucleotide, either RNA or DNA, either single-stranded or double-stranded, either derived from a biological system, generated by restriction enzyme digestion, or produced synthetically which, when placed in the proper environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis. When presented with an appropriate nucleic acid template, suitable nucleoside triphosphate precursors of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as a suitable temperature and pH, the primer may be extended at its 3′ terminus by the addition of nucleotides by the action of a polymerase or similar activity to yield a primer extension product. The primer may vary in length depending on the particular conditions and requirement of the application. For example, in diagnostic applications, the oligonucleotide primer is typically 15-25 or more nucleotides in length, but can be longer as needed. The primer must be of sufficient complementarity to the desired template to prime the synthesis of the desired extension product, that is, to be able to anneal with the desired template strand in a manner sufficient to provide the 3′ hydroxyl moiety of the primer in appropriate juxtaposition for use in the initiation of synthesis by a polymerase or similar enzyme. It is not required that the primer sequence represent an exact complement of the desired template. For example, a non-complementary nucleotide sequence may be attached to the 5′ end of an otherwise complementary primer. Alternatively, non-complementary bases may be interspersed within the oligonucleotide primer sequence, provided that the primer sequence has sufficient complementarity with the sequence of the desired template strand to functionally provide a template-primer complex for the synthesis of the extension product.

In some embodiments, the term “complementary” as used herein refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds (“base pairing”) with a residue of a second nucleic acid region which is anti-parallel to the first region if the residue is thymine (for DNA) or uracil (for RNA). Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is anti-parallel to the first strand if the residue is guanine. A cytosine residue of a first nucleic acid strand is also capable of base pairing with a residue of a second nucleic acid strand which is anti-parallel to the first strand if the residue is uracil—such interactions are referred to as “non-Watson-Crick” or “G:U wobbles.” A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region, when the two regions are arranged in an anti-parallel fashion. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an anti-parallel fashion, such that at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% or at least 100% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. A first region of a nucleic acid is “near-complementary” to a second region of the same or a different nucleic acid it, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region, when the two regions are arranged in an anti-parallel fashion, and not all of the nucleotides of the two regions are base-paired. Such interactions are exemplified by heteroduplexes of miRNAs with mRNAs where the typical interaction between the two molecules is effected by only a subset of the residues spanning each region. Additionally, the two interacting regions need not have the same length.

The term “antisense” generally refers to a nucleotide or a ribonucleotide sequence being complementary to the gene's messenger RNA (mRNA), which is called the “sense” sequence. For example, a sense segment of mRNA “5′-AAGGUC-3′ ” would be blocked by the anti-sense mRNA segment “3′-UUCCAG-5′”).

The term “antisense oligonucleotide” refers to a nucleotide sequence including a “region of complementarity” that is substantially complementary to a sequence, for example a target sequence. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, 3, or 2 nucleotides of the 5′ and/or 3′ terminus.

As used herein, the term “antisense oligonucleotides comprising a nucleotide sequence” refers to an antisense oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured herein by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods described herein.

EXAMPLES

The following examples illustrate some embodiments and aspects of the invention. It will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be performed without altering the spirit or scope of the invention, and such modifications and variations are encompassed within the scope of the invention as defined in the claims which follow. The following examples do not in any way limit the invention.

Example 1 An Exemplary Methodology to Identify Novel miRNAs

Identification of Candidate Hairpin Precursors within a Dataset

To identify novel miRNAs the following three steps are carried out; candidates that satisfy the conditions of all these stages are labeled ‘novel miRNAs’:

-   (i) For each sample, only those short RNA sequence reads that mapped     unambiguously on the human genome are considered. The sequence reads     were expanded into putative “sequence islands”, and only those     islands ranging in length from 20-30 nts were retained. From these     islands, only those overlapping sequence reads whose length ranged     between 20 and 24 nts inclusive were considered for further     analysis. -   (ii) Each 20-24 nt sequence reads was expanded out into a putative     precursor segment of 70-75 nts in length. To ensure that we tested     all possible arrangements, the following 4 options were considered:

a. Addition of 45 nts to the 5′-end and of 5 nts to the 3′-end of the sequence island

b. Addition of 35 nts to the 5′-end and 15 nts to the 3′-end of the sequence island

c. Addition of 5 nts to the 5′-end and 45 nts to the 3′-end of the sequence island

d. Addition of 15 nts to the 5′-end and 35 nts to the 3′-end of the sequence island

For each of the four conditions, RNAfold from the ‘Vienna package’ (Hofacker et al. “Fast Folding and comparison of RNA secondary structures,” Monatshefte fuer Chemie, Vol 125, 167-188, 1996) was used to predict the folding structure of the resulting sequence segment and to examine whether it folded into a hairpin with the miRNA product on either the hairpin's 5′ (a. and b.) or 3′ (c. and d.) arm, The two different sets of hairpin lengths that were tested (conditions a and b; and c and d above) allowed control for the offset of the mature miRNA from the loop within the hairpin structure, a distance that can be variable.

-   (iii) Only those candidate segments, and their associated miRNA     candidates, which folded into a hairpin structure, had at least 15     base pairs between the two arms, and an energy value of -12 Kcal/mol     or less were kept.     Identification of Mature miRNA and Precursor Sequence Boundaries

The boundaries of the mature miRNA candidates at each locus were determined by identifying the segment with the highest percentage of sequenced reads among the isomiRs. The most abundant segment with length between 20 and 24 nts was considered to be the representative mature miRNA from the locus at hand. The genomic locations of the hairpin were determined from the folded hairpin structures surrounding a potential miRNA. The hairpin with the highest folding energy was determined as the most likely candidate.

Determination of False Discovery Rate

Each one of the 962 datasets was considered in turn. Counts for unambiguously mapped reads were generated for each known and novel miRNA in the sample under consideration. Significant miRNAs (whether known or novel) were determined using a method adapted from CHIP-seq peak calling (Xu, J. & Mang, Y. “A generalized linear model for peak calling in ChIP-Seq data.” Journal of computational biology: a journal of computational molecular cell biology 19, 826-838, 2012.), maximum likelihood estimates of the parameters of the negative binomial distribution are calculated from the probability density function and subsequent p-values determined from the cumulative distribution function of the fitted data. P-values were corrected for multiple testing using the Benjamini-Hochberg procedure and an FDR calculated for each miRNA. Only those miRNAs (known or novel) with a FDR<=0.001 were kept. Sequences that were already contained in Rel. 20 of miRBase or the public mirtron repository were removed from further consideration. Additionally, any sequences that overlapped with tRNAs, rRNAs and snRNAs were removed from further consideration.

Example 2 Conservation Properties of the Novel miRNAs Described Herein in Other Species

For about 9,877 novel miRNAs listed in Table 1 that were discovered by the inventors using the method that they developed as described in Example 1, it was sought to determine the extent to which the mature miRNA and the corresponding precursor miRNA are conserved across model organisms. In particular, the inventors performed a stringent search where they sought instances not only of the mature miRNA but also of the full-length precursor in several model organisms (referred to as “novel hairpin: mature miRNA combination” or “mature miRNA:novel hairpin combination”). For this purpose, the inventors used GLSEARCH (Pearson W R. 2000. “Flexible sequence similarity searching with the FASTA3 program package.” Methods in molecular biology (Clifton, N.J.) 132: 185-219) to look for each of the identified novel miRNA precursors and their corresponding mature miRNA(s) in the chimpanzee, gorilla, orangutan, macaque, mouse, drosophila and worm genome assemblies. During these searches it was required that (a) at least 70% of the miRNA precursor positions be identically present in the searched genome; and, (b) at least 85% of the human mature miRNA positions be identically present in the identified orthologous precursor including an identically present seed. It was found that the vast majority of these miRNAs are conserved in primates with only a small fraction of them being present in rodents or invertebrates. Table 4 below summarizes the conservation properties of this collection of miRNAs:

TABLE 4 Number of novel hairpin:mature miRNA combinations conserved in genomes of various species for the novel miRNAs discovered using the inventors' method as described in Example 1 Present in Which Number of Novel hairpins:Mature Genome miRNA Combinations (n = 9,877) Human (Hu) 9,877 Chimpanzee (Ch) 8,536 Gorilla (Go) 8,303 Orangutan (Or) 7,013 Macaque (Ma) 5,434 Mouse (Mo) 160 Drosophila (Dr) 1 Worm (Wo) 1

Of the 9,877 cases, 499 miRNA:hairpin combinations (5.1%) are present exclusively in the human genome. This finding shows that these 499 instances could be involved in molecular mechanisms that may not be present in mouse models.

The following Table 5 shows in more detail the conservation properties of each of the 9,877 novel miRNA:hairpin combinations (discovered using the inventor's own method as described in Example 1) across the examined model organisms. The actual miRNA and hairpin sequences and corresponding SEQ ID NOs. can be identified in Table 1 according to the “Novel miRNA ID” and “Hairpin ID” listed in Table 5. In Table 5, “Hu” stands for Human; “Ch” stands for Chimpanzee; “Go” stands for Gorilla; “Or” stands for Orangutan or Pongo; “Ma” stands for “Macaque”; “Mo” stands for “Mouse”; “Dr” stands for Drosophia or fruit-fly; “Wo” stands for “worm.”

Lengthy table referenced here US20230041359A1-20230209-T00001 Please refer to the end of the specification for access instructions.

The inventors also examined the 3,707 novel miRNAs that they discovered using the miRDeep2 method (as listed in Table 2) for conservation of the corresponding miRNA:hairpin combination across model organisms (using the above mentioned approach). As with the collection of the 9,877 novel miRNAs that the inventors discovered using their own method, they find that the vast majority of the miRNAs discovered using the miRDeep2 method are conserved in primates with only a small fraction of them being present in rodents or invertebrates. Table 6 below summarizes the conservation properties or this collection of miRNAs.

TABLE 6 Number of novel hairpin:mature miRNA combinations conserved in genomes of various species for the novel miRNAs discovered using the miRDeep2 method. Present in Number of Novel Which hairpins:Mature miRNA Genome Combinations (n = 3,707) Human (Hu) 3,707 Chimpanzee (Ch) 1,242 Gorilla (Go) 1,273 Orangutan (Or) 999 Macaque (Ma) 661 Mouse (Mo) 109 Drosophila (Dr) 1 Worm (Wo) 0

Of these 3,707 cases, 2,140 novel miRNA:hairpin combinations (57.7%) are present exclusively in the human genome. The following Table 7 shows in more detail the conservation properties of each of the 3,707 novel miRNA hairpin combinations across the examined model organisms. The actual miRNA and hairpin sequences and corresponding SEQ ID NOs. can be identified in Table 2 according to the “Novel miRNA ID” and “Hairpin ID” listed in Table 7. In Table 7, “Hu” stands for Human; “Ch” stands for Chimpanzee; “Go” stands for Gorilla; “Or” stands for Orangutan or Pongo; “Ma” stands for “Macaque”; “Mo” stands for “Mouse”; “Dr” stands for Drosophia or fruit-fly; “Wu” stands for “worm.”

TABLE 7 Conservation properties across the examined model organisms for the novel miRNA:hairpin combinations identified using the miRDeep2 method Novel miRNA ID Hairpin ID Hu Ch Go Or Ma Mo Dr Wo TJU_CMC_MD2.ID00001.5p-miR TJU_CMC_MD2.ID00001.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00002.5p-miR TJU_CMC_MD2.ID00002.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID00003.5p-miR TJU_CMC_MD2.ID00003.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00004.3p-miR TJU_CMC_MD2.ID00004.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00004.5p-miR TJU_CMC_MD2.ID00004.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00005.5p-miR TJU_CMC_MD2.ID00005.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00006.3p-miR TJU_CMC_MD2.ID00006.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00007.3p-miR TJU_CMC_MD2.ID00007.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00008.3p-miR TJU_CMC_MD2.ID00008.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00009.3p-miR TJU_CMC_MD2.ID00009.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00010.3p-miR TJU_CMC_MD2.ID00010.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00011.3p-miR TJU_CMC_MD2.ID00011.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00011.5p-miR TJU_CMC_MD2.ID00011.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00012.3p-miR TJU_CMC_MD2.ID00012.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00013.3p-miR TJU_CMC_MD2.ID00013.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00014.3p-miR TJU_CMC_MD2.ID00014.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00015.5p-miR TJU_CMC_MD2.ID00015.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00016.5p-miR TJU_CMC_MD2.ID00016.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00017.3p-miR TJU_CMC_MD2.ID00017.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00018.5p-miR TJU_CMC_MD2.ID00018.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00019.3p-miR TJU_CMC_MD2.ID00019.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00020.5p-miR TJU_CMC_MD2.ID00020.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00021.5p-miR TJU_CMC_MD2.ID00021.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00022.3p-miR TJU_CMC_MD2.ID00022.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00023.3p-miR TJU_CMC_MD2.ID00023.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00024.5p-miR TJU_CMC_MD2.ID00024.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00025.5p-miR TJU_CMC_MD2.ID00025.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00026.3p-miR TJU_CMC_MD2.ID00026.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00027.5p-miR TJU_CMC_MD2.ID00027.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00028.3p-miR TJU_CMC_MD2.ID00028.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00029.5p-miR TJU_CMC_MD2.ID00029.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00030.3p-miR TJU_CMC_MD2.ID00030.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00031.3p-miR TJU_CMC_MD2.ID00031.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00032.5p-miR TJU_CMC_MD2.ID00032.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00033.5p-miR TJU_CMC_MD2.ID00033.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00034.3p-miR TJU_CMC_MD2.ID00034.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00035.3p-miR TJU_CMC_MD2.ID00035.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00036.3p-miR TJU_CMC_MD2.ID00036.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00037.3p-miR TJU_CMC_MD2.ID00037.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00038.3p-miR TJU_CMC_MD2.ID00038.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00039.3p-miR TJU_CMC_MD2.ID00039.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00040.5p-miR TJU_CMC_MD2.ID00040.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00041.3p-miR TJU_CMC_MD2.ID00041.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00041.5p-miR TJU_CMC_MD2.ID00041.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00042.3p-miR TJU_CMC_MD2.ID00042.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00043.5p-miR TJU_CMC_MD2.ID00043.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00044.3p-miR TJU_CMC_MD2.ID00044.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00045.5p-miR TJU_CMC_MD2.ID00045.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00046.3p-miR TJU_CMC_MD2.ID00046.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00046.5p-miR TJU_CMC_MD2.ID00046.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00047.3p-miR TJU_CMC_MD2.ID00047.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00048.5p-miR TJU_CMC_MD2.ID00048.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00049.5p-miR TJU_CMC_MD2.ID00049.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00050.5p-miR TJU_CMC_MD2.ID00050.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00051.3p-miR TJU_CMC_MD2.ID00051.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00052.3p-miR TJU_CMC_MD2.ID00052.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00053.5p-miR TJU_CMC_MD2.ID00053.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00054.5p-miR TJU_CMC_MD2.ID00054.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00055.5p-miR TJU_CMC_MD2.ID00055.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00056.3p-miR TJU_CMC_MD2.ID00056.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00057.3p-miR TJU_CMC_MD2.ID00057.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00058.5p-miR TJU_CMC_MD2.ID00058.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00059.5p-miR TJU_CMC_MD2.ID00059.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00060.3p-miR TJU_CMC_MD2.ID00060.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00061.3p-miR TJU_CMC_MD2.ID00061.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00062.5p-miR TJU_CMC_MD2.ID00062.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00063.5p-miR TJU_CMC_MD2.ID00063.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00064.3p-miR TJU_CMC_MD2.ID00064.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00065.3p-miR TJU_CMC_MD2.ID00065.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00066.3p-miR TJU_CMC_MD2.ID00066.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00067.3p-miR TJU_CMC_MD2.ID00067.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00068.5p-miR TJU_CMC_MD2.ID00068.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00069.3p-miR TJU_CMC_MD2.ID00069.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00070.5p-miR TJU_CMC_MD2.ID00070.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00071.3p-miR TJU_CMC_MD2.ID00071.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00072.5p-miR TJU_CMC_MD2.ID00072.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00073.3p-miR TJU_CMC_MD2.ID00073.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00074.3p-miR TJU_CMC_MD2.ID00074.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00075.5p-miR TJU_CMC_MD2.ID00075.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00076.5p-miR TJU_CMC_MD2.ID00076.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00077.3p-miR TJU_CMC_MD2.ID00077.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00078.3p-miR TJU_CMC_MD2.ID00078.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00079.3p-miR TJU_CMC_MD2.ID00079.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00080.3p-miR TJU_CMC_MD2.ID00080.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00081.3p-miR TJU_CMC_MD2.ID00081.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00082.3p-miR TJU_CMC_MD2.ID00082.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00083.3p-miR TJU_CMC_MD2.ID00083.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00084.5p-miR TJU_CMC_MD2.ID00084.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00085.3p-miR TJU_CMC_MD2.ID00085.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00086.3p-miR TJU_CMC_MD2.ID00086.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00087.3p-miR TJU_CMC_MD2.ID00087.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00088.5p-miR TJU_CMC_MD2.ID00088.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00089.3p-miR TJU_CMC_MD2.ID00089.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00090.3p-miR TJU_CMC_MD2.ID00090.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00091.5p-miR TJU_CMC_MD2.ID00091.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00092.3p-miR TJU_CMC_MD2.ID00092.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00093.5p-miR TJU_CMC_MD2.ID00093.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00094.3p-miR TJU_CMC_MD2.ID00094.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00095.5p-miR TJU_CMC_MD2.ID00095.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00096.5p-miR TJU_CMC_MD2.ID00096.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00097.5p-miR TJU_CMC_MD2.ID00097.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00098.5p-miR TJU_CMC_MD2.ID00098.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00099.3p-miR TJU_CMC_MD2.ID00099.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00100.5p-miR TJU_CMC_MD2.ID00100.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00101.3p-miR TJU_CMC_MD2.ID00101.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00102.3p-miR TJU_CMC_MD2.ID00102.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00103.5p-miR TJU_CMC_MD2.ID00103.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID00104.5p-miR TJU_CMC_MD2.ID00104.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00105.5p-miR TJU_CMC_MD2.ID00105.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00106.5p-miR TJU_CMC_MD2.ID00106.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00107.3p-miR TJU_CMC_MD2.ID00107.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00108.3p-miR TJU_CMC_MD2.ID00108.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00109.3p-miR TJU_CMC_MD2.ID00109.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00110.5p-miR TJU_CMC_MD2.ID00110.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00111.3p-miR TJU_CMC_MD2.ID00111.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00112.5p-miR TJU_CMC_MD2.ID00112.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00113.5p-miR TJU_CMC_MD2.ID00113.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00114.5p-miR TJU_CMC_MD2.ID00114.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00115.5p-miR TJU_CMC_MD2.ID00115.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00116.3p-miR TJU_CMC_MD2.ID00116.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00117.5p-miR TJU_CMC_MD2.ID00117.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00118.5p-miR TJU_CMC_MD2.ID00118.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00119.3p-miR TJU_CMC_MD2.ID00119.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00120.3p-miR TJU_CMC_MD2.ID00120.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00121.5p-miR TJU_CMC_MD2.ID00121.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00122.3p-miR TJU_CMC_MD2.ID00122.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00122.5p-miR TJU_CMC_MD2.ID00122.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00123.5p-miR TJU_CMC_MD2.ID00123.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00124.5p-miR TJU_CMC_MD2.ID00124.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00125.3p-miR TJU_CMC_MD2.ID00125.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00126.5p-miR TJU_CMC_MD2.ID00126.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00127.3p-miR TJU_CMC_MD2.ID00127.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00128.3p-miR TJU_CMC_MD2.ID00128.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00129.5p-miR TJU_CMC_MD2.ID00129.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00130.3p-miR TJU_CMC_MD2.ID00130.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00131.5p-miR TJU_CMC_MD2.ID00131.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00132.5p-miR TJU_CMC_MD2.ID00132.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00133.3p-miR TJU_CMC_MD2.ID00133.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00134.3p-miR TJU_CMC_MD2.ID00134.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00135.5p-miR TJU_CMC_MD2.ID00135.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00136.5p-miR TJU_CMC_MD2.ID00136.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00137.3p-miR TJU_CMC_MD2.ID00137.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00138.3p-miR TJU_CMC_MD2.ID00138.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00139.5p-miR TJU_CMC_MD2.ID00139.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00140.3p-miR TJU_CMC_MD2.ID00140.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00141.3p-miR TJU_CMC_MD2.ID00141.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00142.3p-miR TJU_CMC_MD2.ID00142.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00143.3p-miR TJU_CMC_MD2.ID00143.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00144.3p-miR TJU_CMC_MD2.ID00144.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00145.3p-miR TJU_CMC_MD2.ID00145.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00145.5p-miR TJU_CMC_MD2.ID00145.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00146.3p-miR TJU_CMC_MD2.ID00146.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00146.5p-miR TJU_CMC_MD2.ID00146.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00147.5p-miR TJU_CMC_MD2.ID00147.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID00148.5p-miR TJU_CMC_MD2.ID00148.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00149.3p-miR TJU_CMC_MD2.ID00149.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00150.5p-miR TJU_CMC_MD2.ID00150.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00151.3p-miR TJU_CMC_MD2.ID00151.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00152.3p-miR TJU_CMC_MD2.ID00152.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00153.3p-miR TJU_CMC_MD2.ID00153.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00154.3p-miR TJU_CMC_MD2.ID00154.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00155.5p-miR TJU_CMC_MD2.ID00155.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00156.5p-miR TJU_CMC_MD2.ID00156.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00157.3p-miR TJU_CMC_MD2.ID00157.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00158.5p-miR TJU_CMC_MD2.ID00158.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00159.5p-miR TJU_CMC_MD2.ID00159.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00160.5p-miR TJU_CMC_MD2.ID00160.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00161.3p-miR TJU_CMC_MD2.ID00161.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00162.3p-miR TJU_CMC_MD2.ID00162.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00163.5p-miR TJU_CMC_MD2.ID00163.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00164.5p-miR TJU_CMC_MD2.ID00164.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00165.3p-miR TJU_CMC_MD2.ID00165.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00166.5p-miR TJU_CMC_MD2.ID00166.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00167.5p-miR TJU_CMC_MD2.ID00167.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00168.3p-miR TJU_CMC_MD2.ID00168.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00169.3p-miR TJU_CMC_MD2.ID00169.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00170.3p-miR TJU_CMC_MD2.ID00170.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00171.3p-miR TJU_CMC_MD2.ID00171.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00172.3p-miR TJU_CMC_MD2.ID00172.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00173.3p-miR TJU_CMC_MD2.ID00173.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00174.5p-miR TJU_CMC_MD2.ID00174.hairpin YES YES NO YES YES YES NO NO TJU_CMC_MD2.ID00175.3p-miR TJU_CMC_MD2.ID00175.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00176.5p-miR TJU_CMC_MD2.ID00176.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00177.5p-miR TJU_CMC_MD2.ID00177.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00178.5p-miR TJU_CMC_MD2.ID00178.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00179.3p-miR TJU_CMC_MD2.ID00179.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00180.5p-miR TJU_CMC_MD2.ID00180.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00181.5p-miR TJU_CMC_MD2.ID00181.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00182.5p-miR TJU_CMC_MD2.ID00182.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00183.3p-miR TJU_CMC_MD2.ID00183.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00183.5p-miR TJU_CMC_MD2.ID00183.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00184.3p-miR TJU_CMC_MD2.ID00184.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00185.5p-miR TJU_CMC_MD2.ID00185.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00186.5p-miR TJU_CMC_MD2.ID00186.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00187.3p-miR TJU_CMC_MD2.ID00187.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00188.3p-miR TJU_CMC_MD2.ID00188.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00189.5p-miR TJU_CMC_MD2.ID00189.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00190.3p-miR TJU_CMC_MD2.ID00190.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00191.5p-miR TJU_CMC_MD2.ID00191.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00192.3p-miR TJU_CMC_MD2.ID00192.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00193.5p-miR TJU_CMC_MD2.ID00193.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00194.3p-miR TJU_CMC_MD2.ID00194.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00195.3p-miR TJU_CMC_MD2.ID00195.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00196.3p-miR TJU_CMC_MD2.ID00196.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00197.5p-miR TJU_CMC_MD2.ID00197.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00198.3p-miR TJU_CMC_MD2.ID00198.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00199.3p-miR TJU_CMC_MD2.ID00199.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00200.5p-miR TJU_CMC_MD2.ID00200.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00201.3p-miR TJU_CMC_MD2.ID00201.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00202.5p-miR TJU_CMC_MD2.ID00202.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00203.3p-miR TJU_CMC_MD2.ID00203.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00204.5p-miR TJU_CMC_MD2.ID00204.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00205.3p-miR TJU_CMC_MD2.ID00205.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00206.3p-miR TJU_CMC_MD2.ID00206.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00207.5p-miR TJU_CMC_MD2.ID00207.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00208.5p-miR TJU_CMC_MD2.ID00208.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00209.3p-miR TJU_CMC_MD2.ID00209.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00210.5p-miR TJU_CMC_MD2.ID00210.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00211.3p-miR TJU_CMC_MD2.ID00211.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00212.3p-miR TJU_CMC_MD2.ID00212.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00213.3p-miR TJU_CMC_MD2.ID00213.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00214.3p-miR TJU_CMC_MD2.ID00214.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00215.3p-miR TJU_CMC_MD2.ID00215.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00216.3p-miR TJU_CMC_MD2.ID00216.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00217.3p-miR TJU_CMC_MD2.ID00217.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00217.5p-miR TJU_CMC_MD2.ID00217.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00218.3p-miR TJU_CMC_MD2.ID00218.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00219.3p-miR TJU_CMC_MD2.ID00219.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00220.3p-miR TJU_CMC_MD2.ID00220.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00221.5p-miR TJU_CMC_MD2.ID00221.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00222.3p-miR TJU_CMC_MD2.ID00222.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00223.5p-miR TJU_CMC_MD2.ID00223.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00224.5p-miR TJU_CMC_MD2.ID00224.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00225.3p-miR TJU_CMC_MD2.ID00225.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00226.5p-miR TJU_CMC_MD2.ID00226.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00227.5p-miR TJU_CMC_MD2.ID00227.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00228.5p-miR TJU_CMC_MD2.ID00228.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00229.5p-miR TJU_CMC_MD2.ID00229.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00230.5p-miR TJU_CMC_MD2.ID00230.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00231.3p-miR TJU_CMC_MD2.ID00231.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00231.5p-miR TJU_CMC_MD2.ID00231.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00232.3p-miR TJU_CMC_MD2.ID00232.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00233.5p-miR TJU_CMC_MD2.ID00233.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00234.3p-miR TJU_CMC_MD2.ID00234.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00235.5p-miR TJU_CMC_MD2.ID00235.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00236.5p-miR TJU_CMC_MD2.ID00236.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00237.5p-miR TJU_CMC_MD2.ID00237.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00238.3p-miR TJU_CMC_MD2.ID00238.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00239.3p-miR TJU_CMC_MD2.ID00239.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00240.5p-miR TJU_CMC_MD2.ID00240.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00241.3p-miR TJU_CMC_MD2.ID00241.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00242.3p-miR TJU_CMC_MD2.ID00242.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00243.3p-miR TJU_CMC_MD2.ID00243.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00244.3p-miR TJU_CMC_MD2.ID00244.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00245.3p-miR TJU_CMC_MD2.ID00245.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00246.3p-miR TJU_CMC_MD2.ID00246.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00247.3p-miR TJU_CMC_MD2.ID00247.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00247.5p-miR TJU_CMC_MD2.ID00247.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00248.5p-miR TJU_CMC_MD2.ID00248.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00249.3p-miR TJU_CMC_MD2.ID00249.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00250.5p-miR TJU_CMC_MD2.ID00250.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00251.5p-miR TJU_CMC_MD2.ID00251.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00252.5p-miR TJU_CMC_MD2.ID00252.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00253.5p-miR TJU_CMC_MD2.ID00253.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00254.3p-miR TJU_CMC_MD2.ID00254.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00255.5p-miR TJU_CMC_MD2.ID00255.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00256.3p-miR TJU_CMC_MD2.ID00256.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00257.3p-miR TJU_CMC_MD2.ID00257.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00258.5p-miR TJU_CMC_MD2.ID00258.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00259.5p-miR TJU_CMC_MD2.ID00259.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00260.3p-miR TJU_CMC_MD2.ID00260.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00261.3p-miR TJU_CMC_MD2.ID00261.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00262.3p-miR TJU_CMC_MD2.ID00262.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00263.3p-miR TJU_CMC_MD2.ID00263.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00264.5p-miR TJU_CMC_MD2.ID00264.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00265.3p-miR TJU_CMC_MD2.ID00265.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00266.3p-miR TJU_CMC_MD2.ID00266.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00267.3p-miR TJU_CMC_MD2.ID00267.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00268.3p-miR TJU_CMC_MD2.ID00268.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00269.3p-miR TJU_CMC_MD2.ID00269.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00270.5p-miR TJU_CMC_MD2.ID00270.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00271.5p-miR TJU_CMC_MD2.ID00271.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00272.3p-miR TJU_CMC_MD2.ID00272.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00273.3p-miR TJU_CMC_MD2.ID00273.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00274.5p-miR TJU_CMC_MD2.ID00274.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00275.3p-miR TJU_CMC_MD2.ID00275.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00276.3p-miR TJU_CMC_MD2.ID00276.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00277.3p-miR TJU_CMC_MD2.ID00277.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00278.3p-miR TJU_CMC_MD2.ID00278.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00279.5p-miR TJU_CMC_MD2.ID00279.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00280.3p-miR TJU_CMC_MD2.ID00280.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00281.5p-miR TJU_CMC_MD2.ID00281.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00282.5p-miR TJU_CMC_MD2.ID00282.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00283.3p-miR TJU_CMC_MD2.ID00283.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00284.5p-miR TJU_CMC_MD2.ID00284.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00285.3p-miR TJU_CMC_MD2.ID00285.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00286.3p-miR TJU_CMC_MD2.ID00286.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00287.3p-miR TJU_CMC_MD2.ID00287.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00288.3p-miR TJU_CMC_MD2.ID00288.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00288.5p-miR TJU_CMC_MD2.ID00288.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00289.5p-miR TJU_CMC_MD2.ID00289.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00290.5p-miR TJU_CMC_MD2.ID00290.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00291.3p-miR TJU_CMC_MD2.ID00291.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00292.3p-miR TJU_CMC_MD2.ID00292.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00293.3p-miR TJU_CMC_MD2.ID00293.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00293.5p-miR TJU_CMC_MD2.ID00293.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00294.5p-miR TJU_CMC_MD2.ID00294.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00295.3p-miR TJU_CMC_MD2.ID00295.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00296.3p-miR TJU_CMC_MD2.ID00296.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00297.5p-miR TJU_CMC_MD2.ID00297.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00298.3p-miR TJU_CMC_MD2.ID00298.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00299.3p-miR TJU_CMC_MD2.ID00299.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00300.5p-miR TJU_CMC_MD2.ID00300.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00301.3p-miR TJU_CMC_MD2.ID00301.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00302.5p-miR TJU_CMC_MD2.ID00302.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00303.5p-miR TJU_CMC_MD2.ID00303.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00304.5p-miR TJU_CMC_MD2.ID00304.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00305.3p-miR TJU_CMC_MD2.ID00305.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00306.5p-miR TJU_CMC_MD2.ID00306.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00307.5p-miR TJU_CMC_MD2.ID00307.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00308.3p-miR TJU_CMC_MD2.ID00308.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00309.5p-miR TJU_CMC_MD2.ID00309.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00310.3p-miR TJU_CMC_MD2.ID00310.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00311.5p-miR TJU_CMC_MD2.ID00311.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00312.3p-miR TJU_CMC_MD2.ID00312.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00313.3p-miR TJU_CMC_MD2.ID00313.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00314.3p-miR TJU_CMC_MD2.ID00314.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00314.5p-miR TJU_CMC_MD2.ID00314.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00315.3p-miR TJU_CMC_MD2.ID00315.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00315.5p-miR TJU_CMC_MD2.ID00315.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00316.3p-miR TJU_CMC_MD2.ID00316.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00317.5p-miR TJU_CMC_MD2.ID00317.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00318.3p-miR TJU_CMC_MD2.ID00318.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00319.3p-miR TJU_CMC_MD2.ID00319.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00320.3p-miR TJU_CMC_MD2.ID00320.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00321.5p-miR TJU_CMC_MD2.ID00321.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00322.5p-miR TJU_CMC_MD2.ID00322.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00323.3p-miR TJU_CMC_MD2.ID00323.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00324.3p-miR TJU_CMC_MD2.ID00324.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00325.3p-miR TJU_CMC_MD2.ID00325.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00326.5p-miR TJU_CMC_MD2.ID00326.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00327.3p-miR TJU_CMC_MD2.ID00327.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00327.5p-miR TJU_CMC_MD2.ID00327.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00328.3p-miR TJU_CMC_MD2.ID00328.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00329.3p-miR TJU_CMC_MD2.ID00329.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00330.5p-miR TJU_CMC_MD2.ID00330.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID00331.5p-miR TJU_CMC_MD2.ID00331.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00332.3p-miR TJU_CMC_MD2.ID00332.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00333.3p-miR TJU_CMC_MD2.ID00333.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00334.3p-miR TJU_CMC_MD2.ID00334.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00335.5p-miR TJU_CMC_MD2.ID00335.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00336.3p-miR TJU_CMC_MD2.ID00336.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00337.3p-miR TJU_CMC_MD2.ID00337.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00338.3p-miR TJU_CMC_MD2.ID00338.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00339.3p-miR TJU_CMC_MD2.ID00339.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00340.5p-miR TJU_CMC_MD2.ID00340.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00341.5p-miR TJU_CMC_MD2.ID00341.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00342.5p-miR TJU_CMC_MD2.ID00342.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00343.3p-miR TJU_CMC_MD2.ID00343.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00344.5p-miR TJU_CMC_MD2.ID00344.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00345.3p-miR TJU_CMC_MD2.ID00345.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00346.3p-miR TJU_CMC_MD2.ID00346.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00347.3p-miR TJU_CMC_MD2.ID00347.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00348.3p-miR TJU_CMC_MD2.ID00348.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00349.3p-miR TJU_CMC_MD2.ID00349.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00350.3p-miR TJU_CMC_MD2.ID00350.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00350.5p-miR TJU_CMC_MD2.ID00350.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00351.3p-miR TJU_CMC_MD2.ID00351.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00352.3p-miR TJU_CMC_MD2.ID00352.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00353.5p-miR TJU_CMC_MD2.ID00353.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00354.3p-miR TJU_CMC_MD2.ID00354.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00355.5p-miR TJU_CMC_MD2.ID00355.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00356.3p-miR TJU_CMC_MD2.ID00356.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00357.3p-miR TJU_CMC_MD2.ID00357.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00357.5p-miR TJU_CMC_MD2.ID00357.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00358.3p-miR TJU_CMC_MD2.ID00358.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00358.5p-miR TJU_CMC_MD2.ID00358.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00359.5p-miR TJU_CMC_MD2.ID00359.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00360.3p-miR TJU_CMC_MD2.ID00360.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00361.3p-miR TJU_CMC_MD2.ID00361.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00362.5p-miR TJU_CMC_MD2.ID00362.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00363.3p-miR TJU_CMC_MD2.ID00363.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00364.5p-miR TJU_CMC_MD2.ID00364.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00365.3p-miR TJU_CMC_MD2.ID00365.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00365.5p-miR TJU_CMC_MD2.ID00365.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00366.3p-miR TJU_CMC_MD2.ID00366.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00367.5p-miR TJU_CMC_MD2.ID00367.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00368.3p-miR TJU_CMC_MD2.ID00368.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00369.3p-miR TJU_CMC_MD2.ID00369.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00370.3p-miR TJU_CMC_MD2.ID00370.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00370.5p-miR TJU_CMC_MD2.ID00370.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00371.5p-miR TJU_CMC_MD2.ID00371.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00372.5p-miR TJU_CMC_MD2.ID00372.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00373.3p-miR TJU_CMC_MD2.ID00373.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00374.3p-miR TJU_CMC_MD2.ID00374.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00375.3p-miR TJU_CMC_MD2.ID00375.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00376.5p-miR TJU_CMC_MD2.ID00376.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00377.3p-miR TJU_CMC_MD2.ID00377.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00378.3p-miR TJU_CMC_MD2.ID00378.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00379.3p-miR TJU_CMC_MD2.ID00379.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00380.3p-miR TJU_CMC_MD2.ID00380.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00381.3p-miR TJU_CMC_MD2.ID00381.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00382.3p-miR TJU_CMC_MD2.ID00382.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00382.5p-miR TJU_CMC_MD2.ID00382.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00383.3p-miR TJU_CMC_MD2.ID00383.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00383.5p-miR TJU_CMC_MD2.ID00383.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00384.3p-miR TJU_CMC_MD2.ID00384.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00385.5p-miR TJU_CMC_MD2.ID00385.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00386.3p-miR TJU_CMC_MD2.ID00386.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00387.3p-miR TJU_CMC_MD2.ID00387.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00388.3p-miR TJU_CMC_MD2.ID00388.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00389.5p-miR TJU_CMC_MD2.ID00389.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00390.5p-miR TJU_CMC_MD2.ID00390.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00391.5p-miR TJU_CMC_MD2.ID00391.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00392.3p-miR TJU_CMC_MD2.ID00392.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00392.5p-miR TJU_CMC_MD2.ID00392.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00393.3p-miR TJU_CMC_MD2.ID00393.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00394.3p-miR TJU_CMC_MD2.ID00394.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00395.5p-miR TJU_CMC_MD2.ID00395.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00396.3p-miR TJU_CMC_MD2.ID00396.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00397.5p-miR TJU_CMC_MD2.ID00397.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00398.3p-miR TJU_CMC_MD2.ID00398.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00399.3p-miR TJU_CMC_MD2.ID00399.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00400.5p-miR TJU_CMC_MD2.ID00400.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00401.5p-miR TJU_CMC_MD2.ID00401.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00402.5p-miR TJU_CMC_MD2.ID00402.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00403.3p-miR TJU_CMC_MD2.ID00403.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00404.3p-miR TJU_CMC_MD2.ID00404.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00405.3p-miR TJU_CMC_MD2.ID00405.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00406.3p-miR TJU_CMC_MD2.ID00406.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00407.3p-miR TJU_CMC_MD2.ID00407.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00408.5p-miR TJU_CMC_MD2.ID00408.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00409.5p-miR TJU_CMC_MD2.ID00409.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00410.3p-miR TJU_CMC_MD2.ID00410.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00411.5p-miR TJU_CMC_MD2.ID00411.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00412.3p-miR TJU_CMC_MD2.ID00412.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00413.5p-miR TJU_CMC_MD2.ID00413.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00414.3p-miR TJU_CMC_MD2.ID00414.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00415.5p-miR TJU_CMC_MD2.ID00415.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00416.5p-miR TJU_CMC_MD2.ID00416.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00417.3p-miR TJU_CMC_MD2.ID00417.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00418.5p-miR TJU_CMC_MD2.ID00418.hairpin YES NO YES YES YES YES NO NO TJU_CMC_MD2.ID00419.3p-miR TJU_CMC_MD2.ID00419.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00420.3p-miR TJU_CMC_MD2.ID00420.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00421.3p-miR TJU_CMC_MD2.ID00421.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00422.3p-miR TJU_CMC_MD2.ID00422.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00423.3p-miR TJU_CMC_MD2.ID00423.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00424.5p-miR TJU_CMC_MD2.ID00424.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00425.5p-miR TJU_CMC_MD2.ID00425.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00426.3p-miR TJU_CMC_MD2.ID00426.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00427.5p-miR TJU_CMC_MD2.ID00427.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00428.3p-miR TJU_CMC_MD2.ID00428.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00429.3p-miR TJU_CMC_MD2.ID00429.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00430.3p-miR TJU_CMC_MD2.ID00430.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00431.5p-miR TJU_CMC_MD2.ID00431.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00432.3p-miR TJU_CMC_MD2.ID00432.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00433.3p-miR TJU_CMC_MD2.ID00433.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00434.3p-miR TJU_CMC_MD2.ID00434.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00435.3p-miR TJU_CMC_MD2.ID00435.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00435.5p-miR TJU_CMC_MD2.ID00435.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00436.3p-miR TJU_CMC_MD2.ID00436.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00437.3p-miR TJU_CMC_MD2.ID00437.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00438.3p-miR TJU_CMC_MD2.ID00438.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00439.3p-miR TJU_CMC_MD2.ID00439.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00440.5p-miR TJU_CMC_MD2.ID00440.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00441.3p-miR TJU_CMC_MD2.ID00441.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00442.5p-miR TJU_CMC_MD2.ID00442.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00443.5p-miR TJU_CMC_MD2.ID00443.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00444.5p-miR TJU_CMC_MD2.ID00444.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00445.3p-miR TJU_CMC_MD2.ID00445.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00446.3p-miR TJU_CMC_MD2.ID00446.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00447.5p-miR TJU_CMC_MD2.ID00447.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00448.3p-miR TJU_CMC_MD2.ID00448.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00448.5p-miR TJU_CMC_MD2.ID00448.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00449.5p-miR TJU_CMC_MD2.ID00449.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00450.3p-miR TJU_CMC_MD2.ID00450.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00451.3p-miR TJU_CMC_MD2.ID00451.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00452.3p-miR TJU_CMC_MD2.ID00452.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00453.3p-miR TJU_CMC_MD2.ID00453.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00454.3p-miR TJU_CMC_MD2.ID00454.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00455.5p-miR TJU_CMC_MD2.ID00455.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00456.5p-miR TJU_CMC_MD2.ID00456.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00457.3p-miR TJU_CMC_MD2.ID00457.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00458.5p-miR TJU_CMC_MD2.ID00458.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00459.5p-miR TJU_CMC_MD2.ID00459.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00460.5p-miR TJU_CMC_MD2.ID00460.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00461.3p-miR TJU_CMC_MD2.ID00461.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00462.3p-miR TJU_CMC_MD2.ID00462.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00463.3p-miR TJU_CMC_MD2.ID00463.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00464.3p-miR TJU_CMC_MD2.ID00464.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00464.5p-miR TJU_CMC_MD2.ID00464.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00465.5p-miR TJU_CMC_MD2.ID00465.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00466.5p-miR TJU_CMC_MD2.ID00466.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00467.5p-miR TJU_CMC_MD2.ID00467.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00468.3p-miR TJU_CMC_MD2.ID00468.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00469.3p-miR TJU_CMC_MD2.ID00469.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00470.5p-miR TJU_CMC_MD2.ID00470.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00471.3p-miR TJU_CMC_MD2.ID00471.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00472.3p-miR TJU_CMC_MD2.ID00472.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00472.5p-miR TJU_CMC_MD2.ID00472.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00473.3p-miR TJU_CMC_MD2.ID00473.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00474.3p-miR TJU_CMC_MD2.ID00474.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00475.3p-miR TJU_CMC_MD2.ID00475.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00476.3p-miR TJU_CMC_MD2.ID00476.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00477.5p-miR TJU_CMC_MD2.ID00477.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00478.3p-miR TJU_CMC_MD2.ID00478.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00479.5p-miR TJU_CMC_MD2.ID00479.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00480.3p-miR TJU_CMC_MD2.ID00480.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00480.5p-miR TJU_CMC_MD2.ID00480.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00481.5p-miR TJU_CMC_MD2.ID00481.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00482.5p-miR TJU_CMC_MD2.ID00482.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00483.3p-miR TJU_CMC_MD2.ID00483.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00484.3p-miR TJU_CMC_MD2.ID00484.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00485.5p-miR TJU_CMC_MD2.ID00485.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00486.3p-miR TJU_CMC_MD2.ID00486.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00487.3p-miR TJU_CMC_MD2.ID00487.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00488.5p-miR TJU_CMC_MD2.ID00488.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00489.3p-miR TJU_CMC_MD2.ID00489.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00490.5p-miR TJU_CMC_MD2.ID00490.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00491.5p-miR TJU_CMC_MD2.ID00491.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00492.5p-miR TJU_CMC_MD2.ID00492.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00493.3p-miR TJU_CMC_MD2.ID00493.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00494.5p-miR TJU_CMC_MD2.ID00494.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00495.5p-miR TJU_CMC_MD2.ID00495.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00496.5p-miR TJU_CMC_MD2.ID00496.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00497.3p-miR TJU_CMC_MD2.ID00497.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00498.5p-miR TJU_CMC_MD2.ID00498.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00499.3p-miR TJU_CMC_MD2.ID00499.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00500.3p-miR TJU_CMC_MD2.ID00500.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00501.5p-miR TJU_CMC_MD2.ID00501.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00502.5p-miR TJU_CMC_MD2.ID00502.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00503.5p-miR TJU_CMC_MD2.ID00503.hairpin YES YES NO YES NO YES NO NO TJU_CMC_MD2.ID00504.3p-miR TJU_CMC_MD2.ID00504.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00505.3p-miR TJU_CMC_MD2.ID00505.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00506.3p-miR TJU_CMC_MD2.ID00506.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00507.3p-miR TJU_CMC_MD2.ID00507.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00508.3p-miR TJU_CMC_MD2.ID00508.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00509.3p-miR TJU_CMC_MD2.ID00509.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00510.5p-miR TJU_CMC_MD2.ID00510.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00511.5p-miR TJU_CMC_MD2.ID00511.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00512.3p-miR TJU_CMC_MD2.ID00512.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00513.3p-miR TJU_CMC_MD2.ID00513.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00514.3p-miR TJU_CMC_MD2.ID00514.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00515.5p-miR TJU_CMC_MD2.ID00515.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00516.5p-miR TJU_CMC_MD2.ID00516.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00517.5p-miR TJU_CMC_MD2.ID00517.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00518.5p-miR TJU_CMC_MD2.ID00518.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00519.3p-miR TJU_CMC_MD2.ID00519.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00520.5p-miR TJU_CMC_MD2.ID00520.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00521.5p-miR TJU_CMC_MD2.ID00521.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00522.5p-miR TJU_CMC_MD2.ID00522.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00523.3p-miR TJU_CMC_MD2.ID00523.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00524.3p-miR TJU_CMC_MD2.ID00524.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00525.3p-miR TJU_CMC_MD2.ID00525.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00526.3p-miR TJU_CMC_MD2.ID00526.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00526.5p-miR TJU_CMC_MD2.ID00526.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00527.5p-miR TJU_CMC_MD2.ID00527.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00528.3p-miR TJU_CMC_MD2.ID00528.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00529.3p-miR TJU_CMC_MD2.ID00529.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00529.5p-miR TJU_CMC_MD2.ID00529.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00530.3p-miR TJU_CMC_MD2.ID00530.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00531.5p-miR TJU_CMC_MD2.ID00531.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00532.3p-miR TJU_CMC_MD2.ID00532.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00532.5p-miR TJU_CMC_MD2.ID00532.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00533.3p-miR TJU_CMC_MD2.ID00533.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00533.5p-miR TJU_CMC_MD2.ID00533.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00534.3p-miR TJU_CMC_MD2.ID00534.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00535.3p-miR TJU_CMC_MD2.ID00535.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00536.3p-miR TJU_CMC_MD2.ID00536.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00537.3p-miR TJU_CMC_MD2.ID00537.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00538.5p-miR TJU_CMC_MD2.ID00538.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00539.3p-miR TJU_CMC_MD2.ID00539.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00539.5p-miR TJU_CMC_MD2.ID00539.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00540.3p-miR TJU_CMC_MD2.ID00540.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00541.5p-miR TJU_CMC_MD2.ID00541.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00542.3p-miR TJU_CMC_MD2.ID00542.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00543.3p-miR TJU_CMC_MD2.ID00543.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00544.3p-miR TJU_CMC_MD2.ID00544.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00545.3p-miR TJU_CMC_MD2.ID00545.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00546.5p-miR TJU_CMC_MD2.ID00546.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00547.3p-miR TJU_CMC_MD2.ID00547.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00548.3p-miR TJU_CMC_MD2.ID00548.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00549.3p-miR TJU_CMC_MD2.ID00549.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00550.3p-miR TJU_CMC_MD2.ID00550.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00550.5p-miR TJU_CMC_MD2.ID00550.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00551.3p-miR TJU_CMC_MD2.ID00551.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00552.3p-miR TJU_CMC_MD2.ID00552.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00553.3p-miR TJU_CMC_MD2.ID00553.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00554.3p-miR TJU_CMC_MD2.ID00554.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00555.3p-miR TJU_CMC_MD2.ID00555.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00556.5p-miR TJU_CMC_MD2.ID00556.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00557.3p-miR TJU_CMC_MD2.ID00557.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00558.3p-miR TJU_CMC_MD2.ID00558.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00558.5p-miR TJU_CMC_MD2.ID00558.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00559.3p-miR TJU_CMC_MD2.ID00559.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00560.3p-miR TJU_CMC_MD2.ID00560.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00561.3p-miR TJU_CMC_MD2.ID00561.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00562.3p-miR TJU_CMC_MD2.ID00562.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00563.3p-miR TJU_CMC_MD2.ID00563.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00564.5p-miR TJU_CMC_MD2.ID00564.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00565.3p-miR TJU_CMC_MD2.ID00565.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00566.5p-miR TJU_CMC_MD2.ID00566.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00567.3p-miR TJU_CMC_MD2.ID00567.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00568.3p-miR TJU_CMC_MD2.ID00568.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00569.3p-miR TJU_CMC_MD2.ID00569.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00570.3p-miR TJU_CMC_MD2.ID00570.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00571.3p-miR TJU_CMC_MD2.ID00571.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00572.5p-miR TJU_CMC_MD2.ID00572.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00573.5p-miR TJU_CMC_MD2.ID00573.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00574.3p-miR TJU_CMC_MD2.ID00574.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00574.5p-miR TJU_CMC_MD2.ID00574.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00575.5p-miR TJU_CMC_MD2.ID00575.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00576.5p-miR TJU_CMC_MD2.ID00576.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00577.3p-miR TJU_CMC_MD2.ID00577.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00578.3p-miR TJU_CMC_MD2.ID00578.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00579.3p-miR TJU_CMC_MD2.ID00579.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00580.3p-miR TJU_CMC_MD2.ID00580.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00581.3p-miR TJU_CMC_MD2.ID00581.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00582.3p-miR TJU_CMC_MD2.ID00582.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00583.3p-miR TJU_CMC_MD2.ID00583.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00584.5p-miR TJU_CMC_MD2.ID00584.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00585.5p-miR TJU_CMC_MD2.ID00585.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00586.3p-miR TJU_CMC_MD2.ID00586.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00587.3p-miR TJU_CMC_MD2.ID00587.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00588.3p-miR TJU_CMC_MD2.ID00588.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00589.3p-miR TJU_CMC_MD2.ID00589.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00590.5p-miR TJU_CMC_MD2.ID00590.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00591.3p-miR TJU_CMC_MD2.ID00591.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00591.5p-miR TJU_CMC_MD2.ID00591.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00592.3p-miR TJU_CMC_MD2.ID00592.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00593.3p-miR TJU_CMC_MD2.ID00593.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00594.3p-miR TJU_CMC_MD2.ID00594.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00595.3p-miR TJU_CMC_MD2.ID00595.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00596.5p-miR TJU_CMC_MD2.ID00596.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00597.3p-miR TJU_CMC_MD2.ID00597.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00598.3p-miR TJU_CMC_MD2.ID00598.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00599.5p-miR TJU_CMC_MD2.ID00599.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00600.3p-miR TJU_CMC_MD2.ID00600.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00601.3p-miR TJU_CMC_MD2.ID00601.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00602.3p-miR TJU_CMC_MD2.ID00602.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00603.5p-miR TJU_CMC_MD2.ID00603.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00604.3p-miR TJU_CMC_MD2.ID00604.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00605.5p-miR TJU_CMC_MD2.ID00605.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00606.5p-miR TJU_CMC_MD2.ID00606.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00607.3p-miR TJU_CMC_MD2.ID00607.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00608.3p-miR TJU_CMC_MD2.ID00608.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00609.5p-miR TJU_CMC_MD2.ID00609.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00610.3p-miR TJU_CMC_MD2.ID00610.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00611.5p-miR TJU_CMC_MD2.ID00611.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00612.3p-miR TJU_CMC_MD2.ID00612.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00613.3p-miR TJU_CMC_MD2.ID00613.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00614.3p-miR TJU_CMC_MD2.ID00614.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00615.5p-miR TJU_CMC_MD2.ID00615.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00616.5p-miR TJU_CMC_MD2.ID00616.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00617.3p-miR TJU_CMC_MD2.ID00617.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00618.3p-miR TJU_CMC_MD2.ID00618.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00619.5p-miR TJU_CMC_MD2.ID00619.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00620.3p-miR TJU_CMC_MD2.ID00620.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00621.3p-miR TJU_CMC_MD2.ID00621.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00622.3p-miR TJU_CMC_MD2.ID00622.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00623.3p-miR TJU_CMC_MD2.ID00623.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00623.5p-miR TJU_CMC_MD2.ID00623.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00624.3p-miR TJU_CMC_MD2.ID00624.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00625.5p-miR TJU_CMC_MD2.ID00625.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00626.5p-miR TJU_CMC_MD2.ID00626.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00627.5p-miR TJU_CMC_MD2.ID00627.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00628.5p-miR TJU_CMC_MD2.ID00628.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00629.3p-miR TJU_CMC_MD2.ID00629.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00630.3p-miR TJU_CMC_MD2.ID00630.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00631.5p-miR TJU_CMC_MD2.ID00631.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00632.3p-miR TJU_CMC_MD2.ID00632.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00633.3p-miR TJU_CMC_MD2.ID00633.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00634.5p-miR TJU_CMC_MD2.ID00634.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00635.5p-miR TJU_CMC_MD2.ID00635.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00636.3p-miR TJU_CMC_MD2.ID00636.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00637.5p-miR TJU_CMC_MD2.ID00637.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00638.5p-miR TJU_CMC_MD2.ID00638.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00639.3p-miR TJU_CMC_MD2.ID00639.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00639.5p-miR TJU_CMC_MD2.ID00639.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00640.3p-miR TJU_CMC_MD2.ID00640.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00640.5p-miR TJU_CMC_MD2.ID00640.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00641.3p-miR TJU_CMC_MD2.ID00641.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00642.3p-miR TJU_CMC_MD2.ID00642.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00643.3p-miR TJU_CMC_MD2.ID00643.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00644.5p-miR TJU_CMC_MD2.ID00644.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00645.5p-miR TJU_CMC_MD2.ID00645.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00646.5p-miR TJU_CMC_MD2.ID00646.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00647.3p-miR TJU_CMC_MD2.ID00647.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00648.5p-miR TJU_CMC_MD2.ID00648.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID00649.3p-miR TJU_CMC_MD2.ID00649.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00649.5p-miR TJU_CMC_MD2.ID00649.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00650.5p-miR TJU_CMC_MD2.ID00650.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00651.3p-miR TJU_CMC_MD2.ID00651.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00651.5p-miR TJU_CMC_MD2.ID00651.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00652.5p-miR TJU_CMC_MD2.ID00652.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00653.3p-miR TJU_CMC_MD2.ID00653.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00654.3p-miR TJU_CMC_MD2.ID00654.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00655.3p-miR TJU_CMC_MD2.ID00655.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00656.5p-miR TJU_CMC_MD2.ID00656.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00657.3p-miR TJU_CMC_MD2.ID00657.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00657.5p-miR TJU_CMC_MD2.ID00657.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00658.5p-miR TJU_CMC_MD2.ID00658.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00659.3p-miR TJU_CMC_MD2.ID00659.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00660.5p-miR TJU_CMC_MD2.ID00660.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00661.5p-miR TJU_CMC_MD2.ID00661.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00662.3p-miR TJU_CMC_MD2.ID00662.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00663.5p-miR TJU_CMC_MD2.ID00663.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00664.3p-miR TJU_CMC_MD2.ID00664.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00665.3p-miR TJU_CMC_MD2.ID00665.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00666.3p-miR TJU_CMC_MD2.ID00666.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00667.5p-miR TJU_CMC_MD2.ID00667.hairpin YES NO NO YES NO YES NO NO TJU_CMC_MD2.ID00668.3p-miR TJU_CMC_MD2.ID00668.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00669.3p-miR TJU_CMC_MD2.ID00669.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00670.3p-miR TJU_CMC_MD2.ID00670.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00671.5p-miR TJU_CMC_MD2.ID00671.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00672.3p-miR TJU_CMC_MD2.ID00672.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00672.5p-miR TJU_CMC_MD2.ID00672.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00673.3p-miR TJU_CMC_MD2.ID00673.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00674.3p-miR TJU_CMC_MD2.ID00674.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00675.3p-miR TJU_CMC_MD2.ID00675.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00676.3p-miR TJU_CMC_MD2.ID00676.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00677.3p-miR TJU_CMC_MD2.ID00677.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00678.3p-miR TJU_CMC_MD2.ID00678.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00679.5p-miR TJU_CMC_MD2.ID00679.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00680.5p-miR TJU_CMC_MD2.ID00680.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00681.5p-miR TJU_CMC_MD2.ID00681.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00682.3p-miR TJU_CMC_MD2.ID00682.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00683.3p-miR TJU_CMC_MD2.ID00683.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00684.3p-miR TJU_CMC_MD2.ID00684.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00685.3p-miR TJU_CMC_MD2.ID00685.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00685.5p-miR TJU_CMC_MD2.ID00685.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00686.3p-miR TJU_CMC_MD2.ID00686.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00687.3p-miR TJU_CMC_MD2.ID00687.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00688.3p-miR TJU_CMC_MD2.ID00688.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00689.3p-miR TJU_CMC_MD2.ID00689.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00690.5p-miR TJU_CMC_MD2.ID00690.hairpin YES YES NO NO NO YES NO NO TJU_CMC_MD2.ID00691.3p-miR TJU_CMC_MD2.ID00691.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00691.5p-miR TJU_CMC_MD2.ID00691.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00692.3p-miR TJU_CMC_MD2.ID00692.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00693.5p-miR TJU_CMC_MD2.ID00693.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00694.5p-miR TJU_CMC_MD2.ID00694.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00695.3p-miR TJU_CMC_MD2.ID00695.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00696.5p-miR TJU_CMC_MD2.ID00696.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00697.3p-miR TJU_CMC_MD2.ID00697.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00698.3p-miR TJU_CMC_MD2.ID00698.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00699.3p-miR TJU_CMC_MD2.ID00699.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00700.5p-miR TJU_CMC_MD2.ID00700.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00701.5p-miR TJU_CMC_MD2.ID00701.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00702.5p-miR TJU_CMC_MD2.ID00702.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00703.3p-miR TJU_CMC_MD2.ID00703.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00704.5p-miR TJU_CMC_MD2.ID00704.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00705.3p-miR TJU_CMC_MD2.ID00705.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00706.5p-miR TJU_CMC_MD2.ID00706.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00707.5p-miR TJU_CMC_MD2.ID00707.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00708.5p-miR TJU_CMC_MD2.ID00708.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00709.3p-miR TJU_CMC_MD2.ID00709.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00710.3p-miR TJU_CMC_MD2.ID00710.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00711.3p-miR TJU_CMC_MD2.ID00711.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00712.3p-miR TJU_CMC_MD2.ID00712.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00713.5p-miR TJU_CMC_MD2.ID00713.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00714.3p-miR TJU_CMC_MD2.ID00714.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00715.3p-miR TJU_CMC_MD2.ID00715.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00716.3p-miR TJU_CMC_MD2.ID00716.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00716.5p-miR TJU_CMC_MD2.ID00716.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00717.3p-miR TJU_CMC_MD2.ID00717.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00718.5p-miR TJU_CMC_MD2.ID00718.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00719.5p-miR TJU_CMC_MD2.ID00719.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00720.5p-miR TJU_CMC_MD2.ID00720.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00721.5p-miR TJU_CMC_MD2.ID00721.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00722.5p-miR TJU_CMC_MD2.ID00722.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00723.5p-miR TJU_CMC_MD2.ID00723.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00724.5p-miR TJU_CMC_MD2.ID00724.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00725.3p-miR TJU_CMC_MD2.ID00725.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00726.3p-miR TJU_CMC_MD2.ID00726.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00726.5p-miR TJU_CMC_MD2.ID00726.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00727.3p-miR TJU_CMC_MD2.ID00727.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00728.3p-miR TJU_CMC_MD2.ID00728.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00729.5p-miR TJU_CMC_MD2.ID00729.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00730.3p-miR TJU_CMC_MD2.ID00730.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00731.5p-miR TJU_CMC_MD2.ID00731.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00732.3p-miR TJU_CMC_MD2.ID00732.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00733.5p-miR TJU_CMC_MD2.ID00733.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00734.5p-miR TJU_CMC_MD2.ID00734.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00735.3p-miR TJU_CMC_MD2.ID00735.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00736.5p-miR TJU_CMC_MD2.ID00736.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00737.3p-miR TJU_CMC_MD2.ID00737.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00738.5p-miR TJU_CMC_MD2.ID00738.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00739.3p-miR TJU_CMC_MD2.ID00739.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00740.3p-miR TJU_CMC_MD2.ID00740.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00741.3p-miR TJU_CMC_MD2.ID00741.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00742.3p-miR TJU_CMC_MD2.ID00742.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00743.5p-miR TJU_CMC_MD2.ID00743.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00744.3p-miR TJU_CMC_MD2.ID00744.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00745.5p-miR TJU_CMC_MD2.ID00745.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00746.5p-miR TJU_CMC_MD2.ID00746.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00747.3p-miR TJU_CMC_MD2.ID00747.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00748.3p-miR TJU_CMC_MD2.ID00748.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00749.3p-miR TJU_CMC_MD2.ID00749.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00750.3p-miR TJU_CMC_MD2.ID00750.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00751.3p-miR TJU_CMC_MD2.ID00751.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00752.3p-miR TJU_CMC_MD2.ID00752.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00753.3p-miR TJU_CMC_MD2.ID00753.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00754.3p-miR TJU_CMC_MD2.ID00754.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00755.3p-miR TJU_CMC_MD2.ID00755.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00755.5p-miR TJU_CMC_MD2.ID00755.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00756.3p-miR TJU_CMC_MD2.ID00756.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00757.3p-miR TJU_CMC_MD2.ID00757.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00757.5p-miR TJU_CMC_MD2.ID00757.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00758.5p-miR TJU_CMC_MD2.ID00758.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00759.5p-miR TJU_CMC_MD2.ID00759.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00760.3p-miR TJU_CMC_MD2.ID00760.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00761.3p-miR TJU_CMC_MD2.ID00761.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00762.3p-miR TJU_CMC_MD2.ID00762.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00763.3p-miR TJU_CMC_MD2.ID00763.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00764.5p-miR TJU_CMC_MD2.ID00764.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00765.5p-miR TJU_CMC_MD2.ID00765.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00766.5p-miR TJU_CMC_MD2.ID00766.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00767.3p-miR TJU_CMC_MD2.ID00767.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00768.3p-miR TJU_CMC_MD2.ID00768.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00769.5p-miR TJU_CMC_MD2.ID00769.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00770.3p-miR TJU_CMC_MD2.ID00770.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00771.3p-miR TJU_CMC_MD2.ID00771.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00771.5p-miR TJU_CMC_MD2.ID00771.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00772.3p-miR TJU_CMC_MD2.ID00772.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00772.5p-miR TJU_CMC_MD2.ID00772.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00773.3p-miR TJU_CMC_MD2.ID00773.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00774.3p-miR TJU_CMC_MD2.ID00774.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00775.3p-miR TJU_CMC_MD2.ID00775.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00776.3p-miR TJU_CMC_MD2.ID00776.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00776.5p-miR TJU_CMC_MD2.ID00776.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00777.3p-miR TJU_CMC_MD2.ID00777.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00778.3p-miR TJU_CMC_MD2.ID00778.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00779.3p-miR TJU_CMC_MD2.ID00779.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00780.3p-miR TJU_CMC_MD2.ID00780.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00781.3p-miR TJU_CMC_MD2.ID00781.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00782.3p-miR TJU_CMC_MD2.ID00782.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00783.3p-miR TJU_CMC_MD2.ID00783.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00784.3p-miR TJU_CMC_MD2.ID00784.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00785.3p-miR TJU_CMC_MD2.ID00785.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00785.5p-miR TJU_CMC_MD2.ID00785.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00786.5p-miR TJU_CMC_MD2.ID00786.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00787.3p-miR TJU_CMC_MD2.ID00787.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00788.5p-miR TJU_CMC_MD2.ID00788.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00789.5p-miR TJU_CMC_MD2.ID00789.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00790.3p-miR TJU_CMC_MD2.ID00790.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00791.5p-miR TJU_CMC_MD2.ID00791.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00792.3p-miR TJU_CMC_MD2.ID00792.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00793.5p-miR TJU_CMC_MD2.ID00793.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00794.3p-miR TJU_CMC_MD2.ID00794.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00795.5p-miR TJU_CMC_MD2.ID00795.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00796.3p-miR TJU_CMC_MD2.ID00796.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00797.3p-miR TJU_CMC_MD2.ID00797.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00798.3p-miR TJU_CMC_MD2.ID00798.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00799.3p-miR TJU_CMC_MD2.ID00799.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00800.5p-miR TJU_CMC_MD2.ID00800.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00801.5p-miR TJU_CMC_MD2.ID00801.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00802.5p-miR TJU_CMC_MD2.ID00802.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID00803.5p-miR TJU_CMC_MD2.ID00803.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00804.3p-miR TJU_CMC_MD2.ID00804.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00805.3p-miR TJU_CMC_MD2.ID00805.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00806.5p-miR TJU_CMC_MD2.ID00806.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00807.5p-miR TJU_CMC_MD2.ID00807.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00808.3p-miR TJU_CMC_MD2.ID00808.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00809.3p-miR TJU_CMC_MD2.ID00809.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00810.3p-miR TJU_CMC_MD2.ID00810.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00810.5p-miR TJU_CMC_MD2.ID00810.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00811.3p-miR TJU_CMC_MD2.ID00811.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00812.5p-miR TJU_CMC_MD2.ID00812.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00813.5p-miR TJU_CMC_MD2.ID00813.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00814.5p-miR TJU_CMC_MD2.ID00814.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00815.5p-miR TJU_CMC_MD2.ID00815.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00816.3p-miR TJU_CMC_MD2.ID00816.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00817.3p-miR TJU_CMC_MD2.ID00817.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00818.3p-miR TJU_CMC_MD2.ID00818.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00819.3p-miR TJU_CMC_MD2.ID00819.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00820.5p-miR TJU_CMC_MD2.ID00820.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00821.3p-miR TJU_CMC_MD2.ID00821.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00822.5p-miR TJU_CMC_MD2.ID00822.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00823.3p-miR TJU_CMC_MD2.ID00823.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00824.5p-miR TJU_CMC_MD2.ID00824.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00825.3p-miR TJU_CMC_MD2.ID00825.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00826.5p-miR TJU_CMC_MD2.ID00826.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00827.3p-miR TJU_CMC_MD2.ID00827.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00828.5p-miR TJU_CMC_MD2.ID00828.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID00829.5p-miR TJU_CMC_MD2.ID00829.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00830.5p-miR TJU_CMC_MD2.ID00830.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID00831.5p-miR TJU_CMC_MD2.ID00831.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00832.5p-miR TJU_CMC_MD2.ID00832.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00833.5p-miR TJU_CMC_MD2.ID00833.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID00834.3p-miR TJU_CMC_MD2.ID00834.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00835.5p-miR TJU_CMC_MD2.ID00835.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00836.5p-miR TJU_CMC_MD2.ID00836.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00837.5p-miR TJU_CMC_MD2.ID00837.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00838.3p-miR TJU_CMC_MD2.ID00838.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00839.3p-miR TJU_CMC_MD2.ID00839.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00840.3p-miR TJU_CMC_MD2.ID00840.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00840.5p-miR TJU_CMC_MD2.ID00840.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00841.3p-miR TJU_CMC_MD2.ID00841.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00842.3p-miR TJU_CMC_MD2.ID00842.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00843.5p-miR TJU_CMC_MD2.ID00843.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00844.3p-miR TJU_CMC_MD2.ID00844.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00845.3p-miR TJU_CMC_MD2.ID00845.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00846.3p-miR TJU_CMC_MD2.ID00846.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00847.3p-miR TJU_CMC_MD2.ID00847.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00848.5p-miR TJU_CMC_MD2.ID00848.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00849.3p-miR TJU_CMC_MD2.ID00849.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00850.3p-miR TJU_CMC_MD2.ID00850.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00851.5p-miR TJU_CMC_MD2.ID00851.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00852.5p-miR TJU_CMC_MD2.ID00852.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00853.5p-miR TJU_CMC_MD2.ID00853.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00854.5p-miR TJU_CMC_MD2.ID00854.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00855.5p-miR TJU_CMC_MD2.ID00855.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00856.3p-miR TJU_CMC_MD2.ID00856.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00857.5p-miR TJU_CMC_MD2.ID00857.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00858.5p-miR TJU_CMC_MD2.ID00858.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00859.5p-miR TJU_CMC_MD2.ID00859.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00860.3p-miR TJU_CMC_MD2.ID00860.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00861.3p-miR TJU_CMC_MD2.ID00861.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00862.3p-miR TJU_CMC_MD2.ID00862.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00863.5p-miR TJU_CMC_MD2.ID00863.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00864.3p-miR TJU_CMC_MD2.ID00864.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00865.5p-miR TJU_CMC_MD2.ID00865.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00866.3p-miR TJU_CMC_MD2.ID00866.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00867.3p-miR TJU_CMC_MD2.ID00867.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00868.5p-miR TJU_CMC_MD2.ID00868.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00869.3p-miR TJU_CMC_MD2.ID00869.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00870.5p-miR TJU_CMC_MD2.ID00870.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00871.3p-miR TJU_CMC_MD2.ID00871.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00872.3p-miR TJU_CMC_MD2.ID00872.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00873.5p-miR TJU_CMC_MD2.ID00873.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00874.3p-miR TJU_CMC_MD2.ID00874.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00875.3p-miR TJU_CMC_MD2.ID00875.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00876.3p-miR TJU_CMC_MD2.ID00876.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00876.5p-miR TJU_CMC_MD2.ID00876.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00877.5p-miR TJU_CMC_MD2.ID00877.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00878.3p-miR TJU_CMC_MD2.ID00878.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00879.3p-miR TJU_CMC_MD2.ID00879.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00880.3p-miR TJU_CMC_MD2.ID00880.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00881.3p-miR TJU_CMC_MD2.ID00881.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00882.3p-miR TJU_CMC_MD2.ID00882.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00883.3p-miR TJU_CMC_MD2.ID00883.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00884.3p-miR TJU_CMC_MD2.ID00884.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00885.3p-miR TJU_CMC_MD2.ID00885.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00886.5p-miR TJU_CMC_MD2.ID00886.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00887.5p-miR TJU_CMC_MD2.ID00887.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00888.5p-miR TJU_CMC_MD2.ID00888.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00889.3p-miR TJU_CMC_MD2.ID00889.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00890.3p-miR TJU_CMC_MD2.ID00890.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00891.5p-miR TJU_CMC_MD2.ID00891.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00892.3p-miR TJU_CMC_MD2.ID00892.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00893.3p-miR TJU_CMC_MD2.ID00893.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00894.5p-miR TJU_CMC_MD2.ID00894.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00895.3p-miR TJU_CMC_MD2.ID00895.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00896.5p-miR TJU_CMC_MD2.ID00896.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00897.3p-miR TJU_CMC_MD2.ID00897.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00898.3p-miR TJU_CMC_MD2.ID00898.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00898.5p-miR TJU_CMC_MD2.ID00898.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00899.5p-miR TJU_CMC_MD2.ID00899.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00900.5p-miR TJU_CMC_MD2.ID00900.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00901.3p-miR TJU_CMC_MD2.ID00901.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00902.5p-miR TJU_CMC_MD2.ID00902.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00903.5p-miR TJU_CMC_MD2.ID00903.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00904.3p-miR TJU_CMC_MD2.ID00904.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00905.3p-miR TJU_CMC_MD2.ID00905.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00906.3p-miR TJU_CMC_MD2.ID00906.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00907.5p-miR TJU_CMC_MD2.ID00907.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00908.5p-miR TJU_CMC_MD2.ID00908.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00909.3p-miR TJU_CMC_MD2.ID00909.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00910.3p-miR TJU_CMC_MD2.ID00910.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00911.5p-miR TJU_CMC_MD2.ID00911.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00912.5p-miR TJU_CMC_MD2.ID00912.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00913.5p-miR TJU_CMC_MD2.ID00913.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00914.3p-miR TJU_CMC_MD2.ID00914.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00915.3p-miR TJU_CMC_MD2.ID00915.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00916.5p-miR TJU_CMC_MD2.ID00916.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00917.5p-miR TJU_CMC_MD2.ID00917.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00918.5p-miR TJU_CMC_MD2.ID00918.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID00919.3p-miR TJU_CMC_MD2.ID00919.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00919.5p-miR TJU_CMC_MD2.ID00919.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00920.5p-miR TJU_CMC_MD2.ID00920.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID00921.3p-miR TJU_CMC_MD2.ID00921.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00922.3p-miR TJU_CMC_MD2.ID00922.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00923.3p-miR TJU_CMC_MD2.ID00923.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00924.3p-miR TJU_CMC_MD2.ID00924.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00925.5p-miR TJU_CMC_MD2.ID00925.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00926.5p-miR TJU_CMC_MD2.ID00926.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00927.3p-miR TJU_CMC_MD2.ID00927.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00928.3p-miR TJU_CMC_MD2.ID00928.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00928.5p-miR TJU_CMC_MD2.ID00928.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00929.5p-miR TJU_CMC_MD2.ID00929.hairpin YES NO YES YES YES YES NO NO TJU_CMC_MD2.ID00930.3p-miR TJU_CMC_MD2.ID00930.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00931.3p-miR TJU_CMC_MD2.ID00931.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00932.3p-miR TJU_CMC_MD2.ID00932.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00933.3p-miR TJU_CMC_MD2.ID00933.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00934.3p-miR TJU_CMC_MD2.ID00934.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00935.5p-miR TJU_CMC_MD2.ID00935.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00936.5p-miR TJU_CMC_MD2.ID00936.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00937.5p-miR TJU_CMC_MD2.ID00937.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00938.5p-miR TJU_CMC_MD2.ID00938.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00939.5p-miR TJU_CMC_MD2.ID00939.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00940.3p-miR TJU_CMC_MD2.ID00940.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00941.3p-miR TJU_CMC_MD2.ID00941.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00942.3p-miR TJU_CMC_MD2.ID00942.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00942.5p-miR TJU_CMC_MD2.ID00942.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID00943.3p-miR TJU_CMC_MD2.ID00943.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00944.5p-miR TJU_CMC_MD2.ID00944.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00945.3p-miR TJU_CMC_MD2.ID00945.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00946.5p-miR TJU_CMC_MD2.ID00946.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00947.3p-miR TJU_CMC_MD2.ID00947.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00948.5p-miR TJU_CMC_MD2.ID00948.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID00949.3p-miR TJU_CMC_MD2.ID00949.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00950.3p-miR TJU_CMC_MD2.ID00950.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00951.5p-miR TJU_CMC_MD2.ID00951.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00952.5p-miR TJU_CMC_MD2.ID00952.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00953.5p-miR TJU_CMC_MD2.ID00953.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00954.3p-miR TJU_CMC_MD2.ID00954.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00955.3p-miR TJU_CMC_MD2.ID00955.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00956.5p-miR TJU_CMC_MD2.ID00956.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00957.5p-miR TJU_CMC_MD2.ID00957.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00958.3p-miR TJU_CMC_MD2.ID00958.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00959.3p-miR TJU_CMC_MD2.ID00959.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00960.5p-miR TJU_CMC_MD2.ID00960.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00961.3p-miR TJU_CMC_MD2.ID00961.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00962.3p-miR TJU_CMC_MD2.ID00962.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00963.3p-miR TJU_CMC_MD2.ID00963.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00964.5p-miR TJU_CMC_MD2.ID00964.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00965.3p-miR TJU_CMC_MD2.ID00965.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00966.5p-miR TJU_CMC_MD2.ID00966.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00967.5p-miR TJU_CMC_MD2.ID00967.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID00968.3p-miR TJU_CMC_MD2.ID00968.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00969.3p-miR TJU_CMC_MD2.ID00969.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00970.3p-miR TJU_CMC_MD2.ID00970.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00971.3p-miR TJU_CMC_MD2.ID00971.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00971.5p-miR TJU_CMC_MD2.ID00971.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID00972.5p-miR TJU_CMC_MD2.ID00972.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID00973.3p-miR TJU_CMC_MD2.ID00973.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00974.3p-miR TJU_CMC_MD2.ID00974.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00975.5p-miR TJU_CMC_MD2.ID00975.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00976.3p-miR TJU_CMC_MD2.ID00976.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00977.3p-miR TJU_CMC_MD2.ID00977.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00978.5p-miR TJU_CMC_MD2.ID00978.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID00979.5p-miR TJU_CMC_MD2.ID00979.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00980.3p-miR TJU_CMC_MD2.ID00980.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00981.3p-miR TJU_CMC_MD2.ID00981.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00982.3p-miR TJU_CMC_MD2.ID00982.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00983.3p-miR TJU_CMC_MD2.ID00983.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00984.5p-miR TJU_CMC_MD2.ID00984.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00985.3p-miR TJU_CMC_MD2.ID00985.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00986.5p-miR TJU_CMC_MD2.ID00986.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00987.3p-miR TJU_CMC_MD2.ID00987.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00988.3p-miR TJU_CMC_MD2.ID00988.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00989.5p-miR TJU_CMC_MD2.ID00989.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00990.5p-miR TJU_CMC_MD2.ID00990.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID00991.5p-miR TJU_CMC_MD2.ID00991.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID00992.5p-miR TJU_CMC_MD2.ID00992.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00993.5p-miR TJU_CMC_MD2.ID00993.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID00994.3p-miR TJU_CMC_MD2.ID00994.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00995.5p-miR TJU_CMC_MD2.ID00995.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID00996.5p-miR TJU_CMC_MD2.ID00996.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID00997.3p-miR TJU_CMC_MD2.ID00997.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00998.3p-miR TJU_CMC_MD2.ID00998.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID00999.3p-miR TJU_CMC_MD2.ID00999.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01000.3p-miR TJU_CMC_MD2.ID01000.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01001.3p-miR TJU_CMC_MD2.ID01001.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01002.3p-miR TJU_CMC_MD2.ID01002.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01003.3p-miR TJU_CMC_MD2.ID01003.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01004.3p-miR TJU_CMC_MD2.ID01004.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01005.5p-miR TJU_CMC_MD2.ID01005.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01006.3p-miR TJU_CMC_MD2.ID01006.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01007.5p-miR TJU_CMC_MD2.ID01007.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01008.3p-miR TJU_CMC_MD2.ID01008.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01009.5p-miR TJU_CMC_MD2.ID01009.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01010.5p-miR TJU_CMC_MD2.ID01010.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01011.5p-miR TJU_CMC_MD2.ID01011.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01012.3p-miR TJU_CMC_MD2.ID01012.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01013.3p-miR TJU_CMC_MD2.ID01013.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01014.3p-miR TJU_CMC_MD2.ID01014.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01015.3p-miR TJU_CMC_MD2.ID01015.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01016.5p-miR TJU_CMC_MD2.ID01016.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01017.3p-miR TJU_CMC_MD2.ID01017.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01018.3p-miR TJU_CMC_MD2.ID01018.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01019.3p-miR TJU_CMC_MD2.ID01019.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01020.5p-miR TJU_CMC_MD2.ID01020.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01021.3p-miR TJU_CMC_MD2.ID01021.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01022.5p-miR TJU_CMC_MD2.ID01022.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01023.3p-miR TJU_CMC_MD2.ID01023.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01023.5p-miR TJU_CMC_MD2.ID01023.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01024.5p-miR TJU_CMC_MD2.ID01024.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01025.3p-miR TJU_CMC_MD2.ID01025.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01025.5p-miR TJU_CMC_MD2.ID01025.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01026.3p-miR TJU_CMC_MD2.ID01026.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01027.5p-miR TJU_CMC_MD2.ID01027.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01028.3p-miR TJU_CMC_MD2.ID01028.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01028.5p-miR TJU_CMC_MD2.ID01028.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01029.5p-miR TJU_CMC_MD2.ID01029.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01030.3p-miR TJU_CMC_MD2.ID01030.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01031.5p-miR TJU_CMC_MD2.ID01031.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01032.3p-miR TJU_CMC_MD2.ID01032.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01033.5p-miR TJU_CMC_MD2.ID01033.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID01034.5p-miR TJU_CMC_MD2.ID01034.hairpin YES NO YES NO NO YES NO NO TJU_CMC_MD2.ID01035.3p-miR TJU_CMC_MD2.ID01035.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01036.3p-miR TJU_CMC_MD2.ID01036.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01037.5p-miR TJU_CMC_MD2.ID01037.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01038.3p-miR TJU_CMC_MD2.ID01038.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01038.5p-miR TJU_CMC_MD2.ID01038.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01039.5p-miR TJU_CMC_MD2.ID01039.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01040.5p-miR TJU_CMC_MD2.ID01040.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01041.5p-miR TJU_CMC_MD2.ID01041.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01042.5p-miR TJU_CMC_MD2.ID01042.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01043.5p-miR TJU_CMC_MD2.ID01043.hairpin YES YES NO YES YES YES NO NO TJU_CMC_MD2.ID01044.5p-miR TJU_CMC_MD2.ID01044.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01045.5p-miR TJU_CMC_MD2.ID01045.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01046.3p-miR TJU_CMC_MD2.ID01046.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01046.5p-miR TJU_CMC_MD2.ID01046.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01047.3p-miR TJU_CMC_MD2.ID01047.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01048.5p-miR TJU_CMC_MD2.ID01048.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01049.5p-miR TJU_CMC_MD2.ID01049.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01050.3p-miR TJU_CMC_MD2.ID01050.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01051.5p-miR TJU_CMC_MD2.ID01051.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01052.3p-miR TJU_CMC_MD2.ID01052.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01053.3p-miR TJU_CMC_MD2.ID01053.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01054.5p-miR TJU_CMC_MD2.ID01054.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01055.3p-miR TJU_CMC_MD2.ID01055.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01056.5p-miR TJU_CMC_MD2.ID01056.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01057.5p-miR TJU_CMC_MD2.ID01057.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01058.5p-miR TJU_CMC_MD2.ID01058.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01059.3p-miR TJU_CMC_MD2.ID01059.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01060.3p-miR TJU_CMC_MD2.ID01060.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01061.5p-miR TJU_CMC_MD2.ID01061.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01062.3p-miR TJU_CMC_MD2.ID01062.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01063.5p-miR TJU_CMC_MD2.ID01063.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01064.5p-miR TJU_CMC_MD2.ID01064.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01065.5p-miR TJU_CMC_MD2.ID01065.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01066.3p-miR TJU_CMC_MD2.ID01066.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01067.5p-miR TJU_CMC_MD2.ID01067.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01068.3p-miR TJU_CMC_MD2.ID01068.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01069.3p-miR TJU_CMC_MD2.ID01069.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01070.3p-miR TJU_CMC_MD2.ID01070.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01071.5p-miR TJU_CMC_MD2.ID01071.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01072.5p-miR TJU_CMC_MD2.ID01072.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01073.3p-miR TJU_CMC_MD2.ID01073.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01074.3p-miR TJU_CMC_MD2.ID01074.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01075.3p-miR TJU_CMC_MD2.ID01075.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01076.5p-miR TJU_CMC_MD2.ID01076.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01077.3p-miR TJU_CMC_MD2.ID01077.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01078.3p-miR TJU_CMC_MD2.ID01078.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01079.5p-miR TJU_CMC_MD2.ID01079.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01080.3p-miR TJU_CMC_MD2.ID01080.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01081.3p-miR TJU_CMC_MD2.ID01081.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01082.3p-miR TJU_CMC_MD2.ID01082.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01083.3p-miR TJU_CMC_MD2.ID01083.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01084.3p-miR TJU_CMC_MD2.ID01084.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01085.3p-miR TJU_CMC_MD2.ID01085.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01086.3p-miR TJU_CMC_MD2.ID01086.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01087.3p-miR TJU_CMC_MD2.ID01087.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01088.3p-miR TJU_CMC_MD2.ID01088.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01089.3p-miR TJU_CMC_MD2.ID01089.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01090.3p-miR TJU_CMC_MD2.ID01090.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01091.3p-miR TJU_CMC_MD2.ID01091.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01092.5p-miR TJU_CMC_MD2.ID01092.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01093.5p-miR TJU_CMC_MD2.ID01093.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01094.3p-miR TJU_CMC_MD2.ID01094.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01095.5p-miR TJU_CMC_MD2.ID01095.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01096.3p-miR TJU_CMC_MD2.ID01096.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01097.3p-miR TJU_CMC_MD2.ID01097.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01098.3p-miR TJU_CMC_MD2.ID01098.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01099.5p-miR TJU_CMC_MD2.ID01099.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01100.5p-miR TJU_CMC_MD2.ID01100.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01101.3p-miR TJU_CMC_MD2.ID01101.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01102.5p-miR TJU_CMC_MD2.ID01102.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01103.3p-miR TJU_CMC_MD2.ID01103.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01104.3p-miR TJU_CMC_MD2.ID01104.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01104.5p-miR TJU_CMC_MD2.ID01104.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01105.5p-miR TJU_CMC_MD2.ID01105.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01106.5p-miR TJU_CMC_MD2.ID01106.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01107.3p-miR TJU_CMC_MD2.ID01107.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01108.3p-miR TJU_CMC_MD2.ID01108.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01109.5p-miR TJU_CMC_MD2.ID01109.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01110.3p-miR TJU_CMC_MD2.ID01110.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01111.3p-miR TJU_CMC_MD2.ID01111.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01112.3p-miR TJU_CMC_MD2.ID01112.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01113.3p-miR TJU_CMC_MD2.ID01113.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01114.3p-miR TJU_CMC_MD2.ID01114.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01115.3p-miR TJU_CMC_MD2.ID01115.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01116.3p-miR TJU_CMC_MD2.ID01116.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01117.5p-miR TJU_CMC_MD2.ID01117.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01118.3p-miR TJU_CMC_MD2.ID01118.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01119.3p-miR TJU_CMC_MD2.ID01119.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01120.5p-miR TJU_CMC_MD2.ID01120.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01121.5p-miR TJU_CMC_MD2.ID01121.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01122.5p-miR TJU_CMC_MD2.ID01122.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01123.3p-miR TJU_CMC_MD2.ID01123.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01124.3p-miR TJU_CMC_MD2.ID01124.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01125.3p-miR TJU_CMC_MD2.ID01125.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01126.3p-miR TJU_CMC_MD2.ID01126.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01127.3p-miR TJU_CMC_MD2.ID01127.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01128.5p-miR TJU_CMC_MD2.ID01128.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01129.5p-miR TJU_CMC_MD2.ID01129.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01130.5p-miR TJU_CMC_MD2.ID01130.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01131.5p-miR TJU_CMC_MD2.ID01131.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01132.3p-miR TJU_CMC_MD2.ID01132.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01133.3p-miR TJU_CMC_MD2.ID01133.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01134.3p-miR TJU_CMC_MD2.ID01134.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01135.5p-miR TJU_CMC_MD2.ID01135.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01136.3p-miR TJU_CMC_MD2.ID01136.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01137.5p-miR TJU_CMC_MD2.ID01137.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID01138.3p-miR TJU_CMC_MD2.ID01138.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01139.3p-miR TJU_CMC_MD2.ID01139.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01140.3p-miR TJU_CMC_MD2.ID01140.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01141.5p-miR TJU_CMC_MD2.ID01141.hairpin YES YES NO NO NO YES NO NO TJU_CMC_MD2.ID01142.3p-miR TJU_CMC_MD2.ID01142.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01143.3p-miR TJU_CMC_MD2.ID01143.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01144.3p-miR TJU_CMC_MD2.ID01144.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01145.3p-miR TJU_CMC_MD2.ID01145.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01145.5p-miR TJU_CMC_MD2.ID01145.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01146.5p-miR TJU_CMC_MD2.ID01146.hairpin YES YES NO YES NO YES NO NO TJU_CMC_MD2.ID01147.3p-miR TJU_CMC_MD2.ID01147.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01148.5p-miR TJU_CMC_MD2.ID01148.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01149.3p-miR TJU_CMC_MD2.ID01149.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01150.3p-miR TJU_CMC_MD2.ID01150.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01151.3p-miR TJU_CMC_MD2.ID01151.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01152.3p-miR TJU_CMC_MD2.ID01152.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01153.3p-miR TJU_CMC_MD2.ID01153.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01154.5p-miR TJU_CMC_MD2.ID01154.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01155.5p-miR TJU_CMC_MD2.ID01155.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01156.3p-miR TJU_CMC_MD2.ID01156.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01157.5p-miR TJU_CMC_MD2.ID01157.hairpin YES YES NO NO NO YES NO NO TJU_CMC_MD2.ID01158.3p-miR TJU_CMC_MD2.ID01158.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01159.5p-miR TJU_CMC_MD2.ID01159.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID01160.3p-miR TJU_CMC_MD2.ID01160.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01161.5p-miR TJU_CMC_MD2.ID01161.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01162.3p-miR TJU_CMC_MD2.ID01162.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01163.3p-miR TJU_CMC_MD2.ID01163.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01164.3p-miR TJU_CMC_MD2.ID01164.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01165.3p-miR TJU_CMC_MD2.ID01165.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01166.3p-miR TJU_CMC_MD2.ID01166.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01167.3p-miR TJU_CMC_MD2.ID01167.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01167.5p-miR TJU_CMC_MD2.ID01167.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01168.5p-miR TJU_CMC_MD2.ID01168.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01169.5p-miR TJU_CMC_MD2.ID01169.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01170.3p-miR TJU_CMC_MD2.ID01170.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01171.3p-miR TJU_CMC_MD2.ID01171.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01172.3p-miR TJU_CMC_MD2.ID01172.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01173.3p-miR TJU_CMC_MD2.ID01173.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01174.5p-miR TJU_CMC_MD2.ID01174.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01175.3p-miR TJU_CMC_MD2.ID01175.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01176.5p-miR TJU_CMC_MD2.ID01176.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01177.5p-miR TJU_CMC_MD2.ID01177.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01178.5p-miR TJU_CMC_MD2.ID01178.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01179.3p-miR TJU_CMC_MD2.ID01179.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01180.3p-miR TJU_CMC_MD2.ID01180.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01181.3p-miR TJU_CMC_MD2.ID01181.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01181.5p-miR TJU_CMC_MD2.ID01181.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01182.5p-miR TJU_CMC_MD2.ID01182.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01183.3p-miR TJU_CMC_MD2.ID01183.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01184.3p-miR TJU_CMC_MD2.ID01184.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01185.3p-miR TJU_CMC_MD2.ID01185.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01186.3p-miR TJU_CMC_MD2.ID01186.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01187.3p-miR TJU_CMC_MD2.ID01187.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01188.3p-miR TJU_CMC_MD2.ID01188.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01188.5p-miR TJU_CMC_MD2.ID01188.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01189.5p-miR TJU_CMC_MD2.ID01189.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01190.5p-miR TJU_CMC_MD2.ID01190.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01191.5p-miR TJU_CMC_MD2.ID01191.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01192.5p-miR TJU_CMC_MD2.ID01192.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01193.3p-miR TJU_CMC_MD2.ID01193.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01194.3p-miR TJU_CMC_MD2.ID01194.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01194.5p-miR TJU_CMC_MD2.ID01194.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01195.3p-miR TJU_CMC_MD2.ID01195.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01196.3p-miR TJU_CMC_MD2.ID01196.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01197.3p-miR TJU_CMC_MD2.ID01197.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01198.3p-miR TJU_CMC_MD2.ID01198.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01198.5p-miR TJU_CMC_MD2.ID01198.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01199.5p-miR TJU_CMC_MD2.ID01199.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01200.3p-miR TJU_CMC_MD2.ID01200.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01201.5p-miR TJU_CMC_MD2.ID01201.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01202.5p-miR TJU_CMC_MD2.ID01202.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01203.3p-miR TJU_CMC_MD2.ID01203.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01204.3p-miR TJU_CMC_MD2.ID01204.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01205.5p-miR TJU_CMC_MD2.ID01205.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01206.3p-miR TJU_CMC_MD2.ID01206.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01207.3p-miR TJU_CMC_MD2.ID01207.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01208.3p-miR TJU_CMC_MD2.ID01208.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01208.5p-miR TJU_CMC_MD2.ID01208.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01209.3p-miR TJU_CMC_MD2.ID01209.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01210.3p-miR TJU_CMC_MD2.ID01210.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01211.3p-miR TJU_CMC_MD2.ID01211.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01212.5p-miR TJU_CMC_MD2.ID01212.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01213.5p-miR TJU_CMC_MD2.ID01213.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01214.5p-miR TJU_CMC_MD2.ID01214.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01215.5p-miR TJU_CMC_MD2.ID01215.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01216.3p-miR TJU_CMC_MD2.ID01216.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01217.5p-miR TJU_CMC_MD2.ID01217.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01218.3p-miR TJU_CMC_MD2.ID01218.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01219.3p-miR TJU_CMC_MD2.ID01219.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01220.5p-miR TJU_CMC_MD2.ID01220.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01221.3p-miR TJU_CMC_MD2.ID01221.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01222.3p-miR TJU_CMC_MD2.ID01222.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01223.5p-miR TJU_CMC_MD2.ID01223.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01224.5p-miR TJU_CMC_MD2.ID01224.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01225.3p-miR TJU_CMC_MD2.ID01225.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01226.5p-miR TJU_CMC_MD2.ID01226.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01227.5p-miR TJU_CMC_MD2.ID01227.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01228.3p-miR TJU_CMC_MD2.ID01228.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01229.3p-miR TJU_CMC_MD2.ID01229.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01230.3p-miR TJU_CMC_MD2.ID01230.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01231.3p-miR TJU_CMC_MD2.ID01231.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01232.3p-miR TJU_CMC_MD2.ID01232.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01233.3p-miR TJU_CMC_MD2.ID01233.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01234.3p-miR TJU_CMC_MD2.ID01234.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01235.3p-miR TJU_CMC_MD2.ID01235.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01236.5p-miR TJU_CMC_MD2.ID01236.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01237.3p-miR TJU_CMC_MD2.ID01237.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01238.5p-miR TJU_CMC_MD2.ID01238.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01239.3p-miR TJU_CMC_MD2.ID01239.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01240.5p-miR TJU_CMC_MD2.ID01240.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01241.3p-miR TJU_CMC_MD2.ID01241.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01242.3p-miR TJU_CMC_MD2.ID01242.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01243.3p-miR TJU_CMC_MD2.ID01243.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01244.3p-miR TJU_CMC_MD2.ID01244.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01245.3p-miR TJU_CMC_MD2.ID01245.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01246.3p-miR TJU_CMC_MD2.ID01246.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01247.3p-miR TJU_CMC_MD2.ID01247.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01248.3p-miR TJU_CMC_MD2.ID01248.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01249.5p-miR TJU_CMC_MD2.ID01249.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01250.3p-miR TJU_CMC_MD2.ID01250.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01250.5p-miR TJU_CMC_MD2.ID01250.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01251.3p-miR TJU_CMC_MD2.ID01251.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01252.3p-miR TJU_CMC_MD2.ID01252.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01253.3p-miR TJU_CMC_MD2.ID01253.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01254.5p-miR TJU_CMC_MD2.ID01254.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01255.5p-miR TJU_CMC_MD2.ID01255.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01256.3p-miR TJU_CMC_MD2.ID01256.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01257.3p-miR TJU_CMC_MD2.ID01257.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01258.3p-miR TJU_CMC_MD2.ID01258.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01259.3p-miR TJU_CMC_MD2.ID01259.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01260.3p-miR TJU_CMC_MD2.ID01260.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01261.5p-miR TJU_CMC_MD2.ID01261.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01262.3p-miR TJU_CMC_MD2.ID01262.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01263.5p-miR TJU_CMC_MD2.ID01263.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01264.3p-miR TJU_CMC_MD2.ID01264.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01265.3p-miR TJU_CMC_MD2.ID01265.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01266.3p-miR TJU_CMC_MD2.ID01266.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01267.3p-miR TJU_CMC_MD2.ID01267.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01268.3p-miR TJU_CMC_MD2.ID01268.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01269.3p-miR TJU_CMC_MD2.ID01269.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01270.3p-miR TJU_CMC_MD2.ID01270.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01271.3p-miR TJU_CMC_MD2.ID01271.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01272.3p-miR TJU_CMC_MD2.ID01272.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01273.3p-miR TJU_CMC_MD2.ID01273.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01273.5p-miR TJU_CMC_MD2.ID01273.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01274.5p-miR TJU_CMC_MD2.ID01274.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01275.5p-miR TJU_CMC_MD2.ID01275.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01276.5p-miR TJU_CMC_MD2.ID01276.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01277.5p-miR TJU_CMC_MD2.ID01277.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01278.3p-miR TJU_CMC_MD2.ID01278.hairpin YES NO YES NO NO YES NO NO TJU_CMC_MD2.ID01278.5p-miR TJU_CMC_MD2.ID01278.hairpin YES NO YES NO NO YES NO NO TJU_CMC_MD2.ID01279.5p-miR TJU_CMC_MD2.ID01279.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01280.3p-miR TJU_CMC_MD2.ID01280.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01281.3p-miR TJU_CMC_MD2.ID01281.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01282.3p-miR TJU_CMC_MD2.ID01282.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01283.3p-miR TJU_CMC_MD2.ID01283.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01284.3p-miR TJU_CMC_MD2.ID01284.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01285.3p-miR TJU_CMC_MD2.ID01285.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01286.3p-miR TJU_CMC_MD2.ID01286.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01287.5p-miR TJU_CMC_MD2.ID01287.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01288.3p-miR TJU_CMC_MD2.ID01288.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01289.5p-miR TJU_CMC_MD2.ID01289.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01290.3p-miR TJU_CMC_MD2.ID01290.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01291.3p-miR TJU_CMC_MD2.ID01291.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01292.5p-miR TJU_CMC_MD2.ID01292.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01293.5p-miR TJU_CMC_MD2.ID01293.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01294.3p-miR TJU_CMC_MD2.ID01294.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01295.3p-miR TJU_CMC_MD2.ID01295.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01296.5p-miR TJU_CMC_MD2.ID01296.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01297.5p-miR TJU_CMC_MD2.ID01297.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01298.5p-miR TJU_CMC_MD2.ID01298.hairpin YES NO YES NO YES YES NO NO TJU_CMC_MD2.ID01299.3p-miR TJU_CMC_MD2.ID01299.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01300.3p-miR TJU_CMC_MD2.ID01300.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01301.3p-miR TJU_CMC_MD2.ID01301.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01302.5p-miR TJU_CMC_MD2.ID01302.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01303.5p-miR TJU_CMC_MD2.ID01303.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01304.5p-miR TJU_CMC_MD2.ID01304.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01305.3p-miR TJU_CMC_MD2.ID01305.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01306.5p-miR TJU_CMC_MD2.ID01306.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01307.3p-miR TJU_CMC_MD2.ID01307.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01308.3p-miR TJU_CMC_MD2.ID01308.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01309.3p-miR TJU_CMC_MD2.ID01309.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01310.3p-miR TJU_CMC_MD2.ID01310.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01310.5p-miR TJU_CMC_MD2.ID01310.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID01311.3p-miR TJU_CMC_MD2.ID01311.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01312.5p-miR TJU_CMC_MD2.ID01312.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01313.3p-miR TJU_CMC_MD2.ID01313.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01314.5p-miR TJU_CMC_MD2.ID01314.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01315.3p-miR TJU_CMC_MD2.ID01315.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01316.5p-miR TJU_CMC_MD2.ID01316.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID01317.5p-miR TJU_CMC_MD2.ID01317.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01318.3p-miR TJU_CMC_MD2.ID01318.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01319.5p-miR TJU_CMC_MD2.ID01319.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01320.3p-miR TJU_CMC_MD2.ID01320.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01321.5p-miR TJU_CMC_MD2.ID01321.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01322.3p-miR TJU_CMC_MD2.ID01322.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01322.5p-miR TJU_CMC_MD2.ID01322.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01323.3p-miR TJU_CMC_MD2.ID01323.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01324.5p-miR TJU_CMC_MD2.ID01324.hairpin YES NO NO YES NO YES NO NO TJU_CMC_MD2.ID01325.3p-miR TJU_CMC_MD2.ID01325.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01326.3p-miR TJU_CMC_MD2.ID01326.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01326.5p-miR TJU_CMC_MD2.ID01326.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01327.3p-miR TJU_CMC_MD2.ID01327.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01328.3p-miR TJU_CMC_MD2.ID01328.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01329.3p-miR TJU_CMC_MD2.ID01329.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01330.3p-miR TJU_CMC_MD2.ID01330.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01331.3p-miR TJU_CMC_MD2.ID01331.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01332.3p-miR TJU_CMC_MD2.ID01332.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01333.3p-miR TJU_CMC_MD2.ID01333.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01334.3p-miR TJU_CMC_MD2.ID01334.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01334.5p-miR TJU_CMC_MD2.ID01334.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01335.3p-miR TJU_CMC_MD2.ID01335.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01336.3p-miR TJU_CMC_MD2.ID01336.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01337.3p-miR TJU_CMC_MD2.ID01337.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01338.5p-miR TJU_CMC_MD2.ID01338.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01339.5p-miR TJU_CMC_MD2.ID01339.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01340.5p-miR TJU_CMC_MD2.ID01340.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01341.5p-miR TJU_CMC_MD2.ID01341.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01342.5p-miR TJU_CMC_MD2.ID01342.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01343.5p-miR TJU_CMC_MD2.ID01343.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01344.3p-miR TJU_CMC_MD2.ID01344.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01345.3p-miR TJU_CMC_MD2.ID01345.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01346.3p-miR TJU_CMC_MD2.ID01346.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01347.3p-miR TJU_CMC_MD2.ID01347.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01348.3p-miR TJU_CMC_MD2.ID01348.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01349.3p-miR TJU_CMC_MD2.ID01349.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01349.5p-miR TJU_CMC_MD2.ID01349.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01350.3p-miR TJU_CMC_MD2.ID01350.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01351.3p-miR TJU_CMC_MD2.ID01351.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01351.5p-miR TJU_CMC_MD2.ID01351.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01352.3p-miR TJU_CMC_MD2.ID01352.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01353.3p-miR TJU_CMC_MD2.ID01353.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01354.3p-miR TJU_CMC_MD2.ID01354.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01355.3p-miR TJU_CMC_MD2.ID01355.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01356.3p-miR TJU_CMC_MD2.ID01356.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01357.5p-miR TJU_CMC_MD2.ID01357.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01358.5p-miR TJU_CMC_MD2.ID01358.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID01359.5p-miR TJU_CMC_MD2.ID01359.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01360.3p-miR TJU_CMC_MD2.ID01360.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01361.5p-miR TJU_CMC_MD2.ID01361.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01362.5p-miR TJU_CMC_MD2.ID01362.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01363.3p-miR TJU_CMC_MD2.ID01363.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01364.3p-miR TJU_CMC_MD2.ID01364.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01365.3p-miR TJU_CMC_MD2.ID01365.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01366.5p-miR TJU_CMC_MD2.ID01366.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01367.5p-miR TJU_CMC_MD2.ID01367.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01368.3p-miR TJU_CMC_MD2.ID01368.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01369.3p-miR TJU_CMC_MD2.ID01369.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01370.5p-miR TJU_CMC_MD2.ID01370.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01371.3p-miR TJU_CMC_MD2.ID01371.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01371.5p-miR TJU_CMC_MD2.ID01371.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID01372.3p-miR TJU_CMC_MD2.ID01372.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01373.3p-miR TJU_CMC_MD2.ID01373.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01374.3p-miR TJU_CMC_MD2.ID01374.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01375.5p-miR TJU_CMC_MD2.ID01375.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01376.5p-miR TJU_CMC_MD2.ID01376.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01377.3p-miR TJU_CMC_MD2.ID01377.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01378.5p-miR TJU_CMC_MD2.ID01378.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01379.3p-miR TJU_CMC_MD2.ID01379.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01380.3p-miR TJU_CMC_MD2.ID01380.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01381.3p-miR TJU_CMC_MD2.ID01381.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01382.3p-miR TJU_CMC_MD2.ID01382.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01383.3p-miR TJU_CMC_MD2.ID01383.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01384.5p-miR TJU_CMC_MD2.ID01384.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01385.5p-miR TJU_CMC_MD2.ID01385.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01386.5p-miR TJU_CMC_MD2.ID01386.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID01387.3p-miR TJU_CMC_MD2.ID01387.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01388.5p-miR TJU_CMC_MD2.ID01388.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01389.5p-miR TJU_CMC_MD2.ID01389.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01390.3p-miR TJU_CMC_MD2.ID01390.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01391.3p-miR TJU_CMC_MD2.ID01391.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01392.3p-miR TJU_CMC_MD2.ID01392.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01393.3p-miR TJU_CMC_MD2.ID01393.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01394.5p-miR TJU_CMC_MD2.ID01394.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01395.5p-miR TJU_CMC_MD2.ID01395.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01396.3p-miR TJU_CMC_MD2.ID01396.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01397.5p-miR TJU_CMC_MD2.ID01397.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01398.3p-miR TJU_CMC_MD2.ID01398.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01399.3p-miR TJU_CMC_MD2.ID01399.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01400.3p-miR TJU_CMC_MD2.ID01400.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01401.3p-miR TJU_CMC_MD2.ID01401.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01402.5p-miR TJU_CMC_MD2.ID01402.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01403.5p-miR TJU_CMC_MD2.ID01403.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01404.5p-miR TJU_CMC_MD2.ID01404.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01405.5p-miR TJU_CMC_MD2.ID01405.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01406.5p-miR TJU_CMC_MD2.ID01406.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01407.3p-miR TJU_CMC_MD2.ID01407.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01408.3p-miR TJU_CMC_MD2.ID01408.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01408.5p-miR TJU_CMC_MD2.ID01408.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01409.3p-miR TJU_CMC_MD2.ID01409.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01410.5p-miR TJU_CMC_MD2.ID01410.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01411.3p-miR TJU_CMC_MD2.ID01411.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01412.5p-miR TJU_CMC_MD2.ID01412.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01413.3p-miR TJU_CMC_MD2.ID01413.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01414.3p-miR TJU_CMC_MD2.ID01414.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01415.3p-miR TJU_CMC_MD2.ID01415.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01415.5p-miR TJU_CMC_MD2.ID01415.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01416.3p-miR TJU_CMC_MD2.ID01416.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01417.3p-miR TJU_CMC_MD2.ID01417.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01418.3p-miR TJU_CMC_MD2.ID01418.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01419.3p-miR TJU_CMC_MD2.ID01419.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01420.3p-miR TJU_CMC_MD2.ID01420.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01421.3p-miR TJU_CMC_MD2.ID01421.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01422.3p-miR TJU_CMC_MD2.ID01422.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01423.3p-miR TJU_CMC_MD2.ID01423.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01424.5p-miR TJU_CMC_MD2.ID01424.hairpin YES YES NO NO NO YES NO NO TJU_CMC_MD2.ID01425.3p-miR TJU_CMC_MD2.ID01425.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01426.5p-miR TJU_CMC_MD2.ID01426.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01427.3p-miR TJU_CMC_MD2.ID01427.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01428.3p-miR TJU_CMC_MD2.ID01428.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01429.5p-miR TJU_CMC_MD2.ID01429.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01430.3p-miR TJU_CMC_MD2.ID01430.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01431.3p-miR TJU_CMC_MD2.ID01431.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01432.3p-miR TJU_CMC_MD2.ID01432.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01433.5p-miR TJU_CMC_MD2.ID01433.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01434.5p-miR TJU_CMC_MD2.ID01434.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01435.3p-miR TJU_CMC_MD2.ID01435.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01436.3p-miR TJU_CMC_MD2.ID01436.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01436.5p-miR TJU_CMC_MD2.ID01436.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01437.5p-miR TJU_CMC_MD2.ID01437.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01438.3p-miR TJU_CMC_MD2.ID01438.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01439.3p-miR TJU_CMC_MD2.ID01439.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01440.3p-miR TJU_CMC_MD2.ID01440.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01441.5p-miR TJU_CMC_MD2.ID01441.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01442.3p-miR TJU_CMC_MD2.ID01442.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01443.3p-miR TJU_CMC_MD2.ID01443.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01444.5p-miR TJU_CMC_MD2.ID01444.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01445.3p-miR TJU_CMC_MD2.ID01445.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01446.5p-miR TJU_CMC_MD2.ID01446.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01447.5p-miR TJU_CMC_MD2.ID01447.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01448.5p-miR TJU_CMC_MD2.ID01448.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01449.3p-miR TJU_CMC_MD2.ID01449.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01450.5p-miR TJU_CMC_MD2.ID01450.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01451.3p-miR TJU_CMC_MD2.ID01451.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01452.3p-miR TJU_CMC_MD2.ID01452.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01453.3p-miR TJU_CMC_MD2.ID01453.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01454.3p-miR TJU_CMC_MD2.ID01454.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01455.5p-miR TJU_CMC_MD2.ID01455.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01456.3p-miR TJU_CMC_MD2.ID01456.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01457.3p-miR TJU_CMC_MD2.ID01457.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01458.5p-miR TJU_CMC_MD2.ID01458.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01459.3p-miR TJU_CMC_MD2.ID01459.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01460.3p-miR TJU_CMC_MD2.ID01460.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01461.3p-miR TJU_CMC_MD2.ID01461.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01462.3p-miR TJU_CMC_MD2.ID01462.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01463.3p-miR TJU_CMC_MD2.ID01463.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01464.5p-miR TJU_CMC_MD2.ID01464.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01465.5p-miR TJU_CMC_MD2.ID01465.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01466.3p-miR TJU_CMC_MD2.ID01466.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01467.3p-miR TJU_CMC_MD2.ID01467.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01468.3p-miR TJU_CMC_MD2.ID01468.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01469.5p-miR TJU_CMC_MD2.ID01469.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01470.3p-miR TJU_CMC_MD2.ID01470.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01471.5p-miR TJU_CMC_MD2.ID01471.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01472.3p-miR TJU_CMC_MD2.ID01472.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01473.3p-miR TJU_CMC_MD2.ID01473.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01474.3p-miR TJU_CMC_MD2.ID01474.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01475.5p-miR TJU_CMC_MD2.ID01475.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID01476.3p-miR TJU_CMC_MD2.ID01476.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01477.5p-miR TJU_CMC_MD2.ID01477.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01478.3p-miR TJU_CMC_MD2.ID01478.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01479.5p-miR TJU_CMC_MD2.ID01479.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01480.5p-miR TJU_CMC_MD2.ID01480.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01481.5p-miR TJU_CMC_MD2.ID01481.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01482.5p-miR TJU_CMC_MD2.ID01482.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01483.5p-miR TJU_CMC_MD2.ID01483.hairpin YES YES YES NO YES YES NO NO TJU_CMC_MD2.ID01484.3p-miR TJU_CMC_MD2.ID01484.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01485.5p-miR TJU_CMC_MD2.ID01485.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01486.3p-miR TJU_CMC_MD2.ID01486.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01487.3p-miR TJU_CMC_MD2.ID01487.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01488.5p-miR TJU_CMC_MD2.ID01488.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01489.3p-miR TJU_CMC_MD2.ID01489.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01490.3p-miR TJU_CMC_MD2.ID01490.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01491.3p-miR TJU_CMC_MD2.ID01491.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01492.3p-miR TJU_CMC_MD2.ID01492.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01493.3p-miR TJU_CMC_MD2.ID01493.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01494.5p-miR TJU_CMC_MD2.ID01494.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01495.3p-miR TJU_CMC_MD2.ID01495.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01496.3p-miR TJU_CMC_MD2.ID01496.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01497.5p-miR TJU_CMC_MD2.ID01497.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01498.3p-miR TJU_CMC_MD2.ID01498.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01499.5p-miR TJU_CMC_MD2.ID01499.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01500.3p-miR TJU_CMC_MD2.ID01500.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01501.5p-miR TJU_CMC_MD2.ID01501.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01502.3p-miR TJU_CMC_MD2.ID01502.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01503.3p-miR TJU_CMC_MD2.ID01503.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01504.3p-miR TJU_CMC_MD2.ID01504.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01505.3p-miR TJU_CMC_MD2.ID01505.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01505.5p-miR TJU_CMC_MD2.ID01505.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01506.3p-miR TJU_CMC_MD2.ID01506.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01507.5p-miR TJU_CMC_MD2.ID01507.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01508.5p-miR TJU_CMC_MD2.ID01508.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01509.3p-miR TJU_CMC_MD2.ID01509.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01510.3p-miR TJU_CMC_MD2.ID01510.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01511.5p-miR TJU_CMC_MD2.ID01511.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01512.3p-miR TJU_CMC_MD2.ID01512.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01513.5p-miR TJU_CMC_MD2.ID01513.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01514.3p-miR TJU_CMC_MD2.ID01514.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01515.3p-miR TJU_CMC_MD2.ID01515.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01516.3p-miR TJU_CMC_MD2.ID01516.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01517.3p-miR TJU_CMC_MD2.ID01517.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01518.3p-miR TJU_CMC_MD2.ID01518.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01519.5p-miR TJU_CMC_MD2.ID01519.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01520.3p-miR TJU_CMC_MD2.ID01520.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01521.3p-miR TJU_CMC_MD2.ID01521.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01522.3p-miR TJU_CMC_MD2.ID01522.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01523.3p-miR TJU_CMC_MD2.ID01523.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01524.3p-miR TJU_CMC_MD2.ID01524.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01525.3p-miR TJU_CMC_MD2.ID01525.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01526.3p-miR TJU_CMC_MD2.ID01526.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01527.3p-miR TJU_CMC_MD2.ID01527.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01528.3p-miR TJU_CMC_MD2.ID01528.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01529.5p-miR TJU_CMC_MD2.ID01529.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01530.5p-miR TJU_CMC_MD2.ID01530.hairpin YES YES YES NO NO YES NO NO TJU_CMC_MD2.ID01531.3p-miR TJU_CMC_MD2.ID01531.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01532.3p-miR TJU_CMC_MD2.ID01532.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01533.3p-miR TJU_CMC_MD2.ID01533.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01534.3p-miR TJU_CMC_MD2.ID01534.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01535.3p-miR TJU_CMC_MD2.ID01535.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01536.3p-miR TJU_CMC_MD2.ID01536.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01537.3p-miR TJU_CMC_MD2.ID01537.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01538.3p-miR TJU_CMC_MD2.ID01538.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01539.3p-miR TJU_CMC_MD2.ID01539.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01540.3p-miR TJU_CMC_MD2.ID01540.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01541.3p-miR TJU_CMC_MD2.ID01541.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01542.3p-miR TJU_CMC_MD2.ID01542.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01543.3p-miR TJU_CMC_MD2.ID01543.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01544.3p-miR TJU_CMC_MD2.ID01544.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01545.3p-miR TJU_CMC_MD2.ID01545.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01546.5p-miR TJU_CMC_MD2.ID01546.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01547.3p-miR TJU_CMC_MD2.ID01547.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01548.5p-miR TJU_CMC_MD2.ID01548.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01549.5p-miR TJU_CMC_MD2.ID01549.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01550.3p-miR TJU_CMC_MD2.ID01550.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01551.3p-miR TJU_CMC_MD2.ID01551.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01552.5p-miR TJU_CMC_MD2.ID01552.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01553.3p-miR TJU_CMC_MD2.ID01553.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01554.3p-miR TJU_CMC_MD2.ID01554.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01555.5p-miR TJU_CMC_MD2.ID01555.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01556.3p-miR TJU_CMC_MD2.ID01556.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01557.5p-miR TJU_CMC_MD2.ID01557.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01558.3p-miR TJU_CMC_MD2.ID01558.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01559.3p-miR TJU_CMC_MD2.ID01559.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01560.3p-miR TJU_CMC_MD2.ID01560.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01561.3p-miR TJU_CMC_MD2.ID01561.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01562.3p-miR TJU_CMC_MD2.ID01562.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01563.5p-miR TJU_CMC_MD2.ID01563.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01564.3p-miR TJU_CMC_MD2.ID01564.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01565.5p-miR TJU_CMC_MD2.ID01565.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01566.3p-miR TJU_CMC_MD2.ID01566.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01567.5p-miR TJU_CMC_MD2.ID01567.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01568.3p-miR TJU_CMC_MD2.ID01568.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01569.3p-miR TJU_CMC_MD2.ID01569.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01570.3p-miR TJU_CMC_MD2.ID01570.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01571.3p-miR TJU_CMC_MD2.ID01571.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01572.5p-miR TJU_CMC_MD2.ID01572.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01573.5p-miR TJU_CMC_MD2.ID01573.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01574.5p-miR TJU_CMC_MD2.ID01574.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01575.5p-miR TJU_CMC_MD2.ID01575.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01576.3p-miR TJU_CMC_MD2.ID01576.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01577.3p-miR TJU_CMC_MD2.ID01577.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01578.5p-miR TJU_CMC_MD2.ID01578.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01579.5p-miR TJU_CMC_MD2.ID01579.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01580.3p-miR TJU_CMC_MD2.ID01580.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01581.5p-miR TJU_CMC_MD2.ID01581.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01582.3p-miR TJU_CMC_MD2.ID01582.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01583.3p-miR TJU_CMC_MD2.ID01583.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01584.3p-miR TJU_CMC_MD2.ID01584.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01585.3p-miR TJU_CMC_MD2.ID01585.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01586.3p-miR TJU_CMC_MD2.ID01586.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01587.3p-miR TJU_CMC_MD2.ID01587.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01587.5p-miR TJU_CMC_MD2.ID01587.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01588.3p-miR TJU_CMC_MD2.ID01588.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01589.3p-miR TJU_CMC_MD2.ID01589.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01590.3p-miR TJU_CMC_MD2.ID01590.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01591.3p-miR TJU_CMC_MD2.ID01591.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01592.3p-miR TJU_CMC_MD2.ID01592.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01593.5p-miR TJU_CMC_MD2.ID01593.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01594.3p-miR TJU_CMC_MD2.ID01594.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01595.3p-miR TJU_CMC_MD2.ID01595.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01596.5p-miR TJU_CMC_MD2.ID01596.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01597.3p-miR TJU_CMC_MD2.ID01597.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01598.3p-miR TJU_CMC_MD2.ID01598.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01599.3p-miR TJU_CMC_MD2.ID01599.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01600.3p-miR TJU_CMC_MD2.ID01600.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01601.3p-miR TJU_CMC_MD2.ID01601.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01602.5p-miR TJU_CMC_MD2.ID01602.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01603.3p-miR TJU_CMC_MD2.ID01603.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01604.3p-miR TJU_CMC_MD2.ID01604.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01605.3p-miR TJU_CMC_MD2.ID01605.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01606.3p-miR TJU_CMC_MD2.ID01606.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01607.3p-miR TJU_CMC_MD2.ID01607.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01607.5p-miR TJU_CMC_MD2.ID01607.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01608.3p-miR TJU_CMC_MD2.ID01608.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01609.5p-miR TJU_CMC_MD2.ID01609.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01610.5p-miR TJU_CMC_MD2.ID01610.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01611.5p-miR TJU_CMC_MD2.ID01611.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01612.3p-miR TJU_CMC_MD2.ID01612.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01613.3p-miR TJU_CMC_MD2.ID01613.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01613.5p-miR TJU_CMC_MD2.ID01613.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01614.5p-miR TJU_CMC_MD2.ID01614.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01615.3p-miR TJU_CMC_MD2.ID01615.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01616.3p-miR TJU_CMC_MD2.ID01616.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01617.3p-miR TJU_CMC_MD2.ID01617.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01618.3p-miR TJU_CMC_MD2.ID01618.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01619.3p-miR TJU_CMC_MD2.ID01619.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01620.3p-miR TJU_CMC_MD2.ID01620.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01621.3p-miR TJU_CMC_MD2.ID01621.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01622.3p-miR TJU_CMC_MD2.ID01622.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01623.3p-miR TJU_CMC_MD2.ID01623.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01624.5p-miR TJU_CMC_MD2.ID01624.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID01625.3p-miR TJU_CMC_MD2.ID01625.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01626.3p-miR TJU_CMC_MD2.ID01626.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01627.5p-miR TJU_CMC_MD2.ID01627.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01628.5p-miR TJU_CMC_MD2.ID01628.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01629.5p-miR TJU_CMC_MD2.ID01629.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01630.5p-miR TJU_CMC_MD2.ID01630.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01631.3p-miR TJU_CMC_MD2.ID01631.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01632.5p-miR TJU_CMC_MD2.ID01632.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01633.3p-miR TJU_CMC_MD2.ID01633.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01634.3p-miR TJU_CMC_MD2.ID01634.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01635.3p-miR TJU_CMC_MD2.ID01635.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01636.5p-miR TJU_CMC_MD2.ID01636.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01637.3p-miR TJU_CMC_MD2.ID01637.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01638.3p-miR TJU_CMC_MD2.ID01638.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01639.5p-miR TJU_CMC_MD2.ID01639.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01640.5p-miR TJU_CMC_MD2.ID01640.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01641.3p-miR TJU_CMC_MD2.ID01641.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01642.3p-miR TJU_CMC_MD2.ID01642.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01642.5p-miR TJU_CMC_MD2.ID01642.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01643.3p-miR TJU_CMC_MD2.ID01643.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01644.3p-miR TJU_CMC_MD2.ID01644.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01645.5p-miR TJU_CMC_MD2.ID01645.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01646.3p-miR TJU_CMC_MD2.ID01646.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01646.5p-miR TJU_CMC_MD2.ID01646.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01647.5p-miR TJU_CMC_MD2.ID01647.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01648.3p-miR TJU_CMC_MD2.ID01648.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01648.5p-miR TJU_CMC_MD2.ID01648.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01649.5p-miR TJU_CMC_MD2.ID01649.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01650.3p-miR TJU_CMC_MD2.ID01650.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01651.5p-miR TJU_CMC_MD2.ID01651.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01652.3p-miR TJU_CMC_MD2.ID01652.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01653.5p-miR TJU_CMC_MD2.ID01653.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01654.3p-miR TJU_CMC_MD2.ID01654.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01655.3p-miR TJU_CMC_MD2.ID01655.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01656.3p-miR TJU_CMC_MD2.ID01656.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01657.5p-miR TJU_CMC_MD2.ID01657.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01658.3p-miR TJU_CMC_MD2.ID01658.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01659.3p-miR TJU_CMC_MD2.ID01659.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01660.3p-miR TJU_CMC_MD2.ID01660.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01661.3p-miR TJU_CMC_MD2.ID01661.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01662.3p-miR TJU_CMC_MD2.ID01662.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01663.3p-miR TJU_CMC_MD2.ID01663.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01664.3p-miR TJU_CMC_MD2.ID01664.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01664.5p-miR TJU_CMC_MD2.ID01664.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01665.3p-miR TJU_CMC_MD2.ID01665.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01666.3p-miR TJU_CMC_MD2.ID01666.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01666.5p-miR TJU_CMC_MD2.ID01666.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01667.3p-miR TJU_CMC_MD2.ID01667.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01668.5p-miR TJU_CMC_MD2.ID01668.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01669.3p-miR TJU_CMC_MD2.ID01669.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01670.5p-miR TJU_CMC_MD2.ID01670.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01671.3p-miR TJU_CMC_MD2.ID01671.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01672.5p-miR TJU_CMC_MD2.ID01672.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01673.3p-miR TJU_CMC_MD2.ID01673.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01674.3p-miR TJU_CMC_MD2.ID01674.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01674.5p-miR TJU_CMC_MD2.ID01674.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01675.5p-miR TJU_CMC_MD2.ID01675.hairpin YES YES YES NO NO YES NO NO TJU_CMC_MD2.ID01676.3p-miR TJU_CMC_MD2.ID01676.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01677.3p-miR TJU_CMC_MD2.ID01677.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01678.5p-miR TJU_CMC_MD2.ID01678.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01679.5p-miR TJU_CMC_MD2.ID01679.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01680.3p-miR TJU_CMC_MD2.ID01680.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01680.5p-miR TJU_CMC_MD2.ID01680.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID01681.3p-miR TJU_CMC_MD2.ID01681.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01682.3p-miR TJU_CMC_MD2.ID01682.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01683.5p-miR TJU_CMC_MD2.ID01683.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01684.3p-miR TJU_CMC_MD2.ID01684.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01685.5p-miR TJU_CMC_MD2.ID01685.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01686.5p-miR TJU_CMC_MD2.ID01686.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID01687.3p-miR TJU_CMC_MD2.ID01687.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01688.3p-miR TJU_CMC_MD2.ID01688.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01689.3p-miR TJU_CMC_MD2.ID01689.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01690.3p-miR TJU_CMC_MD2.ID01690.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01691.5p-miR TJU_CMC_MD2.ID01691.hairpin YES YES NO YES NO YES NO NO TJU_CMC_MD2.ID01692.3p-miR TJU_CMC_MD2.ID01692.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01692.5p-miR TJU_CMC_MD2.ID01692.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01693.5p-miR TJU_CMC_MD2.ID01693.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01694.5p-miR TJU_CMC_MD2.ID01694.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01695.3p-miR TJU_CMC_MD2.ID01695.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01696.3p-miR TJU_CMC_MD2.ID01696.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01697.5p-miR TJU_CMC_MD2.ID01697.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01698.3p-miR TJU_CMC_MD2.ID01698.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01699.5p-miR TJU_CMC_MD2.ID01699.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01700.3p-miR TJU_CMC_MD2.ID01700.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01701.3p-miR TJU_CMC_MD2.ID01701.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01702.3p-miR TJU_CMC_MD2.ID01702.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01703.3p-miR TJU_CMC_MD2.ID01703.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01704.5p-miR TJU_CMC_MD2.ID01704.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01705.3p-miR TJU_CMC_MD2.ID01705.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01706.3p-miR TJU_CMC_MD2.ID01706.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01707.5p-miR TJU_CMC_MD2.ID01707.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01708.5p-miR TJU_CMC_MD2.ID01708.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01709.3p-miR TJU_CMC_MD2.ID01709.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01710.3p-miR TJU_CMC_MD2.ID01710.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01711.3p-miR TJU_CMC_MD2.ID01711.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01712.5p-miR TJU_CMC_MD2.ID01712.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01713.5p-miR TJU_CMC_MD2.ID01713.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01714.3p-miR TJU_CMC_MD2.ID01714.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01715.3p-miR TJU_CMC_MD2.ID01715.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01716.3p-miR TJU_CMC_MD2.ID01716.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01717.3p-miR TJU_CMC_MD2.ID01717.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01718.3p-miR TJU_CMC_MD2.ID01718.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01719.3p-miR TJU_CMC_MD2.ID01719.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01720.5p-miR TJU_CMC_MD2.ID01720.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01721.3p-miR TJU_CMC_MD2.ID01721.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01722.3p-miR TJU_CMC_MD2.ID01722.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01723.5p-miR TJU_CMC_MD2.ID01723.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01724.3p-miR TJU_CMC_MD2.ID01724.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01725.3p-miR TJU_CMC_MD2.ID01725.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01726.3p-miR TJU_CMC_MD2.ID01726.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01727.5p-miR TJU_CMC_MD2.ID01727.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01728.3p-miR TJU_CMC_MD2.ID01728.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01729.3p-miR TJU_CMC_MD2.ID01729.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01730.3p-miR TJU_CMC_MD2.ID01730.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01731.5p-miR TJU_CMC_MD2.ID01731.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01732.3p-miR TJU_CMC_MD2.ID01732.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01733.3p-miR TJU_CMC_MD2.ID01733.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01734.5p-miR TJU_CMC_MD2.ID01734.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01735.3p-miR TJU_CMC_MD2.ID01735.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01736.3p-miR TJU_CMC_MD2.ID01736.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01737.3p-miR TJU_CMC_MD2.ID01737.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01738.5p-miR TJU_CMC_MD2.ID01738.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01739.3p-miR TJU_CMC_MD2.ID01739.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01740.5p-miR TJU_CMC_MD2.ID01740.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01741.5p-miR TJU_CMC_MD2.ID01741.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01742.3p-miR TJU_CMC_MD2.ID01742.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01743.5p-miR TJU_CMC_MD2.ID01743.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01744.3p-miR TJU_CMC_MD2.ID01744.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01745.3p-miR TJU_CMC_MD2.ID01745.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01746.3p-miR TJU_CMC_MD2.ID01746.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01747.5p-miR TJU_CMC_MD2.ID01747.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01748.3p-miR TJU_CMC_MD2.ID01748.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01749.3p-miR TJU_CMC_MD2.ID01749.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01750.5p-miR TJU_CMC_MD2.ID01750.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01751.5p-miR TJU_CMC_MD2.ID01751.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01752.5p-miR TJU_CMC_MD2.ID01752.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01753.3p-miR TJU_CMC_MD2.ID01753.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01754.3p-miR TJU_CMC_MD2.ID01754.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01755.3p-miR TJU_CMC_MD2.ID01755.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01756.5p-miR TJU_CMC_MD2.ID01756.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01757.3p-miR TJU_CMC_MD2.ID01757.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01758.3p-miR TJU_CMC_MD2.ID01758.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01759.3p-miR TJU_CMC_MD2.ID01759.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01760.3p-miR TJU_CMC_MD2.ID01760.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01761.3p-miR TJU_CMC_MD2.ID01761.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01762.5p-miR TJU_CMC_MD2.ID01762.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01763.5p-miR TJU_CMC_MD2.ID01763.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01764.5p-miR TJU_CMC_MD2.ID01764.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01765.3p-miR TJU_CMC_MD2.ID01765.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01766.5p-miR TJU_CMC_MD2.ID01766.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01767.5p-miR TJU_CMC_MD2.ID01767.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01768.3p-miR TJU_CMC_MD2.ID01768.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01769.5p-miR TJU_CMC_MD2.ID01769.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID01770.3p-miR TJU_CMC_MD2.ID01770.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01771.5p-miR TJU_CMC_MD2.ID01771.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID01772.3p-miR TJU_CMC_MD2.ID01772.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01772.5p-miR TJU_CMC_MD2.ID01772.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01773.3p-miR TJU_CMC_MD2.ID01773.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01774.5p-miR TJU_CMC_MD2.ID01774.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01775.3p-miR TJU_CMC_MD2.ID01775.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01776.3p-miR TJU_CMC_MD2.ID01776.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01777.3p-miR TJU_CMC_MD2.ID01777.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01778.3p-miR TJU_CMC_MD2.ID01778.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01779.3p-miR TJU_CMC_MD2.ID01779.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01780.5p-miR TJU_CMC_MD2.ID01780.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01781.5p-miR TJU_CMC_MD2.ID01781.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01782.3p-miR TJU_CMC_MD2.ID01782.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01783.3p-miR TJU_CMC_MD2.ID01783.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01784.5p-miR TJU_CMC_MD2.ID01784.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01785.3p-miR TJU_CMC_MD2.ID01785.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01786.5p-miR TJU_CMC_MD2.ID01786.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01787.3p-miR TJU_CMC_MD2.ID01787.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01788.3p-miR TJU_CMC_MD2.ID01788.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01789.3p-miR TJU_CMC_MD2.ID01789.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01790.5p-miR TJU_CMC_MD2.ID01790.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01791.3p-miR TJU_CMC_MD2.ID01791.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01792.5p-miR TJU_CMC_MD2.ID01792.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01793.3p-miR TJU_CMC_MD2.ID01793.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01793.5p-miR TJU_CMC_MD2.ID01793.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01794.5p-miR TJU_CMC_MD2.ID01794.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01795.5p-miR TJU_CMC_MD2.ID01795.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01796.3p-miR TJU_CMC_MD2.ID01796.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01797.3p-miR TJU_CMC_MD2.ID01797.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01798.3p-miR TJU_CMC_MD2.ID01798.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01799.5p-miR TJU_CMC_MD2.ID01799.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01800.5p-miR TJU_CMC_MD2.ID01800.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01801.3p-miR TJU_CMC_MD2.ID01801.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01801.5p-miR TJU_CMC_MD2.ID01801.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01802.5p-miR TJU_CMC_MD2.ID01802.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01803.5p-miR TJU_CMC_MD2.ID01803.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01804.3p-miR TJU_CMC_MD2.ID01804.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01805.3p-miR TJU_CMC_MD2.ID01805.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01805.5p-miR TJU_CMC_MD2.ID01805.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01806.3p-miR TJU_CMC_MD2.ID01806.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01807.3p-miR TJU_CMC_MD2.ID01807.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01808.5p-miR TJU_CMC_MD2.ID01808.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01809.3p-miR TJU_CMC_MD2.ID01809.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01810.3p-miR TJU_CMC_MD2.ID01810.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01811.5p-miR TJU_CMC_MD2.ID01811.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01812.5p-miR TJU_CMC_MD2.ID01812.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01813.3p-miR TJU_CMC_MD2.ID01813.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01813.5p-miR TJU_CMC_MD2.ID01813.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01814.3p-miR TJU_CMC_MD2.ID01814.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01815.5p-miR TJU_CMC_MD2.ID01815.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01816.3p-miR TJU_CMC_MD2.ID01816.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01817.3p-miR TJU_CMC_MD2.ID01817.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01818.3p-miR TJU_CMC_MD2.ID01818.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01819.5p-miR TJU_CMC_MD2.ID01819.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01820.3p-miR TJU_CMC_MD2.ID01820.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01821.3p-miR TJU_CMC_MD2.ID01821.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01822.3p-miR TJU_CMC_MD2.ID01822.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01822.5p-miR TJU_CMC_MD2.ID01822.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01823.5p-miR TJU_CMC_MD2.ID01823.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01824.3p-miR TJU_CMC_MD2.ID01824.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01825.3p-miR TJU_CMC_MD2.ID01825.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01826.3p-miR TJU_CMC_MD2.ID01826.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01826.5p-miR TJU_CMC_MD2.ID01826.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01827.3p-miR TJU_CMC_MD2.ID01827.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01828.3p-miR TJU_CMC_MD2.ID01828.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01829.5p-miR TJU_CMC_MD2.ID01829.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01830.5p-miR TJU_CMC_MD2.ID01830.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01831.3p-miR TJU_CMC_MD2.ID01831.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01832.5p-miR TJU_CMC_MD2.ID01832.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01833.3p-miR TJU_CMC_MD2.ID01833.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01834.5p-miR TJU_CMC_MD2.ID01834.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01835.3p-miR TJU_CMC_MD2.ID01835.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01836.5p-miR TJU_CMC_MD2.ID01836.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID01837.3p-miR TJU_CMC_MD2.ID01837.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01838.5p-miR TJU_CMC_MD2.ID01838.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01839.3p-miR TJU_CMC_MD2.ID01839.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01840.5p-miR TJU_CMC_MD2.ID01840.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01841.3p-miR TJU_CMC_MD2.ID01841.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01842.3p-miR TJU_CMC_MD2.ID01842.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01842.5p-miR TJU_CMC_MD2.ID01842.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01843.3p-miR TJU_CMC_MD2.ID01843.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01844.5p-miR TJU_CMC_MD2.ID01844.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01845.5p-miR TJU_CMC_MD2.ID01845.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01846.5p-miR TJU_CMC_MD2.ID01846.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01847.5p-miR TJU_CMC_MD2.ID01847.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID01848.5p-miR TJU_CMC_MD2.ID01848.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01849.5p-miR TJU_CMC_MD2.ID01849.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01850.5p-miR TJU_CMC_MD2.ID01850.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01851.5p-miR TJU_CMC_MD2.ID01851.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01852.3p-miR TJU_CMC_MD2.ID01852.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01853.3p-miR TJU_CMC_MD2.ID01853.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01854.5p-miR TJU_CMC_MD2.ID01854.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01855.3p-miR TJU_CMC_MD2.ID01855.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01856.3p-miR TJU_CMC_MD2.ID01856.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01857.3p-miR TJU_CMC_MD2.ID01857.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01858.3p-miR TJU_CMC_MD2.ID01858.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01859.5p-miR TJU_CMC_MD2.ID01859.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID01860.3p-miR TJU_CMC_MD2.ID01860.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01860.5p-miR TJU_CMC_MD2.ID01860.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01861.3p-miR TJU_CMC_MD2.ID01861.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01862.5p-miR TJU_CMC_MD2.ID01862.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01863.5p-miR TJU_CMC_MD2.ID01863.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01864.5p-miR TJU_CMC_MD2.ID01864.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01865.3p-miR TJU_CMC_MD2.ID01865.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01866.5p-miR TJU_CMC_MD2.ID01866.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01867.3p-miR TJU_CMC_MD2.ID01867.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01868.3p-miR TJU_CMC_MD2.ID01868.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01869.3p-miR TJU_CMC_MD2.ID01869.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01870.5p-miR TJU_CMC_MD2.ID01870.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01871.3p-miR TJU_CMC_MD2.ID01871.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01872.3p-miR TJU_CMC_MD2.ID01872.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01873.3p-miR TJU_CMC_MD2.ID01873.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01874.3p-miR TJU_CMC_MD2.ID01874.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01875.3p-miR TJU_CMC_MD2.ID01875.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01876.3p-miR TJU_CMC_MD2.ID01876.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01877.3p-miR TJU_CMC_MD2.ID01877.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01878.5p-miR TJU_CMC_MD2.ID01878.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01879.5p-miR TJU_CMC_MD2.ID01879.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01880.5p-miR TJU_CMC_MD2.ID01880.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01881.5p-miR TJU_CMC_MD2.ID01881.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01882.5p-miR TJU_CMC_MD2.ID01882.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01883.5p-miR TJU_CMC_MD2.ID01883.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID01884.5p-miR TJU_CMC_MD2.ID01884.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01885.5p-miR TJU_CMC_MD2.ID01885.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01886.3p-miR TJU_CMC_MD2.ID01886.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01887.5p-miR TJU_CMC_MD2.ID01887.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01888.3p-miR TJU_CMC_MD2.ID01888.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01889.3p-miR TJU_CMC_MD2.ID01889.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01890.5p-miR TJU_CMC_MD2.ID01890.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01891.3p-miR TJU_CMC_MD2.ID01891.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01892.3p-miR TJU_CMC_MD2.ID01892.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01893.3p-miR TJU_CMC_MD2.ID01893.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01893.5p-miR TJU_CMC_MD2.ID01893.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01894.3p-miR TJU_CMC_MD2.ID01894.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01895.5p-miR TJU_CMC_MD2.ID01895.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01896.3p-miR TJU_CMC_MD2.ID01896.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01897.3p-miR TJU_CMC_MD2.ID01897.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01898.3p-miR TJU_CMC_MD2.ID01898.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01899.5p-miR TJU_CMC_MD2.ID01899.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01900.5p-miR TJU_CMC_MD2.ID01900.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01901.5p-miR TJU_CMC_MD2.ID01901.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01902.5p-miR TJU_CMC_MD2.ID01902.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01903.3p-miR TJU_CMC_MD2.ID01903.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01904.3p-miR TJU_CMC_MD2.ID01904.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01905.5p-miR TJU_CMC_MD2.ID01905.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01906.3p-miR TJU_CMC_MD2.ID01906.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01907.5p-miR TJU_CMC_MD2.ID01907.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01908.3p-miR TJU_CMC_MD2.ID01908.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01909.3p-miR TJU_CMC_MD2.ID01909.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01910.3p-miR TJU_CMC_MD2.ID01910.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01911.5p-miR TJU_CMC_MD2.ID01911.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01912.5p-miR TJU_CMC_MD2.ID01912.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01913.3p-miR TJU_CMC_MD2.ID01913.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01914.5p-miR TJU_CMC_MD2.ID01914.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01915.5p-miR TJU_CMC_MD2.ID01915.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01916.5p-miR TJU_CMC_MD2.ID01916.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01917.3p-miR TJU_CMC_MD2.ID01917.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01918.5p-miR TJU_CMC_MD2.ID01918.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01919.5p-miR TJU_CMC_MD2.ID01919.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01920.3p-miR TJU_CMC_MD2.ID01920.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01921.5p-miR TJU_CMC_MD2.ID01921.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID01922.3p-miR TJU_CMC_MD2.ID01922.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01923.3p-miR TJU_CMC_MD2.ID01923.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01924.5p-miR TJU_CMC_MD2.ID01924.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01925.5p-miR TJU_CMC_MD2.ID01925.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID01926.3p-miR TJU_CMC_MD2.ID01926.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01927.5p-miR TJU_CMC_MD2.ID01927.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01928.3p-miR TJU_CMC_MD2.ID01928.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01929.3p-miR TJU_CMC_MD2.ID01929.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01930.3p-miR TJU_CMC_MD2.ID01930.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01931.5p-miR TJU_CMC_MD2.ID01931.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01932.5p-miR TJU_CMC_MD2.ID01932.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01933.3p-miR TJU_CMC_MD2.ID01933.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01934.5p-miR TJU_CMC_MD2.ID01934.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01935.5p-miR TJU_CMC_MD2.ID01935.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01936.5p-miR TJU_CMC_MD2.ID01936.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01937.3p-miR TJU_CMC_MD2.ID01937.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01938.5p-miR TJU_CMC_MD2.ID01938.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01939.5p-miR TJU_CMC_MD2.ID01939.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01940.3p-miR TJU_CMC_MD2.ID01940.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01941.5p-miR TJU_CMC_MD2.ID01941.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01942.3p-miR TJU_CMC_MD2.ID01942.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01943.5p-miR TJU_CMC_MD2.ID01943.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID01944.5p-miR TJU_CMC_MD2.ID01944.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01945.3p-miR TJU_CMC_MD2.ID01945.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01946.3p-miR TJU_CMC_MD2.ID01946.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01947.5p-miR TJU_CMC_MD2.ID01947.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01948.5p-miR TJU_CMC_MD2.ID01948.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01949.3p-miR TJU_CMC_MD2.ID01949.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01950.3p-miR TJU_CMC_MD2.ID01950.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01950.5p-miR TJU_CMC_MD2.ID01950.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01951.3p-miR TJU_CMC_MD2.ID01951.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01952.5p-miR TJU_CMC_MD2.ID01952.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01953.5p-miR TJU_CMC_MD2.ID01953.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01954.3p-miR TJU_CMC_MD2.ID01954.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01955.3p-miR TJU_CMC_MD2.ID01955.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01956.5p-miR TJU_CMC_MD2.ID01956.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID01957.3p-miR TJU_CMC_MD2.ID01957.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01958.3p-miR TJU_CMC_MD2.ID01958.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01959.3p-miR TJU_CMC_MD2.ID01959.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01959.5p-miR TJU_CMC_MD2.ID01959.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01960.3p-miR TJU_CMC_MD2.ID01960.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01961.5p-miR TJU_CMC_MD2.ID01961.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01962.3p-miR TJU_CMC_MD2.ID01962.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01963.3p-miR TJU_CMC_MD2.ID01963.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01963.5p-miR TJU_CMC_MD2.ID01963.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01964.3p-miR TJU_CMC_MD2.ID01964.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01965.5p-miR TJU_CMC_MD2.ID01965.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01966.5p-miR TJU_CMC_MD2.ID01966.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID01967.5p-miR TJU_CMC_MD2.ID01967.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01968.3p-miR TJU_CMC_MD2.ID01968.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01969.3p-miR TJU_CMC_MD2.ID01969.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01970.3p-miR TJU_CMC_MD2.ID01970.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01971.3p-miR TJU_CMC_MD2.ID01971.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01972.5p-miR TJU_CMC_MD2.ID01972.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01973.3p-miR TJU_CMC_MD2.ID01973.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01974.5p-miR TJU_CMC_MD2.ID01974.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID01975.3p-miR TJU_CMC_MD2.ID01975.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01976.5p-miR TJU_CMC_MD2.ID01976.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01977.3p-miR TJU_CMC_MD2.ID01977.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01978.5p-miR TJU_CMC_MD2.ID01978.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01979.3p-miR TJU_CMC_MD2.ID01979.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01980.5p-miR TJU_CMC_MD2.ID01980.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID01981.3p-miR TJU_CMC_MD2.ID01981.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01982.5p-miR TJU_CMC_MD2.ID01982.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID01983.3p-miR TJU_CMC_MD2.ID01983.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01984.3p-miR TJU_CMC_MD2.ID01984.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01985.5p-miR TJU_CMC_MD2.ID01985.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01986.5p-miR TJU_CMC_MD2.ID01986.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01987.3p-miR TJU_CMC_MD2.ID01987.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01988.5p-miR TJU_CMC_MD2.ID01988.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID01989.5p-miR TJU_CMC_MD2.ID01989.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID01990.3p-miR TJU_CMC_MD2.ID01990.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01991.5p-miR TJU_CMC_MD2.ID01991.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID01992.3p-miR TJU_CMC_MD2.ID01992.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01993.3p-miR TJU_CMC_MD2.ID01993.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01994.3p-miR TJU_CMC_MD2.ID01994.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01995.3p-miR TJU_CMC_MD2.ID01995.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01996.3p-miR TJU_CMC_MD2.ID01996.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01997.5p-miR TJU_CMC_MD2.ID01997.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID01998.3p-miR TJU_CMC_MD2.ID01998.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01999.3p-miR TJU_CMC_MD2.ID01999.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID01999.5p-miR TJU_CMC_MD2.ID01999.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02000.3p-miR TJU_CMC_MD2.ID02000.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02001.5p-miR TJU_CMC_MD2.ID02001.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02002.5p-miR TJU_CMC_MD2.ID02002.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02003.3p-miR TJU_CMC_MD2.ID02003.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02004.3p-miR TJU_CMC_MD2.ID02004.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02005.5p-miR TJU_CMC_MD2.ID02005.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02006.3p-miR TJU_CMC_MD2.ID02006.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02007.3p-miR TJU_CMC_MD2.ID02007.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02008.5p-miR TJU_CMC_MD2.ID02008.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02009.5p-miR TJU_CMC_MD2.ID02009.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02010.3p-miR TJU_CMC_MD2.ID02010.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02011.3p-miR TJU_CMC_MD2.ID02011.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02012.5p-miR TJU_CMC_MD2.ID02012.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02013.3p-miR TJU_CMC_MD2.ID02013.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02014.5p-miR TJU_CMC_MD2.ID02014.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02015.5p-miR TJU_CMC_MD2.ID02015.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02016.3p-miR TJU_CMC_MD2.ID02016.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02017.3p-miR TJU_CMC_MD2.ID02017.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02018.3p-miR TJU_CMC_MD2.ID02018.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02019.3p-miR TJU_CMC_MD2.ID02019.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02020.3p-miR TJU_CMC_MD2.ID02020.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02021.3p-miR TJU_CMC_MD2.ID02021.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02022.5p-miR TJU_CMC_MD2.ID02022.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02023.5p-miR TJU_CMC_MD2.ID02023.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02024.3p-miR TJU_CMC_MD2.ID02024.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02025.5p-miR TJU_CMC_MD2.ID02025.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02026.5p-miR TJU_CMC_MD2.ID02026.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02027.3p-miR TJU_CMC_MD2.ID02027.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02028.3p-miR TJU_CMC_MD2.ID02028.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02029.5p-miR TJU_CMC_MD2.ID02029.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02030.3p-miR TJU_CMC_MD2.ID02030.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02031.5p-miR TJU_CMC_MD2.ID02031.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02032.5p-miR TJU_CMC_MD2.ID02032.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02033.5p-miR TJU_CMC_MD2.ID02033.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02034.5p-miR TJU_CMC_MD2.ID02034.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02035.5p-miR TJU_CMC_MD2.ID02035.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02036.3p-miR TJU_CMC_MD2.ID02036.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02037.5p-miR TJU_CMC_MD2.ID02037.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02038.5p-miR TJU_CMC_MD2.ID02038.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02039.3p-miR TJU_CMC_MD2.ID02039.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02040.5p-miR TJU_CMC_MD2.ID02040.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02041.3p-miR TJU_CMC_MD2.ID02041.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02042.5p-miR TJU_CMC_MD2.ID02042.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02043.3p-miR TJU_CMC_MD2.ID02043.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02043.5p-miR TJU_CMC_MD2.ID02043.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02044.3p-miR TJU_CMC_MD2.ID02044.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02045.3p-miR TJU_CMC_MD2.ID02045.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02046.3p-miR TJU_CMC_MD2.ID02046.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02047.5p-miR TJU_CMC_MD2.ID02047.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02048.3p-miR TJU_CMC_MD2.ID02048.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02049.3p-miR TJU_CMC_MD2.ID02049.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02050.3p-miR TJU_CMC_MD2.ID02050.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02050.5p-miR TJU_CMC_MD2.ID02050.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02051.3p-miR TJU_CMC_MD2.ID02051.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02052.5p-miR TJU_CMC_MD2.ID02052.hairpin YES NO NO NO NO YES NO NO TJU_CMC_MD2.ID02053.5p-miR TJU_CMC_MD2.ID02053.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02054.3p-miR TJU_CMC_MD2.ID02054.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02055.5p-miR TJU_CMC_MD2.ID02055.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02056.3p-miR TJU_CMC_MD2.ID02056.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02057.3p-miR TJU_CMC_MD2.ID02057.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02058.5p-miR TJU_CMC_MD2.ID02058.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02059.3p-miR TJU_CMC_MD2.ID02059.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02059.5p-miR TJU_CMC_MD2.ID02059.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02060.3p-miR TJU_CMC_MD2.ID02060.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02061.3p-miR TJU_CMC_MD2.ID02061.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02062.3p-miR TJU_CMC_MD2.ID02062.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02063.5p-miR TJU_CMC_MD2.ID02063.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02064.5p-miR TJU_CMC_MD2.ID02064.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02065.5p-miR TJU_CMC_MD2.ID02065.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02066.5p-miR TJU_CMC_MD2.ID02066.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02067.3p-miR TJU_CMC_MD2.ID02067.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02068.5p-miR TJU_CMC_MD2.ID02068.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02069.5p-miR TJU_CMC_MD2.ID02069.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02070.5p-miR TJU_CMC_MD2.ID02070.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02071.3p-miR TJU_CMC_MD2.ID02071.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02072.3p-miR TJU_CMC_MD2.ID02072.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02073.5p-miR TJU_CMC_MD2.ID02073.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02074.3p-miR TJU_CMC_MD2.ID02074.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02074.5p-miR TJU_CMC_MD2.ID02074.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02075.3p-miR TJU_CMC_MD2.ID02075.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02076.5p-miR TJU_CMC_MD2.ID02076.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID02077.3p-miR TJU_CMC_MD2.ID02077.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02078.5p-miR TJU_CMC_MD2.ID02078.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02079.5p-miR TJU_CMC_MD2.ID02079.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02080.3p-miR TJU_CMC_MD2.ID02080.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02081.5p-miR TJU_CMC_MD2.ID02081.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02082.3p-miR TJU_CMC_MD2.ID02082.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02083.3p-miR TJU_CMC_MD2.ID02083.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02084.3p-miR TJU_CMC_MD2.ID02084.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02085.3p-miR TJU_CMC_MD2.ID02085.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02085.5p-miR TJU_CMC_MD2.ID02085.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02086.5p-miR TJU_CMC_MD2.ID02086.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02087.5p-miR TJU_CMC_MD2.ID02087.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02088.3p-miR TJU_CMC_MD2.ID02088.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02088.5p-miR TJU_CMC_MD2.ID02088.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02089.3p-miR TJU_CMC_MD2.ID02089.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02090.3p-miR TJU_CMC_MD2.ID02090.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02091.5p-miR TJU_CMC_MD2.ID02091.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02092.5p-miR TJU_CMC_MD2.ID02092.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02093.5p-miR TJU_CMC_MD2.ID02093.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02094.3p-miR TJU_CMC_MD2.ID02094.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02095.3p-miR TJU_CMC_MD2.ID02095.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02096.3p-miR TJU_CMC_MD2.ID02096.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02096.5p-miR TJU_CMC_MD2.ID02096.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02097.3p-miR TJU_CMC_MD2.ID02097.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02098.3p-miR TJU_CMC_MD2.ID02098.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02099.5p-miR TJU_CMC_MD2.ID02099.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02100.3p-miR TJU_CMC_MD2.ID02100.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02101.3p-miR TJU_CMC_MD2.ID02101.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02102.5p-miR TJU_CMC_MD2.ID02102.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02103.5p-miR TJU_CMC_MD2.ID02103.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02104.5p-miR TJU_CMC_MD2.ID02104.hairpin YES YES NO YES YES YES NO NO TJU_CMC_MD2.ID02105.3p-miR TJU_CMC_MD2.ID02105.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02106.3p-miR TJU_CMC_MD2.ID02106.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02107.5p-miR TJU_CMC_MD2.ID02107.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02108.3p-miR TJU_CMC_MD2.ID02108.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02109.5p-miR TJU_CMC_MD2.ID02109.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02110.5p-miR TJU_CMC_MD2.ID02110.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02111.3p-miR TJU_CMC_MD2.ID02111.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02112.3p-miR TJU_CMC_MD2.ID02112.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02113.5p-miR TJU_CMC_MD2.ID02113.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02114.3p-miR TJU_CMC_MD2.ID02114.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02115.5p-miR TJU_CMC_MD2.ID02115.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02116.3p-miR TJU_CMC_MD2.ID02116.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02117.3p-miR TJU_CMC_MD2.ID02117.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02118.3p-miR TJU_CMC_MD2.ID02118.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02119.3p-miR TJU_CMC_MD2.ID02119.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02120.3p-miR TJU_CMC_MD2.ID02120.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02121.3p-miR TJU_CMC_MD2.ID02121.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02122.5p-miR TJU_CMC_MD2.ID02122.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02123.3p-miR TJU_CMC_MD2.ID02123.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02124.5p-miR TJU_CMC_MD2.ID02124.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02125.3p-miR TJU_CMC_MD2.ID02125.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02125.5p-miR TJU_CMC_MD2.ID02125.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02126.3p-miR TJU_CMC_MD2.ID02126.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02126.5p-miR TJU_CMC_MD2.ID02126.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02127.5p-miR TJU_CMC_MD2.ID02127.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02128.5p-miR TJU_CMC_MD2.ID02128.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02129.5p-miR TJU_CMC_MD2.ID02129.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02130.3p-miR TJU_CMC_MD2.ID02130.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02131.5p-miR TJU_CMC_MD2.ID02131.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02132.3p-miR TJU_CMC_MD2.ID02132.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02133.5p-miR TJU_CMC_MD2.ID02133.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02134.5p-miR TJU_CMC_MD2.ID02134.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02135.5p-miR TJU_CMC_MD2.ID02135.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02136.3p-miR TJU_CMC_MD2.ID02136.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02137.5p-miR TJU_CMC_MD2.ID02137.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID02138.5p-miR TJU_CMC_MD2.ID02138.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02139.3p-miR TJU_CMC_MD2.ID02139.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02140.5p-miR TJU_CMC_MD2.ID02140.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02141.5p-miR TJU_CMC_MD2.ID02141.hairpin YES NO YES YES YES YES NO NO TJU_CMC_MD2.ID02142.3p-miR TJU_CMC_MD2.ID02142.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02143.3p-miR TJU_CMC_MD2.ID02143.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02143.5p-miR TJU_CMC_MD2.ID02143.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02144.5p-miR TJU_CMC_MD2.ID02144.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02145.5p-miR TJU_CMC_MD2.ID02145.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02146.5p-miR TJU_CMC_MD2.ID02146.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02147.5p-miR TJU_CMC_MD2.ID02147.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02148.3p-miR TJU_CMC_MD2.ID02148.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02149.3p-miR TJU_CMC_MD2.ID02149.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02150.5p-miR TJU_CMC_MD2.ID02150.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02151.5p-miR TJU_CMC_MD2.ID02151.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02152.3p-miR TJU_CMC_MD2.ID02152.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02153.5p-miR TJU_CMC_MD2.ID02153.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02154.3p-miR TJU_CMC_MD2.ID02154.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02155.3p-miR TJU_CMC_MD2.ID02155.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02156.3p-miR TJU_CMC_MD2.ID02156.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02157.5p-miR TJU_CMC_MD2.ID02157.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02158.5p-miR TJU_CMC_MD2.ID02158.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02159.3p-miR TJU_CMC_MD2.ID02159.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02160.3p-miR TJU_CMC_MD2.ID02160.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02161.3p-miR TJU_CMC_MD2.ID02161.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02162.5p-miR TJU_CMC_MD2.ID02162.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02163.3p-miR TJU_CMC_MD2.ID02163.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02164.3p-miR TJU_CMC_MD2.ID02164.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02165.3p-miR TJU_CMC_MD2.ID02165.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02165.5p-miR TJU_CMC_MD2.ID02165.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02166.3p-miR TJU_CMC_MD2.ID02166.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02167.3p-miR TJU_CMC_MD2.ID02167.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02168.5p-miR TJU_CMC_MD2.ID02168.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02169.3p-miR TJU_CMC_MD2.ID02169.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02169.5p-miR TJU_CMC_MD2.ID02169.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02170.3p-miR TJU_CMC_MD2.ID02170.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02171.5p-miR TJU_CMC_MD2.ID02171.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID02172.5p-miR TJU_CMC_MD2.ID02172.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02173.3p-miR TJU_CMC_MD2.ID02173.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02174.5p-miR TJU_CMC_MD2.ID02174.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02175.3p-miR TJU_CMC_MD2.ID02175.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02176.3p-miR TJU_CMC_MD2.ID02176.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02176.5p-miR TJU_CMC_MD2.ID02176.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02177.5p-miR TJU_CMC_MD2.ID02177.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02178.5p-miR TJU_CMC_MD2.ID02178.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02179.3p-miR TJU_CMC_MD2.ID02179.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02180.3p-miR TJU_CMC_MD2.ID02180.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02181.3p-miR TJU_CMC_MD2.ID02181.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02182.5p-miR TJU_CMC_MD2.ID02182.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID02183.5p-miR TJU_CMC_MD2.ID02183.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02184.3p-miR TJU_CMC_MD2.ID02184.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02185.5p-miR TJU_CMC_MD2.ID02185.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02186.5p-miR TJU_CMC_MD2.ID02186.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02187.5p-miR TJU_CMC_MD2.ID02187.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02188.3p-miR TJU_CMC_MD2.ID02188.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02188.5p-miR TJU_CMC_MD2.ID02188.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02189.5p-miR TJU_CMC_MD2.ID02189.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02190.5p-miR TJU_CMC_MD2.ID02190.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02191.5p-miR TJU_CMC_MD2.ID02191.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02192.5p-miR TJU_CMC_MD2.ID02192.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02193.3p-miR TJU_CMC_MD2.ID02193.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02194.3p-miR TJU_CMC_MD2.ID02194.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02195.3p-miR TJU_CMC_MD2.ID02195.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02196.5p-miR TJU_CMC_MD2.ID02196.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID02197.3p-miR TJU_CMC_MD2.ID02197.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02198.3p-miR TJU_CMC_MD2.ID02198.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02199.5p-miR TJU_CMC_MD2.ID02199.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02200.3p-miR TJU_CMC_MD2.ID02200.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02201.3p-miR TJU_CMC_MD2.ID02201.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02202.5p-miR TJU_CMC_MD2.ID02202.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02203.5p-miR TJU_CMC_MD2.ID02203.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02204.5p-miR TJU_CMC_MD2.ID02204.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02205.5p-miR TJU_CMC_MD2.ID02205.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02206.5p-miR TJU_CMC_MD2.ID02206.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02207.5p-miR TJU_CMC_MD2.ID02207.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02208.5p-miR TJU_CMC_MD2.ID02208.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02209.3p-miR TJU_CMC_MD2.ID02209.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02210.5p-miR TJU_CMC_MD2.ID02210.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02211.5p-miR TJU_CMC_MD2.ID02211.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02212.5p-miR TJU_CMC_MD2.ID02212.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02213.3p-miR TJU_CMC_MD2.ID02213.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02214.3p-miR TJU_CMC_MD2.ID02214.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02215.5p-miR TJU_CMC_MD2.ID02215.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02216.3p-miR TJU_CMC_MD2.ID02216.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02217.5p-miR TJU_CMC_MD2.ID02217.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02218.3p-miR TJU_CMC_MD2.ID02218.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02219.3p-miR TJU_CMC_MD2.ID02219.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02220.5p-miR TJU_CMC_MD2.ID02220.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02221.3p-miR TJU_CMC_MD2.ID02221.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02222.3p-miR TJU_CMC_MD2.ID02222.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02223.3p-miR TJU_CMC_MD2.ID02223.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02224.3p-miR TJU_CMC_MD2.ID02224.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02224.5p-miR TJU_CMC_MD2.ID02224.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02225.5p-miR TJU_CMC_MD2.ID02225.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02226.3p-miR TJU_CMC_MD2.ID02226.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02227.3p-miR TJU_CMC_MD2.ID02227.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02228.3p-miR TJU_CMC_MD2.ID02228.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02229.3p-miR TJU_CMC_MD2.ID02229.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02230.3p-miR TJU_CMC_MD2.ID02230.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02231.3p-miR TJU_CMC_MD2.ID02231.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02232.3p-miR TJU_CMC_MD2.ID02232.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02233.3p-miR TJU_CMC_MD2.ID02233.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02234.5p-miR TJU_CMC_MD2.ID02234.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02235.5p-miR TJU_CMC_MD2.ID02235.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02236.3p-miR TJU_CMC_MD2.ID02236.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02236.5p-miR TJU_CMC_MD2.ID02236.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02237.3p-miR TJU_CMC_MD2.ID02237.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02237.5p-miR TJU_CMC_MD2.ID02237.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02238.5p-miR TJU_CMC_MD2.ID02238.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02239.3p-miR TJU_CMC_MD2.ID02239.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02240.3p-miR TJU_CMC_MD2.ID02240.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02241.3p-miR TJU_CMC_MD2.ID02241.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02242.3p-miR TJU_CMC_MD2.ID02242.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02243.5p-miR TJU_CMC_MD2.ID02243.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02244.3p-miR TJU_CMC_MD2.ID02244.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02245.5p-miR TJU_CMC_MD2.ID02245.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02246.3p-miR TJU_CMC_MD2.ID02246.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02247.3p-miR TJU_CMC_MD2.ID02247.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02248.5p-miR TJU_CMC_MD2.ID02248.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02249.3p-miR TJU_CMC_MD2.ID02249.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02250.3p-miR TJU_CMC_MD2.ID02250.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02251.5p-miR TJU_CMC_MD2.ID02251.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02252.3p-miR TJU_CMC_MD2.ID02252.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02253.3p-miR TJU_CMC_MD2.ID02253.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02254.5p-miR TJU_CMC_MD2.ID02254.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02255.5p-miR TJU_CMC_MD2.ID02255.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02256.3p-miR TJU_CMC_MD2.ID02256.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02257.3p-miR TJU_CMC_MD2.ID02257.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02258.3p-miR TJU_CMC_MD2.ID02258.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02259.5p-miR TJU_CMC_MD2.ID02259.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02260.5p-miR TJU_CMC_MD2.ID02260.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02261.5p-miR TJU_CMC_MD2.ID02261.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02262.3p-miR TJU_CMC_MD2.ID02262.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02263.3p-miR TJU_CMC_MD2.ID02263.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02264.3p-miR TJU_CMC_MD2.ID02264.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02264.5p-miR TJU_CMC_MD2.ID02264.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02265.5p-miR TJU_CMC_MD2.ID02265.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02266.5p-miR TJU_CMC_MD2.ID02266.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02267.3p-miR TJU_CMC_MD2.ID02267.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02268.3p-miR TJU_CMC_MD2.ID02268.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02269.3p-miR TJU_CMC_MD2.ID02269.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02270.3p-miR TJU_CMC_MD2.ID02270.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02271.3p-miR TJU_CMC_MD2.ID02271.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02272.5p-miR TJU_CMC_MD2.ID02272.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02273.3p-miR TJU_CMC_MD2.ID02273.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02274.3p-miR TJU_CMC_MD2.ID02274.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02275.5p-miR TJU_CMC_MD2.ID02275.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02276.3p-miR TJU_CMC_MD2.ID02276.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02276.5p-miR TJU_CMC_MD2.ID02276.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02277.3p-miR TJU_CMC_MD2.ID02277.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02277.5p-miR TJU_CMC_MD2.ID02277.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02278.5p-miR TJU_CMC_MD2.ID02278.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02279.3p-miR TJU_CMC_MD2.ID02279.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02280.3p-miR TJU_CMC_MD2.ID02280.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02280.5p-miR TJU_CMC_MD2.ID02280.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02281.5p-miR TJU_CMC_MD2.ID02281.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02282.5p-miR TJU_CMC_MD2.ID02282.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02283.3p-miR TJU_CMC_MD2.ID02283.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02284.3p-miR TJU_CMC_MD2.ID02284.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02285.5p-miR TJU_CMC_MD2.ID02285.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02286.3p-miR TJU_CMC_MD2.ID02286.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02287.5p-miR TJU_CMC_MD2.ID02287.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02288.5p-miR TJU_CMC_MD2.ID02288.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02289.3p-miR TJU_CMC_MD2.ID02289.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02289.5p-miR TJU_CMC_MD2.ID02289.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02290.3p-miR TJU_CMC_MD2.ID02290.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02290.5p-miR TJU_CMC_MD2.ID02290.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02291.3p-miR TJU_CMC_MD2.ID02291.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02291.5p-miR TJU_CMC_MD2.ID02291.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02292.5p-miR TJU_CMC_MD2.ID02292.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02293.3p-miR TJU_CMC_MD2.ID02293.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02294.5p-miR TJU_CMC_MD2.ID02294.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02295.3p-miR TJU_CMC_MD2.ID02295.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02295.5p-miR TJU_CMC_MD2.ID02295.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02296.5p-miR TJU_CMC_MD2.ID02296.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02297.3p-miR TJU_CMC_MD2.ID02297.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02298.3p-miR TJU_CMC_MD2.ID02298.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02299.5p-miR TJU_CMC_MD2.ID02299.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02300.3p-miR TJU_CMC_MD2.ID02300.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02301.5p-miR TJU_CMC_MD2.ID02301.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02302.3p-miR TJU_CMC_MD2.ID02302.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02303.5p-miR TJU_CMC_MD2.ID02303.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02304.5p-miR TJU_CMC_MD2.ID02304.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02305.3p-miR TJU_CMC_MD2.ID02305.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02306.3p-miR TJU_CMC_MD2.ID02306.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02307.3p-miR TJU_CMC_MD2.ID02307.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02308.3p-miR TJU_CMC_MD2.ID02308.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02309.3p-miR TJU_CMC_MD2.ID02309.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02310.3p-miR TJU_CMC_MD2.ID02310.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02311.3p-miR TJU_CMC_MD2.ID02311.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02312.5p-miR TJU_CMC_MD2.ID02312.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02313.3p-miR TJU_CMC_MD2.ID02313.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02314.3p-miR TJU_CMC_MD2.ID02314.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02315.3p-miR TJU_CMC_MD2.ID02315.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02316.3p-miR TJU_CMC_MD2.ID02316.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02317.3p-miR TJU_CMC_MD2.ID02317.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02318.5p-miR TJU_CMC_MD2.ID02318.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02319.3p-miR TJU_CMC_MD2.ID02319.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02320.3p-miR TJU_CMC_MD2.ID02320.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02321.5p-miR TJU_CMC_MD2.ID02321.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02322.5p-miR TJU_CMC_MD2.ID02322.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02323.3p-miR TJU_CMC_MD2.ID02323.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02324.3p-miR TJU_CMC_MD2.ID02324.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02325.3p-miR TJU_CMC_MD2.ID02325.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02325.5p-miR TJU_CMC_MD2.ID02325.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02326.5p-miR TJU_CMC_MD2.ID02326.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02327.5p-miR TJU_CMC_MD2.ID02327.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02328.5p-miR TJU_CMC_MD2.ID02328.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02329.3p-miR TJU_CMC_MD2.ID02329.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02330.3p-miR TJU_CMC_MD2.ID02330.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02331.3p-miR TJU_CMC_MD2.ID02331.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02332.3p-miR TJU_CMC_MD2.ID02332.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02333.3p-miR TJU_CMC_MD2.ID02333.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02334.5p-miR TJU_CMC_MD2.ID02334.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02335.5p-miR TJU_CMC_MD2.ID02335.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02336.3p-miR TJU_CMC_MD2.ID02336.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02337.3p-miR TJU_CMC_MD2.ID02337.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02338.3p-miR TJU_CMC_MD2.ID02338.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02338.5p-miR TJU_CMC_MD2.ID02338.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02339.5p-miR TJU_CMC_MD2.ID02339.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02340.3p-miR TJU_CMC_MD2.ID02340.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02341.3p-miR TJU_CMC_MD2.ID02341.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02342.5p-miR TJU_CMC_MD2.ID02342.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID02343.3p-miR TJU_CMC_MD2.ID02343.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02344.3p-miR TJU_CMC_MD2.ID02344.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02345.3p-miR TJU_CMC_MD2.ID02345.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02346.3p-miR TJU_CMC_MD2.ID02346.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02347.5p-miR TJU_CMC_MD2.ID02347.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02348.3p-miR TJU_CMC_MD2.ID02348.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02348.5p-miR TJU_CMC_MD2.ID02348.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02349.3p-miR TJU_CMC_MD2.ID02349.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02350.5p-miR TJU_CMC_MD2.ID02350.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02351.5p-miR TJU_CMC_MD2.ID02351.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02352.5p-miR TJU_CMC_MD2.ID02352.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02353.3p-miR TJU_CMC_MD2.ID02353.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02354.3p-miR TJU_CMC_MD2.ID02354.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02355.3p-miR TJU_CMC_MD2.ID02355.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02355.5p-miR TJU_CMC_MD2.ID02355.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02356.3p-miR TJU_CMC_MD2.ID02356.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02357.3p-miR TJU_CMC_MD2.ID02357.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02358.3p-miR TJU_CMC_MD2.ID02358.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02359.5p-miR TJU_CMC_MD2.ID02359.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02360.5p-miR TJU_CMC_MD2.ID02360.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02361.3p-miR TJU_CMC_MD2.ID02361.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02362.5p-miR TJU_CMC_MD2.ID02362.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02363.5p-miR TJU_CMC_MD2.ID02363.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02364.3p-miR TJU_CMC_MD2.ID02364.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02365.5p-miR TJU_CMC_MD2.ID02365.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02366.3p-miR TJU_CMC_MD2.ID02366.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02367.3p-miR TJU_CMC_MD2.ID02367.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02367.5p-miR TJU_CMC_MD2.ID02367.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02368.3p-miR TJU_CMC_MD2.ID02368.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02369.5p-miR TJU_CMC_MD2.ID02369.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02370.3p-miR TJU_CMC_MD2.ID02370.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02371.5p-miR TJU_CMC_MD2.ID02371.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02372.3p-miR TJU_CMC_MD2.ID02372.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02373.5p-miR TJU_CMC_MD2.ID02373.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02374.3p-miR TJU_CMC_MD2.ID02374.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02375.3p-miR TJU_CMC_MD2.ID02375.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02376.3p-miR TJU_CMC_MD2.ID02376.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02376.5p-miR TJU_CMC_MD2.ID02376.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02377.5p-miR TJU_CMC_MD2.ID02377.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02378.5p-miR TJU_CMC_MD2.ID02378.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02379.3p-miR TJU_CMC_MD2.ID02379.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02380.5p-miR TJU_CMC_MD2.ID02380.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02381.3p-miR TJU_CMC_MD2.ID02381.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02382.3p-miR TJU_CMC_MD2.ID02382.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02383.5p-miR TJU_CMC_MD2.ID02383.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02384.5p-miR TJU_CMC_MD2.ID02384.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02385.3p-miR TJU_CMC_MD2.ID02385.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02386.3p-miR TJU_CMC_MD2.ID02386.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02387.5p-miR TJU_CMC_MD2.ID02387.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02388.3p-miR TJU_CMC_MD2.ID02388.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02389.3p-miR TJU_CMC_MD2.ID02389.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02390.3p-miR TJU_CMC_MD2.ID02390.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02391.3p-miR TJU_CMC_MD2.ID02391.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02392.3p-miR TJU_CMC_MD2.ID02392.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02393.5p-miR TJU_CMC_MD2.ID02393.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02394.5p-miR TJU_CMC_MD2.ID02394.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02395.3p-miR TJU_CMC_MD2.ID02395.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02396.3p-miR TJU_CMC_MD2.ID02396.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02396.5p-miR TJU_CMC_MD2.ID02396.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02397.3p-miR TJU_CMC_MD2.ID02397.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02398.3p-miR TJU_CMC_MD2.ID02398.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02399.3p-miR TJU_CMC_MD2.ID02399.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02400.5p-miR TJU_CMC_MD2.ID02400.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02401.3p-miR TJU_CMC_MD2.ID02401.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02402.3p-miR TJU_CMC_MD2.ID02402.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02403.3p-miR TJU_CMC_MD2.ID02403.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02404.3p-miR TJU_CMC_MD2.ID02404.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02405.5p-miR TJU_CMC_MD2.ID02405.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02406.5p-miR TJU_CMC_MD2.ID02406.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02407.3p-miR TJU_CMC_MD2.ID02407.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02408.3p-miR TJU_CMC_MD2.ID02408.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02409.3p-miR TJU_CMC_MD2.ID02409.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02410.3p-miR TJU_CMC_MD2.ID02410.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02410.5p-miR TJU_CMC_MD2.ID02410.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02411.3p-miR TJU_CMC_MD2.ID02411.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02411.5p-miR TJU_CMC_MD2.ID02411.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02412.3p-miR TJU_CMC_MD2.ID02412.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02413.5p-miR TJU_CMC_MD2.ID02413.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02414.3p-miR TJU_CMC_MD2.ID02414.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02415.3p-miR TJU_CMC_MD2.ID02415.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02416.5p-miR TJU_CMC_MD2.ID02416.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02417.5p-miR TJU_CMC_MD2.ID02417.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02418.3p-miR TJU_CMC_MD2.ID02418.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02419.3p-miR TJU_CMC_MD2.ID02419.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02420.5p-miR TJU_CMC_MD2.ID02420.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02421.5p-miR TJU_CMC_MD2.ID02421.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02422.3p-miR TJU_CMC_MD2.ID02422.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02422.5p-miR TJU_CMC_MD2.ID02422.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02423.5p-miR TJU_CMC_MD2.ID02423.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID02424.3p-miR TJU_CMC_MD2.ID02424.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02425.3p-miR TJU_CMC_MD2.ID02425.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02426.5p-miR TJU_CMC_MD2.ID02426.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02427.3p-miR TJU_CMC_MD2.ID02427.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02428.3p-miR TJU_CMC_MD2.ID02428.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02429.3p-miR TJU_CMC_MD2.ID02429.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02430.3p-miR TJU_CMC_MD2.ID02430.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02431.3p-miR TJU_CMC_MD2.ID02431.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02432.3p-miR TJU_CMC_MD2.ID02432.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02433.5p-miR TJU_CMC_MD2.ID02433.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02434.3p-miR TJU_CMC_MD2.ID02434.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02434.5p-miR TJU_CMC_MD2.ID02434.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02435.5p-miR TJU_CMC_MD2.ID02435.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02436.3p-miR TJU_CMC_MD2.ID02436.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02437.3p-miR TJU_CMC_MD2.ID02437.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02438.5p-miR TJU_CMC_MD2.ID02438.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02439.5p-miR TJU_CMC_MD2.ID02439.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02440.3p-miR TJU_CMC_MD2.ID02440.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02441.5p-miR TJU_CMC_MD2.ID02441.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02442.5p-miR TJU_CMC_MD2.ID02442.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02443.3p-miR TJU_CMC_MD2.ID02443.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02444.5p-miR TJU_CMC_MD2.ID02444.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02445.3p-miR TJU_CMC_MD2.ID02445.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02446.5p-miR TJU_CMC_MD2.ID02446.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02447.5p-miR TJU_CMC_MD2.ID02447.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02448.5p-miR TJU_CMC_MD2.ID02448.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02449.3p-miR TJU_CMC_MD2.ID02449.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02450.3p-miR TJU_CMC_MD2.ID02450.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02451.5p-miR TJU_CMC_MD2.ID02451.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02452.3p-miR TJU_CMC_MD2.ID02452.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02453.3p-miR TJU_CMC_MD2.ID02453.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02453.5p-miR TJU_CMC_MD2.ID02453.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02454.5p-miR TJU_CMC_MD2.ID02454.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02455.3p-miR TJU_CMC_MD2.ID02455.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02456.3p-miR TJU_CMC_MD2.ID02456.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02457.3p-miR TJU_CMC_MD2.ID02457.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02458.3p-miR TJU_CMC_MD2.ID02458.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02459.5p-miR TJU_CMC_MD2.ID02459.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02460.5p-miR TJU_CMC_MD2.ID02460.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02461.5p-miR TJU_CMC_MD2.ID02461.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02462.5p-miR TJU_CMC_MD2.ID02462.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02463.3p-miR TJU_CMC_MD2.ID02463.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02464.5p-miR TJU_CMC_MD2.ID02464.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02465.3p-miR TJU_CMC_MD2.ID02465.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02466.3p-miR TJU_CMC_MD2.ID02466.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02467.3p-miR TJU_CMC_MD2.ID02467.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02468.5p-miR TJU_CMC_MD2.ID02468.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02469.3p-miR TJU_CMC_MD2.ID02469.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02470.3p-miR TJU_CMC_MD2.ID02470.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02471.3p-miR TJU_CMC_MD2.ID02471.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02472.3p-miR TJU_CMC_MD2.ID02472.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02473.3p-miR TJU_CMC_MD2.ID02473.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02474.3p-miR TJU_CMC_MD2.ID02474.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02475.5p-miR TJU_CMC_MD2.ID02475.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02476.3p-miR TJU_CMC_MD2.ID02476.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02477.3p-miR TJU_CMC_MD2.ID02477.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02478.3p-miR TJU_CMC_MD2.ID02478.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02479.3p-miR TJU_CMC_MD2.ID02479.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02480.5p-miR TJU_CMC_MD2.ID02480.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02481.5p-miR TJU_CMC_MD2.ID02481.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02482.3p-miR TJU_CMC_MD2.ID02482.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02483.3p-miR TJU_CMC_MD2.ID02483.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02484.3p-miR TJU_CMC_MD2.ID02484.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02485.5p-miR TJU_CMC_MD2.ID02485.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02486.3p-miR TJU_CMC_MD2.ID02486.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02487.5p-miR TJU_CMC_MD2.ID02487.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02488.3p-miR TJU_CMC_MD2.ID02488.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02488.5p-miR TJU_CMC_MD2.ID02488.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02489.3p-miR TJU_CMC_MD2.ID02489.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02490.5p-miR TJU_CMC_MD2.ID02490.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02491.3p-miR TJU_CMC_MD2.ID02491.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02491.5p-miR TJU_CMC_MD2.ID02491.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02492.3p-miR TJU_CMC_MD2.ID02492.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02493.3p-miR TJU_CMC_MD2.ID02493.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02494.3p-miR TJU_CMC_MD2.ID02494.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02495.3p-miR TJU_CMC_MD2.ID02495.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02496.5p-miR TJU_CMC_MD2.ID02496.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02497.3p-miR TJU_CMC_MD2.ID02497.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02498.5p-miR TJU_CMC_MD2.ID02498.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02499.3p-miR TJU_CMC_MD2.ID02499.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02500.3p-miR TJU_CMC_MD2.ID02500.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02501.3p-miR TJU_CMC_MD2.ID02501.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02502.3p-miR TJU_CMC_MD2.ID02502.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02503.3p-miR TJU_CMC_MD2.ID02503.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02504.5p-miR TJU_CMC_MD2.ID02504.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02505.5p-miR TJU_CMC_MD2.ID02505.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02506.3p-miR TJU_CMC_MD2.ID02506.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02507.3p-miR TJU_CMC_MD2.ID02507.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02508.5p-miR TJU_CMC_MD2.ID02508.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02509.3p-miR TJU_CMC_MD2.ID02509.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02510.3p-miR TJU_CMC_MD2.ID02510.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02510.5p-miR TJU_CMC_MD2.ID02510.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02511.3p-miR TJU_CMC_MD2.ID02511.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02512.3p-miR TJU_CMC_MD2.ID02512.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02513.5p-miR TJU_CMC_MD2.ID02513.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02514.3p-miR TJU_CMC_MD2.ID02514.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02514.5p-miR TJU_CMC_MD2.ID02514.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02515.3p-miR TJU_CMC_MD2.ID02515.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02516.3p-miR TJU_CMC_MD2.ID02516.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02517.3p-miR TJU_CMC_MD2.ID02517.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02518.3p-miR TJU_CMC_MD2.ID02518.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02519.3p-miR TJU_CMC_MD2.ID02519.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02520.5p-miR TJU_CMC_MD2.ID02520.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID02521.5p-miR TJU_CMC_MD2.ID02521.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02522.3p-miR TJU_CMC_MD2.ID02522.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02523.3p-miR TJU_CMC_MD2.ID02523.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02524.5p-miR TJU_CMC_MD2.ID02524.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02525.5p-miR TJU_CMC_MD2.ID02525.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02526.3p-miR TJU_CMC_MD2.ID02526.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02527.5p-miR TJU_CMC_MD2.ID02527.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02528.3p-miR TJU_CMC_MD2.ID02528.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02528.5p-miR TJU_CMC_MD2.ID02528.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02529.5p-miR TJU_CMC_MD2.ID02529.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02530.5p-miR TJU_CMC_MD2.ID02530.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID02531.3p-miR TJU_CMC_MD2.ID02531.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02532.3p-miR TJU_CMC_MD2.ID02532.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02533.3p-miR TJU_CMC_MD2.ID02533.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02534.5p-miR TJU_CMC_MD2.ID02534.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02535.3p-miR TJU_CMC_MD2.ID02535.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02536.5p-miR TJU_CMC_MD2.ID02536.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID02537.5p-miR TJU_CMC_MD2.ID02537.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02538.3p-miR TJU_CMC_MD2.ID02538.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02539.3p-miR TJU_CMC_MD2.ID02539.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02540.3p-miR TJU_CMC_MD2.ID02540.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02541.5p-miR TJU_CMC_MD2.ID02541.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02542.5p-miR TJU_CMC_MD2.ID02542.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02543.3p-miR TJU_CMC_MD2.ID02543.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02544.5p-miR TJU_CMC_MD2.ID02544.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02545.3p-miR TJU_CMC_MD2.ID02545.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02545.5p-miR TJU_CMC_MD2.ID02545.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02546.5p-miR TJU_CMC_MD2.ID02546.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02547.5p-miR TJU_CMC_MD2.ID02547.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02548.5p-miR TJU_CMC_MD2.ID02548.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02549.3p-miR TJU_CMC_MD2.ID02549.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02550.3p-miR TJU_CMC_MD2.ID02550.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02551.3p-miR TJU_CMC_MD2.ID02551.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02552.3p-miR TJU_CMC_MD2.ID02552.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02553.3p-miR TJU_CMC_MD2.ID02553.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02554.3p-miR TJU_CMC_MD2.ID02554.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02555.5p-miR TJU_CMC_MD2.ID02555.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02556.3p-miR TJU_CMC_MD2.ID02556.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02556.5p-miR TJU_CMC_MD2.ID02556.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02557.3p-miR TJU_CMC_MD2.ID02557.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02558.3p-miR TJU_CMC_MD2.ID02558.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02559.5p-miR TJU_CMC_MD2.ID02559.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02560.3p-miR TJU_CMC_MD2.ID02560.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02561.5p-miR TJU_CMC_MD2.ID02561.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02562.3p-miR TJU_CMC_MD2.ID02562.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02563.3p-miR TJU_CMC_MD2.ID02563.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02564.3p-miR TJU_CMC_MD2.ID02564.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02565.3p-miR TJU_CMC_MD2.ID02565.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02565.5p-miR TJU_CMC_MD2.ID02565.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02566.3p-miR TJU_CMC_MD2.ID02566.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02567.3p-miR TJU_CMC_MD2.ID02567.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02568.3p-miR TJU_CMC_MD2.ID02568.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02569.3p-miR TJU_CMC_MD2.ID02569.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02570.3p-miR TJU_CMC_MD2.ID02570.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02571.5p-miR TJU_CMC_MD2.ID02571.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02572.5p-miR TJU_CMC_MD2.ID02572.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02573.5p-miR TJU_CMC_MD2.ID02573.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02574.3p-miR TJU_CMC_MD2.ID02574.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02575.3p-miR TJU_CMC_MD2.ID02575.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02576.5p-miR TJU_CMC_MD2.ID02576.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02577.3p-miR TJU_CMC_MD2.ID02577.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02578.3p-miR TJU_CMC_MD2.ID02578.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02579.3p-miR TJU_CMC_MD2.ID02579.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02579.5p-miR TJU_CMC_MD2.ID02579.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02580.3p-miR TJU_CMC_MD2.ID02580.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02581.5p-miR TJU_CMC_MD2.ID02581.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02582.3p-miR TJU_CMC_MD2.ID02582.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02583.5p-miR TJU_CMC_MD2.ID02583.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02584.3p-miR TJU_CMC_MD2.ID02584.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02585.5p-miR TJU_CMC_MD2.ID02585.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02586.3p-miR TJU_CMC_MD2.ID02586.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02587.3p-miR TJU_CMC_MD2.ID02587.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02588.3p-miR TJU_CMC_MD2.ID02588.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02589.5p-miR TJU_CMC_MD2.ID02589.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02590.3p-miR TJU_CMC_MD2.ID02590.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02591.5p-miR TJU_CMC_MD2.ID02591.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02592.5p-miR TJU_CMC_MD2.ID02592.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02593.5p-miR TJU_CMC_MD2.ID02593.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02594.3p-miR TJU_CMC_MD2.ID02594.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02595.5p-miR TJU_CMC_MD2.ID02595.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02596.5p-miR TJU_CMC_MD2.ID02596.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02597.3p-miR TJU_CMC_MD2.ID02597.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02598.3p-miR TJU_CMC_MD2.ID02598.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02599.3p-miR TJU_CMC_MD2.ID02599.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02600.3p-miR TJU_CMC_MD2.ID02600.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02601.5p-miR TJU_CMC_MD2.ID02601.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02602.5p-miR TJU_CMC_MD2.ID02602.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02603.3p-miR TJU_CMC_MD2.ID02603.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02604.3p-miR TJU_CMC_MD2.ID02604.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02604.5p-miR TJU_CMC_MD2.ID02604.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02605.3p-miR TJU_CMC_MD2.ID02605.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02606.5p-miR TJU_CMC_MD2.ID02606.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02607.3p-miR TJU_CMC_MD2.ID02607.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02608.5p-miR TJU_CMC_MD2.ID02608.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02609.3p-miR TJU_CMC_MD2.ID02609.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02610.3p-miR TJU_CMC_MD2.ID02610.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02611.3p-miR TJU_CMC_MD2.ID02611.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02612.5p-miR TJU_CMC_MD2.ID02612.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02613.3p-miR TJU_CMC_MD2.ID02613.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02614.3p-miR TJU_CMC_MD2.ID02614.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02615.5p-miR TJU_CMC_MD2.ID02615.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02616.5p-miR TJU_CMC_MD2.ID02616.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02617.5p-miR TJU_CMC_MD2.ID02617.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02618.3p-miR TJU_CMC_MD2.ID02618.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02619.5p-miR TJU_CMC_MD2.ID02619.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02620.5p-miR TJU_CMC_MD2.ID02620.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02621.3p-miR TJU_CMC_MD2.ID02621.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02622.3p-miR TJU_CMC_MD2.ID02622.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02623.3p-miR TJU_CMC_MD2.ID02623.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02624.3p-miR TJU_CMC_MD2.ID02624.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02625.5p-miR TJU_CMC_MD2.ID02625.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02626.5p-miR TJU_CMC_MD2.ID02626.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID02627.5p-miR TJU_CMC_MD2.ID02627.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02628.5p-miR TJU_CMC_MD2.ID02628.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02629.3p-miR TJU_CMC_MD2.ID02629.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02629.5p-miR TJU_CMC_MD2.ID02629.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02630.3p-miR TJU_CMC_MD2.ID02630.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02631.5p-miR TJU_CMC_MD2.ID02631.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02632.5p-miR TJU_CMC_MD2.ID02632.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02633.3p-miR TJU_CMC_MD2.ID02633.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02634.3p-miR TJU_CMC_MD2.ID02634.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02635.5p-miR TJU_CMC_MD2.ID02635.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02636.5p-miR TJU_CMC_MD2.ID02636.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02637.3p-miR TJU_CMC_MD2.ID02637.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02638.3p-miR TJU_CMC_MD2.ID02638.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02638.5p-miR TJU_CMC_MD2.ID02638.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02639.5p-miR TJU_CMC_MD2.ID02639.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02640.3p-miR TJU_CMC_MD2.ID02640.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02641.5p-miR TJU_CMC_MD2.ID02641.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02642.3p-miR TJU_CMC_MD2.ID02642.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02642.5p-miR TJU_CMC_MD2.ID02642.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02643.3p-miR TJU_CMC_MD2.ID02643.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02644.3p-miR TJU_CMC_MD2.ID02644.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02645.5p-miR TJU_CMC_MD2.ID02645.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02646.3p-miR TJU_CMC_MD2.ID02646.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02647.3p-miR TJU_CMC_MD2.ID02647.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02648.5p-miR TJU_CMC_MD2.ID02648.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02649.5p-miR TJU_CMC_MD2.ID02649.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02650.3p-miR TJU_CMC_MD2.ID02650.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02651.5p-miR TJU_CMC_MD2.ID02651.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02652.5p-miR TJU_CMC_MD2.ID02652.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02653.3p-miR TJU_CMC_MD2.ID02653.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02654.3p-miR TJU_CMC_MD2.ID02654.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02655.3p-miR TJU_CMC_MD2.ID02655.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02656.5p-miR TJU_CMC_MD2.ID02656.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02657.5p-miR TJU_CMC_MD2.ID02657.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02658.5p-miR TJU_CMC_MD2.ID02658.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02659.3p-miR TJU_CMC_MD2.ID02659.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02660.3p-miR TJU_CMC_MD2.ID02660.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02661.5p-miR TJU_CMC_MD2.ID02661.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02662.5p-miR TJU_CMC_MD2.ID02662.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02663.5p-miR TJU_CMC_MD2.ID02663.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02664.5p-miR TJU_CMC_MD2.ID02664.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02665.3p-miR TJU_CMC_MD2.ID02665.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02666.5p-miR TJU_CMC_MD2.ID02666.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02667.5p-miR TJU_CMC_MD2.ID02667.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02668.5p-miR TJU_CMC_MD2.ID02668.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02669.5p-miR TJU_CMC_MD2.ID02669.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02670.3p-miR TJU_CMC_MD2.ID02670.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02670.5p-miR TJU_CMC_MD2.ID02670.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02671.5p-miR TJU_CMC_MD2.ID02671.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02672.5p-miR TJU_CMC_MD2.ID02672.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02673.5p-miR TJU_CMC_MD2.ID02673.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02674.3p-miR TJU_CMC_MD2.ID02674.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02675.3p-miR TJU_CMC_MD2.ID02675.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02676.5p-miR TJU_CMC_MD2.ID02676.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02677.5p-miR TJU_CMC_MD2.ID02677.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02678.3p-miR TJU_CMC_MD2.ID02678.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02679.3p-miR TJU_CMC_MD2.ID02679.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02680.3p-miR TJU_CMC_MD2.ID02680.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02681.3p-miR TJU_CMC_MD2.ID02681.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02682.5p-miR TJU_CMC_MD2.ID02682.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02683.3p-miR TJU_CMC_MD2.ID02683.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02683.5p-miR TJU_CMC_MD2.ID02683.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02684.5p-miR TJU_CMC_MD2.ID02684.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02685.3p-miR TJU_CMC_MD2.ID02685.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02686.5p-miR TJU_CMC_MD2.ID02686.hairpin YES NO NO YES NO YES NO NO TJU_CMC_MD2.ID02687.3p-miR TJU_CMC_MD2.ID02687.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02687.5p-miR TJU_CMC_MD2.ID02687.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02688.5p-miR TJU_CMC_MD2.ID02688.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02689.3p-miR TJU_CMC_MD2.ID02689.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02690.3p-miR TJU_CMC_MD2.ID02690.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02690.5p-miR TJU_CMC_MD2.ID02690.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02691.5p-miR TJU_CMC_MD2.ID02691.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02692.3p-miR TJU_CMC_MD2.ID02692.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02692.5p-miR TJU_CMC_MD2.ID02692.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02693.3p-miR TJU_CMC_MD2.ID02693.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02694.3p-miR TJU_CMC_MD2.ID02694.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02695.3p-miR TJU_CMC_MD2.ID02695.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02696.5p-miR TJU_CMC_MD2.ID02696.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02697.3p-miR TJU_CMC_MD2.ID02697.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02698.3p-miR TJU_CMC_MD2.ID02698.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02699.5p-miR TJU_CMC_MD2.ID02699.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02700.3p-miR TJU_CMC_MD2.ID02700.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02700.5p-miR TJU_CMC_MD2.ID02700.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02701.5p-miR TJU_CMC_MD2.ID02701.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02702.3p-miR TJU_CMC_MD2.ID02702.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02703.3p-miR TJU_CMC_MD2.ID02703.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02704.3p-miR TJU_CMC_MD2.ID02704.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02704.5p-miR TJU_CMC_MD2.ID02704.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02705.3p-miR TJU_CMC_MD2.ID02705.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02706.5p-miR TJU_CMC_MD2.ID02706.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02707.3p-miR TJU_CMC_MD2.ID02707.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02708.5p-miR TJU_CMC_MD2.ID02708.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02709.3p-miR TJU_CMC_MD2.ID02709.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02710.3p-miR TJU_CMC_MD2.ID02710.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02711.5p-miR TJU_CMC_MD2.ID02711.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02712.3p-miR TJU_CMC_MD2.ID02712.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02712.5p-miR TJU_CMC_MD2.ID02712.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02713.3p-miR TJU_CMC_MD2.ID02713.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02713.5p-miR TJU_CMC_MD2.ID02713.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02714.5p-miR TJU_CMC_MD2.ID02714.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02715.3p-miR TJU_CMC_MD2.ID02715.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02716.5p-miR TJU_CMC_MD2.ID02716.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02717.5p-miR TJU_CMC_MD2.ID02717.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02718.3p-miR TJU_CMC_MD2.ID02718.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02719.3p-miR TJU_CMC_MD2.ID02719.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02720.3p-miR TJU_CMC_MD2.ID02720.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02721.5p-miR TJU_CMC_MD2.ID02721.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02722.3p-miR TJU_CMC_MD2.ID02722.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02723.3p-miR TJU_CMC_MD2.ID02723.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02724.5p-miR TJU_CMC_MD2.ID02724.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02725.3p-miR TJU_CMC_MD2.ID02725.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02726.3p-miR TJU_CMC_MD2.ID02726.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02727.5p-miR TJU_CMC_MD2.ID02727.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02728.5p-miR TJU_CMC_MD2.ID02728.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID02729.5p-miR TJU_CMC_MD2.ID02729.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02730.5p-miR TJU_CMC_MD2.ID02730.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02731.3p-miR TJU_CMC_MD2.ID02731.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02732.3p-miR TJU_CMC_MD2.ID02732.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02733.5p-miR TJU_CMC_MD2.ID02733.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02734.3p-miR TJU_CMC_MD2.ID02734.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02735.3p-miR TJU_CMC_MD2.ID02735.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02736.5p-miR TJU_CMC_MD2.ID02736.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID02737.3p-miR TJU_CMC_MD2.ID02737.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02738.3p-miR TJU_CMC_MD2.ID02738.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02739.5p-miR TJU_CMC_MD2.ID02739.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02740.3p-miR TJU_CMC_MD2.ID02740.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02741.3p-miR TJU_CMC_MD2.ID02741.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02742.5p-miR TJU_CMC_MD2.ID02742.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID02743.5p-miR TJU_CMC_MD2.ID02743.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02744.3p-miR TJU_CMC_MD2.ID02744.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02745.3p-miR TJU_CMC_MD2.ID02745.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02746.5p-miR TJU_CMC_MD2.ID02746.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02747.5p-miR TJU_CMC_MD2.ID02747.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02748.3p-miR TJU_CMC_MD2.ID02748.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02749.5p-miR TJU_CMC_MD2.ID02749.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02750.3p-miR TJU_CMC_MD2.ID02750.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02751.3p-miR TJU_CMC_MD2.ID02751.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02752.3p-miR TJU_CMC_MD2.ID02752.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02753.3p-miR TJU_CMC_MD2.ID02753.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02753.5p-miR TJU_CMC_MD2.ID02753.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02754.5p-miR TJU_CMC_MD2.ID02754.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02755.3p-miR TJU_CMC_MD2.ID02755.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02756.3p-miR TJU_CMC_MD2.ID02756.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02757.3p-miR TJU_CMC_MD2.ID02757.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02758.3p-miR TJU_CMC_MD2.ID02758.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02759.3p-miR TJU_CMC_MD2.ID02759.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02759.5p-miR TJU_CMC_MD2.ID02759.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02760.3p-miR TJU_CMC_MD2.ID02760.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02761.3p-miR TJU_CMC_MD2.ID02761.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02762.5p-miR TJU_CMC_MD2.ID02762.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02763.3p-miR TJU_CMC_MD2.ID02763.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02764.5p-miR TJU_CMC_MD2.ID02764.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02765.3p-miR TJU_CMC_MD2.ID02765.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02766.3p-miR TJU_CMC_MD2.ID02766.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02767.3p-miR TJU_CMC_MD2.ID02767.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02768.3p-miR TJU_CMC_MD2.ID02768.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02769.5p-miR TJU_CMC_MD2.ID02769.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02770.5p-miR TJU_CMC_MD2.ID02770.hairpin YES YES NO NO NO YES NO NO TJU_CMC_MD2.ID02771.3p-miR TJU_CMC_MD2.ID02771.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02772.5p-miR TJU_CMC_MD2.ID02772.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02773.3p-miR TJU_CMC_MD2.ID02773.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02774.5p-miR TJU_CMC_MD2.ID02774.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02775.5p-miR TJU_CMC_MD2.ID02775.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02776.5p-miR TJU_CMC_MD2.ID02776.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02777.3p-miR TJU_CMC_MD2.ID02777.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02778.3p-miR TJU_CMC_MD2.ID02778.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02779.3p-miR TJU_CMC_MD2.ID02779.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02780.3p-miR TJU_CMC_MD2.ID02780.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02781.3p-miR TJU_CMC_MD2.ID02781.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02782.5p-miR TJU_CMC_MD2.ID02782.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02783.5p-miR TJU_CMC_MD2.ID02783.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02784.3p-miR TJU_CMC_MD2.ID02784.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02785.3p-miR TJU_CMC_MD2.ID02785.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02786.5p-miR TJU_CMC_MD2.ID02786.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02787.5p-miR TJU_CMC_MD2.ID02787.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02788.3p-miR TJU_CMC_MD2.ID02788.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02789.5p-miR TJU_CMC_MD2.ID02789.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02790.5p-miR TJU_CMC_MD2.ID02790.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02791.5p-miR TJU_CMC_MD2.ID02791.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02792.3p-miR TJU_CMC_MD2.ID02792.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02793.3p-miR TJU_CMC_MD2.ID02793.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02794.3p-miR TJU_CMC_MD2.ID02794.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02795.3p-miR TJU_CMC_MD2.ID02795.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02795.5p-miR TJU_CMC_MD2.ID02795.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02796.3p-miR TJU_CMC_MD2.ID02796.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02797.3p-miR TJU_CMC_MD2.ID02797.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02798.3p-miR TJU_CMC_MD2.ID02798.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02799.5p-miR TJU_CMC_MD2.ID02799.hairpin YES NO YES YES NO YES NO NO TJU_CMC_MD2.ID02800.3p-miR TJU_CMC_MD2.ID02800.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02801.3p-miR TJU_CMC_MD2.ID02801.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02802.3p-miR TJU_CMC_MD2.ID02802.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02803.5p-miR TJU_CMC_MD2.ID02803.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02804.5p-miR TJU_CMC_MD2.ID02804.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02805.5p-miR TJU_CMC_MD2.ID02805.hairpin YES YES YES NO NO YES NO NO TJU_CMC_MD2.ID02806.3p-miR TJU_CMC_MD2.ID02806.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02807.3p-miR TJU_CMC_MD2.ID02807.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02808.3p-miR TJU_CMC_MD2.ID02808.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02808.5p-miR TJU_CMC_MD2.ID02808.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02809.3p-miR TJU_CMC_MD2.ID02809.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02810.5p-miR TJU_CMC_MD2.ID02810.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02811.5p-miR TJU_CMC_MD2.ID02811.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02812.3p-miR TJU_CMC_MD2.ID02812.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02813.3p-miR TJU_CMC_MD2.ID02813.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02814.5p-miR TJU_CMC_MD2.ID02814.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02815.3p-miR TJU_CMC_MD2.ID02815.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02816.3p-miR TJU_CMC_MD2.ID02816.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02817.3p-miR TJU_CMC_MD2.ID02817.hairpin YES YES YES NO YES YES NO NO TJU_CMC_MD2.ID02817.5p-miR TJU_CMC_MD2.ID02817.hairpin YES YES YES NO YES YES NO NO TJU_CMC_MD2.ID02818.5p-miR TJU_CMC_MD2.ID02818.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02819.5p-miR TJU_CMC_MD2.ID02819.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02820.3p-miR TJU_CMC_MD2.ID02820.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02821.3p-miR TJU_CMC_MD2.ID02821.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02821.5p-miR TJU_CMC_MD2.ID02821.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02822.5p-miR TJU_CMC_MD2.ID02822.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02823.3p-miR TJU_CMC_MD2.ID02823.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02824.3p-miR TJU_CMC_MD2.ID02824.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02825.3p-miR TJU_CMC_MD2.ID02825.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02826.3p-miR TJU_CMC_MD2.ID02826.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02827.3p-miR TJU_CMC_MD2.ID02827.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02828.3p-miR TJU_CMC_MD2.ID02828.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02829.5p-miR TJU_CMC_MD2.ID02829.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID02830.3p-miR TJU_CMC_MD2.ID02830.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02831.3p-miR TJU_CMC_MD2.ID02831.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02831.5p-miR TJU_CMC_MD2.ID02831.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02832.3p-miR TJU_CMC_MD2.ID02832.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02833.5p-miR TJU_CMC_MD2.ID02833.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02834.3p-miR TJU_CMC_MD2.ID02834.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02835.3p-miR TJU_CMC_MD2.ID02835.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02835.5p-miR TJU_CMC_MD2.ID02835.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02836.3p-miR TJU_CMC_MD2.ID02836.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02837.5p-miR TJU_CMC_MD2.ID02837.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02838.5p-miR TJU_CMC_MD2.ID02838.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02839.3p-miR TJU_CMC_MD2.ID02839.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02840.3p-miR TJU_CMC_MD2.ID02840.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02841.5p-miR TJU_CMC_MD2.ID02841.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02842.5p-miR TJU_CMC_MD2.ID02842.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02843.5p-miR TJU_CMC_MD2.ID02843.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02844.5p-miR TJU_CMC_MD2.ID02844.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02845.5p-miR TJU_CMC_MD2.ID02845.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02846.3p-miR TJU_CMC_MD2.ID02846.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02847.5p-miR TJU_CMC_MD2.ID02847.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02848.3p-miR TJU_CMC_MD2.ID02848.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02849.5p-miR TJU_CMC_MD2.ID02849.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02850.3p-miR TJU_CMC_MD2.ID02850.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02851.5p-miR TJU_CMC_MD2.ID02851.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02852.5p-miR TJU_CMC_MD2.ID02852.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02853.3p-miR TJU_CMC_MD2.ID02853.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02854.5p-miR TJU_CMC_MD2.ID02854.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02855.5p-miR TJU_CMC_MD2.ID02855.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02856.5p-miR TJU_CMC_MD2.ID02856.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02857.3p-miR TJU_CMC_MD2.ID02857.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02858.3p-miR TJU_CMC_MD2.ID02858.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02859.3p-miR TJU_CMC_MD2.ID02859.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02860.5p-miR TJU_CMC_MD2.ID02860.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID02861.3p-miR TJU_CMC_MD2.ID02861.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02862.3p-miR TJU_CMC_MD2.ID02862.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02863.3p-miR TJU_CMC_MD2.ID02863.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02864.5p-miR TJU_CMC_MD2.ID02864.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02865.5p-miR TJU_CMC_MD2.ID02865.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02866.5p-miR TJU_CMC_MD2.ID02866.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02867.3p-miR TJU_CMC_MD2.ID02867.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02868.3p-miR TJU_CMC_MD2.ID02868.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02869.3p-miR TJU_CMC_MD2.ID02869.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02870.5p-miR TJU_CMC_MD2.ID02870.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02871.5p-miR TJU_CMC_MD2.ID02871.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02872.3p-miR TJU_CMC_MD2.ID02872.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02873.3p-miR TJU_CMC_MD2.ID02873.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02874.5p-miR TJU_CMC_MD2.ID02874.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02875.5p-miR TJU_CMC_MD2.ID02875.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02876.3p-miR TJU_CMC_MD2.ID02876.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02876.5p-miR TJU_CMC_MD2.ID02876.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID02877.5p-miR TJU_CMC_MD2.ID02877.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02878.3p-miR TJU_CMC_MD2.ID02878.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02878.5p-miR TJU_CMC_MD2.ID02878.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02879.3p-miR TJU_CMC_MD2.ID02879.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02880.3p-miR TJU_CMC_MD2.ID02880.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02881.3p-miR TJU_CMC_MD2.ID02881.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02882.3p-miR TJU_CMC_MD2.ID02882.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02883.3p-miR TJU_CMC_MD2.ID02883.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02884.3p-miR TJU_CMC_MD2.ID02884.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02885.3p-miR TJU_CMC_MD2.ID02885.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02886.5p-miR TJU_CMC_MD2.ID02886.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02887.3p-miR TJU_CMC_MD2.ID02887.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02888.5p-miR TJU_CMC_MD2.ID02888.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02889.3p-miR TJU_CMC_MD2.ID02889.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02890.3p-miR TJU_CMC_MD2.ID02890.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02890.5p-miR TJU_CMC_MD2.ID02890.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02891.3p-miR TJU_CMC_MD2.ID02891.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02892.3p-miR TJU_CMC_MD2.ID02892.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02893.5p-miR TJU_CMC_MD2.ID02893.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02894.3p-miR TJU_CMC_MD2.ID02894.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02895.3p-miR TJU_CMC_MD2.ID02895.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02896.5p-miR TJU_CMC_MD2.ID02896.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02897.3p-miR TJU_CMC_MD2.ID02897.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02898.3p-miR TJU_CMC_MD2.ID02898.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02899.3p-miR TJU_CMC_MD2.ID02899.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02900.5p-miR TJU_CMC_MD2.ID02900.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02901.3p-miR TJU_CMC_MD2.ID02901.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02902.5p-miR TJU_CMC_MD2.ID02902.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02903.3p-miR TJU_CMC_MD2.ID02903.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02904.5p-miR TJU_CMC_MD2.ID02904.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02905.3p-miR TJU_CMC_MD2.ID02905.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02906.3p-miR TJU_CMC_MD2.ID02906.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02907.3p-miR TJU_CMC_MD2.ID02907.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02908.3p-miR TJU_CMC_MD2.ID02908.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02909.5p-miR TJU_CMC_MD2.ID02909.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02910.5p-miR TJU_CMC_MD2.ID02910.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02911.5p-miR TJU_CMC_MD2.ID02911.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02912.3p-miR TJU_CMC_MD2.ID02912.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02912.5p-miR TJU_CMC_MD2.ID02912.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02913.5p-miR TJU_CMC_MD2.ID02913.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02914.3p-miR TJU_CMC_MD2.ID02914.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02915.3p-miR TJU_CMC_MD2.ID02915.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02916.5p-miR TJU_CMC_MD2.ID02916.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02917.3p-miR TJU_CMC_MD2.ID02917.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02918.5p-miR TJU_CMC_MD2.ID02918.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02919.5p-miR TJU_CMC_MD2.ID02919.hairpin YES YES NO NO YES NO NO NO TJU_CMC_MD2.ID02920.3p-miR TJU_CMC_MD2.ID02920.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02921.3p-miR TJU_CMC_MD2.ID02921.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02921.5p-miR TJU_CMC_MD2.ID02921.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02922.3p-miR TJU_CMC_MD2.ID02922.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02923.5p-miR TJU_CMC_MD2.ID02923.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02924.3p-miR TJU_CMC_MD2.ID02924.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02925.3p-miR TJU_CMC_MD2.ID02925.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02926.5p-miR TJU_CMC_MD2.ID02926.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02927.5p-miR TJU_CMC_MD2.ID02927.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02928.3p-miR TJU_CMC_MD2.ID02928.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02929.3p-miR TJU_CMC_MD2.ID02929.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02930.3p-miR TJU_CMC_MD2.ID02930.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02931.3p-miR TJU_CMC_MD2.ID02931.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02931.5p-miR TJU_CMC_MD2.ID02931.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02932.5p-miR TJU_CMC_MD2.ID02932.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02933.5p-miR TJU_CMC_MD2.ID02933.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02934.5p-miR TJU_CMC_MD2.ID02934.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID02935.3p-miR TJU_CMC_MD2.ID02935.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02936.5p-miR TJU_CMC_MD2.ID02936.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID02937.5p-miR TJU_CMC_MD2.ID02937.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02938.3p-miR TJU_CMC_MD2.ID02938.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02939.5p-miR TJU_CMC_MD2.ID02939.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02940.3p-miR TJU_CMC_MD2.ID02940.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02941.3p-miR TJU_CMC_MD2.ID02941.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02942.5p-miR TJU_CMC_MD2.ID02942.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02943.5p-miR TJU_CMC_MD2.ID02943.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02944.5p-miR TJU_CMC_MD2.ID02944.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID02945.3p-miR TJU_CMC_MD2.ID02945.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02945.5p-miR TJU_CMC_MD2.ID02945.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02946.5p-miR TJU_CMC_MD2.ID02946.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02947.3p-miR TJU_CMC_MD2.ID02947.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02948.5p-miR TJU_CMC_MD2.ID02948.hairpin YES YES NO NO NO YES NO NO TJU_CMC_MD2.ID02949.3p-miR TJU_CMC_MD2.ID02949.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02950.3p-miR TJU_CMC_MD2.ID02950.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02951.3p-miR TJU_CMC_MD2.ID02951.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02952.3p-miR TJU_CMC_MD2.ID02952.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02953.5p-miR TJU_CMC_MD2.ID02953.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02954.3p-miR TJU_CMC_MD2.ID02954.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02955.3p-miR TJU_CMC_MD2.ID02955.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02956.5p-miR TJU_CMC_MD2.ID02956.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02957.5p-miR TJU_CMC_MD2.ID02957.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02958.3p-miR TJU_CMC_MD2.ID02958.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02959.3p-miR TJU_CMC_MD2.ID02959.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02960.3p-miR TJU_CMC_MD2.ID02960.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02961.5p-miR TJU_CMC_MD2.ID02961.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02962.3p-miR TJU_CMC_MD2.ID02962.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02963.5p-miR TJU_CMC_MD2.ID02963.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02964.3p-miR TJU_CMC_MD2.ID02964.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02965.5p-miR TJU_CMC_MD2.ID02965.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02966.5p-miR TJU_CMC_MD2.ID02966.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02967.3p-miR TJU_CMC_MD2.ID02967.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02968.3p-miR TJU_CMC_MD2.ID02968.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02969.3p-miR TJU_CMC_MD2.ID02969.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02970.5p-miR TJU_CMC_MD2.ID02970.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02971.3p-miR TJU_CMC_MD2.ID02971.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02972.5p-miR TJU_CMC_MD2.ID02972.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02973.3p-miR TJU_CMC_MD2.ID02973.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02974.3p-miR TJU_CMC_MD2.ID02974.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02975.3p-miR TJU_CMC_MD2.ID02975.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02976.5p-miR TJU_CMC_MD2.ID02976.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02977.3p-miR TJU_CMC_MD2.ID02977.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02978.3p-miR TJU_CMC_MD2.ID02978.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02979.5p-miR TJU_CMC_MD2.ID02979.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02980.3p-miR TJU_CMC_MD2.ID02980.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02981.3p-miR TJU_CMC_MD2.ID02981.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02982.3p-miR TJU_CMC_MD2.ID02982.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02983.3p-miR TJU_CMC_MD2.ID02983.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02984.3p-miR TJU_CMC_MD2.ID02984.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02985.3p-miR TJU_CMC_MD2.ID02985.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02986.5p-miR TJU_CMC_MD2.ID02986.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02987.5p-miR TJU_CMC_MD2.ID02987.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02988.5p-miR TJU_CMC_MD2.ID02988.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID02989.3p-miR TJU_CMC_MD2.ID02989.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02990.3p-miR TJU_CMC_MD2.ID02990.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02991.3p-miR TJU_CMC_MD2.ID02991.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02992.5p-miR TJU_CMC_MD2.ID02992.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID02993.5p-miR TJU_CMC_MD2.ID02993.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID02994.3p-miR TJU_CMC_MD2.ID02994.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02995.3p-miR TJU_CMC_MD2.ID02995.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02996.5p-miR TJU_CMC_MD2.ID02996.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID02997.5p-miR TJU_CMC_MD2.ID02997.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID02998.3p-miR TJU_CMC_MD2.ID02998.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID02999.5p-miR TJU_CMC_MD2.ID02999.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03000.5p-miR TJU_CMC_MD2.ID03000.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03001.3p-miR TJU_CMC_MD2.ID03001.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03002.5p-miR TJU_CMC_MD2.ID03002.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03003.5p-miR TJU_CMC_MD2.ID03003.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03004.3p-miR TJU_CMC_MD2.ID03004.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03005.3p-miR TJU_CMC_MD2.ID03005.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03006.5p-miR TJU_CMC_MD2.ID03006.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03007.5p-miR TJU_CMC_MD2.ID03007.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03008.5p-miR TJU_CMC_MD2.ID03008.hairpin YES YES YES NO NO YES NO NO TJU_CMC_MD2.ID03009.3p-miR TJU_CMC_MD2.ID03009.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03010.5p-miR TJU_CMC_MD2.ID03010.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03011.5p-miR TJU_CMC_MD2.ID03011.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03012.3p-miR TJU_CMC_MD2.ID03012.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03013.5p-miR TJU_CMC_MD2.ID03013.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03014.3p-miR TJU_CMC_MD2.ID03014.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03015.3p-miR TJU_CMC_MD2.ID03015.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03016.3p-miR TJU_CMC_MD2.ID03016.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03017.5p-miR TJU_CMC_MD2.ID03017.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03018.3p-miR TJU_CMC_MD2.ID03018.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03019.5p-miR TJU_CMC_MD2.ID03019.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03020.3p-miR TJU_CMC_MD2.ID03020.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03021.5p-miR TJU_CMC_MD2.ID03021.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03022.3p-miR TJU_CMC_MD2.ID03022.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03023.3p-miR TJU_CMC_MD2.ID03023.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03024.5p-miR TJU_CMC_MD2.ID03024.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03025.5p-miR TJU_CMC_MD2.ID03025.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03026.5p-miR TJU_CMC_MD2.ID03026.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03027.3p-miR TJU_CMC_MD2.ID03027.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03028.3p-miR TJU_CMC_MD2.ID03028.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03029.3p-miR TJU_CMC_MD2.ID03029.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03030.3p-miR TJU_CMC_MD2.ID03030.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03031.5p-miR TJU_CMC_MD2.ID03031.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03032.3p-miR TJU_CMC_MD2.ID03032.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03033.3p-miR TJU_CMC_MD2.ID03033.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03034.5p-miR TJU_CMC_MD2.ID03034.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03035.3p-miR TJU_CMC_MD2.ID03035.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03036.3p-miR TJU_CMC_MD2.ID03036.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03037.3p-miR TJU_CMC_MD2.ID03037.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03038.3p-miR TJU_CMC_MD2.ID03038.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03039.3p-miR TJU_CMC_MD2.ID03039.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03040.3p-miR TJU_CMC_MD2.ID03040.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03041.3p-miR TJU_CMC_MD2.ID03041.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03042.5p-miR TJU_CMC_MD2.ID03042.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03043.5p-miR TJU_CMC_MD2.ID03043.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03044.3p-miR TJU_CMC_MD2.ID03044.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03045.3p-miR TJU_CMC_MD2.ID03045.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03046.3p-miR TJU_CMC_MD2.ID03046.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03047.3p-miR TJU_CMC_MD2.ID03047.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03048.3p-miR TJU_CMC_MD2.ID03048.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03049.5p-miR TJU_CMC_MD2.ID03049.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03050.3p-miR TJU_CMC_MD2.ID03050.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03051.3p-miR TJU_CMC_MD2.ID03051.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03052.5p-miR TJU_CMC_MD2.ID03052.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03053.3p-miR TJU_CMC_MD2.ID03053.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03054.3p-miR TJU_CMC_MD2.ID03054.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03055.5p-miR TJU_CMC_MD2.ID03055.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03056.3p-miR TJU_CMC_MD2.ID03056.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03057.3p-miR TJU_CMC_MD2.ID03057.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03058.3p-miR TJU_CMC_MD2.ID03058.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03059.3p-miR TJU_CMC_MD2.ID03059.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03060.3p-miR TJU_CMC_MD2.ID03060.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03061.3p-miR TJU_CMC_MD2.ID03061.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03061.5p-miR TJU_CMC_MD2.ID03061.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03062.3p-miR TJU_CMC_MD2.ID03062.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03063.3p-miR TJU_CMC_MD2.ID03063.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03063.5p-miR TJU_CMC_MD2.ID03063.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03064.3p-miR TJU_CMC_MD2.ID03064.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03065.3p-miR TJU_CMC_MD2.ID03065.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03066.3p-miR TJU_CMC_MD2.ID03066.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03066.5p-miR TJU_CMC_MD2.ID03066.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03067.5p-miR TJU_CMC_MD2.ID03067.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03068.3p-miR TJU_CMC_MD2.ID03068.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03069.5p-miR TJU_CMC_MD2.ID03069.hairpin YES NO YES YES NO YES NO NO TJU_CMC_MD2.ID03070.3p-miR TJU_CMC_MD2.ID03070.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03071.3p-miR TJU_CMC_MD2.ID03071.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03072.5p-miR TJU_CMC_MD2.ID03072.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03073.3p-miR TJU_CMC_MD2.ID03073.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03074.5p-miR TJU_CMC_MD2.ID03074.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03075.5p-miR TJU_CMC_MD2.ID03075.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03076.5p-miR TJU_CMC_MD2.ID03076.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID03077.3p-miR TJU_CMC_MD2.ID03077.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03078.3p-miR TJU_CMC_MD2.ID03078.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03079.5p-miR TJU_CMC_MD2.ID03079.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03080.5p-miR TJU_CMC_MD2.ID03080.hairpin YES YES YES NO NO YES NO NO TJU_CMC_MD2.ID03081.5p-miR TJU_CMC_MD2.ID03081.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03082.3p-miR TJU_CMC_MD2.ID03082.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03083.5p-miR TJU_CMC_MD2.ID03083.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03084.3p-miR TJU_CMC_MD2.ID03084.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03085.5p-miR TJU_CMC_MD2.ID03085.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03086.5p-miR TJU_CMC_MD2.ID03086.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03087.3p-miR TJU_CMC_MD2.ID03087.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03088.3p-miR TJU_CMC_MD2.ID03088.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03089.5p-miR TJU_CMC_MD2.ID03089.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03090.3p-miR TJU_CMC_MD2.ID03090.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03091.5p-miR TJU_CMC_MD2.ID03091.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03092.3p-miR TJU_CMC_MD2.ID03092.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03093.3p-miR TJU_CMC_MD2.ID03093.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03093.5p-miR TJU_CMC_MD2.ID03093.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03094.3p-miR TJU_CMC_MD2.ID03094.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03094.5p-miR TJU_CMC_MD2.ID03094.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03095.3p-miR TJU_CMC_MD2.ID03095.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03095.5p-miR TJU_CMC_MD2.ID03095.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03096.5p-miR TJU_CMC_MD2.ID03096.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03097.3p-miR TJU_CMC_MD2.ID03097.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03098.3p-miR TJU_CMC_MD2.ID03098.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03099.3p-miR TJU_CMC_MD2.ID03099.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03100.3p-miR TJU_CMC_MD2.ID03100.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03101.3p-miR TJU_CMC_MD2.ID03101.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03102.5p-miR TJU_CMC_MD2.ID03102.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03103.3p-miR TJU_CMC_MD2.ID03103.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03104.3p-miR TJU_CMC_MD2.ID03104.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03105.3p-miR TJU_CMC_MD2.ID03105.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03106.3p-miR TJU_CMC_MD2.ID03106.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03107.3p-miR TJU_CMC_MD2.ID03107.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03108.5p-miR TJU_CMC_MD2.ID03108.hairpin YES YES YES NO NO YES NO NO TJU_CMC_MD2.ID03109.3p-miR TJU_CMC_MD2.ID03109.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03109.5p-miR TJU_CMC_MD2.ID03109.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03110.3p-miR TJU_CMC_MD2.ID03110.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03111.5p-miR TJU_CMC_MD2.ID03111.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03112.5p-miR TJU_CMC_MD2.ID03112.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03113.3p-miR TJU_CMC_MD2.ID03113.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03114.3p-miR TJU_CMC_MD2.ID03114.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03115.5p-miR TJU_CMC_MD2.ID03115.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03116.3p-miR TJU_CMC_MD2.ID03116.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03117.3p-miR TJU_CMC_MD2.ID03117.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03118.3p-miR TJU_CMC_MD2.ID03118.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03119.5p-miR TJU_CMC_MD2.ID03119.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03120.3p-miR TJU_CMC_MD2.ID03120.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03121.3p-miR TJU_CMC_MD2.ID03121.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03122.3p-miR TJU_CMC_MD2.ID03122.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03123.5p-miR TJU_CMC_MD2.ID03123.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03124.3p-miR TJU_CMC_MD2.ID03124.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03125.3p-miR TJU_CMC_MD2.ID03125.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03126.5p-miR TJU_CMC_MD2.ID03126.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03127.5p-miR TJU_CMC_MD2.ID03127.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03128.5p-miR TJU_CMC_MD2.ID03128.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03129.3p-miR TJU_CMC_MD2.ID03129.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03130.5p-miR TJU_CMC_MD2.ID03130.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03131.3p-miR TJU_CMC_MD2.ID03131.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03132.5p-miR TJU_CMC_MD2.ID03132.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03133.3p-miR TJU_CMC_MD2.ID03133.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03134.3p-miR TJU_CMC_MD2.ID03134.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03135.5p-miR TJU_CMC_MD2.ID03135.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03136.3p-miR TJU_CMC_MD2.ID03136.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03137.5p-miR TJU_CMC_MD2.ID03137.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03138.3p-miR TJU_CMC_MD2.ID03138.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03138.5p-miR TJU_CMC_MD2.ID03138.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03139.5p-miR TJU_CMC_MD2.ID03139.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03140.3p-miR TJU_CMC_MD2.ID03140.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03141.3p-miR TJU_CMC_MD2.ID03141.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03141.5p-miR TJU_CMC_MD2.ID03141.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03142.5p-miR TJU_CMC_MD2.ID03142.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03143.3p-miR TJU_CMC_MD2.ID03143.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03144.5p-miR TJU_CMC_MD2.ID03144.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03145.5p-miR TJU_CMC_MD2.ID03145.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03146.5p-miR TJU_CMC_MD2.ID03146.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03147.5p-miR TJU_CMC_MD2.ID03147.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03148.3p-miR TJU_CMC_MD2.ID03148.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03149.5p-miR TJU_CMC_MD2.ID03149.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03150.3p-miR TJU_CMC_MD2.ID03150.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03151.3p-miR TJU_CMC_MD2.ID03151.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03152.3p-miR TJU_CMC_MD2.ID03152.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03153.3p-miR TJU_CMC_MD2.ID03153.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03154.3p-miR TJU_CMC_MD2.ID03154.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03155.3p-miR TJU_CMC_MD2.ID03155.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03156.5p-miR TJU_CMC_MD2.ID03156.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03157.5p-miR TJU_CMC_MD2.ID03157.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03158.5p-miR TJU_CMC_MD2.ID03158.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03159.3p-miR TJU_CMC_MD2.ID03159.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03159.5p-miR TJU_CMC_MD2.ID03159.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03160.5p-miR TJU_CMC_MD2.ID03160.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03161.3p-miR TJU_CMC_MD2.ID03161.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03162.3p-miR TJU_CMC_MD2.ID03162.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03163.3p-miR TJU_CMC_MD2.ID03163.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03164.3p-miR TJU_CMC_MD2.ID03164.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03165.5p-miR TJU_CMC_MD2.ID03165.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03166.5p-miR TJU_CMC_MD2.ID03166.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03167.3p-miR TJU_CMC_MD2.ID03167.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03168.3p-miR TJU_CMC_MD2.ID03168.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03169.5p-miR TJU_CMC_MD2.ID03169.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03170.3p-miR TJU_CMC_MD2.ID03170.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03170.5p-miR TJU_CMC_MD2.ID03170.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03171.5p-miR TJU_CMC_MD2.ID03171.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03172.3p-miR TJU_CMC_MD2.ID03172.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03173.3p-miR TJU_CMC_MD2.ID03173.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03174.5p-miR TJU_CMC_MD2.ID03174.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03175.3p-miR TJU_CMC_MD2.ID03175.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03176.5p-miR TJU_CMC_MD2.ID03176.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03177.5p-miR TJU_CMC_MD2.ID03177.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03178.5p-miR TJU_CMC_MD2.ID03178.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID03179.5p-miR TJU_CMC_MD2.ID03179.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03180.5p-miR TJU_CMC_MD2.ID03180.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03181.3p-miR TJU_CMC_MD2.ID03181.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03182.3p-miR TJU_CMC_MD2.ID03182.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03183.3p-miR TJU_CMC_MD2.ID03183.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03184.3p-miR TJU_CMC_MD2.ID03184.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03185.5p-miR TJU_CMC_MD2.ID03185.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03186.3p-miR TJU_CMC_MD2.ID03186.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03187.3p-miR TJU_CMC_MD2.ID03187.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03188.3p-miR TJU_CMC_MD2.ID03188.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03188.5p-miR TJU_CMC_MD2.ID03188.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03189.3p-miR TJU_CMC_MD2.ID03189.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03190.5p-miR TJU_CMC_MD2.ID03190.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03191.3p-miR TJU_CMC_MD2.ID03191.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03192.5p-miR TJU_CMC_MD2.ID03192.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03193.3p-miR TJU_CMC_MD2.ID03193.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03194.3p-miR TJU_CMC_MD2.ID03194.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03195.3p-miR TJU_CMC_MD2.ID03195.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03196.3p-miR TJU_CMC_MD2.ID03196.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03197.5p-miR TJU_CMC_MD2.ID03197.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03198.3p-miR TJU_CMC_MD2.ID03198.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03199.5p-miR TJU_CMC_MD2.ID03199.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03200.3p-miR TJU_CMC_MD2.ID03200.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03201.3p-miR TJU_CMC_MD2.ID03201.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03202.3p-miR TJU_CMC_MD2.ID03202.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03203.3p-miR TJU_CMC_MD2.ID03203.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03204.3p-miR TJU_CMC_MD2.ID03204.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03205.3p-miR TJU_CMC_MD2.ID03205.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03206.5p-miR TJU_CMC_MD2.ID03206.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03207.3p-miR TJU_CMC_MD2.ID03207.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03208.5p-miR TJU_CMC_MD2.ID03208.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03209.5p-miR TJU_CMC_MD2.ID03209.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03210.5p-miR TJU_CMC_MD2.ID03210.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID03211.3p-miR TJU_CMC_MD2.ID03211.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03212.5p-miR TJU_CMC_MD2.ID03212.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03213.5p-miR TJU_CMC_MD2.ID03213.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03214.3p-miR TJU_CMC_MD2.ID03214.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03215.3p-miR TJU_CMC_MD2.ID03215.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03216.3p-miR TJU_CMC_MD2.ID03216.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03217.5p-miR TJU_CMC_MD2.ID03217.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03218.3p-miR TJU_CMC_MD2.ID03218.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03219.3p-miR TJU_CMC_MD2.ID03219.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03220.3p-miR TJU_CMC_MD2.ID03220.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03221.5p-miR TJU_CMC_MD2.ID03221.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03222.5p-miR TJU_CMC_MD2.ID03222.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03223.5p-miR TJU_CMC_MD2.ID03223.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03224.5p-miR TJU_CMC_MD2.ID03224.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03225.3p-miR TJU_CMC_MD2.ID03225.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03226.3p-miR TJU_CMC_MD2.ID03226.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03227.3p-miR TJU_CMC_MD2.ID03227.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03228.5p-miR TJU_CMC_MD2.ID03228.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID03229.5p-miR TJU_CMC_MD2.ID03229.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03230.5p-miR TJU_CMC_MD2.ID03230.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03231.5p-miR TJU_CMC_MD2.ID03231.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03232.3p-miR TJU_CMC_MD2.ID03232.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03233.5p-miR TJU_CMC_MD2.ID03233.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03234.5p-miR TJU_CMC_MD2.ID03234.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03235.3p-miR TJU_CMC_MD2.ID03235.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03236.3p-miR TJU_CMC_MD2.ID03236.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03236.5p-miR TJU_CMC_MD2.ID03236.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03237.3p-miR TJU_CMC_MD2.ID03237.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03238.3p-miR TJU_CMC_MD2.ID03238.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03239.5p-miR TJU_CMC_MD2.ID03239.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03240.3p-miR TJU_CMC_MD2.ID03240.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03241.5p-miR TJU_CMC_MD2.ID03241.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03242.5p-miR TJU_CMC_MD2.ID03242.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03243.3p-miR TJU_CMC_MD2.ID03243.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03244.3p-miR TJU_CMC_MD2.ID03244.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03244.5p-miR TJU_CMC_MD2.ID03244.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03245.5p-miR TJU_CMC_MD2.ID03245.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03246.3p-miR TJU_CMC_MD2.ID03246.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03247.3p-miR TJU_CMC_MD2.ID03247.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03248.3p-miR TJU_CMC_MD2.ID03248.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03249.3p-miR TJU_CMC_MD2.ID03249.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03250.5p-miR TJU_CMC_MD2.ID03250.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03251.5p-miR TJU_CMC_MD2.ID03251.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03252.5p-miR TJU_CMC_MD2.ID03252.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03253.3p-miR TJU_CMC_MD2.ID03253.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03254.5p-miR TJU_CMC_MD2.ID03254.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03255.5p-miR TJU_CMC_MD2.ID03255.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03256.3p-miR TJU_CMC_MD2.ID03256.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03257.3p-miR TJU_CMC_MD2.ID03257.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03258.5p-miR TJU_CMC_MD2.ID03258.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03259.3p-miR TJU_CMC_MD2.ID03259.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03260.3p-miR TJU_CMC_MD2.ID03260.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03261.5p-miR TJU_CMC_MD2.ID03261.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03262.5p-miR TJU_CMC_MD2.ID03262.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03263.3p-miR TJU_CMC_MD2.ID03263.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03263.5p-miR TJU_CMC_MD2.ID03263.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03264.3p-miR TJU_CMC_MD2.ID03264.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03265.3p-miR TJU_CMC_MD2.ID03265.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03266.5p-miR TJU_CMC_MD2.ID03266.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03267.3p-miR TJU_CMC_MD2.ID03267.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03268.3p-miR TJU_CMC_MD2.ID03268.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03269.5p-miR TJU_CMC_MD2.ID03269.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03270.3p-miR TJU_CMC_MD2.ID03270.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03271.5p-miR TJU_CMC_MD2.ID03271.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03272.5p-miR TJU_CMC_MD2.ID03272.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03273.3p-miR TJU_CMC_MD2.ID03273.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03274.3p-miR TJU_CMC_MD2.ID03274.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03275.5p-miR TJU_CMC_MD2.ID03275.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03276.5p-miR TJU_CMC_MD2.ID03276.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03277.5p-miR TJU_CMC_MD2.ID03277.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03278.3p-miR TJU_CMC_MD2.ID03278.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03279.3p-miR TJU_CMC_MD2.ID03279.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03279.5p-miR TJU_CMC_MD2.ID03279.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03280.3p-miR TJU_CMC_MD2.ID03280.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03281.3p-miR TJU_CMC_MD2.ID03281.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03282.3p-miR TJU_CMC_MD2.ID03282.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03283.5p-miR TJU_CMC_MD2.ID03283.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03284.3p-miR TJU_CMC_MD2.ID03284.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03285.3p-miR TJU_CMC_MD2.ID03285.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03286.5p-miR TJU_CMC_MD2.ID03286.hairpin YES YES YES NO YES YES NO NO TJU_CMC_MD2.ID03287.3p-miR TJU_CMC_MD2.ID03287.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03288.5p-miR TJU_CMC_MD2.ID03288.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03289.5p-miR TJU_CMC_MD2.ID03289.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03290.3p-miR TJU_CMC_MD2.ID03290.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03291.3p-miR TJU_CMC_MD2.ID03291.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03292.3p-miR TJU_CMC_MD2.ID03292.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03293.3p-miR TJU_CMC_MD2.ID03293.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03294.5p-miR TJU_CMC_MD2.ID03294.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03295.3p-miR TJU_CMC_MD2.ID03295.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03296.3p-miR TJU_CMC_MD2.ID03296.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03296.5p-miR TJU_CMC_MD2.ID03296.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03297.3p-miR TJU_CMC_MD2.ID03297.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03298.3p-miR TJU_CMC_MD2.ID03298.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03299.5p-miR TJU_CMC_MD2.ID03299.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03300.5p-miR TJU_CMC_MD2.ID03300.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03301.3p-miR TJU_CMC_MD2.ID03301.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03302.3p-miR TJU_CMC_MD2.ID03302.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03303.3p-miR TJU_CMC_MD2.ID03303.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03304.3p-miR TJU_CMC_MD2.ID03304.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03305.5p-miR TJU_CMC_MD2.ID03305.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03306.3p-miR TJU_CMC_MD2.ID03306.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03307.3p-miR TJU_CMC_MD2.ID03307.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03308.3p-miR TJU_CMC_MD2.ID03308.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03309.5p-miR TJU_CMC_MD2.ID03309.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03310.5p-miR TJU_CMC_MD2.ID03310.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03311.5p-miR TJU_CMC_MD2.ID03311.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03312.5p-miR TJU_CMC_MD2.ID03312.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID03313.3p-miR TJU_CMC_MD2.ID03313.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03314.5p-miR TJU_CMC_MD2.ID03314.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03315.3p-miR TJU_CMC_MD2.ID03315.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03316.3p-miR TJU_CMC_MD2.ID03316.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03317.3p-miR TJU_CMC_MD2.ID03317.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03318.3p-miR TJU_CMC_MD2.ID03318.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03319.3p-miR TJU_CMC_MD2.ID03319.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03320.3p-miR TJU_CMC_MD2.ID03320.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03321.3p-miR TJU_CMC_MD2.ID03321.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03322.3p-miR TJU_CMC_MD2.ID03322.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03323.5p-miR TJU_CMC_MD2.ID03323.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03324.3p-miR TJU_CMC_MD2.ID03324.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03325.5p-miR TJU_CMC_MD2.ID03325.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03326.3p-miR TJU_CMC_MD2.ID03326.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03327.3p-miR TJU_CMC_MD2.ID03327.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03328.5p-miR TJU_CMC_MD2.ID03328.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03329.3p-miR TJU_CMC_MD2.ID03329.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03330.3p-miR TJU_CMC_MD2.ID03330.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03331.3p-miR TJU_CMC_MD2.ID03331.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03332.3p-miR TJU_CMC_MD2.ID03332.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03333.3p-miR TJU_CMC_MD2.ID03333.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03334.5p-miR TJU_CMC_MD2.ID03334.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03335.3p-miR TJU_CMC_MD2.ID03335.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03336.5p-miR TJU_CMC_MD2.ID03336.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03337.3p-miR TJU_CMC_MD2.ID03337.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03338.5p-miR TJU_CMC_MD2.ID03338.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03339.5p-miR TJU_CMC_MD2.ID03339.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03340.3p-miR TJU_CMC_MD2.ID03340.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03340.5p-miR TJU_CMC_MD2.ID03340.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03341.5p-miR TJU_CMC_MD2.ID03341.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03342.3p-miR TJU_CMC_MD2.ID03342.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03343.3p-miR TJU_CMC_MD2.ID03343.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03344.3p-miR TJU_CMC_MD2.ID03344.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03345.5p-miR TJU_CMC_MD2.ID03345.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03346.3p-miR TJU_CMC_MD2.ID03346.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03347.5p-miR TJU_CMC_MD2.ID03347.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03348.3p-miR TJU_CMC_MD2.ID03348.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03349.3p-miR TJU_CMC_MD2.ID03349.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03350.5p-miR TJU_CMC_MD2.ID03350.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03351.5p-miR TJU_CMC_MD2.ID03351.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03352.3p-miR TJU_CMC_MD2.ID03352.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID03353.5p-miR TJU_CMC_MD2.ID03353.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03354.5p-miR TJU_CMC_MD2.ID03354.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03355.5p-miR TJU_CMC_MD2.ID03355.hairpin YES YES NO YES YES NO NO NO TJU_CMC_MD2.ID03356.5p-miR TJU_CMC_MD2.ID03356.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID03357.3p-miR TJU_CMC_MD2.ID03357.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03358.3p-miR TJU_CMC_MD2.ID03358.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03359.5p-miR TJU_CMC_MD2.ID03359.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03360.3p-miR TJU_CMC_MD2.ID03360.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03361.5p-miR TJU_CMC_MD2.ID03361.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03362.5p-miR TJU_CMC_MD2.ID03362.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03363.5p-miR TJU_CMC_MD2.ID03363.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03364.3p-miR TJU_CMC_MD2.ID03364.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03365.5p-miR TJU_CMC_MD2.ID03365.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03366.3p-miR TJU_CMC_MD2.ID03366.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03367.5p-miR TJU_CMC_MD2.ID03367.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03368.3p-miR TJU_CMC_MD2.ID03368.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03369.3p-miR TJU_CMC_MD2.ID03369.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03370.5p-miR TJU_CMC_MD2.ID03370.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03371.3p-miR TJU_CMC_MD2.ID03371.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03372.3p-miR TJU_CMC_MD2.ID03372.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03373.3p-miR TJU_CMC_MD2.ID03373.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03374.3p-miR TJU_CMC_MD2.ID03374.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03375.5p-miR TJU_CMC_MD2.ID03375.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03376.3p-miR TJU_CMC_MD2.ID03376.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03377.3p-miR TJU_CMC_MD2.ID03377.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03378.3p-miR TJU_CMC_MD2.ID03378.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03379.3p-miR TJU_CMC_MD2.ID03379.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03380.3p-miR TJU_CMC_MD2.ID03380.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03381.3p-miR TJU_CMC_MD2.ID03381.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03381.5p-miR TJU_CMC_MD2.ID03381.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03382.3p-miR TJU_CMC_MD2.ID03382.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03383.3p-miR TJU_CMC_MD2.ID03383.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03384.3p-miR TJU_CMC_MD2.ID03384.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03385.3p-miR TJU_CMC_MD2.ID03385.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03386.5p-miR TJU_CMC_MD2.ID03386.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03387.3p-miR TJU_CMC_MD2.ID03387.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03388.5p-miR TJU_CMC_MD2.ID03388.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03389.3p-miR TJU_CMC_MD2.ID03389.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03390.3p-miR TJU_CMC_MD2.ID03390.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03391.5p-miR TJU_CMC_MD2.ID03391.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03392.3p-miR TJU_CMC_MD2.ID03392.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03393.3p-miR TJU_CMC_MD2.ID03393.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03394.3p-miR TJU_CMC_MD2.ID03394.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03395.3p-miR TJU_CMC_MD2.ID03395.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03396.5p-miR TJU_CMC_MD2.ID03396.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03397.3p-miR TJU_CMC_MD2.ID03397.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03398.5p-miR TJU_CMC_MD2.ID03398.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03399.5p-miR TJU_CMC_MD2.ID03399.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID03400.3p-miR TJU_CMC_MD2.ID03400.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03402.5p-miR TJU_CMC_MD2.ID03402.hairpin YES YES YES NO NO NO NO NO TJU_CMC_MD2.ID03403.5p-miR TJU_CMC_MD2.ID03403.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03404.5p-miR TJU_CMC_MD2.ID03404.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03405.3p-miR TJU_CMC_MD2.ID03405.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03406.5p-miR TJU_CMC_MD2.ID03406.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03407.3p-miR TJU_CMC_MD2.ID03407.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03408.3p-miR TJU_CMC_MD2.ID03408.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03409.3p-miR TJU_CMC_MD2.ID03409.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03409.5p-miR TJU_CMC_MD2.ID03409.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03410.5p-miR TJU_CMC_MD2.ID03410.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03411.3p-miR TJU_CMC_MD2.ID03411.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03412.5p-miR TJU_CMC_MD2.ID03412.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03413.5p-miR TJU_CMC_MD2.ID03413.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03414.3p-miR TJU_CMC_MD2.ID03414.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03415.5p-miR TJU_CMC_MD2.ID03415.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03416.5p-miR TJU_CMC_MD2.ID03416.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03417.5p-miR TJU_CMC_MD2.ID03417.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03418.3p-miR TJU_CMC_MD2.ID03418.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03419.5p-miR TJU_CMC_MD2.ID03419.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03420.3p-miR TJU_CMC_MD2.ID03420.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03421.5p-miR TJU_CMC_MD2.ID03421.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03422.3p-miR TJU_CMC_MD2.ID03422.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03423.5p-miR TJU_CMC_MD2.ID03423.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03424.3p-miR TJU_CMC_MD2.ID03424.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03425.5p-miR TJU_CMC_MD2.ID03425.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03426.5p-miR TJU_CMC_MD2.ID03426.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03427.3p-miR TJU_CMC_MD2.ID03427.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03428.5p-miR TJU_CMC_MD2.ID03428.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID03429.3p-miR TJU_CMC_MD2.ID03429.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03430.3p-miR TJU_CMC_MD2.ID03430.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03431.5p-miR TJU_CMC_MD2.ID03431.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03432.3p-miR TJU_CMC_MD2.ID03432.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03433.3p-miR TJU_CMC_MD2.ID03433.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03434.5p-miR TJU_CMC_MD2.ID03434.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03435.3p-miR TJU_CMC_MD2.ID03435.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03436.5p-miR TJU_CMC_MD2.ID03436.hairpin YES NO YES YES NO NO NO NO TJU_CMC_MD2.ID03437.5p-miR TJU_CMC_MD2.ID03437.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03438.5p-miR TJU_CMC_MD2.ID03438.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03439.5p-miR TJU_CMC_MD2.ID03439.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03440.5p-miR TJU_CMC_MD2.ID03440.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03441.3p-miR TJU_CMC_MD2.ID03441.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03442.3p-miR TJU_CMC_MD2.ID03442.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03443.3p-miR TJU_CMC_MD2.ID03443.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03444.3p-miR TJU_CMC_MD2.ID03444.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03444.5p-miR TJU_CMC_MD2.ID03444.hairpin YES YES NO YES NO NO NO NO TJU_CMC_MD2.ID03445.3p-miR TJU_CMC_MD2.ID03445.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03446.3p-miR TJU_CMC_MD2.ID03446.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03447.3p-miR TJU_CMC_MD2.ID03447.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03448.3p-miR TJU_CMC_MD2.ID03448.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03449.3p-miR TJU_CMC_MD2.ID03449.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03450.5p-miR TJU_CMC_MD2.ID03450.hairpin YES YES YES NO YES NO NO NO TJU_CMC_MD2.ID03451.3p-miR TJU_CMC_MD2.ID03451.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03452.5p-miR TJU_CMC_MD2.ID03452.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID03453.3p-miR TJU_CMC_MD2.ID03453.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03454.3p-miR TJU_CMC_MD2.ID03454.hairpin YES YES YES YES NO YES NO NO TJU_CMC_MD2.ID03455.5p-miR TJU_CMC_MD2.ID03455.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03456.5p-miR TJU_CMC_MD2.ID03456.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03457.3p-miR TJU_CMC_MD2.ID03457.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03458.5p-miR TJU_CMC_MD2.ID03458.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03459.3p-miR TJU_CMC_MD2.ID03459.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03459.5p-miR TJU_CMC_MD2.ID03459.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03460.3p-miR TJU_CMC_MD2.ID03460.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03461.3p-miR TJU_CMC_MD2.ID03461.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03462.5p-miR TJU_CMC_MD2.ID03462.hairpin YES NO NO YES NO NO NO NO TJU_CMC_MD2.ID03463.3p-miR TJU_CMC_MD2.ID03463.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03464.3p-miR TJU_CMC_MD2.ID03464.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03465.3p-miR TJU_CMC_MD2.ID03465.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03466.3p-miR TJU_CMC_MD2.ID03466.hairpin YES YES YES YES YES YES NO NO TJU_CMC_MD2.ID03467.5p-miR TJU_CMC_MD2.ID03467.hairpin YES NO YES YES YES NO NO NO TJU_CMC_MD2.ID03468.3p-miR TJU_CMC_MD2.ID03468.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03469.5p-miR TJU_CMC_MD2.ID03469.hairpin YES NO NO YES YES NO NO NO TJU_CMC_MD2.ID03470.5p-miR TJU_CMC_MD2.ID03470.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03471.3p-miR TJU_CMC_MD2.ID03471.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03472.3p-miR TJU_CMC_MD2.ID03472.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03473.3p-miR TJU_CMC_MD2.ID03473.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03474.3p-miR TJU_CMC_MD2.ID03474.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03475.5p-miR TJU_CMC_MD2.ID03475.hairpin YES YES YES YES YES NO NO NO TJU_CMC_MD2.ID03476.3p-miR TJU_CMC_MD2.ID03476.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03477.3p-miR TJU_CMC_MD2.ID03477.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03478.3p-miR TJU_CMC_MD2.ID03478.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03479.3p-miR TJU_CMC_MD2.ID03479.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03480.3p-miR TJU_CMC_MD2.ID03480.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03481.3p-miR TJU_CMC_MD2.ID03481.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03481.5p-miR TJU_CMC_MD2.ID03481.hairpin YES NO YES NO NO NO NO NO TJU_CMC_MD2.ID03482.3p-miR TJU_CMC_MD2.ID03482.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03483.3p-miR TJU_CMC_MD2.ID03483.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03484.3p-miR TJU_CMC_MD2.ID03484.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03485.5p-miR TJU_CMC_MD2.ID03485.hairpin YES YES YES YES NO NO NO NO TJU_CMC_MD2.ID03486.3p-miR TJU_CMC_MD2.ID03486.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03487.3p-miR TJU_CMC_MD2.ID03487.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03488.3p-miR TJU_CMC_MD2.ID03488.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03489.3p-miR TJU_CMC_MD2.ID03489.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03489.5p-miR TJU_CMC_MD2.ID03489.hairpin YES NO YES NO YES NO NO NO TJU_CMC_MD2.ID03490.3p-miR TJU_CMC_MD2.ID03490.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03491.3p-miR TJU_CMC_MD2.ID03491.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03492.5p-miR TJU_CMC_MD2.ID03492.hairpin YES NO NO NO YES NO NO NO TJU_CMC_MD2.ID03493.3p-miR TJU_CMC_MD2.ID03493.hairpin YES NO NO NO NO NO NO NO TJU_CMC_MD2.ID03494.5p-miR TJU_CMC_MD2.ID03494.hairpin YES YES NO NO NO NO NO NO TJU_CMC_MD2.ID03495.5p-miR TJU_CMC_MD2.ID03495.hairpin YES YES NO NO NO NO NO NO

Example 3 Tissue Specificity of the Novel miRNAs Described Herein

An additional property of the novel miRNAs described herein is that they are for the most part specific to the tissue in which they were discovered. This finding indicates that these novel miRNAs can be used to form distinguishing “signatures” with application to diagnostic and/or prognostic activities. Their participation in such distinguishing signatures directly implicates these sequences in molecular mechanisms that are currently either unknown or poorly understood: as such, some of these sequences can be eventually used to design appropriate therapeutics that are relevant for the corresponding tissue and tissue-state.

As an example, the inventors focused on the 3,707 novel miRNAs listed in Table 2 that they discovered using the miRDeep2 method and for each pair of tissues they computed the number of novel miRNAs that are in common. The following Table 8 shows the results of this computation:

TABLE 8 Number of novel miRNAs described herein that are in common for each pair of tissues Lympho- Peripheral CD3+ blastoid Blood Mono- Number of B- Lympho- Fibro- Gastric cell lines Pan- Plate- nuclear Cells Pros- Samples cells Brain Breast cytes blasts Tissue (LCLs) creas lets (PBMC) tate Serum Skin 37 B-cells 317 100 116 15 91 57 118 149 176 88 94 166 30 24 Brain 100 455 104 14 115 59 98 160 204 210 146 166 25 604 Breast 116 104 432 12 91 56 122 125 115 95 87 142 34 1 CD3+ 15 14 12 18 12 13 14 14 18 12 15 17 7 Lympho- cytes 4 Fibro- 91 115 91 12 260 61 75 150 149 96 117 116 22 blasts 25 Gastric 57 59 56 13 61 136 47 79 70 57 66 62 16 Tissue 488 LCLs 118 98 122 14 75 47 268 99 127 86 75 122 32 12 Pancreas 149 160 125 14 150 79 99 527 199 152 151 178 26 15 Platelets 176 204 115 18 149 70 127 199 633 377 155 354 21 18 PBMC 88 210 95 12 96 57 86 152 377 881 123 288 12 10 Prostate 94 146 87 15 117 66 75 151 155 123 273 134 20 24 Serum 166 166 142 17 116 62 122 178 354 288 134 698 21 63 Skin 30 25 34 7 22 16 32 26 21 12 20 21 48

The Jaccard coefficients are also computed for each pair above and shown in Table 9. The lower the Jaccard coefficient is when comparing the novel miRNAs discovered in two tissues types, the higher the number of novel miRNAs that are present in one of the two tissue types but not the other tissue type.

TABLE 9 Jaccard coefficients for each pair of tissues based on the number of novel miRNAs described herein that are in common shown in Table 8 above CD3+ Lympho- Fibro- Gastric B-cells Brain Breast cytes blasts Tissue LCLs Pancreas Platelets PBMC Prostate Serum Skin B-cells 1 0.1488 0.1833 0.0469 0.1872 0.1439 0.2527 0.2144 0.2274 0.0793 0.1895 0.1955 0.0896 Brain 0.1488 1 0.1328 0.0305 0.1917 0.1109 0.1568 0.1946 0.2308 0.1865 0.2509 0.1682 0.0523 Breast 0.1833 0.1328 1 0.0274 0.1514 0.1094 0.2111 0.1499 0.1211 0.078 0.1408 0.1437 0.0762 CD3+ 0.0469 0.0305 0.0274 1 0.0451 0.0922 0.0515 0.0264 0.0284 0.0135 0.0543 0.0243 0.1186 Lymphocytes Fibroblasts 0.1872 0.1917 0.1514 0.0451 1 0.1821 0.1656 0.2355 0.2003 0.0919 0.2812 0.1378 0.0769 Gastric 0.1439 0.1109 0.1094 0.0922 0.1821 1 0.1317 0.1353 0.1001 0.0594 0.1924 0.0803 0.0952 Tissue LCLs 0.2527 0.1568 0.2111 0.0515 0.1656 0.1317 1 0.1422 0.1641 0.0809 0.1609 0.1445 0.1127 Pancreas 0.2144 0.1946 0.1499 0.0264 0.2355 0.1353 0.1422 1 0.2071 0.121 0.2327 0.17 0.0474 Platelets 0.2274 0.2308 0.1211 0.0284 0.2003 0.1001 0.1641 0.2071 1 0.3316 0.2064 0.3623 0.0318 PBMC 0.0793 0.1865 0.078 0.0135 0.0919 0.0594 0.0809 0.121 0.3316 1 0.1193 0.2231 0.0131 Prostate 0.1895 0.2509 0.1408 0.0543 0.2812 0.1924 0.1609 0.2327 0.2064 0.1193 1 0.1601 0.0664 Serum 0.1955 0.1682 0.1437 0.0243 0.1378 0.0803 0.1445 0.17 0.3623 0.2231 0.1601 1 0.029 Skin 0.0896 0.0523 0.0762 0.1186 0.0769 0.0952 0.1127 0.0474 0.0318 0.0131 0.0664 0.029 1

Example 4 Exemplary Applications of the isomiRs in Patient Segmentation or Diagnosis

In Examples 4-7 below, the isomiRs as listed in Table 3 are found to exhibit different expression behavior between two states of the same tissue, between same-gender members of two different human populations, etc. These examples show that isomiRs, just like miRNAs, can be used to form distinguishing “signatures” with application to diagnostic and/or prognostic activities. Their participation in such distinguishing signatures directly implicates these sequences in molecular mechanisms that are currently either unknown or poorly understood: as such, some of these sequences can be used to design appropriate therapeutics that are relevant for the corresponding tissue and tissue-state.

This Example shows that differentially expressed isomiRs listed in Table 3 can be used to separate individuals with platelet antigen hyper-reactivity vs. hypo-reactivity. Platelets derived from 10 healthy male individuals were tested for their aggregation properties in response to the PAR1-AP, PAR4-AP, anti-CD9, ADP, and CRP antigens. The individuals were split into two groups (“hyper-reactive” and “hypo-reactive”) based on their response to the antigens and time to clot. Short RNA sequencing was used to profile the short RNA populations of the platelets from all 10 individuals and isomiR expression was examined across the hyper-reactive and hypo-reactive group. Differential expression of isomiRs was calculated using the DESeq2 algorithm. An isomiR is considered to be differentially expressed if it had a mean expression of at least 50 sequenced reads, a log2-change in expression of >0.58 or <-0.58, and a p-Value<0.05. FIG. 3 shows a heatmap that summarizes the results of Table 10 shown below: each row in the heatmap corresponds to a different isomiR as listed in Table 3. FIG. 3 shows that the two groups of individuals with platelet antigen hyper-reactivity or hypo-reactivity have distinct isomiR expression profiles. Since this is a gray-scale image, a two dashed lines was used to separate the drawing in quadrants. The upper left quadrant includes miRNAs/isomiRs that are more abundant in hyper-reactive than in hypo-reactive individuals. The upper right quadrant includes miRNAs/isomiRs that are less abundant in hypo-reactive than in hyper-reactive individuals. The lower left quadrant includes miRNAs/isomiRs that are less abundant in hyper-reactive than in hypo-reactive individuals. The lower right quadrant includes miRNAs/isomiRs that are more abundant in hypo-reactive than in hyper-reactive individuals.

Table 10 below shows the fold-change of the miRNAs and isomiRs in the two groups of individuals with platelet antigen hyper-reactivity or hypo-reactivity that are depicted in the heatmap of FIG. 3 . The actual miRNA and corresponding SEQ ID NOs. can be identified in Table 3 according to the “miRNA ID” listed in Table 10.

TABLE 10 Differential expression of isomiR or miRNA in individuals with platelet antigen hyper- reactivity vs. hypo-reactivity log2FoldChange of miRNA ID Is it a miRNA or an isomiR? Chromo- some Strand IsomiR Start IsomiR End $\frac{{HYPO} - {reactive}}{{HYPER} - {reactive}}$ ID = MIMAT0016844; hsa-miR-4295 isomiR 10 + 114393939 114393960 1.693050804 ID = MIMAT0000098; hsa-miR-100-5p isomiR 11 − 122022982 122023004 1.823802128 ID = MIMAT0000098; hsa-miR-100-5p mirBase 11 − 122022983 122023004 1.814040075 ID = MIMAT0019774; hsa-miR-4687-5p isomiR 11 + 3877303 3877322 −1.208797144 ID = MIMAT0000267; hsa-miR-210-3p isomiR 11 − 568113 568133 −1.050732203 ID = MIMAT0014982; hsa-miR-3120-3p isomiR  1 + 172107998 172108019 0.975239935 ID = MIMAT0000256; hsa-miR-181a-5p mirBase  1 − 198828237 198828259 1.174507982 ID = MIMAT0000681; hsa-miR-29c-3p isomiR  1 − 207975209 207975231 0.536818398 ID = MIMAT0017991; hsa-miR-3613-3p isomiR 13 − 50570564 50570585 1.608621193 ID = MIMAT0000772; hsa-miR-345-5p isomiR 14 + 100774213 100774232 −0.840570448 ID = MIMAT0000772; hsa-miR-345-5p isomiR 14 + 100774213 100774233 −0.614388579 ID = MIMAT0004604; hsa-miR-127-5p isomiR 14 + 101349338 101349358 −1.307212535 ID = MIMAT0000722; hsa-miR-370-3p isomiR 14 + 101377523 101377543 −0.973765428 ID = MIMAT0002178; hsa-miR-487a-3p mirBase 14 + 101518831 101518852 1.069025151 ID = MIMAT0000447; hsa-miR-134-5p mirBase 14 + 101521031 101521052 0.709528735 ID = MIMAT0000447; hsa-miR-134-5p isomiR 14 + 101521031 101521053 0.860800629 ID = MIMAT0002176; hsa-miR-485-3p isomiR 14 + 101521800 101521822 1.844384975 ID = MIMAT0015050; hsa-miR-323b-3p isomiR 14 + 101522605 101522626 −1.480187879 ID = MIMAT0000452; hsa-miR-154-5p mirBase 14 + 101526106 101526127 0.750616377 ID = MIMAT0000453; hsa-miR-154-3p mirBase 14 + 101526142 101526163 1.920772298 ID = MIMAT0000730; hsa-miR-377-3p isomiR 14 + 101528431 101528451 2.220079064 ID = MIMAT0000730; hsa-miR-377-3p mirBase 14 + 101528431 101528452 1.234206271 ID = MIMAT0001639; hsa-miR-409-3p isomiR 14 + 101531684 101531705 1.008026114 ID = MIMAT0015054; hsa-miR-3177-3p isomiR 16 + 1785039 1785060 −1.070825052 ID = MIMAT0003301; hsa-miR-33b-5p mirBase 17 − 17717211 17717230 −0.8778958 ID = MIMAT0000433; hsa-miR-142-5p isomiR 17 − 56408647 56408666 −0.679403276 ID = MIMAT0002820; hsa-miR-497-5p isomiR 17 − 6921297 6921318 −1.022619012 ID = MIMAT0002820; hsa-miR-497-5p mirBase 17 − 6921298 6921318 −1.103842786 ID = MIMAT0000763; hsa-miR-338-3p isomiR 17 − 79099686 79099707 0.755685679 ID = MIMAT0000763; hsa-miR-338-3p isomiR 17 − 79099686 79099708 0.585798504 ID = MIMAT0000763; hsa-miR-338-3p mirBase 17 − 79099687 79099708 0.637201072 ID = MIMAT0000078; hsa-miR-23a-3p isomiR 19 − 13947406 13947427 0.92049045 ID = MIMAT0000078; hsa-miR-23a-3p isomiR 19 − 13947407 13947427 1.139296411 ID = MIMAT0000078; hsa-miR-23a-3p isomiR 19 − 13947407 13947429 0.605379042 ID = MIMAT0000078; hsa-miR-23a-3p isomiR 19 − 13947408 13947429 0.545064371 ID = MIMAT0000258; hsa-miR-181c-5p isomiR 19 + 13985539 13985561 0.599867208 ID = MIMAT0000258; hsa-miR-181c-5p isomiR 19 + 13985539 13985562 0.643018885 ID = MIMAT0000255; hsa-miR-34a-5p isomiR  1 − 9211793 9211815 −1.144365962 ID = MIMAT0000255; hsa-miR-34a-5p mirBase  1 − 9211794 9211815 −0.940567745 ID = MIMAT0003311; hsa-miR-641 isomiR 19 − 40788511 40788534 1.173498381 ID = MIMAT0019880; hsa-miR-4746-5p mirBase 19 + 4445984 4446006 −1.081673049 ID = MIMAT0000689; hsa-miR-99b-5p isomiR 19 + 52195871 52195890 1.288028476 ID = MIMAT0000689; hsa-miR-99b-5p isomiR 19 + 52195871 52195891 0.942329444 ID = MIMAT0000689; hsa-miR-99b-5p mirBase 19 + 52195871 52195892 1.168595698 ID = MIMAT0000689; hsa-miR-99b-5p isomiR 19 + 52195871 52195893 1.273940998 ID = MIMAT0004978; hsa-miR-935 isomiR 19 + 54485617 54485638 −1.290340375 ID = MIMAT0016888; hsa-miR-4326 isomiR 20 + 61918170 61918192 −2.189171494 ID = MIMAT0000424; hsa-miR-128-3p isomiR  2 + 136423017 136423037 1.008351354 ID = MIMAT0022726; hsa-miR-1306-5p isomiR 22 + 20073595 20073615 −0.687810261 ID = MIMAT0004502; hsa-miR-28-3p mirBase  3 + 188406622 188406643 0.805567557 ID = MIMAT0004502; hsa-miR-28-3p isomiR  3 + 188406622 188406644 0.98178236 ID = MIMAT0003241; hsa-miR-576-5p mirBase  4 + 110409869 110409890 0.702664876 ID = MIMAT0003241; hsa-miR-576-5p isomiR  4 + 110409869 110409892 0.918510564 ID = MIMAT0003239; hsa-miR-574-3p isomiR  4 + 38869714 38869734 −0.905946749 ID = MIMAT0003239; hsa-miR-574-3p isomiR  4 + 38869714 38869735 −0.716936715 ID = MIMAT0003239; hsa-miR-574-3p isomiR  4 + 38869714 38869736 −0.907113522 ID = MIMAT0003239; hsa-miR-574-3p isomiR  4 + 38869715 38869734 −1.143751103 ID = MIMAT0003239; hsa-miR-574-3p isomiR  4 + 38869715 38869735 −0.800015321 ID = MIMAT0003239; hsa-miR-574-3p isomiR  4 + 38869715 38869736 −0.684840113 ID = MIMAT0004601; hsa-miR-145-3p mirBase  5 + 148810262 148810283 0.903088739 ID = MIMAT0000449; hsa-miR-146a-5p isomiR  5 + 159912380 159912401 0.787529544 ID = MIMAT0000449; hsa-miR-146a-5p isomiR  5 + 159912380 159912402 0.77307406 ID = MIMAT0000449; hsa-miR-146a-5p isomiR  5 + 159912381 159912401 0.657010583 ID = MIMAT0004702; hsa-miR-339-3p isomiR  7 − 1062592 1062611 −0.777037637 ID = MIMAT0000764; hsa-miR-339-5p isomiR  7 − 1062625 1062647 −0.781301482 ID = MIMAT0000765; hsa-miR-335-5p isomiR  7 + 130135967 130135988 0.53296691 ID = MIMAT0000765; hsa-miR-335-5p mirBase  7 + 130135967 130135989 0.582659429 ID = MIMAT0000086; hsa-miR-29a-3p isomiR  7 − 130561506 130561528 0.563158034 ID = MIMAT0004672; hsa-miR-106b-3p mirBase  7 − 99691625 99691646 −0.774615259 ID = MIMAT0004672; hsa-miR-106b-3p isomiR  7 − 99691625 99691647 −1.206525491 ID = MIMAT0000420; hsa-miR-30b-5p isomiR  8 − 135812811 135812834 0.656327955 ID = MIMAT0000420; hsa-miR-30b-5p isomiR  8 − 135812812 135812834 0.59271139 ID = MIMAT0027604; hsa-miR-6852-5p isomiR  9 − 35710711 35710733 −0.978676086 ID = MIMAT0027604; hsa-miR-6852-5p isomiR  9 − 35710712 35710733 −0.623346064 ID = MIMAT0027604; hsa-miR-6852-5p mirBase  9 − 35710713 35710733 −0.608678796 ID = MIMAT0000099_1; hsa-miR-101-3p isomiR  9 + 4850347 4850368 1.057868333 ID = MIMAT0000418; hsa-miR-23b-3p isomiR  9 + 97847547 97847568 0.759475648 ID = MIMAT0000418; hsa-miR-23b-3p isomiR  9 + 97847547 97847569 0.596830114 ID = MIMAT0000418; hsa-miR-23b-3p isomiR  9 + 97847547 97847570 0.670886728 ID = MIMAT0000418; hsa-miR-23b-3p isomiR  9 + 97847549 97847568 1.160734587 ID = MIMAT0000418; hsa-miR-23b-3p isomiR  9 + 97847549 97847569 1.014775501 ID = MIMAT0000418; hsa-miR-23b-3p isomiR  9 + 97847549 97847570 1.28609021 ID = MIMAT0022709; hsa-miR-652-5p isomiR X + 109298576 109298595 0.967684929 ID = MIMAT0000707; hsa-miR-363-3p isomiR X − 133303411 133303433 0.631364682 ID = MIMAT0003389; hsa-miR-542-3p isomiR X − 133675393 133675415 1.304170278 ID = MIMAT0000096; hsa-miR-98-5p isomiR X − 53583259 53583281 0.693686608 ID = MIMAT0019919; hsa-miR-4767 isomiR X + 7065909 7065931 −1.260816811 ID = MIMAT0000727; hsa-miR-374a-5p isomiR X − 73507158 73507181 1.387909088 ID = MIMAT0000727; hsa-miR-374a-5p isomiR X − 73507159 73507180 0.80294068 ID = MIMAT0000727; hsa-miR-374a-5p isomiR X − 73507159 73507181 0.58382585

Example 5 Differential Expression of isomiRs Across Populations by Ethnicity

This Example is drawn from the analysis of the deep sequencing data of 482 lymphoblastoid cell line (LCL) samples from the Geuvadis RNA deep-sequencing project, where its information is accessible online at http://www.geuvadis.org/web/geuvadis/RNAseq-project. In particular, the inventors focused and analyzed the 452 unique samples among the collection of 482 datasets (the remaining samples are technical replicates). The 452 samples represent five human populations: Utah Residents with Northern and Western European ancestry (CEU, 87 subjects), Finnish from Finland (FIN, 93 subjects), British in England and Scotland (GBR, 94 subjects), Toscani Italians (TSI, 89 subjects), and Yoruban Africans from the city of Ibadan (YRI, 89 subjects).

Using samples from both genders, the inventors identified differentially expressed isomiRs separately for each pair of populations. FIG. 4 shows the resulting heatmap for the identified isomiRs listed in Table 3. Cells shown as white correspond to cases that did not reach statistical significance for the corresponding combination of miRNA/isomiR and population-pair. The color intensity scale is logarithmic (log2 base). For all statistically significant combinations the associated FDR value is ≤0.05. This example shows that miRNAs and isomiRs can be used in principle to distinguish among human populations. Thus, combinations of isomiRs and miRNAs can be used to form distinguishing “signatures” with application to diagnostic and/or prognostic activities. Their participation in such distinguishing signatures directly implicates these sequences in molecular mechanisms that are currently either unknown or poorly understood: as such, some of these sequences can be eventually used to design appropriate therapeutics that are relevant for the corresponding tissue and tissue-state.

Example 6 Differential Expression of isomiRs Across Populations by Gender

Like in Example 5, this Example is drawn from the analysis of the deep sequencing data of 482 LCL samples from the Geuvadis RNA deep-sequencing project, where its information is accessible online at http://www.geuvadis.org/web/geuvadis/RNAseq-project. In particular, the inventors focused and analyzed the 452 unique samples among the collection of 482 datasets (the remaining samples are technical replicates). The 452 samples represent five human populations: Utah Residents with Northern and Western European ancestry (CEU, 87 subjects), Finnish from Finland (FIN, 93 subjects), British in England and Scotland (GBR, 94 subjects), Toscani Italians (TSI, 89 subjects), and Yoruban Africans from the city of Ibadan (YRI, 89 subjects).

Using samples of the same gender, the inventors identified differentially expressed isomiRs separately for each pair of populations. FIGS. 5A-5B show the resulting heatmap for the isomiRs (identified in Table 3) in male samples and female samples, respectively. Cells shown as white correspond to cases that did not reach statistical significance for the corresponding combination of miRNA/isomiR and population-pair. The color intensity scale is logarithmic (log2 base). For all statistically significant combinations the associated FDR value is ≤0.05. This example shows that miRNAs and isomiRs have different expression profiles among populations when only males are considered vs. when only females are considered. This shows the presence of different miRNAs/isomiRs and/or different expression patterns between females and males and thus the potential presence of differences in the underlying molecular mechanisms for the corresponding tissue and tissue-state.

Example 7 Differential Expression of Novel miRNAs by Disease States

There are three collections of novel miRNA sequences: (1) novel miRNAs that were discovered using the inventors' developed method as described in Example 1 (as listed in Table 11 below, they are prefixed by “TJU_CMC” only, e.g. TJU_CMC.ID02768.5p-miR); (2) novel miRNAs that were discovered using the miRDeep2 method and listed in Table 11 below, they are prefixed by “TJU_CMC.MD2” i.e. TJU_CMC MD2.ID01023.3p-miR); and (3) isomiRs from miRNA loci that are in Rel. 20 of the miRBase repository and listed in Table 12 below, they are prefixed by “NovelMiR_KnownLoci” e.g. NovelMiR_KnownLoci_ID0001566).

The inventors processed numerous samples from different tissues and tissue states and sought to determine instances of miRNAs from each of these categories that were differentially expressed between pairs of states of the same tissue. A novel miRNA/isomiR is considered to be differentially expressed if it has a mean expression of at least 50 sequenced reads, a log2-change in expression between the compared states of ≥0.58 or ≤−0.58, and a p-Value≤0.05.

Using samples from different disease states, the inventors identified differentially expressed novel miRNAs that were either discovered using their own developed method (prefixed by “TJU_CMC” only, e.g. TJU_CMC.ID02768.5p-miR) or discovered using the miRDeep2 method (prefixed by “TJU_CMC.MD2” i.e. TJU_CMC MD2.ID01023.3p-miR). As stated above, a miRNA is considered to be differentially expressed if it had a mean expression of at least 50 sequenced reads, a log2-change in expression between the compared states of ≥0.58 or ≤−0.58, and a p-Value≤0.05.

Examples 7-8 show that these novel sequences (either novel miRNAs or novel isomiRs from previously reported loci) can be used to form distinguishing “signatures” with application to diagnostic and/or prognostic activities. Again, their very participation in such distinguishing signatures directly implicates these sequences in molecular mechanisms that currently are either unknown or poorly understood: as such, some of these sequences could be eventually used to design appropriate therapeutics that are relevant for the corresponding tissue and tissue-state.

Table 11 below shows the fold-change of the miRNAs in pairs of the same tissue of different states. Abbreviations: TCGA=The Cancer Genome Atlas; PBMC=Peripheral Blood Mononuclear Cells; GEO=Gene Expression Omnibus. The actual miRNA or isomiR sequences and corresponding SEQ ID NOs. can be identified in Tables 1-2 according to the the “Name” listed in Table 11.

TABLE 11 Differential expression of miRNAs in tissues of various disease states Log2 fold change of Name Set A/Set B p-Val Sets Compared (A/B) TJU_CMC.ID06653.3p-miR −5.350055999 1.82E−11 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09612.5p-miR −6.143612864 1.62E−09 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02842.5p-miR 10.61146501 1.24E−08 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02528.3p-miR −999999 1.79E−08 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09305.5p-miR −6.666005566 6.04E−08 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02503.5p-miR 10.87508867 9.50E−08 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02528.5p-miR −999999 1.07E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03278.3p-miR 5.641662569 1.40E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04657.3p-miR −9.866230829 1.86E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06600.5p-miR −8.103688639 1.93E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01860.5p-miR −999999 1.94E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02768.5p-miR 8.369781246 2.13E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01023.3p-miR 999999 3.16E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03256.3p-miR −3.917708041 2.39E−08 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09799.3p-miR −4.887841727 2.14E−07 HER2− Breast Cancer/HER2+ Breast Cancer (TCGA) TJU_CMC_MD2.ID00953.5p-miR −999999 8.82E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01023.5p-miR 999999 8.97E−07 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00558.3p-miR −999999 1.01E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02912.5p-miR 999999 1.24E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04299.5p-miR −5.000995116 1.22E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00258.5p-miR 8.714626517 1.36E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02465.3p-miR −8.206164944 1.99E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08100.5p-miR 10.78227313 5.45E−07 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC_MD2.ID00964.5p-miR −999999 3.18E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05256.5p-miR −9.115766175 3.58E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03524.5p-miR 7.056227807 4.18E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03856.5p-miR −8.692614532 4.12E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03519.3p-miR 8.82432173 4.31E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00299.5p-miR 4.167117002 7.05E−07 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09200.5p-miR 4.147086478 8.81E−07 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03504.3p-miR 6.413198125 6.21E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00744.3p-miR 7.100628383 6.80E−06 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00225.3p-miR 4.242952027 1.68E−06 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08731.3p-miR −5.94141269 2.10E−06 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01316.3p-miR −6.870251682 1.52E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03300.5p-miR 6.702083272 1.49E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01494.3p-miR 5.289938285 1.83E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07022.5p-miR 7.623615595 1.58E−05 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID03454.5p-miR 6.77674742 2.31E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05541.3p-miR 5.718371954 2.29E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06289.5p-miR −6.055179931 2.34E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08042.5p-miR −4.371634744 2.74E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02508.5p-miR 5.957071622 2.89E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05571.3p-miR 4.87676621 2.94E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02844.3p-miR 6.131098482 3.07E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07466.3p-miR 5.998317527 3.03E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01558.5p-miR −6.679700391 3.49E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01152.5p-miR 7.246723864 3.58E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00581.3p-miR 5.112712713 5.53E−05 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID09045.5p-miR 5.996981054 5.01E−05 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID08817.5p-miR −7.040237443 4.01E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01743.5p-miR 5.687787729 4.52E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06261.5p-miR 3.978728907 4.80E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06075.5p-miR 5.198810713 5.11E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03003.3p-miR −5.282487816 9.27E−06 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08644.5p-miR 3.698764073 1.02E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09315.5p-miR 4.202589537 9.98E−06 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04909.5p-miR −5.426714465 5.61E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02721.5p-miR −6.028345639 5.92E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02172.3p-miR 4.17893251 6.33E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03495.5p-miR −4.565082803 6.28E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06967.3p-miR −6.51771449 7.17E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04559.5p-miR 5.435199575 7.57E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01232.3p-miR 6.558455622 0.000110459 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID09362.5p-miR 8.068986534 0.000122719 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID05136.3p-miR −6.462794459 7.96E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09211.5p-miR −6.096317714 8.22E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01436.3p-miR −6.844516944 9.18E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05232.3p-miR 5.269136783 9.66E−05 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08857.5p-miR −5.185841009 0.000101318 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04776.3p-miR −5.968840199 0.000108755 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03322.5p-miR 3.62089628 1.74E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05498.3p-miR −5.923985039 0.00012389 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09556.5p-miR 4.358490643 0.000128181 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05794.5p-miR −7.275302525 0.000129705 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01160.3p-miR 9.981234895 0.000134237 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09464.5p-miR 6.954848435 0.000193258 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID06420.5p-miR 999999 0.000146696 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00602.3p-miR −5.398215307 1.51E−04 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05591.5p-miR −5.202141235 0.000150691 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03158.3p-miR −5.18709673 0.000154642 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00326.5p-miR 7.22768428 0.000249828 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID03778.3p-miR −3.575821691 2.81E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08027.5p-miR −4.38644661 0.0001772 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08731.3p-miR −5.399172552 5.44E−06 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01135.3p-miR 2.930131702 3.31E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08946.3p-miR 5.279650918 0.000208462 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09118.5p-miR 6.714196096 0.000218512 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID03494.5p-miR 4.14958141 0.000220218 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06656.5p-miR 3.336125897 5.06E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05992.3p-miR 5.78174404 5.26E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07790.5p-miR −3.836018874 5.10E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08272.3p-miR 4.113667399 4.77E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06876.5p-miR 4.690963487 0.000271606 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08177.5p-miR 5.155337948 0.000289999 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08261.5p-miR 4.640781533 0.000296545 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04632.3p-miR 7.838923587 0.00029972 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01563.5p-miR 4.858443966 0.000303636 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04558.3p-miR −5.709826486 0.00030917 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04581.5p-miR −6.24534738 0.000309428 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01077.5p-miR −5.111571124 0.000317661 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06657.3p-miR 4.787416739 0.000325 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05096.5p-miR 6.230029943 0.000341974 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06065.3p-miR −5.558341447 0.000343083 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09115.5p-miR 4.779747152 7.19E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05175.5p-miR −1.378776682 0.000201196 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID02914.3p-miR 4.169060369 8.69E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02650.5p-miR 4.66315875 0.000449771 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09493.5p-miR −5.34762686 0.000456447 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05918.3p-miR 5.145167112 0.000511849 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07047.3p-miR −5.580371457 0.000524814 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01631.5p-miR 4.195376808 0.000545762 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02628.3p-miR 5.277749364 0.000543955 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07634.3p-miR 5.49736396 0.000602502 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02766.3p-miR −3.543069652 0.00062563 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00395.3p-miR 5.213282626 0.000646725 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03304.3p-miR −5.166631344 0.000651137 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01362.5p-miR 4.410814146 0.000668225 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05001.3p-miR 4.203854064 0.00068091 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01606.3p-miR 6.338522361 0.000124339 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04661.5p-miR 3.449210388 0.000146579 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09327.3p-miR −5.04132634 0.000774951 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05693.5p-miR −3.875915893 0.000798401 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06834.3p-miR −2.587635697 0.000835388 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00711.5p-miR 6.255640602 0.0008649 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04683.5p-miR 2.781068193 0.000178069 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08301.3p-miR 4.376235733 0.000886208 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05046.5p-miR −4.905172311 0.000896889 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06865.5p-miR −3.999286886 0.000926659 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08236.3p-miR 4.960820226 0.000937113 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03885.3p-miR 4.25503448 0.000950814 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04994.5p-miR −4.640194729 0.000954192 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00522.5p-miR −4.153838602 0.000967384 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01739.3p-miR 4.398158234 0.000987773 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08957.5p-miR −4.550746438 0.00105123 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02282.3p-miR −4.167884941 0.001077348 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06539.3p-miR 3.25231861 0.000215381 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01852.5p-miR 4.280188721 0.001138706 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03898.3p-miR 6.209813253 0.001142411 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08652.5p-miR −3.632869643 0.001147199 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08763.5p-miR 3.130267045 0.000234446 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08292.3p-miR −4.550226948 0.001253063 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08520.5p-miR 6.374585156 0.001261675 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00107.3p-miR −3.863162301 0.000271664 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04757.3p-miR 5.379247431 5.82E−06 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06916.5p-miR −4.342335935 0.001362215 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07737.3p-miR 3.089872089 0.000285267 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09230.3p-miR −3.135381546 0.000292281 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06765.5p-miR 4.568486219 0.000301392 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09799.3p-miR 3.785717025 0.000309793 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00020.3p-miR 4.687645247 0.001406275 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01975.3p-miR 3.961680472 0.001446071 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09306.3p-miR −5.136399176 0.001488952 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06325.3p-miR 3.524257076 0.000356331 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06673.3p-miR −3.813753745 0.000352979 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01131.5p-miR −4.519895228 0.001519536 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06092.3p-miR 3.862574726 0.001518102 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03353.3p-miR −4.160245232 0.001573503 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07866.3p-miR 5.214946608 0.001576663 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03982.5p-miR −4.102714902 0.001635801 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00141.3p-miR 3.825644909 0.001653643 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00055.3p-miR 6.007583643 0.001698155 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02091.5p-miR −4.262258924 0.001695972 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00442.3p-miR 4.627278196 0.001815043 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04345.3p-miR 3.993726787 0.001845504 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04197.5p-miR 4.026699918 0.001925506 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07695.3p-miR 3.844254186 0.001942029 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01416.3p-miR −4.356600708 0.00195735 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05727.5p-miR 4.587677454 0.002022729 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03098.3p-miR 5.656770601 0.002044575 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02066.3p-miR 3.561817067 0.00213419 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05175.5p-miR −1.185922549 0.001482037 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID00403.3p-miR 3.756954798 0.002198099 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08111.5p-miR −3.807724286 0.002214865 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00506.3p-miR 5.164155584 0.002253642 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00730.5p-miR 5.330307488 0.002250791 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05115.5p-miR −4.453529341 0.002252647 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06844.3p-miR 3.978840637 0.002267126 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01478.3p-miR 3.972503878 0.002290871 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02970.3p-miR 2.931980044 0.000514428 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07009.3p-miR 3.839672259 0.002356424 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02773.3p-miR 4.518529043 0.002394422 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02905.3p-miR −3.68657312 0.002434754 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08831.3p-miR 4.054510317 0.002463378 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05841.5p-miR −3.957415667 0.002498411 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02050.5p-miR −5.234003958 0.002482054 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07824.5p-miR 4.60201983 2.45E−05 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02554.5p-miR 4.555190677 0.00252341 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03893.3p-miR 3.593847173 0.004045668 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC_MD2.ID02126.3p-miR 1.451827053 0.001782406 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID06433.3p-miR 4.295307413 0.00273945 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06390.5p-miR 3.991012698 0.002755294 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03823.5p-miR 3.879328689 0.002812429 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06009.3p-miR −3.989755274 0.002830427 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03653.5p-miR 4.883752181 0.002923736 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07934.5p-miR −4.078319656 0.002929015 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03131.3p-miR 3.751722034 0.00300768 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03972.3p-miR 3.784569846 0.003032851 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02000.5p-miR 5.392634372 0.003143169 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02154.3p-miR −4.396251781 0.003146609 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06554.3p-miR 4.387798596 0.003139251 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07572.3p-miR −3.915312372 0.00320242 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08486.5p-miR −3.887475153 0.003232179 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09605.3p-miR −4.158036816 0.003226871 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03066.3p-miR −1.599224259 0.001625123 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC_MD2.ID00088.5p-miR −4.093459824 0.003338064 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01339.5p-miR 3.170500627 0.000694131 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02355.3p-miR −4.222175444 0.003602964 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07153.5p-miR 3.740413618 0.003588639 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08371.3p-miR −3.873087387 0.003590353 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06215.3p-miR 3.702159521 0.003651192 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03548.3p-miR 5.023324428 0.003714428 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08211.3p-miR −4.705342525 0.003717942 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04133.5p-miR −1.657029037 0.00248944 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID02903.5p-miR −4.144824332 0.003739725 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05770.3p-miR 6.865129325 0.003793287 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08135.3p-miR 4.153903665 0.003946667 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00684.3p-miR 6.195031347 0.004034179 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08434.5p-miR −3.741904172 0.004018306 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01093.3p-miR −3.207971266 0.000808878 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01019.3p-miR −3.947784983 0.00414436 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04387.5p-miR −3.518005909 0.004170622 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02329.5p-miR 3.875903033 0.004198355 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00051.5p-miR 3.736006102 0.004367628 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01767.3p-miR 5.538641135 0.004377749 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05633.3p-miR 5.02784088 0.004264183 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05673.5p-miR −3.764399583 0.004329739 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06451.5p-miR 3.771384312 0.00427519 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06926.3p-miR −4.135406749 0.004289928 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02125.3p-miR −3.886256183 0.004382399 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02796.5p-miR 4.182424269 0.004407616 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02785.3p-miR 4.324652154 0.004614631 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07294.3p-miR −3.510999533 0.004639479 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07864.5p-miR −3.662633681 5.35E−05 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08927.5p-miR −3.731813089 0.000868055 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02027.3p-miR −5.340729298 0.004736291 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08389.5p-miR 3.373648505 0.000893978 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09745.3p-miR −3.76806725 0.00476875 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04996.5p-miR −5.907575247 0.004992966 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03448.5p-miR 3.305828171 0.001003754 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06731.3p-miR −2.627421791 0.001010748 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09120.3p-miR −2.799361236 0.001005158 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09799.3p-miR 4.988057257 0.000156714 HER2-type Breast Cancer/Basal-like Breast Cancer (TCGA) TJU_CMC.ID03066.3p-miR −1.525246872 0.003710768 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID00808.5p-miR 4.45455467 0.005359437 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04999.3p-miR 4.55163693 0.005443038 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04293.5p-miR −3.975913396 0.005473644 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07897.3p-miR 3.262292955 0.005460879 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04734.3p-miR 3.31390565 0.005513998 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09827.5p-miR −2.428009406 0.005517439 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09669.3p-miR −3.458782703 0.005677504 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03560.3p-miR 999999 0.005760813 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01860.3p-miR −999999 0.005819237 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08066.3p-miR 4.287744017 0.005869927 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06825.3p-miR −3.522675208 0.001127059 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02186.3p-miR 3.721624573 0.006069033 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05680.3p-miR −3.487688128 0.006066361 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03810.3p-miR 3.615932991 0.006213076 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09849.5p-miR −3.493578587 0.006186266 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08219.3p-miR 4.875280596 0.006322887 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01848.5p-miR −3.750885689 0.006378115 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04261.3p-miR 4.129878547 0.006400059 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01104.3p-miR −3.925384235 0.006412455 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03499.3p-miR 3.397485958 0.006456307 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08877.5p-miR 4.015540666 5.83E−05 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05581.5p-miR 4.983456978 0.006763951 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06430.5p-miR −3.425154896 0.006796496 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09687.3p-miR −3.605372058 0.006791673 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02946.5p-miR −4.006709967 0.00669263 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03249.5p-miR 3.736002726 0.006864919 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03497.5p-miR −2.826827067 0.006934821 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01429.5p-miR 3.845168153 0.001272276 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04813.5p-miR −2.734683848 0.001279186 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02519.3p-miR 6.626008984 0.007071927 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07881.5p-miR −4.645626441 0.007132922 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09682.5p-miR −3.694229362 0.007468685 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00644.5p-miR −3.975809646 0.007567406 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07033.5p-miR 3.38977647 0.007574289 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09781.3p-miR −3.952929903 0.007576322 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09464.5p-miR −1.268418493 0.003556504 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID05902.3p-miR 3.520306132 0.007741627 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00419.3p-miR −3.22974304 0.00777046 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07864.5p-miR −2.782784628 0.00145645 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02392.3p-miR −3.395999263 0.007852482 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08744.3p-miR 3.823547998 0.007842493 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00802.5p-miR −3.761374318 0.007825048 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05451.5p-miR −3.601834058 0.007958604 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05889.3p-miR 3.767260997 0.00794515 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07409.3p-miR 3.713000924 0.007961062 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07851.5p-miR −0.848685228 0.003847746 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID05259.5p-miR 3.238887474 0.008207578 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08501.5p-miR −3.68015595 0.008378015 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03695.5p-miR −3.629989137 0.008416202 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01679.5p-miR −2.72629129 0.001586112 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04861.3p-miR −3.49968115 0.008701215 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04105.5p-miR 3.465260213 0.008745639 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01675.3p-miR 3.424525025 0.008770798 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00858.5p-miR −2.738680205 0.008834193 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00538.3p-miR −3.58189314 0.008891839 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06335.5p-miR −8.56605621 0.008900687 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09270.3p-miR 3.076343437 0.001696361 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01817.3p-miR −5.905477213 0.009056318 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09441.5p-miR −3.474391593 0.009067118 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03485.5p-miR −3.449134377 0.009097675 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09034.5p-miR 3.336180378 0.009309824 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06503.5p-miR 3.649753645 0.009412983 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03683.3p-miR −3.033501491 0.009501326 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02126.3p-miR 1.329339479 0.004688008 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID04846.5p-miR 2.507408703 0.009784292 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03615.3p-miR 4.380853312 0.009830812 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05919.3p-miR 3.25341944 0.009927145 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05362.5p-miR −3.481303728 0.010097837 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08830.3p-miR 4.348247017 0.010090991 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06942.5p-miR 4.752723586 0.010149942 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08906.5p-miR −7.174478753 0.000452493 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID01532.5p-miR −3.38421841 0.010349591 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00590.5p-miR 2.594449484 0.01047864 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04494.5p-miR −2.928055747 0.010485439 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02447.3p-miR −3.049395422 0.002016216 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03129.3p-miR 3.721639697 0.001947997 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04431.3p-miR 2.421432866 0.001984674 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01967.5p-miR −4.82691252 0.010622482 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05791.3p-miR 4.041554977 0.000123848 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08760.5p-miR 3.213735394 0.010692497 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07726.5p-miR −3.275093222 0.01078539 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06201.5p-miR 3.243655826 0.010829525 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08567.3p-miR 3.441135965 0.010931409 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04355.3p-miR −7.774051135 0.011020162 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04470.5p-miR −999999 0.002097664 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05510.3p-miR 3.762851965 0.002131497 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08188.3p-miR 3.632361015 0.011095653 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05198.3p-miR 3.606212091 0.011215348 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01964.3p-miR 3.485799512 0.011320868 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01548.3p-miR 4.06463058 0.00016661 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02965.5p-miR 4.073358618 0.000182467 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04119.3p-miR 6.354604426 0.000151789 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06401.3p-miR 2.937429039 0.011418415 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00897.3p-miR 3.242235398 0.011701414 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04312.3p-miR −2.839092601 0.002316521 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00367.5p-miR 3.612335212 0.012015975 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03089.5p-miR 3.871229705 0.011982943 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06918.3p-miR 3.277969503 0.012019111 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07026.3p-miR 3.21069785 0.011993843 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08755.5p-miR −3.474241921 0.012057449 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01584.3p-miR 2.538363808 0.012227387 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06706.3p-miR 3.229974177 0.012225456 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00546.5p-miR −2.930199773 0.012196577 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03479.5p-miR 5.138235153 0.012283946 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05652.3p-miR −3.801193157 0.012410555 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04133.5p-miR −1.395446103 0.006247856 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID02661.3p-miR −3.416158149 0.012498757 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07851.5p-miR −0.746966944 0.008090463 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID08923.3p-miR −3.354714759 0.012687656 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00084.5p-miR 3.251317323 0.002568033 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00409.5p-miR −2.355643659 0.002594432 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02895.5p-miR 3.067023182 0.002518555 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03038.3p-miR −2.406007669 0.002497207 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06178.3p-miR 3.30228222 0.012921953 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00712.3p-miR −2.583984196 0.002706236 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00535.5p-miR 3.272381812 0.013317849 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02225.3p-miR 3.135280669 0.013300742 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02802.3p-miR −3.361521606 0.013277157 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID03407.3p-miR 5.253149789 0.01340197 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06787.5p-miR 3.365836898 0.013537796 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09586.3p-miR −4.303430541 0.013592915 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07029.5p-miR 2.549642485 0.013794616 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03316.5p-miR −5.594060316 0.014229027 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07174.5p-miR 3.108044351 0.014262938 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01826.5p-miR 4.009674068 0.014512746 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03381.5p-miR −2.022944804 0.014523235 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04092.3p-miR −3.067669024 0.014458501 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06103.3p-miR −3.017564221 0.014477798 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09253.3p-miR −5.174658694 0.014509172 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06029.5p-miR 2.146941799 0.002907061 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01099.3p-miR −2.904791212 0.002996927 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03444.5p-miR 2.306240096 0.003077447 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08716.5p-miR 2.830640101 0.003016562 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06167.3p-miR 5.117000177 0.014670432 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03541.3p-miR 3.480171069 0.014845228 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09776.5p-miR 2.605647153 0.015609005 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC_MD2.ID00492.5p-miR −1.885086231 0.007448445 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID06948.3p-miR 3.09443663 0.014984398 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06610.5p-miR 2.508138788 0.003182417 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02254.5p-miR 1.037361726 0.00965459 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID04304.5p-miR −3.034487907 0.015176374 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05336.5p-miR −3.326587969 0.015295193 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06510.3p-miR −2.961506778 0.015296259 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03515.3p-miR 3.113144145 0.015407568 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08821.5p-miR −8.212551762 0.015353105 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09722.3p-miR −1.147397694 0.007755472 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID07521.3p-miR 4.000690248 0.015505981 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04182.3p-miR −9.074339415 0.015816824 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00706.5p-miR −2.872784647 0.015913657 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06339.3p-miR 2.569368917 0.003366898 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02375.5p-miR −3.243638159 0.01623186 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04862.5p-miR 4.27159012 0.016239499 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08840.3p-miR −2.941710453 0.016148847 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00700.3p-miR 2.896017129 0.003539638 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08202.5p-miR 3.891607394 0.003500977 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07681.3p-miR −2.781127573 0.016574899 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04643.5p-miR −2.685076893 0.016782143 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02023.5p-miR 2.749119483 0.016983926 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05546.5p-miR 2.084155351 0.003652502 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08362.3p-miR 2.968005513 0.003638234 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07568.5p-miR 7.428627427 0.017073055 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03979.5p-miR 4.67551264 0.017159213 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01151.5p-miR −3.312262041 0.017458394 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03087.3p-miR 3.038386397 0.017407724 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02715.3p-miR −3.116026893 0.017439889 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01679.3p-miR −999999 0.017623252 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03599.5p-miR 4.282056224 0.017639021 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05141.5p-miR −2.784882252 0.017823221 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06381.5p-miR −3.383671724 0.017801519 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09346.3p-miR 2.281824718 0.01784029 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09080.5p-miR 3.045680239 0.017987293 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01924.5p-miR 2.622848898 0.018307235 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07390.3p-miR 7.011168408 0.018332359 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02858.3p-miR −5.832375062 0.018415983 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00528.5p-miR 5.787064141 0.01858266 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04082.3p-miR −2.426940063 0.003982178 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04444.3p-miR 2.741083034 0.003953415 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08750.3p-miR −2.862400301 0.00393965 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00637.3p-miR 6.058184025 0.018701103 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02676.5p-miR −3.39730811 0.018730489 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08828.3p-miR 3.001424354 0.018742632 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00970.5p-miR −4.896585032 0.018951843 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05223.5p-miR 4.613596249 0.01898245 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06204.3p-miR −3.292787893 0.01918446 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01953.5p-miR 6.457921839 0.004130506 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08158.3p-miR 2.719385226 0.019780941 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00536.3p-miR 5.690336637 0.019835689 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00672.3p-miR 3.128585419 0.019904416 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00847.3p-miR 2.327739347 0.020065155 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02654.3p-miR 3.030401524 0.020072372 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04467.5p-miR 3.051362959 0.020037318 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07647.3p-miR −3.261142395 0.019998013 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02635.5p-miR −3.168203988 0.020258028 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00862.5p-miR 2.666454872 0.02028583 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06821.5p-miR −3.105629789 0.004269169 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04958.5p-miR 2.674148083 0.020416847 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09041.3p-miR −6.077795644 0.020488339 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07842.5p-miR 3.255613703 0.020621318 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04877.3p-miR 3.545625034 0.020689356 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00795.3p-miR 2.69704536 0.020894454 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08067.3p-miR −4.163384881 0.021285039 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08640.5p-miR −3.078424476 0.021476099 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04299.5p-miR 2.245847544 0.00463289 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04613.3p-miR 8.376174999 0.004594609 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08197.5p-miR −2.37595939 0.004608642 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03014.5p-miR −3.72049997 0.021530771 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01698.5p-miR −3.897128686 0.02165587 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00325.3p-miR −4.298352365 0.021716858 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09179.3p-miR 3.499124516 0.021737413 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05532.5p-miR −2.800723762 0.021866388 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06173.5p-miR −4.142784796 0.021812138 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02550.3p-miR 2.839572543 0.021923458 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04190.5p-miR 4.887393981 0.00035747 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09189.5p-miR 4.448951859 0.022140339 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03233.3p-miR 2.886399829 0.022207984 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01091.3p-miR 2.682059506 0.022422522 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04249.3p-miR −2.851528998 0.022519412 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02486.3p-miR 3.565057498 0.022456975 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01877.3p-miR 3.408842979 0.022778055 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04106.3p-miR 2.679758478 0.022818898 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00938.5p-miR −2.537156423 0.004921329 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02270.5p-miR 2.5676745 0.023088502 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01138.5p-miR 2.626576454 0.023250686 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05537.5p-miR −2.279834527 0.023422243 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05200.5p-miR −8.02556359 0.00110676 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID01023.5p-miR 2.395829761 0.0050136 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00746.5p-miR 5.09545691 0.023619774 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05806.3p-miR 2.713678593 0.023613813 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00244.3p-miR −2.949064286 0.023785381 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05479.3p-miR −2.923242703 0.023892528 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01506.3p-miR −5.501488348 0.024039293 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03855.5p-miR −3.324653343 0.024115172 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04136.5p-miR 2.963836967 0.024002725 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06295.3p-miR −2.621546871 0.024139807 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04598.3p-miR 3.070250447 0.024244748 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07317.3p-miR 5.409734034 0.024418766 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00600.3p-miR −2.957496647 0.024937555 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07021.5p-miR −3.006798222 0.024888573 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07249.3p-miR −2.309085736 0.024894649 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08808.5p-miR −2.876100294 0.024654888 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02793.3p-miR −2.744299539 0.024676699 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03724.3p-miR 3.168829498 0.025598591 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08577.5p-miR 2.728949814 0.025625947 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02213.5p-miR 4.034035398 0.000431332 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID03948.5p-miR 4.031522549 0.00051144 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05204.5p-miR 3.534617933 0.000461617 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00474.5p-miR −3.273098191 0.005235566 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03053.3p-miR 2.264928957 0.005317008 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC_MD2.ID00590.5p-miR 3.198726848 0.026219482 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03671.3p-miR 3.335933612 0.026339 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01287.3p-miR 3.090214346 0.026553324 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05125.3p-miR −2.981887028 0.026892611 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05191.3p-miR 2.703208548 0.026757187 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02043.3p-miR −3.328877283 0.026694567 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09116.3p-miR 2.234253027 0.005488804 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05745.5p-miR 2.793252473 0.027209357 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07158.5p-miR 2.770719295 0.027289652 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05776.5p-miR 2.580231001 0.027373375 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04424.5p-miR 2.049503056 0.005607578 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00117.3p-miR −2.413142856 0.005761416 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05823.5p-miR 4.392611417 0.005676082 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03197.3p-miR 2.924645557 0.028182015 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06019.5p-miR 4.516508691 0.000563694 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC_MD2.ID01945.3p-miR 3.43074861 0.028395532 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01483.3p-miR −4.25712926 0.006193215 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06205.3p-miR −2.958120365 0.006137108 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06799.5p-miR 2.472851563 0.028500375 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02016.5p-miR 3.069788723 0.028705269 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02385.3p-miR 2.522779608 0.028683259 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02695.3p-miR −5.511362209 0.028676056 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00208.3p-miR 5.264354571 0.028857486 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02153.5p-miR 2.612771596 0.029056618 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00531.3p-miR −2.927976732 0.029162333 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04567.3p-miR 2.430514625 0.029164041 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09154.3p-miR −2.352812441 0.029226599 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08726.5p-miR 2.589983043 0.006329591 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00594.3p-miR 2.698714332 0.029666266 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07185.5p-miR −2.643656815 0.029712357 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07652.3p-miR 2.472825117 0.030047125 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02595.3p-miR −5.860895396 0.030268541 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06528.3p-miR −3.065102364 0.030623702 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06108.3p-miR 2.627764154 0.030913846 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09057.5p-miR 2.493058232 0.031093477 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05094.3p-miR 3.981816007 0.031258199 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07930.3p-miR 2.791865669 0.031218091 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07725.3p-miR 3.11140989 0.03151947 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01609.3p-miR 3.034109734 0.031724563 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07454.3p-miR 2.767698905 0.031834835 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01683.5p-miR 2.783748545 0.03213857 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02746.3p-miR 2.740860826 0.032318065 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05663.3p-miR −2.606628114 0.032312028 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08849.3p-miR 2.428322284 0.032381642 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03819.3p-miR −2.959305937 0.032487237 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05844.3p-miR −2.901395389 0.032863215 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00123.5p-miR −2.589222168 0.03303298 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05538.5p-miR −3.518323724 0.033311984 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01155.5p-miR −4.328614352 0.033315366 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05868.3p-miR 2.381088277 0.006854152 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04089.5p-miR −6.938537055 0.033396886 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00604.5p-miR −2.183178506 0.006979761 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05105.3p-miR −3.748274568 0.033879031 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07218.3p-miR −2.845161695 0.03388715 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05399.3p-miR −5.443303801 0.034175132 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02704.3p-miR −2.863958791 0.034174026 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04691.5p-miR −2.373867578 0.007247164 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08017.3p-miR −1.960032406 0.007208365 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08439.5p-miR 2.619626927 0.028759019 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID06040.5p-miR −2.950733453 0.034656982 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06732.5p-miR −8.486934482 0.034845755 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00235.5p-miR 2.758952353 0.035035243 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01649.3p-miR 2.2909278 0.035157649 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05869.3p-miR 2.48044966 0.035575191 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08031.5p-miR −3.266960297 0.035568557 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09363.5p-miR 2.109515609 0.035580324 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00891.5p-miR −3.542326164 0.035508611 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00512.3p-miR −1.585565585 0.035922998 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02417.5p-miR 3.252147992 0.03593434 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03110.3p-miR 3.456131986 0.03585254 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09474.5p-miR −2.926892522 0.035840209 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00167.5p-miR 2.265225917 0.036221926 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00269.3p-miR 3.553813176 0.00797452 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01470.5p-miR −2.412404392 0.007746582 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01900.5p-miR 2.062213287 0.007966914 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01910.3p-miR −2.876806803 0.00788604 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02820.5p-miR 2.137825806 0.007948537 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06804.5p-miR 2.759182496 0.007867192 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07941.3p-miR 3.564568697 0.007923931 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08188.3p-miR −4.859953321 0.00780588 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09566.3p-miR −2.499761469 0.007670309 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03020.5p-miR −2.513997914 0.036537429 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02644.5p-miR 2.924896392 0.036574534 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00853.3p-miR 2.548731231 0.008132425 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04896.3p-miR −2.356304907 0.008138933 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04233.3p-miR 3.02093281 0.03676 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00467.3p-miR 2.471447378 0.036877618 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02097.3p-miR 3.427980707 0.008361803 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05571.3p-miR 2.5736205 0.008436838 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09348.3p-miR −2.540339155 0.008667802 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08204.3p-miR 2.473750463 0.038189412 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08793.5p-miR −2.611932298 0.008750634 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01742.3p-miR −2.456680699 0.038466617 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04356.5p-miR −4.540040887 0.03841956 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01789.5p-miR −1.905920815 0.008923227 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04702.3p-miR 2.428493724 0.009016307 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08714.3p-miR 2.357174319 0.008975537 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06000.3p-miR 2.829086018 0.038796939 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03049.3p-miR 2.690202949 0.038943165 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00477.3p-miR 2.075310793 0.009202389 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01538.3p-miR 1.974172003 0.009399986 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08835.3p-miR −2.678557786 0.009422952 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01842.3p-miR −2.175939651 0.009537435 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08812.3p-miR −2.388382571 0.039782219 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07949.5p-miR 3.302646452 0.039894119 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02447.3p-miR 2.535368209 0.040012763 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05372.3p-miR −3.702075727 0.040103443 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02886.5p-miR 2.722208909 0.040119191 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06513.5p-miR 2.941490989 0.040341719 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02587.3p-miR −2.853027083 0.040483761 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05236.5p-miR 2.255052835 0.040457277 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04253.5p-miR −2.060363535 0.009923538 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06838.5p-miR −1.974424997 0.009915512 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09040.5p-miR 2.89714561 0.00981689 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06200.5p-miR 5.929738732 0.041116714 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04313.5p-miR 2.689009758 0.041411831 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07911.3p-miR −2.762768146 0.041579908 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00469.5p-miR 2.654255133 0.041653536 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03307.5p-miR 2.667635911 0.041794598 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03971.5p-miR −2.331922089 0.041708705 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00796.5p-miR −2.70664484 0.010202348 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04948.3p-miR 2.226044701 0.010185066 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03157.3p-miR −2.674224631 0.042826516 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07044.5p-miR −2.514589588 0.042517078 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID07513.3p-miR −2.667481055 0.04283258 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID09174.5p-miR −2.073064939 0.042602947 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID00448.3p-miR −2.815676604 0.042238491 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID01627.5p-miR −2.449972503 0.042376064 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02925.3p-miR −2.791352543 0.043037206 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08008.3p-miR 2.552995689 0.043247261 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04118.3p-miR −1.966661969 0.010544399 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05018.3p-miR 1.987601722 0.010506792 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05503.5p-miR 5.113686357 0.010521132 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC_MD2.ID03086.5p-miR 2.885461243 0.010512505 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01366.5p-miR −2.560722335 0.043676335 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08624.3p-miR −3.563081204 0.043626761 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06421.5p-miR 2.461360557 0.043942278 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05772.5p-miR 2.493499888 0.044083642 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01925.3p-miR 2.572862146 0.044153843 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05711.5p-miR 2.814087841 0.044727116 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01536.3p-miR −4.105353872 0.044982419 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06984.3p-miR −2.67863973 0.045340989 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01926.3p-miR 5.115238652 0.045633062 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04621.5p-miR 11.43699463 0.045793414 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC_MD2.ID02236.3p-miR −2.022691596 0.045777842 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00599.3p-miR 2.745303697 0.045982413 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06814.3p-miR −3.100226571 0.046031206 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08511.3p-miR 2.144631348 0.046138461 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05662.5p-miR 4.003914487 0.046965172 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05481.5p-miR 5.631202084 0.047061598 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02239.5p-miR 1.666720863 0.047287595 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID03380.5p-miR 2.74818524 0.047370756 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID04832.5p-miR −2.503859524 0.047279009 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID05861.5p-miR 2.727277509 0.047371096 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02422.3p-miR 2.133753278 0.011528269 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08218.5p-miR 6.641461595 0.047959303 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00473.3p-miR 1.751557155 0.011781402 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04227.5p-miR 2.545716489 0.048385438 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08725.3p-miR −10.72268832 0.048771568 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00431.5p-miR 2.148214933 0.048901953 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID01155.3p-miR −4.671805316 0.049206737 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID02221.3p-miR −2.340384796 0.049640476 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00234.3p-miR −3.547988725 0.049841816 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID06607.3p-miR 2.424293579 0.049864733 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID08109.3p-miR 2.655905187 0.049787226 Chronic Lymphocytic Leukemia/Normal B cells TJU_CMC.ID00215.3p-miR −1.885337275 0.011970371 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05108.3p-miR 2.582621485 0.011935898 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02577.5p-miR 2.317229523 0.012067212 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05561.5p-miR −1.789531226 0.012278689 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07189.5p-miR 1.716924712 0.012380786 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07383.5p-miR 1.820527264 0.012532463 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07957.5p-miR −1.935121699 0.012588246 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07520.3p-miR −2.783427678 0.012704742 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00375.3p-miR −2.131326172 0.013098444 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01864.5p-miR 1.643025886 0.012849988 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04851.3p-miR 2.241577679 0.01310761 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08174.3p-miR 1.681512554 0.013319781 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09722.3p-miR −0.986418344 0.024951349 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID00579.3p-miR −3.598339659 0.013560547 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02730.5p-miR −1.818547003 0.013562724 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04620.5p-miR 2.649212636 0.013587286 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03538.3p-miR 2.582017311 0.037828562 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID02628.3p-miR −2.201026055 0.013732821 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07261.5p-miR 2.189831384 0.01389691 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01297.3p-miR 3.390718513 0.000847778 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00654.5p-miR 3.454910509 0.000915643 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05313.5p-miR −3.764364769 0.040079878 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic)/Normal Breast Tissue (GEO: GSE28884) TJU_CMC.ID00921.3p-miR −3.350218667 0.014497451 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC_MD2.ID00492.5p-miR −1.620933739 0.027178806 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID01025.5p-miR 2.811768795 0.015092124 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05045.3p-miR 2.405659845 0.015056884 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07022.5p-miR 5.684162776 0.015055519 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08442.5p-miR 2.725006334 0.014965452 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04423.3p-miR −1.725831913 0.015145701 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05148.5p-miR −2.235695907 0.015232917 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07709.5p-miR −2.024192806 0.015314902 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC_MD2.ID00121.5p-miR −0.715200567 0.028326407 ER− Breast Cancer/ER+ Breast Cancer (TCGA) TJU_CMC.ID05312.5p-miR −2.171325441 0.016199312 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06773.3p-miR 2.47772879 0.016239106 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08458.3p-miR −2.453214057 0.016075598 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01174.5p-miR 4.539765114 0.016909714 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00909.5p-miR −2.266728504 0.01735875 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03916.3p-miR 2.045002013 0.017418935 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08289.5p-miR −2.161273244 0.017696904 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01819.5p-miR 2.295373401 0.01783452 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08998.3p-miR −2.005443142 0.017866735 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00512.3p-miR 2.252872227 0.018141777 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02102.3p-miR 2.36718115 0.018321663 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04681.3p-miR −2.176188804 0.018286169 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05039.5p-miR −1.953170666 0.018285911 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07345.5p-miR 1.837615276 0.018278214 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07698.3p-miR 2.310253622 0.018146438 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06033.5p-miR 2.492889092 0.018503478 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08663.3p-miR 2.385002504 0.018459247 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01474.3p-miR 2.175335304 0.018752613 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06994.3p-miR 1.770534605 0.019217521 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07215.5p-miR −2.02153499 0.01920981 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02450.5p-miR 3.074617894 0.019501436 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03700.3p-miR 2.022040445 0.019483381 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00543.3p-miR −2.559793688 0.020403857 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04635.5p-miR −1.768150111 0.020050026 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05313.5p-miR 2.332004891 0.020192941 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08825.5p-miR 2.129189041 0.020016639 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02254.5p-miR 0.846597348 0.030022777 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID06634.3p-miR 2.793694953 0.020783262 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07607.3p-miR −1.755779331 0.020832546 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02033.5p-miR −2.025781962 0.021296034 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09450.3p-miR 4.075418332 0.021239077 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07790.5p-miR −3.448884632 0.000406238 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04803.5p-miR −1.6802627 0.021607623 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01178.5p-miR 2.113761409 0.022144989 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01987.5p-miR 2.338536342 0.02197785 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06322.5p-miR −2.288854644 0.022044522 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06548.3p-miR −2.35561253 0.022687276 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03007.3p-miR −4.782773106 0.023567016 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05203.3p-miR 1.645460066 0.023573626 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02573.5p-miR 1.910333851 0.023943836 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC_MD2.ID00121.5p-miR −0.677750071 0.036899736 PR− Breast Cancer/PR+ Breast Cancer (TCGA) TJU_CMC.ID01756.3p-miR 1.800767716 0.024285856 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04427.3p-miR 1.777738941 0.024584722 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09661.5p-miR −2.13052798 0.024499508 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03290.3p-miR 1.861979216 0.024898137 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04435.5p-miR 1.901680316 0.025033691 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03542.5p-miR 1.458859282 0.025368833 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01979.3p-miR −2.200462458 0.026533005 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02232.3p-miR 2.820569719 0.026297322 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02658.5p-miR −2.091347003 0.025541927 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03781.3p-miR 3.583905629 0.026450254 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05049.5p-miR −2.160540938 0.025854201 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06537.3p-miR 2.90612632 0.025947367 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08597.5p-miR −1.657859844 0.025898359 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09273.3p-miR 3.49373008 0.02566989 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03886.3p-miR 3.846813383 0.027325624 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00362.3p-miR 2.004690628 0.027537299 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04015.5p-miR −1.696789953 0.027738226 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04848.3p-miR 1.504367112 0.027970622 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00399.3p-miR 1.86923165 0.028478098 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02696.5p-miR 3.394279871 0.028852121 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03641.5p-miR −1.537500732 0.028218629 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03895.5p-miR 2.117157524 0.028771843 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05169.3p-miR −2.254702741 0.02873992 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07831.3p-miR 1.857964134 0.028906939 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09027.5p-miR −1.730870257 0.028240138 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09251.3p-miR 2.099237579 0.028783856 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00316.5p-miR 5.391193344 0.029285182 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02122.5p-miR −2.083758565 0.02957992 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06120.5p-miR 10.07874658 0.029951987 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02928.3p-miR 1.439304727 0.030421372 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01384.3p-miR −1.514093873 0.030652927 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00657.5p-miR −1.95472253 0.031165954 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06067.5p-miR 2.020483018 0.031338715 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06171.5p-miR 2.192147142 0.031661783 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07621.5p-miR −1.627568334 0.031656234 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01475.5p-miR −1.650495677 0.032045423 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05551.3p-miR 1.743804934 0.031958613 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05497.5p-miR −1.925503003 0.032980165 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06140.3p-miR −3.695678844 0.032857827 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05355.5p-miR −1.668282195 0.033340954 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01897.5p-miR −1.670761008 0.034026544 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07980.3p-miR 1.947577562 0.033775432 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00655.5p-miR 1.724749947 0.034445379 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07746.3p-miR −1.512560985 0.035394075 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00649.3p-miR −1.417671335 0.036131597 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01354.5p-miR −1.568861306 0.036080821 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04796.5p-miR −2.01546058 0.036177296 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05864.5p-miR −3.573410271 0.035660449 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07502.3p-miR 1.743984055 0.035703936 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07611.5p-miR −1.714093241 0.035869892 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01593.3p-miR 1.605664473 0.036412631 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03574.5p-miR −1.664336846 0.036445651 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02897.3p-miR 1.359871297 0.036639227 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00028.5p-miR 999999 0.037217161 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06935.5p-miR 1.970997085 0.037249063 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00529.5p-miR −1.87499046 0.037915223 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03321.3p-miR 2.510429351 0.038074992 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05942.5p-miR −2.052000935 0.0380364 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01056.3p-miR 2.323343113 0.038188637 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02982.3p-miR 1.827891802 0.038229827 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01560.3p-miR 1.561285467 0.038391402 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02513.5p-miR 1.935460253 0.038528593 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01950.5p-miR −1.740687512 0.038938428 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00712.3p-miR −3.578820565 0.000802636 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03003.3p-miR −4.105448707 0.000602992 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC_MD2.ID01679.5p-miR −2.857222319 0.000800548 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03818.3p-miR 2.771556746 0.039337222 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04845.5p-miR −1.862684838 0.039680261 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01893.3p-miR −1.985105144 0.039854534 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01219.5p-miR −1.534319701 0.040088793 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID04676.3p-miR −1.8439995 0.04021418 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07163.3p-miR −1.531242371 0.040236773 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05587.5p-miR 1.869978992 0.040353167 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07537.5p-miR −1.872554033 0.040625072 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07356.3p-miR −2.118855359 0.041199329 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05439.5p-miR 1.508153637 0.041577774 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06989.3p-miR 2.006062026 0.041594159 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01444.3p-miR 2.555115061 0.046060647 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01479.3p-miR 2.058604722 0.045693455 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID01480.3p-miR 3.687615024 0.044941569 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02100.3p-miR 1.489891693 0.045528966 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02150.3p-miR 1.391882669 0.044235737 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID02856.5p-miR −1.504663531 0.044931996 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03480.3p-miR −1.480600601 0.045814693 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03814.3p-miR −2.042242263 0.045171368 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03817.3p-miR 3.621894525 0.047175638 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03994.5p-miR −1.518059123 0.045706439 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05164.5p-miR −1.544533389 0.044049298 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05184.3p-miR 3.267063409 0.047372465 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05337.3p-miR 1.833858164 0.043601761 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06035.3p-miR −999999 0.042638355 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06232.3p-miR 3.246545679 0.046176078 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06262.5p-miR 1.698765745 0.043332951 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06636.5p-miR 1.919980395 0.04699867 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06724.5p-miR 2.168014304 0.045874228 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07132.3p-miR −1.721871795 0.046320233 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07608.3p-miR 1.628464608 0.04428472 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID07932.3p-miR 2.369370345 0.04736313 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID08106.5p-miR 1.786172532 0.042705749 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09086.3p-miR 1.758695636 0.042816967 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09269.3p-miR 2.219421129 0.04599574 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID09371.5p-miR 1.896231138 0.043158252 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05831.5p-miR −4.761579292 0.048202506 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00767.5p-miR −2.527150757 0.048321 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID05812.3p-miR −2.517265076 0.048359017 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID06419.5p-miR −5.793641439 0.003012534 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04247.5p-miR 4.395280759 0.001679836 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01210.3p-miR 999999 0.049941853 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03472.3p-miR −1.475216055 0.049699193 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID03557.5p-miR 1.533416634 0.049795982 Stage 1 Gastric Cancer/Normal Gastric Tissue TJU_CMC.ID00512.3p-miR 2.029773173 0.002051085 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01099.3p-miR −3.269626886 0.001077378 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02447.3p-miR −3.138250987 0.001684081 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03472.3p-miR −2.770632211 0.002091258 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03778.3p-miR −2.566149717 0.001432757 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04082.3p-miR −2.292365086 0.001517484 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04470.5p-miR −9.863088018 0.001502956 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06821.5p-miR −3.25417007 0.002307217 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06444.3p-miR 1.653214013 0.000185226 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07305.3p-miR 2.42654381 0.0002754 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09231.3p-miR 2.335032738 0.000381281 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09257.3p-miR 1.774945288 0.000320958 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06656.5p-miR 2.943589432 0.002959778 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00543.3p-miR −2.952746517 0.002860035 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03641.5p-miR −1.737261622 0.003077421 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06731.3p-miR −2.157167272 0.002987265 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06081.3p-miR 1.613609556 0.000795092 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07748.3p-miR 3.632924218 0.000734968 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08608.5p-miR −4.761294513 0.000494056 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09409.5p-miR 2.051129669 0.000679156 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01835.5p-miR 3.18205863 0.002083819 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06439.5p-miR −1.977866648 0.000932038 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04635.5p-miR −1.934426287 0.003545121 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07938.3p-miR 3.311028792 0.002242892 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05537.5p-miR 2.641046763 0.0026369 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00225.3p-miR 3.951746463 0.004153786 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01606.3p-miR 6.346718292 0.004046096 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02015.5p-miR −2.21281534 0.004111365 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00641.5p-miR 2.868879593 0.00453698 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01724.5p-miR 3.457748523 0.003316639 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01869.5p-miR −999999 0.003192327 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01093.3p-miR −2.897451699 0.004835397 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02648.3p-miR 2.950522108 0.004231351 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04455.3p-miR 999999 0.004199682 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06720.3p-miR 4.543488868 0.004329511 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00955.3p-miR 6.831164867 0.004772912 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09015.3p-miR 3.12609034 0.004830775 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00649.3p-miR −1.82174396 0.005864792 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02426.3p-miR 999999 0.00558375 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01200.5p-miR 5.20008035 0.005742175 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05623.3p-miR 2.925825533 0.005784479 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00340.3p-miR 1.993239112 0.001601574 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04683.5p-miR 2.246604768 0.006516713 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00956.5p-miR −1.644563996 0.006872914 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04312.3p-miR −2.480319042 0.007310973 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05355.5p-miR −1.855768435 0.00715091 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05823.5p-miR 4.284212647 0.007316774 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06673.3p-miR −3.150401134 0.007470134 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07039.3p-miR 3.463613833 0.007037541 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06649.3p-miR −1.934587257 0.007616704 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03702.5p-miR 3.461908651 0.006315937 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08197.5p-miR −2.348254142 0.008018667 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00773.5p-miR 2.301016376 0.008162097 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00912.5p-miR 1.96238007 0.001862198 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00409.5p-miR −1.824781674 0.010067209 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02510.3p-miR −1.939092573 0.010071596 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02658.5p-miR −2.196705585 0.009912383 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08835.3p-miR −2.675705482 0.009634574 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC_MD2.ID00858.5p-miR 4.323371122 0.010095344 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00299.5p-miR 3.787100783 0.010281539 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05262.3p-miR 3.427190631 0.007094902 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID03383.3p-miR 3.451124625 0.00782853 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID07583.3p-miR −4.673021177 0.007512288 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08289.5p-miR −2.373992253 0.010900817 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03699.3p-miR −1.742638842 0.011043398 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01788.5p-miR −999999 0.008110928 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02580.5p-miR 1.61352745 0.002330424 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00747.3p-miR 1.691988375 0.003680397 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01720.5p-miR 1.714723319 0.004129298 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02109.3p-miR −1.975837467 0.004168064 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06436.3p-miR 1.503891979 0.003179432 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07393.3p-miR −1.619332054 0.004050664 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09218.5p-miR 3.556651643 0.003192236 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00341.3p-miR −1.726729129 0.011967311 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09085.5p-miR 2.437603929 0.012499213 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07062.5p-miR 1.574930362 0.00458083 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07941.3p-miR 2.999225899 0.012768627 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00107.3p-miR −2.229420458 0.01311175 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06672.3p-miR 2.248698546 0.004908521 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03038.3p-miR −1.908413945 0.01358092 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03048.5p-miR −2.237365771 0.00617588 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04575.5p-miR 1.374083779 0.005749961 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07579.5p-miR 1.513417789 0.005707046 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00117.3p-miR −2.013676533 0.014763149 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08644.5p-miR 3.07740616 0.014681356 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01789.5p-miR −1.528641892 0.015622037 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04560.3p-miR 1.926472464 0.015686032 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07132.3p-miR −2.145459446 0.015765732 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03166.3p-miR −1.367271523 0.007441783 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06406.3p-miR 1.503842206 0.007351872 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07180.5p-miR 2.534389089 0.007426857 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02391.5p-miR 2.065765985 0.017318452 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09252.5p-miR 1.45046237 0.008429204 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01025.5p-miR 2.165904826 0.023339219 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01304.5p-miR 3.221546361 0.024071294 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01746.5p-miR −1.583604032 0.026592602 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01910.3p-miR −2.441311954 0.018396986 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02033.5p-miR −1.774828076 0.027084114 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02628.3p-miR −1.787353578 0.023789006 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03007.3p-miR −3.612174848 0.019862328 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03895.5p-miR 1.981250026 0.020003969 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04157.3p-miR −1.717742097 0.023237959 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04253.5p-miR −1.766416339 0.020243759 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04299.5p-miR 1.997983535 0.026818988 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04423.3p-miR −1.306189429 0.027161254 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04427.3p-miR 1.989335741 0.023912734 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04609.5p-miR −1.598892336 0.021224882 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04627.3p-miR −1.738444442 0.027126725 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05571.3p-miR 2.001384289 0.027073479 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05587.5p-miR 1.889486869 0.023685507 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05831.5p-miR −4.315550633 0.025696698 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06140.3p-miR −2.938939032 0.018689128 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07032.3p-miR −2.678233377 0.022403467 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07163.3p-miR −1.551579634 0.018813489 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07328.3p-miR −1.812228701 0.018202268 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07621.5p-miR −1.630123804 0.019632235 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07831.3p-miR 2.22789396 0.023659153 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07957.5p-miR −1.640732883 0.022518983 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08188.3p-miR −2.548460682 0.019403294 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08433.5p-miR 1.837320352 0.02452899 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08542.3p-miR −1.641071987 0.020214569 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08726.5p-miR 2.41129203 0.020897802 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08763.5p-miR 2.352548471 0.025146309 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08919.5p-miR −1.571636109 0.025768628 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09200.5p-miR 3.751805405 0.022814355 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09566.3p-miR −2.039506479 0.027493623 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09661.5p-miR −1.801675613 0.019398026 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01161.5p-miR −1.871147808 0.029528949 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04906.3p-miR −1.621951722 0.029550075 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05795.3p-miR 2.58568564 0.029598595 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07769.3p-miR 9.292014054 0.028305422 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08178.3p-miR −1.642677666 0.028858406 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03480.3p-miR −1.545934793 0.03021484 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05411.3p-miR 1.93344821 0.031313051 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05815.3p-miR −1.667436954 0.031498296 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02123.5p-miR −1.748033387 0.033136473 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02311.3p-miR 2.312634562 0.03349258 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04010.5p-miR −2.448628541 0.03400175 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05546.5p-miR 1.629003531 0.031926249 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06935.5p-miR 1.854549293 0.033391047 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01479.3p-miR 1.986409421 0.035272638 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC_MD2.ID03086.5p-miR 2.111181769 0.035337682 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08761.5p-miR −4.267548625 0.010203613 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00938.5p-miR −1.613840774 0.040784364 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00977.5p-miR −1.341670399 0.039528803 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00993.3p-miR 1.970492029 0.038198466 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01429.5p-miR 2.867504225 0.036707831 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02586.5p-miR 999999 0.036738061 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03305.5p-miR −1.609862851 0.037390013 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03732.5p-miR 2.004244641 0.040079898 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04015.5p-miR −1.498719744 0.039679831 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04681.3p-miR −1.63555378 0.038292529 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04702.3p-miR 2.271594216 0.039538409 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID04813.5p-miR −1.58255416 0.038834773 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05559.5p-miR −1.375051006 0.040184485 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07960.3p-miR 2.165855447 0.038981849 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08674.5p-miR 1.601114325 0.038080565 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09116.3p-miR 1.968435382 0.04000353 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02809.3p-miR −2.771104044 0.041691648 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID06403.5p-miR −1.920068702 0.041883968 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03494.5p-miR 3.95939225 0.010418164 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00900.5p-miR 1.895343037 0.043922464 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID01174.5p-miR 4.633172229 0.042653376 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08272.3p-miR 3.508139003 0.043302973 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00815.3p-miR −1.772489511 0.044945986 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID07737.3p-miR 2.504446699 0.045000353 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID00269.3p-miR 2.505206495 0.046165249 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID03292.3p-miR −1.424577368 0.045752924 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID08442.5p-miR 2.030145449 0.0470639 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID05497.5p-miR −1.294583047 0.048367954 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID02249.3p-miR 1.895760363 0.049410912 Gastric Cancer (All Stages)/Normal Gastric Tissue TJU_CMC.ID09776.5p-miR 1.489037083 0.038181576 Prostate Cancer/Normal Prostate TJU_CMC_MD2.ID01581.5p-miR −1.263595505 0.039312083 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00009.3p-miR 1.477830676 0.047912781 Stage 4/Stage 3 (Gastric Cancer) TJU_CMC.ID00052.3p-miR −1.563173 0.012266671 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00084.5p-miR −2.939458889 0.016355399 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID00195.5p-miR 1.079999173 0.032878597 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00244.3p-miR 7.100886471 0.038288489 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00247.5p-miR 1.3472225 0.036882313 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00297.3p-miR 7.738409678 0.012633237 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00314.3p-miR −3.076506181 0.03766979 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID00348.3p-miR 1.327956897 0.015928599 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00350.3p-miR 1.885888423 0.042088708 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00362.3p-miR −2.085240193 0.042942951 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID00382.5p-miR −999999 0.030703538 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID00568.5p-miR 2.344610964 0.01887733 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00768.5p-miR 1.193133606 0.047495635 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00768.5p-miR 2.432325887 0.018620428 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00789.3p-miR 1.181960622 0.043194929 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00863.3p-miR −1.360451143 0.01096608 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID00894.5p-miR −2.728939887 0.043569208 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID00919.5p-miR −2.002438715 0.033421367 Prostate Cancer/Normal Prostate TJU_CMC.ID00971.3p-miR −2.743521401 0.028929917 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID01018.3p-miR 5.635072153 0.022841887 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID01069.3p-miR 2.605972125 0.021994098 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID01080.3p-miR 0.916170345 0.015991941 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01085.3p-miR 1.678188162 0.015798823 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01088.3p-miR 0.979367272 0.042853103 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01135.3p-miR −1.838228767 0.01684644 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID01162.3p-miR −1.077075181 0.048758702 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01261.3p-miR 4.587419352 0.01645577 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01273.3p-miR 1.108485397 0.025187843 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01296.3p-miR −6.537795507 0.030638518 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID01339.5p-miR −2.919610922 0.012677767 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID01410.3p-miR 1.564842602 0.010625095 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01421.5p-miR 2.445206236 0.038660729 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01517.5p-miR 2.510345858 0.043562113 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID01546.3p-miR 3.849540809 0.03881563 Prostate Cancer/Normal Prostate TJU_CMC.ID01589.5p-miR 7.52282662 0.01203502 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01637.5p-miR −0.951688288 0.046805673 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01657.5p-miR 1.200240685 0.044669458 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01691.3p-miR 6.706337157 0.048069193 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01706.5p-miR 1.143990065 0.049962547 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID01719.5p-miR −4.87303582 0.022572743 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID01763.5p-miR −6.573089908 0.038624619 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID01805.5p-miR −3.499450023 0.022188591 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01806.3p-miR 4.789701655 0.026115412 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID01864.5p-miR −2.332814508 0.016055 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID01909.3p-miR 3.565702913 0.014056536 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID01943.5p-miR −2.212509523 0.010809204 Prostate Cancer/Normal Prostate TJU_CMC.ID01953.5p-miR −4.342884428 0.045146045 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID02018.5p-miR −1.781518856 0.028018214 Prostate Cancer/Normal Prostate TJU_CMC.ID02034.5p-miR −1.555519162 0.012591791 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02138.5p-miR 2.512632326 0.032846065 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02211.5p-miR −3.428004423 0.014486957 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02258.3p-miR 7.462523283 0.044389508 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID02289.5p-miR 4.806026864 0.040544693 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID02290.5p-miR 6.550642842 0.041935162 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02305.3p-miR 1.215472034 0.031476713 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02326.5p-miR 4.891081095 0.027029515 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02376.5p-miR 2.889831458 0.0367707 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID02420.5p-miR 1.134690166 0.024073365 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID02453.5p-miR 2.283757315 0.042273906 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02479.3p-miR 1.340706073 0.022305849 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02495.5p-miR 3.40896854 0.046205988 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02499.3p-miR −2.561743968 0.048800688 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID02522.5p-miR −1.327874509 0.020841274 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02561.5p-miR −2.513059732 0.035711835 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID02629.3p-miR −999999 0.048131214 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID02630.5p-miR 1.267984776 0.012279347 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02641.5p-miR 3.851807621 0.019760885 Prostate Cancer/Normal Prostate TJU_CMC.ID02702.5p-miR −0.848362775 0.044000798 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02760.3p-miR 2.015420588 0.044677375 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02819.5p-miR 1.080945126 0.021311897 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02835.3p-miR −1.268285688 0.047845428 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02909.3p-miR −0.997536853 0.019442636 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02914.3p-miR −2.5089258 0.018325608 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID02928.3p-miR −1.823624294 0.026092911 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID02936.3p-miR 2.230440371 0.028695444 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02951.5p-miR 3.370149449 0.017946247 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02963.3p-miR 1.346154092 0.049843133 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID02974.3p-miR −3.445625017 0.025122478 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID02983.5p-miR 1.475207022 0.019934104 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03009.3p-miR 1.649167015 0.02902873 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03046.3p-miR −1.19936191 0.042007511 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03054.3p-miR −999999 0.013013719 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID03078.3p-miR 1.531824418 0.016192411 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03104.5p-miR 2.23497465 0.029259981 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID03128.3p-miR 1.359735036 0.026875852 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03148.5p-miR 1.363629432 0.017882699 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03152.5p-miR −1.058108022 0.043698842 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03322.5p-miR −2.726379148 0.003149937 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID03328.5p-miR 7.228105391 0.041174743 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID03395.3p-miR −999999 0.024920128 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03444.5p-miR −2.425956557 0.014239203 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID03468.3p-miR −999999 0.026548308 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID03469.3p-miR −999999 0.02046219 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID03525.5p-miR 2.024236382 0.043013288 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03547.3p-miR 1.088942611 0.031389761 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03569.5p-miR −1.783878949 0.041663766 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID03579.3p-miR 2.339529876 0.031743547 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID03586.5p-miR 1.559085474 0.038078855 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03705.5p-miR 2.314969901 0.01268648 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03708.5p-miR −2.037179611 0.043388527 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID03820.3p-miR 2.846686172 0.022838815 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID03902.3p-miR 1.198598227 0.039618344 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID03912.5p-miR 1.25809572 0.027856237 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04075.5p-miR 2.310361088 0.040051908 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04080.5p-miR 3.19306214 0.028960073 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04092.3p-miR −4.408668432 0.024276182 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04286.5p-miR 4.478044918 0.027879142 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04324.5p-miR −999999 0.043530936 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04342.5p-miR 1.800326099 0.047129364 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID04424.5p-miR −2.001146748 0.019798024 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID04572.5p-miR −1.08873462 0.048571828 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04614.5p-miR 3.732040576 0.049558403 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04617.3p-miR 2.237425363 0.035202753 Prostate Cancer/Normal Prostate TJU_CMC.ID04630.3p-miR 1.247278138 0.0465399 HER2-type Breast Cancer/Basal-like Breast Cancer (TCGA) TJU_CMC.ID04668.3p-miR 3.319215229 0.018021822 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04740.3p-miR −2.346176139 0.043984837 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04779.3p-miR 6.486114799 0.045280745 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04788.5p-miR −999999 0.0487335 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04803.5p-miR −999999 0.043205027 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04820.3p-miR 2.452780432 0.017802552 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID04842.5p-miR −2.421514896 0.047905247 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID04865.5p-miR −999999 0.047614773 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID04868.5p-miR −1.002409588 0.025247313 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04928.5p-miR 1.359874336 0.024281153 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID04992.3p-miR 1.741755955 0.033510108 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID05017.5p-miR −2.266144482 0.027216363 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID05313.5p-miR −3.770479664 0.003877615 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID05357.3p-miR 2.339487344 0.049616356 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05397.3p-miR 1.526453747 0.010537367 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05415.3p-miR −1.455138672 0.041024695 Prostate Cancer/Normal Prostate TJU_CMC.ID05419.5p-miR 3.086717415 0.01653433 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID05478.5p-miR 2.6303543 0.012681579 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05499.5p-miR 2.419491 0.014931304 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05510.3p-miR −2.538816142 0.041195298 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID05546.5p-miR 3.2306874 0.0184641 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID05548.3p-miR 2.704833671 0.034293728 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID05639.5p-miR −1.086178426 0.029198929 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05664.5p-miR −3.396746446 0.048216431 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID05700.5p-miR −999999 0.042411288 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05758.5p-miR −2.925617594 0.017181581 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID05781.3p-miR 1.434647567 0.019638069 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05857.5p-miR 1.447991864 0.010024548 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05896.3p-miR 1.235764812 0.016312488 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05937.5p-miR −1.273568266 0.040227023 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID05970.3p-miR 2.879521084 0.017012637 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID05977.3p-miR 999999 0.046469869 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID06037.5p-miR −3.081541785 0.030474184 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06061.5p-miR 0.94952706 0.035513757 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06076.5p-miR 1.344256788 0.029915762 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06115.3p-miR 3.10982229 0.031329725 Prostate Cancer/Normal Prostate TJU_CMC.ID06117.5p-miR 4.085677992 0.037262132 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID06146.3p-miR −1.277339046 0.037711719 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06228.3p-miR −1.444106832 0.01997565 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06339.3p-miR −2.809713442 0.008258968 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID06484.5p-miR −1.573142702 0.049709755 Prostate Cancer/Normal Prostate TJU_CMC.ID06539.3p-miR −3.729993502 0.000799716 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID06553.5p-miR 1.216440491 0.017832843 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06610.5p-miR −2.398369481 0.021323249 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID06620.5p-miR 4.717528041 0.029027538 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID06651.3p-miR 1.503525114 0.029348763 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06672.3p-miR 2.363876542 0.014376798 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06684.5p-miR 1.184849137 0.012498505 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06736.5p-miR 1.027632873 0.022289989 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID06760.3p-miR 5.719410568 0.038997076 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID06765.5p-miR −2.734935036 0.022526889 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID06798.3p-miR −999999 0.040991372 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID06865.5p-miR 2.266458461 0.049772174 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID06987.5p-miR 1.32602718 0.013148506 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07029.5p-miR 1.025819086 0.039590943 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07034.5p-miR −999999 0.026977278 Prostate Cancer/Normal Prostate TJU_CMC.ID07073.3p-miR 1.362074466 0.025985874 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07118.3p-miR 1.358192938 0.025833509 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07253.3p-miR 2.141867332 0.042181369 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID07263.3p-miR −1.422644797 0.017719 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07272.3p-miR 2.336599302 0.04398778 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID07373.5p-miR −9.715672414 0.01529549 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID07383.5p-miR −3.198512488 0.004985778 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID07421.5p-miR 2.135062062 0.043113573 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID07469.3p-miR 1.025498261 0.032668928 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07488.5p-miR 1.195912797 0.026248769 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07510.3p-miR 1.275122876 0.035611377 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07519.3p-miR 3.836738075 0.022542145 Prostate Cancer/Normal Prostate TJU_CMC.ID07559.3p-miR −1.460592419 0.030481404 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07610.5p-miR 2.552174284 0.022439374 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID07769.3p-miR 999999 0.044834717 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID07801.3p-miR −1.119418093 0.013262881 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07809.5p-miR −1.107946725 0.031809701 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07834.3p-miR 2.63743159 0.041377417 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID07841.3p-miR 2.465873748 0.027102666 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID07861.5p-miR 0.985777139 0.049157741 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07871.3p-miR 1.397277995 0.018354634 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07914.5p-miR 1.28398237 0.049006487 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID07954.3p-miR −3.239335055 0.03042949 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID07960.3p-miR −2.422033216 0.022135075 Prostate Cancer/Normal Prostate TJU_CMC.ID07973.3p-miR 2.613660743 0.018542662 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08019.5p-miR −1.394101883 0.029579628 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08043.3p-miR 1.951144233 0.045679546 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID08074.3p-miR 1.194016545 0.016403084 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08202.5p-miR −2.711995889 0.039866728 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID08252.3p-miR −2.005602975 0.031304754 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID08284.5p-miR 1.270489064 0.036750125 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08389.5p-miR −2.706964681 0.03043225 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID08391.3p-miR 4.402016384 0.016291452 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08401.5p-miR −5.124839457 0.017106129 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08486.5p-miR −1.294807018 0.032293633 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08586.3p-miR 2.133653292 0.047329924 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08622.3p-miR −1.266121461 0.025040345 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08632.3p-miR 1.277309014 0.019995413 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08687.5p-miR 1.209697855 0.032166429 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID08726.5p-miR 3.241011862 0.001321656 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC.ID08800.3p-miR 2.124294119 0.024098946 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08803.3p-miR 2.325924074 0.040336565 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID08842.3p-miR −1.501463396 0.030740633 Prostate Cancer/Normal Prostate TJU_CMC.ID08880.5p-miR −3.156695744 0.019176545 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09005.3p-miR −5.489788623 0.012212712 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09009.3p-miR 2.705944072 0.033944204 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09016.3p-miR 4.989971469 0.041187184 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID09037.3p-miR −1.737934328 0.030312535 Prostate Cancer/Normal Prostate TJU_CMC.ID09069.5p-miR 1.353962462 0.045436789 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09079.3p-miR 2.222284363 0.018051479 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID09120.3p-miR 2.195852413 0.029115755 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID09230.3p-miR 2.171964668 0.048313984 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID09232.5p-miR −4.639075346 0.026129589 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09235.5p-miR 3.134775183 0.008287097 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID09235.5p-miR −2.943457352 0.044162599 Stage 4/Stage 3 (Gastric Cancer) TJU_CMC.ID09252.5p-miR 2.856342709 0.024364685 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09261.5p-miR 1.736182465 0.011353491 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC.ID09273.3p-miR −5.126428551 0.005936221 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID09283.5p-miR 999999 0.038985348 Stage 3/Stage 2 (Gastric Cancer) TJU_CMC.ID09315.5p-miR −3.038172331 0.006109781 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC.ID09441.5p-miR 4.08569959 0.025506003 Prostate Cancer/Normal Prostate TJU_CMC.ID09442.5p-miR 1.710183562 0.03839507 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC.ID09660.3p-miR 4.907722665 0.020611751 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID09753.5p-miR −6.066785381 0.020677688 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC.ID09799.3p-miR 2.576122738 0.040874487 Psoriasis Biopsy/Normal Skin Biopsy TJU_CMC_MD2.ID00602.3p-miR 3.794286038 0.042507991 MIA PaCa-2 cells/HPNE cells (Pancreas cell lines) TJU_CMC_MD2.ID00858.5p-miR 2.538206626 0.043510714 Prostate Cancer/Normal Prostate TJU_CMC_MD2.ID01526.3p-miR −1.195280658 0.049628324 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC_MD2.ID01878.5p-miR 2.011665229 0.010441931 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC_MD2.ID01959.5p-miR −1.286480278 0.030700595 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC_MD2.ID02369.5p-miR 2.913986759 0.046604875 PBMC Scleroderma Patients/PBMC Control Individuals TJU_CMC_MD2.ID02968.3p-miR −1.19449432 0.038131744 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC_MD2.ID03322.3p-miR −1.191709316 0.034506286 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC_MD2.ID03345.5p-miR −1.709921748 0.011392242 Hypo-reactive/Hyper-reactive (Platelets) TJU_CMC_MD2.ID03472.3p-miR 5.102327203 0.029176763 Stage 2/Stage 1 (Gastric Cancer) TJU_CMC_MD2.ID03495.5p-miR 2.563610753 0.023443767 PBMC Scleroderma Patients/PBMC Control Individuals

Example 8 Differential Expression by Disease States for Novel isomiRs Derived from Known miRNA Loci

Using samples from different disease states, the inventors identified differentially expressed novel isomiRs (as listed in Table 3) that were identified as arising from known miRNA loci. As stated above, an isomiR is considered to be differentially expressed if it had a mean expression of at least 50 sequenced reads, a log2-change in expression between the compared states of ≥0.58 or ≤−0.58, and a p-Value≤0.05.

Table 12 below shows the fold-change of the isomiRs in pairs of the same tissue of different states. Abbreviations: TCGA=The Cancer Genome Atlas; PBMC=Peripheral Blood Mononuclear Cells; GEO=Gene Expression Omnibus. The actual miRNA/isomiR sequences and corresponding SEQ ID NOs. can be identified in Table 3 according to the the “Name” listed in Table 12.

TABLE 12 Differential expression of isomiRs in tissues of various disease states Log2 fold change of Name Set A/Set B p-Val Sets Compared (A / B) NovelMiR_KnownLoci_ID0005632 −9.449019057 3.11E−24 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005626 −7.795023849 2.08E−19 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002601 −5.915269502 8.38E−18 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006812 −5.344785584 1.15E−16 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008665 5.34176987 4.07E−15 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016689 −4.666623356 6.46E−15 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018483 −999999 3.26E−14 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014279 −4.266134953 7.65E−14 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006814 −5.190619236 3.65E−13 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007177 −4.689737551 2.80E−13 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014280 −4.872763416 3.12E−13 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018486 −7.878955778 3.35E−13 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007176 −3.933533992 5.85E−13 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005625 −7.050750549 7.26E−13 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001499 −3.290788446 4.31E−14 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0006816 −7.413616584 3.30E−12 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007797 −999999 3.24E−12 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005633 −7.82482339 4.19E−12 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007178 −4.438548379 4.94E−12 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018488 −999999 1.64E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015398 −6.344748434 2.57E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014278 −4.584344269 3.41E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002219 6.388645072 4.30E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001366 −7.573149249 4.72E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014277 −4.369431233 5.00E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014281 −5.625271605 7.03E−11 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018600 −6.575438939 1.96E−10 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008648 5.390055579 3.16E−10 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016861 −999999 3.19E−10 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006811 −5.979046087 5.18E−10 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008656 4.63871832 7.80E−10 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006815 −4.656366312 1.26E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002600 −4.255842937 2.01E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005627 −5.9237278 2.23E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006813 −4.997412766 3.19E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001367 −999999 5.74E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002602 −6.566977183 6.72E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018660 −3.888337722 7.10E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008649 6.412110977 7.46E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014290 −4.717404086 8.92E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007179 −4.753089157 9.70E−09 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016688 −6.129238535 1.44E−08 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002595 −4.569121805 2.62E−08 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002289 −5.785799567 3.69E−08 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020072 2.22973986 7.25E−09 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0014285 −6.709099051 7.22E−08 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002692 2.564939997 1.03E−08 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007782 3.993706559 1.68E−09 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0007784 4.336805868 2.61E−09 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0002593 −4.535144583 9.75E−08 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014733 5.845053014 2.06E−08 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016685 −7.385271628 1.73E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007796 −8.103036319 1.85E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001499 −2.184137246 1.58E−08 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019195 −5.688267903 4.30E−09 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013332 3.004107376 2.51E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015798 6.27244168 2.51E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017560 6.523377655 2.92E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014429 −2.558794358 4.13E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015579 4.096538558 4.51E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019676 −4.073174456 6.14E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014997 3.221678472 6.95E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016690 −3.122517655 7.95E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019196 −4.996100236 2.61E−08 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002220 3.435531715 8.71E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002579 −3.571205913 9.10E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018652 −4.421238031 9.28E−07 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000489 −5.679573104 1.23E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018662 −4.188585908 1.77E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017195 7.053837237 7.63E−08 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015279 1.40741001 3.85E−07 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001051 −4.918229781 2.28E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014995 2.810933016 2.39E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007775 −3.40934988 2.84E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018609 −6.473840401 2.99E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014996 2.854799318 3.10E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002771 −4.011821848 3.42E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004440 −2.65895029 3.56E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016691 −3.141725845 3.52E−06 Chronic Lymphocytic LeukemiavNormal B cells NovelMiR_KnownLoci_ID0017884 −4.022903211 3.54E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017883 −2.528154892 3.99E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013331 3.142631897 5.63E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018661 −3.524045545 6.01E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015584 3.207078823 6.86E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012646 −2.39031083 6.94E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007780 3.914117266 1.86E−07 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018601 −999999 8.07E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002692 2.341885742 5.29E−07 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0018412 4.02433692 8.32E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010253 2.125689188 8.48E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019651 −2.393563543 9.31E−06 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020074 2.232477393 1.98E−06 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020098 1.813004042 2.40E−06 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020072 1.927137408 1.05E−06 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008662 2.291496076 1.52E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001365 −7.098519582 1.63E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002773 −2.537871799 1.62E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014733 5.073680715 1.76E−06 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0018605 −5.43833329 2.09E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019599 −3.117959681 2.16E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017195 7.525739017 3.09E−07 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019195 −4.628750466 3.52E−07 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016860 −4.212059759 2.27E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016683 −3.974758136 2.46E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002690 3.712339815 1.06E−06 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015279 1.225051913 2.91E−06 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016905 3.881381966 8.67E−07 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004105 −3.779096123 3.36E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004424 1.482397111 7.15E−06 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010260 2.77887709 3.66E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015757 −3.510950334 3.78E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001215 3.153367686 3.84E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002611 −7.115089022 3.94E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004441 −3.069751002 4.00E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002689 4.297158875 2.97E−06 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013953 −3.507976963 2.59E−06 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019192 −4.306221425 2.27E−06 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019193 −4.115018139 3.22E−06 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007164 3.696025911 4.56E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002615 −5.006545534 4.79E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007781 3.024188132 1.61E−06 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0017556 3.187052011 4.17E−06 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018604 1.250212472 1.03E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007790 4.104979694 2.32E−06 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0016691 −1.37981859 1.28E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019196 −4.039295764 1.26E−06 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015582 4.086672544 6.24E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010264 2.072839546 6.87E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015811 2.514071239 6.88E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013158 −1.512902014 1.50E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002592 −3.332225795 7.28E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007793 3.518175143 3.24E−06 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0001566 −2.867117121 7.60E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019703 −2.4358094 7.93E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004423 1.457852756 1.92E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015803 5.691245111 9.04E−05 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004428 −3.269623123 0.000105243 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004429 −2.260476872 0.000107437 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016681 −3.660212585 0.000109259 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004446 −2.83643266 0.000119554 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015810 4.035438782 0.000118139 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018693 2.197175969 0.000119071 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001567 −2.754675043 0.000123009 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019678 −3.14532339 0.000124852 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016692 −1.225979062 1.69E−05 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020585 2.300080863 0.000135248 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010247 2.57139954 0.000138066 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003918 2.756085064 1.22E−05 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006811 −3.451689481 1.12E−05 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004269 3.637803325 0.000151992 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019653 −2.144583878 0.000169188 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004516 0.956731109 3.91E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010261 2.630935295 0.000172729 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004424 1.369346896 2.57E−05 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020074 2.064494742 2.45E−05 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020098 1.563170714 2.38E−05 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002287 −3.189927854 0.000181679 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016692 −1.199650594 4.23E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007063 −3.464203654 0.000185001 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019704 −2.421244563 0.000188082 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016963 2.026253552 0.000200222 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016970 2.396112803 0.000200218 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015578 3.018753561 0.000202092 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018605 1.248555356 4.71E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019723 2.950995722 8.79E−06 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0015580 3.345584622 0.000221207 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018604 −4.763985083 0.000221239 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002772 −2.116780705 0.000223571 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010262 2.529516648 0.00023177 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019598 −1.92605706 0.000232379 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001366 −4.732516964 2.18E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0013158 −1.36896036 3.72E−05 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016686 −1.31397251 3.82E−05 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017880 −2.888384672 0.000246416 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004574 −1.335364905 5.55E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007285 3.174352485 0.000252162 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010248 2.128634759 0.00025835 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004435 1.295459545 5.90E−05 ER- Breast Cancer/ ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004577 −1.540890388 6.01E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008466 1.044558803 6.07E−05 ER- Breast Cancer/ ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016691 −1.284021183 4.45E−05 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013156 −1.375997576 7.33E−05 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017869 −1.746468436 0.000331124 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000306 2.094667856 0.000334366 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002692 4.694081922 3.24E−05 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004548 −2.071552492 0.000360601 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002721 −3.02578764 4.32E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004577 −1.516485401 7.02E−05 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015808 4.011792169 0.000407344 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017560 2.658006195 4.87E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0002715 −1.40477947 0.000109649 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020586 2.98832932 0.000424742 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013157 −1.444740717 0.000113576 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001565 −2.397751201 0.000448179 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018653 −2.928261041 0.00045157 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007795 2.786043137 2.03E−05 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0008548 2.546369525 2.12E−05 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010259 2.597981641 0.000483607 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006813 −2.98652604 6.04E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0008550 2.673434027 6.32E−05 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004516 0.875850868 8.84E−05 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016956 2.303723339 0.000504552 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018604 1.053022649 9.18E−05 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019677 −2.754002867 0.000530842 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001918 1.910562143 0.000552624 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018694 2.397635013 0.000550623 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016686 −1.238325687 0.000157107 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016960 2.071246642 0.000576612 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016964 1.645734282 0.000578397 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011763 6.697688386 0.000586334 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018664 −2.44337049 0.000587267 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004423 1.306781054 0.000108879 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004968 4.876587226 0.00063666 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015759 −3.940891446 0.000668663 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002283 −2.327737827 0.000685894 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013325 1.726135773 0.000693455 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015319 1.246119369 0.000202816 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016693 −1.083852311 0.000208795 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019654 −2.00236845 0.000722271 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007771 3.808955353 3.18E−05 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010919 −3.400406143 0.000804834 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012650 −2.485796917 0.000803006 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014054 2.007375149 0.000802301 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019597 −2.014594515 0.00080872 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008650 4.442352955 0.000824106 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007478 −2.562706433 0.000829881 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004435 1.210514234 0.000155326 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017162 1.043139843 0.000146998 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013209 −1.71521059 0.000859315 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020588 2.628778376 0.000877719 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019193 −3.750502817 1.42E−05 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015743 −3.591431584 0.00090166 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016883 −2.827493237 0.000931029 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016933 2.359380192 9.31E−04 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007168 2.256272928 0.000973675 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015806 6.128333235 0.000998481 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014428 −1.608285233 0.001006227 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016934 1.912002474 0.001022426 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004574 −1.221609745 0.000203016 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016922 2.671928498 0.000125934 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015804 6.022203554 0.00105651 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004445 −2.36840788 0.001130985 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010252 2.602232395 0.001119774 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010254 2.372957721 0.001123197 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019645 −2.600208304 0.001130939 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008365 −1.448400935 0.000347376 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008464 1.059250686 0.000357779 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015079 2.748618146 0.000353705 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016681 −1.075637178 0.000350915 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013915 −1.771144069 0.001177077 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002719 −2.709469791 0.000141557 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017567 −2.122827187 0.001201663 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018663 −3.384833492 0.00121394 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016920 −2.984291417 0.001263572 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017555 −1.669751782 0.001273464 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004472 3.23376914 0.000162714 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020266 2.73820545 0.000169978 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0017162 0.810572182 0.000432172 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012629 −1.76848938 0.001316211 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013207 −2.000986561 0.001320655 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020589 2.394986367 0.001327703 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018654 −3.128658867 0.001351344 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015809 2.578941981 0.001373704 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014286 −4.561613433 0.001389771 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008466 0.911914084 2.78E−04 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012619 −4.046684133 0.001439184 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020422 2.813436614 0.001446957 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018605 1.079184158 0.00029458 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010255 2.055313764 0.001496637 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014998 2.9241846 0.001524339 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018651 −2.343023151 0.001521734 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016693 −1.051599309 0.000305036 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003757 2.76325045 0.001547803 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015105 2.651062339 0.000199662 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010924 −3.528997326 0.001573946 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015807 2.996405339 0.00158059 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007614 −2.767626743 0.001589973 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003761 3.248961928 0.001614328 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000112 −2.095874408 0.001670846 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010923 −2.096803431 0.001673871 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020095 1.820558046 0.000534201 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000678 2.19579206 0.000241013 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0006812 −2.750628436 0.000250237 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002749 2.23200986 0.001822131 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002755 −2.924389712 0.001825291 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019600 −2.111319459 0.001818826 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010263 2.076948861 0.001852925 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016971 2.330532941 0.001889893 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009699 −2.405803329 0.001933132 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016961 1.749794835 0.00198488 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004439 −2.056294389 0.002025088 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015800 3.858627088 0.00203331 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019334 −1.711022528 0.002093903 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012528 −2.372666057 0.002105187 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013157 −1.216090081 0.000488246 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004425 1.378189162 0.000680356 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016685 −1.154892234 0.000692879 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000680 3.123004244 0.000299017 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0008363 −1.40457726 0.0007209 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017537 −3.100413593 0.002350094 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001628 3.787173822 0.002400834 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002293 −3.776885349 0.002461011 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010090 2.902074181 0.002476115 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019336 −1.668169484 0.002476349 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019679 −2.117466896 0.002483008 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009086 2.151114026 0.002534486 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017865 −1.426247531 0.002534052 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006957 −2.761274771 0.002575152 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013954 −3.04101722 0.000346446 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015756 −3.957215893 0.002683533 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007539 1.138000545 0.000943187 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001910 1.694537087 0.002890172 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019631 −1.402189277 0.002978739 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015812 2.014711259 0.002993564 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020419 1.935146137 0.003005282 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020591 2.844475931 0.003029205 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002692 −2.270558551 0.003111018 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013322 −1.113269101 0.001057835 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008958 1.913575238 0.003258707 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000948 −1.746737004 0.003309956 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009555 −3.331912076 0.003314826 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018695 2.701744863 0.003302603 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020587 3.235723562 0.003314535 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007166 2.518308639 0.00333477 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008464 0.958171027 0.000756251 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015319 1.104747824 0.000770452 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016681 −1.044526018 0.000775037 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016690 −0.99294676 0.001155158 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003758 2.294029725 0.003467831 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020590 2.168741629 0.003536032 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016155 −2.580700253 0.003549088 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012010 −0.88489665 0.001223649 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020592 2.983096372 0.003655381 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020568 2.746220062 0.003701853 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012010 −0.923770921 0.000847607 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013322 −1.038113309 0.000855057 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002758 −1.154316458 0.001296063 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004438 −2.008563564 0.003939234 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016972 2.009709037 0.003948297 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012006 3.110921882 0.000118337 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0003920 2.304946882 0.000523631 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006814 −2.402200737 0.000526802 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004447 −2.487176351 0.004079115 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010921 −2.066672639 0.004147498 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007794 3.686778597 0.000133134 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0013901 −1.746422312 0.004272362 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004425 1.313311497 0.000978509 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012491 −1.10193364 0.001516023 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001999 −2.792832876 0.004452782 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016685 −1.084847273 0.001053049 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007775 2.523876211 0.000176477 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0012007 2.283258358 0.000159117 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0002774 −3.556531011 0.004730366 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000680 2.705016902 9.83E−05 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013324 1.288764838 0.004912299 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003767 2.529016996 0.004996656 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010074 2.094930841 0.004981577 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002591 −3.417411589 0.005105016 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007603 −1.845102986 0.005131075 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001564 0.697955013 0.001169731 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017556 0.831635074 0.001899712 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001567 0.906311208 0.001221021 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0018606 −3.942455849 0.005425933 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002288 −2.886330414 0.00547652 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005615 1.432916653 0.001253237 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004509 −2.845276947 0.005588546 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005486 2.888046565 0.005586427 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006642 2.349314659 0.005906114 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020425 2.162226301 0.005998595 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004443 −2.364131314 0.006086475 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012645 −1.717145729 0.006077346 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020420 1.808549509 0.006173158 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013156 −0.926539715 0.001431473 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002721 1.54925374 0.006284498 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000679 3.222723385 0.000830792 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008502 −1.822761214 0.006367532 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001564 0.668839642 0.002245374 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017535 −2.591195822 0.006432529 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012493 −1.307365458 0.002305042 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013914 −1.691661216 0.006540428 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001564 −1.580181455 0.00656844 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001909 1.726224442 0.006628617 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010249 2.165175712 0.006615154 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002722 −2.241881522 0.000876661 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008364 −1.177414465 0.002361828 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017567 0.829748 0.002410541 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019601 −1.469930596 0.006740328 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007772 −1.734002885 0.006798517 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011766 1.78550428 0.006980146 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014053 2.174860853 0.006942507 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016975 6.351342646 0.006992257 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019602 −1.867520496 0.006994478 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008522 −2.941563178 0.00702611 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000120 0.840443491 0.002549845 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008360 −1.309616229 0.002558693 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008724 −2.515111671 0.00719913 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002722 1.443161871 0.007223787 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020119 6.960919498 2.11E−05 Stage 3 / Stage 2 (Gastric Cancer) NovelMiR_KnownLoci_ID0007477 −2.598593322 0.007330281 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012488 1.467517617 0.007355761 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008467 0.691183646 0.002666354 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008655 2.814088964 0.00741327 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020095 1.62914076 0.001628377 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017556 0.819500718 0.001655165 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008486 −2.094349281 0.000984135 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007772 3.945782133 0.000277985 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0002745 2.105352368 0.007551835 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004294 1.382668276 0.00766176 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019650 −2.096329258 0.007698367 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010088 −3.41438848 0.00103012 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0001915 1.37580805 0.007771862 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001917 1.793550811 0.007767615 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000679 2.683145996 0.000182692 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003919 2.076484873 0.001260941 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004426 2.149762793 0.00130365 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0016883 2.01275798 0.001262385 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0016923 2.27713265 0.001180979 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019651 −2.395859429 0.001269633 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0020267 3.55676521 0.001161978 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0005737 −2.610462221 0.007866146 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004444 −2.671219431 0.00792084 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019192 −3.502796712 0.000203156 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013208 −1.713119592 0.007996192 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008515 −1.620671337 0.008041357 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017857 −1.447252321 0.008070493 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007539 1.038863036 0.001824028 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003604 −1.109889609 0.002932537 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017862 −1.228793046 0.008229433 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001932 1.978055908 0.001460363 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004422 2.45753516 0.001463568 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0002281 −4.883359537 0.008296225 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016682 −0.917504012 0.001895624 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015593 1.906715539 0.008449642 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020421 1.367171204 0.008422897 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000110 0.799752562 0.003087054 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008468 0.753143343 0.003059834 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012492 −1.065246586 0.003073583 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0005690 0.789356357 0.002058121 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0014066 −1.654867873 0.008681024 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015078 3.270165453 0.003210086 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000661 0.909024838 0.003340043 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0005615 1.348795396 0.003402086 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004576 −1.757045055 0.009026703 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019757 3.160089218 0.009068392 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004435 −1.823895603 0.009406208 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017871 −2.004439661 0.009382388 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012004 −0.827819423 0.003747659 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008365 −1.218262068 0.002275938 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003497 2.200573608 0.009577608 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008524 −2.403727572 0.009792465 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016684 −1.42555027 0.003923327 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001567 0.794457913 0.00395414 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007774 2.200002205 0.000388928 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0012007 −0.820359403 0.003994747 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002721 −2.381249129 0.000277401 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010922 −2.491042629 0.010183346 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003604 −1.127770826 0.002655766 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016690 −0.93830489 0.002659611 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004468 −2.417232033 0.01022936 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000702 −1.778113726 0.010264594 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013322 1.27684058 0.010432977 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008499 −2.403729556 0.010577496 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016969 1.557142906 0.010596271 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012618 −1.891769648 0.010665523 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001650 4.176138459 0.010730528 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009204 1.75409728 0.002807987 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004308 7.292563766 0.001904682 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013156 −2.33414448 0.010868592 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004462 −2.034324285 0.011053179 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002719 1.497365219 0.011283373 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007927 −2.07365728 0.011266542 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010257 1.641332722 0.011438636 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015594 2.504124478 0.011465039 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004300 8.475280388 0.002065466 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008485 −1.730853338 0.002217104 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010262 −1.925326052 0.002128273 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020379 2.098147097 0.002112266 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004437 −1.392076866 0.011618583 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008361 −1.163280169 0.00457303 ER- Breast Cancer/ ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0018836 4.363927993 0.011678115 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016680 −0.92381836 0.003064063 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016682 −0.838495873 0.004661902 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007655 −1.781218669 0.01181093 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015318 1.802717293 0.011931165 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016153 −2.860038651 0.012047601 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013206 −1.70475083 0.012082509 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016680 −0.89045055 0.004822926 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007480 −1.857382955 0.012219276 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007542 0.874288514 0.004965009 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012008 −0.780245351 0.004976426 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020327 1.282710781 0.012530535 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020768 −1.856624537 0.012635337 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012527 −2.368880271 0.012687122 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014454 1.248628452 0.012719234 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013326 1.858481364 0.012889088 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013900 −1.36891233 0.012922823 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019333 −1.917345247 0.013069268 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016982 1.850687669 0.013254608 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012005 −0.770256709 0.005345425 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001930 1.901501577 0.002578012 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004432 0.944644826 0.005445553 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001566 0.719472757 0.003521044 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004517 0.689434068 0.005489577 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015078 3.193248228 0.003659661 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000110 0.761849304 0.003789371 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015586 2.563294128 0.01413631 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012004 −0.818965262 0.003953073 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004019 −1.402285405 0.014373172 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003159 1.817945928 0.002821899 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008467 1.548254607 0.014645834 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009819 −2.391114889 0.014755101 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007543 0.830614558 0.005974772 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001911 1.811777692 0.014922036 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016683 −0.959570594 0.006062251 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012012 −0.73143808 0.006155514 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011541 −2.814648949 0.015251893 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013323 1.053668339 0.015465853 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016886 −0.74632112 0.006364364 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019628 −1.310351002 0.015577551 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002715 −1.067897089 0.004304875 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010259 −1.987601696 0.003093119 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0011766 0.85653046 0.006569403 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0018645 −3.802658963 0.016020078 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008946 1.799585564 0.01642702 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020377 1.861971471 0.016444869 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005692 0.629370106 0.006886783 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007927 −2.038777899 0.003283266 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002758 −0.999040266 0.004675147 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017567 0.747443057 0.004663502 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002717 1.221432414 0.016611271 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003768 1.750370381 0.016636607 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013913 −1.352742551 0.016746468 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004287 −1.971436374 0.016792192 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009698 −1.504338564 0.01684155 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007540 0.771220786 0.007108225 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010261 −1.912078327 0.003411888 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008357 −1.182178043 0.007222186 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002719 −0.820535449 0.007287642 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012005 −0.783334896 0.004848907 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012007 −0.817753528 0.004937664 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000120 0.744182196 0.005025067 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004510 −2.038195068 0.017433827 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019431 1.244266584 0.017448527 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016683 −0.976781106 0.005091263 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019689 −1.601253361 0.017614591 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003180 1.665889794 0.017927745 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006618 1.990371681 0.017839429 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011395 −2.287549913 0.017818462 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012529 −1.526376037 0.017941788 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020669 2.198273454 0.017984824 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009653 1.446616797 0.018212476 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016154 −2.410706901 0.018184451 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020359 0.71569181 0.00757136 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0005690 0.716269578 0.007700159 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004566 −1.687639698 0.018540393 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018692 2.845280824 0.01862873 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013936 2.21349405 0.003693922 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007165 2.233178637 0.018727159 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008516 −1.698370179 0.018784828 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007654 −1.847964541 0.019078198 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008468 1.459667099 0.019008869 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019335 −1.290015551 0.018981152 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006362 2.034285295 0.019125016 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017402 1.626076022 0.019251328 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016811 −1.255887927 0.019317629 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004564 −2.383573793 0.00393534 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017407 1.473704938 0.019825229 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007844 −1.769592513 0.019944967 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008729 −1.795550126 0.019937304 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002599 −2.458940784 0.020053712 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018549 2.33328594 0.020041396 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001630 3.411674814 0.020108784 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006874 −1.794062047 0.020287418 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017408 1.277842701 0.020281495 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000681 1.801031814 0.004011003 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001563 −1.296926848 0.020427058 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004599 1.807512135 0.020550256 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002694 4.778690699 0.004351069 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004468 1.897298086 0.004533451 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005598 −2.161623491 0.004357933 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0008359 2.176074786 0.004402267 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0016815 −2.520462024 0.004260522 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0019221 2.074391887 0.004488637 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010089 −2.194768391 0.004628843 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004469 −1.582535016 0.020982328 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009950 −1.835367652 0.021003065 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017576 0.897767981 0.008356391 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019598 −2.911868321 0.004719265 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016684 −1.322899998 0.005955612 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013323 −0.884618767 0.00605324 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012496 −1.194739853 0.00853833 ER- Breast Cancer/ ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009678 0.870209265 0.0085709 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020667 1.402644879 0.021498724 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017409 1.425838922 0.021900745 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012480 1.433979769 0.022035191 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002719 −0.815710566 0.006293181 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009678 0.876435021 0.00640078 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0014454 −1.692475874 0.005177135 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0015301 −2.30141586 0.005236796 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015801 4.024093662 0.022761153 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017574 −1.363742481 0.022784381 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0010072 2.485148779 0.022903079 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019346 −1.866535757 0.02296269 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007167 1.930970456 0.023231129 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008484 1.432036205 0.023211538 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008732 −1.548338553 0.023091231 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009920 −1.342676668 0.023122491 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009820 −1.975476784 0.023573869 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014049 1.782743078 0.023619862 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004302 6.820308179 0.005491024 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008525 −1.588807573 0.023774026 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020378 1.592691466 0.024333814 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004016 −1.106918626 0.024601979 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0016884 1.735449685 0.00573168 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004425 −0.981813207 0.024863717 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013323 −0.898566444 0.009810795 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017557 0.749482653 0.009820226 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0019603 −1.643054845 0.025214154 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012493 −1.136672195 0.006990382 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004573 −0.813888771 0.009947133 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004474 2.235421954 0.006107709 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017546 1.855446913 0.006028891 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017576 1.700236631 0.006061174 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015799 3.683110389 0.025431238 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019644 −1.919609481 0.025509829 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007918 1.335691717 0.000489354 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007921 1.185867493 0.000505752 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001563 0.638220675 0.010049143 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007774 −1.038159242 0.025950392 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005686 −2.014214263 0.006496753 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0004431 −1.196516054 0.027014726 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011768 0.78433655 0.010696142 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000111 −1.654154093 0.027545665 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014430 −0.785356065 0.011052819 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008469 0.615112905 0.011216553 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012495 −2.095760668 0.000561182 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007497 0.736056464 0.011372763 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016678 −0.901540552 0.011405283 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011767 1.164222127 0.028152766 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003844 1.132038747 0.028263396 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015544 1.128838066 0.028437652 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020754 −1.018133857 0.028417666 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007543 0.811780313 0.008092798 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012495 −1.057202977 0.011726388 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015752 −1.729678451 0.029134744 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008523 −1.947348658 0.029416031 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011767 0.786719019 0.012153112 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004013 −1.73726008 0.02968579 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011539 −2.33767199 0.029694855 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006360 1.690315673 0.029804431 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001934 1.643020534 0.007320428 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006815 −2.069044823 0.007287083 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010264 −3.07054538 0.007314652 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0019628 1.949702586 0.007254697 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012481 −0.702398013 0.012418698 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008683 −1.731776481 0.007665737 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016691 −1.753835221 0.007874877 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0017544 2.027719225 0.007537508 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017568 −1.5192249 0.030576267 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001653 3.391350349 0.030786219 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008686 −1.732632434 0.008083139 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019601 −2.043443473 0.008140446 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010742 2.202608171 0.008253991 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002695 3.911821557 0.008330176 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015077 3.724126375 0.012975456 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012620 −3.373633397 0.031331628 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004573 −0.80262076 0.00881937 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0005692 0.597113056 0.008920264 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017161 0.719815788 0.008885015 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001563 0.610075101 0.008970053 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007226 1.269522323 0.031767389 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001566 0.602106542 0.013247422 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015076 3.671074613 0.013302742 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015402 0.917415326 0.013347815 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020326 0.788483226 0.013329406 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020522 2.08656418 0.032248113 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004432 0.86197041 0.009185009 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016678 −0.938516407 0.009209025 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001903 1.715549497 0.009240535 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004510 1.930723795 0.009303556 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007280 −1.851418003 0.00915848 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008548 1.688920779 0.009234767 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0009679 1.676862531 0.008699352 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010397 −1.606946355 0.009298959 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016861 −3.776663968 0.009179235 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0016941 1.925809331 0.009054327 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020368 1.330640925 0.032396561 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000661 0.833516028 0.009737952 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008468 0.628664188 0.009646144 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008362 −1.034307422 0.013874182 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012011 −0.661923079 0.013925693 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013903 −1.469539729 0.033438954 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013922 1.188143516 0.033432681 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004493 1.666060951 0.010012407 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0020340 2.880135041 0.010142404 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000091 1.306119857 0.034036914 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000106 −1.823695664 0.034102786 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020286 −1.062695398 0.034226958 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008363 −1.069915409 0.010297007 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004517 0.588426341 0.010380023 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003844 −2.089963654 0.010688509 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007282 −1.632632853 0.01048436 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008549 2.179901197 0.010630443 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0008561 2.120608336 0.010694836 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0012005 −1.940058145 0.010544788 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0013322 −1.654697094 0.010349238 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020267 −1.009414199 0.034859443 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007542 0.797949066 0.010907732 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020429 1.946102259 0.011034707 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001632 3.66317848 0.036446054 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001634 3.414214884 0.036564308 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008324 −1.154711005 0.036328253 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0011765 1.78453186 0.036424347 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017416 1.332265492 0.036512026 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017856 −1.328084339 0.036485188 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019705 −1.596397554 0.036509864 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001647 6.186245872 0.036940647 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002748 1.665859697 0.03694993 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012617 −1.316140646 0.036852401 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002717 −1.819260005 0.011342822 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008681 −1.791047861 0.01129398 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018273 1.21877872 0.037102533 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003843 0.800243244 0.015219685 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007284 2.03615445 0.037432861 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012647 −1.115472703 0.037787597 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0006378 −1.72338906 0.038046213 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012479 1.282025614 0.03802995 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013916 −1.185615035 0.038026167 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008358 −1.158952242 0.01555406 ER- Breast Cancer/ ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020776 −1.331430353 0.038363912 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013157 −3.21319857 0.03843842 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0020397 0.713854175 0.01562512 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020619 −1.629834702 0.038631138 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018834 3.313794649 0.039145736 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012492 −0.886553326 0.01245447 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020359 0.651016402 0.012436224 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002368 −1.735461575 0.012449467 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002715 −1.632424875 0.012304057 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008551 2.11707997 0.01248486 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0019140 1.610073826 0.04022371 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008731 −1.177287364 0.040725646 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007847 −1.288149987 0.041033928 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0009672 −1.6792997 0.041137523 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0005628 1.735432384 0.013219076 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012529 1.707586232 0.013340046 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015296 −1.672117175 0.013407021 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020269 1.799898782 0.013387458 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0009689 −1.573491566 0.041582261 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0013899 −1.12352858 0.041549921 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007831 −1.396985463 0.041883841 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0014541 1.164211108 0.041838832 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007540 0.693895084 0.013527781 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015813 1.88289672 0.042311613 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017547 −1.512066453 0.042265853 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004501 2.253969757 0.042608394 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019430 1.767644009 0.042668929 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012491 −0.852756048 0.013828391 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020343 1.867112025 0.013803665 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004018 −1.122692225 0.043244918 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007228 1.14061798 0.043198944 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017575 −0.890256068 0.043032913 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017576 −0.892599091 0.043376169 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001636 3.162022789 0.043709914 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017569 −1.140242368 0.043721211 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015077 3.672456804 0.014100547 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016979 2.276387208 0.043861348 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0012006 −0.618787367 0.01782383 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013198 0.721945197 0.017960996 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020579 1.745707457 0.044163138 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0007833 −1.345731478 0.044293731 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000662 1.035043193 0.044577068 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003178 1.174743927 0.045202625 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019337 −1.306382367 0.045218622 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0015076 3.594025558 0.014887356 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009678 1.497464196 0.014549704 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0011669 −2.075618336 0.01451933 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016930 2.401542945 0.014529019 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016922 −1.981686621 0.045381544 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018533 −1.865844232 0.045719288 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000677 1.494812883 0.014740361 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005596 −1.973933998 0.014774063 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015805 3.934941723 0.045920907 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0018979 2.365172136 0.045902763 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001568 2.030685081 0.015098282 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001629 5.066619272 0.046693453 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0019474 1.800992445 0.015185117 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014452 0.965089206 0.047111218 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0000306 −1.782498926 0.015368291 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0011769 1.765068988 0.015472546 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007481 −1.814419627 0.047284358 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004598 1.202494574 0.047505297 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0003936 0.846247286 0.019721929 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009642 1.056525567 0.047739716 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0001906 1.780946866 0.047825458 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0002758 −1.562446262 0.01576223 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004283 1.706808705 0.01608225 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0007549 −1.469136801 0.016096251 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016882 1.814754986 0.015964068 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0002400 2.233675636 0.048331961 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0008360 −1.039770621 0.01701811 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012012 −0.662967253 0.017020885 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020397 0.679947335 0.017023526 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010261 0.644136333 0.021102643 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015403 1.012223133 0.02113281 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016688 −0.681952085 0.021139361 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002728 −0.960336275 0.021355033 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012486 1.70973855 0.049409085 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0004425 1.445045276 0.016630178 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016814 −2.148998366 0.016739671 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015319 1.047944216 0.049811748 Chronic Lymphocytic Leukemia / Normal B cells NovelMiR_KnownLoci_ID0017576 0.787873031 0.01747815 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012006 −0.635392047 0.01753456 PR- Breast Cancer/ PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009677 1.538250575 0.017205229 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000108 0.683915901 0.022547023 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011673 −2.144816381 0.017720507 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017163 −1.568696561 0.017617867 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012011 −0.656108339 0.017918657 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007288 −1.467113722 0.018279949 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014431 1.595356028 0.018263024 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018143 1.526335327 0.018617186 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008364 −0.9278381 0.018567879 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0014430 −0.669701212 0.018698332 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020280 −1.727311431 0.018801391 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007497 0.669169887 0.018872511 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003155 1.599176234 0.019339865 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000112 0.77585192 0.024666538 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009699 1.50175938 0.019567446 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0011688 −0.595557194 0.019788771 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003936 0.818960743 0.02019105 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011687 −0.614117824 0.02062719 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001906 2.036853004 0.020687343 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007929 −1.847651151 0.020892748 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003843 0.736538824 0.02179155 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001902 2.288419134 0.021751411 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003667 1.594679236 0.021759686 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004466 1.341542977 0.021549539 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007274 −1.795104911 0.021392677 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003918 2.025045425 0.001116001 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016963 −1.988115775 0.022209318 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005626 1.436539468 0.022582116 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003604 3.228588738 0.022704026 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003157 1.45851576 0.023372019 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007283 −1.417902964 0.023245704 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010414 −1.541802854 0.023562928 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010261 0.605489433 0.022319449 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000698 1.764767151 0.02381597 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002719 −2.304627015 0.001191873 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000112 0.784001945 0.023070552 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016690 −1.449615906 0.024833755 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0020370 1.792777004 0.025017328 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018976 −2.314318865 0.0013893 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004476 0.805767981 0.024089687 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011768 0.638416652 0.02404237 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010090 −1.625847586 0.026135506 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0011287 1.554040814 0.025970754 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0016920 1.637001937 0.026037607 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010136 1.780657423 0.026310201 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004818 −1.614771703 0.026591889 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017162 −1.510400512 0.02658692 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019140 −0.602605102 0.028954504 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0009698 1.458337807 0.026863546 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007791 2.172811595 0.001556673 PBMC Scleroderma Patients/PBMC Control Individuals NovelMiR_KnownLoci_ID0007792 2.071347297 0.001605301 PBMC Scleroderma Patients/PBMC Control Individuals NovelMiR_KnownLoci_ID0000108 0.649441086 0.024914632 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002728 −0.912031629 0.025435369 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017557 0.614875588 0.025675801 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001606 −1.525883192 0.027373642 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016812 −1.455098397 0.027663615 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0017528 1.223482805 0.027632813 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015300 −1.655779392 0.02784401 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004596 1.507116667 0.028309364 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012496 −0.988171057 0.026397454 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012495 −0.900397963 0.026766623 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012351 0.619227014 0.031025726 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011765 0.701460351 0.031570028 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007771 5.392197612 0.001609439 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0007772 5.473538017 0.001423306 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0007774 5.961257139 0.000961948 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0007775 6.020255271 0.001196034 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0007837 5.959781409 0.001544416 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0015304 6.574767228 0.000720994 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0018979 −1.642767664 0.02992236 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017192 0.887266955 0.033087353 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012351 0.602548961 0.027929432 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0018653 0.607578204 0.034000752 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013198 0.672692496 0.028125174 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007793 5.881141067 0.002037524 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0007836 5.893085155 0.002050016 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0019597 −2.562717974 0.030480684 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020328 1.413579 0.030832314 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001901 2.06377842 0.031783761 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0013916 1.559430962 0.031889404 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0009659 0.687857559 0.036186232 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012481 −0.607066042 0.029398692 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012008 −0.644779112 0.030659193 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0003917 1.211504753 0.032329533 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006630 1.657822149 0.032721901 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013915 0.789903068 0.037305164 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004644 −1.713349147 0.033044255 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015204 −1.311212375 0.033326286 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005035 4.422770147 0.005445293 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0008706 4.659653296 0.004268206 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0003666 1.378955562 0.033682894 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000931 −0.609134799 0.038951361 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001366 −2.971238498 0.001468286 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013953 −2.230251658 0.001554955 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004476 0.777828368 0.0391602 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017558 0.605044402 0.039583483 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002288 4.147775127 0.010199335 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0004736 3.911611617 0.009367712 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0008710 4.052638655 0.008155259 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0015288 4.047651816 0.007529468 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0016951 4.687395359 0.006264058 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0018145 3.889190068 0.009481078 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0018146 4.179993989 0.006428438 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0018845 4.047707612 0.00868934 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0019818 4.288499762 0.007590392 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0005627 1.349410625 0.034754903 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017568 0.65125386 0.041722093 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008694 −1.526657714 0.035017222 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0019654 −1.604133507 0.03541071 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007919 1.229489207 0.001244217 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017559 0.714400009 0.034604586 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004432 2.230153663 0.036108331 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008529 2.355112473 0.036641731 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010417 −1.314153716 0.036834681 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015287 3.715193903 0.012730993 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0015292 3.689066373 0.012816448 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0019822 3.78094516 0.012239245 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0020764 3.789910354 0.012688852 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0010416 −1.34390027 0.037337629 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018832 3.779199247 0.013315731 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0019820 3.701423586 0.013217196 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0004423 1.510331261 0.037899833 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0005626 1.017353417 0.036043445 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004300 7.357043469 0.00184432 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015402 0.780148322 0.037109753 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016922 2.807383927 0.002060865 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018979 −2.105986906 0.002087069 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012492 −1.968207485 0.002164133 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004438 3.231107525 0.038859568 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013915 0.796280824 0.037891635 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020326 0.669483224 0.038902773 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004465 1.790202789 0.039552966 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019416 −1.480362433 0.040068988 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007291 3.526323668 0.015887342 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0007534 −999999 0.016012461 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0008708 3.524880263 0.014420388 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0010376 3.59104239 0.015432911 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0019759 −1.375528357 0.040391192 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004292 1.244949813 0.040720704 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010415 −1.323948349 0.041103465 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020339 2.225403413 0.041220788 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0015303 3.304513447 0.016604387 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0018970 −1.715060229 0.041567269 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020268 2.228915191 0.04159271 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007773 3.300554017 0.017203684 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0000686 1.583855073 0.041832217 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016685 3.554155827 0.017608274 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0019631 1.283759382 0.042320618 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008359 −1.10694584 0.047976602 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004499 1.261808259 0.043028535 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015299 −1.315640933 0.042783022 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019334 −1.26978706 0.043137874 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0013901 1.175590987 0.043273547 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0017559 0.666181633 0.049772612 ER- Breast Cancer / ER+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007281 −1.252017259 0.044038927 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000700 −1.183504165 0.044755366 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0000732 2.199115317 0.044802494 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0008524 1.365420562 0.044865163 Stage 1 Gastric Cancer/Normal Gastric Tissue NovelMiR_KnownLoci_ID0017172 1.217280041 0.04299497 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017861 −1.29842796 0.045671052 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018845 −1.285863204 0.045305677 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015403 0.921325114 0.043246088 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0011766 0.589424144 0.043600957 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008361 1.233402403 0.046234642 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000741 1.592573417 0.048236417 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001565 1.434933272 0.047261886 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001567 1.488769691 0.048307532 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002367 −1.316487243 0.048290219 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007176 −2.929745098 0.048471001 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0009661 1.61666727 0.048079657 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000320 999999 0.000454896 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0000909 −6.104345173 0.005186164 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0000912 −8.574212007 0.003138338 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002281 −10.94227116 0.005427137 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002287 −11.45657357 0.004256992 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002288 −7.781504238 0.003533327 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002289 −6.81869805 0.002935033 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002293 −999999 0.004743286 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002600 −7.03475837 0.004659698 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002692 6.072847533 0.002130617 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0003642 999999 0.000340531 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004655 −11.27863214 0.004338815 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004662 −7.192611831 0.004213921 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004722 −999999 0.001772252 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004811 −8.037206531 0.002809377 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004874 −999999 0.001546461 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004904 −6.095126994 0.002862054 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004969 −7.01580194 0.002516552 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004973 −999999 0.00272228 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004988 −7.014754599 0.002016504 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005007 −5.889586718 0.005035676 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005008 −6.904427044 0.003884839 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005009 −999999 0.001284511 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005035 −999999 0.000757108 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005036 −6.214547472 0.005198886 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005037 −7.554903404 0.001367255 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005097 −8.529554123 0.00318689 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005156 −999999 0.001036136 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005186 −6.312542478 0.003489759 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005187 −6.161426513 0.002653733 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005195 −7.420889561 0.002624941 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005293 −999999 0.005294755 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005301 −999999 0.001515042 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005313 −999999 0.003477884 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005314 −999999 0.001662621 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005497 −5.877489435 0.003315386 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005498 −999999 0.00053039 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0007177 −8.059885778 0.003470371 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0008948 6.661795434 0.00140914 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0010017 5.748578343 0.00433398 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0011711 −7.287949032 0.003656839 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014278 −6.800850769 0.004921385 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014281 −7.123220695 0.005217086 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014922 −999999 0.005300651 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015398 −9.948048014 0.001290604 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015399 −999999 0.004736851 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016881 6.263902957 0.003210303 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016885 5.260576791 0.005338939 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016922 5.323828824 0.004823113 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016923 5.488049834 0.00139017 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016924 5.288533714 0.003857719 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0019821 3.473898905 0.018658441 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0003604 3.086288934 0.002807574 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010088 −1.932068538 0.002764853 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017162 −1.726511684 0.002595937 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001566 1.363693897 0.049582889 Stage 1 Gastric Cancer / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015757 1.924181878 0.00224191 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0009677 3.348931729 0.019428979 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0015302 3.215071953 0.019450057 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0008361 −0.840888074 0.045924933 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0010380 3.415745482 0.019921154 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0018692 3.451755843 0.019849413 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0004857 −999999 0.005771129 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0011712 −6.310684524 0.005704995 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0009659 0.645727184 0.04650075 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0000912 3.149354147 0.020569125 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0011767 0.583353712 0.049081845 PR- Breast Cancer / PR+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0005079 −10.77823554 0.006043099 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004968 −7.562083434 0.0064295 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005032 −5.994170565 0.006794478 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005080 −7.067089597 0.006723561 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005081 −6.367631305 0.006623473 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0011541 5.272096745 0.006835664 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016921 4.705197146 0.006300768 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0019651 −2.25447345 0.003216531 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019724 2.568864285 0.002444935 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0000680 6.107882666 0.00765359 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002694 5.397879509 0.00750021 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005132 −6.246371338 0.008587791 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005191 −6.343172462 0.00795907 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005486 −9.132641991 0.008649309 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005501 −5.002940417 0.008146309 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014924 −999999 0.008092748 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016920 4.348234829 0.008076126 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0011674 3.049994822 0.024782987 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0004867 −6.516061558 0.008869952 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0001153 −5.623850111 0.009147315 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002283 −5.551284957 0.00991483 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004663 −5.307741503 0.009505287 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0012012 −5.794877122 0.009891707 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0007920 1.120377478 0.001772344 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016923 2.093895995 0.003688696 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014057 −4.627012849 0.00272654 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004987 −4.672830488 0.010437619 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016681 3.108943208 0.027427687 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0005496 −999999 0.010920154 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002694 4.130118613 0.004060994 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005488 −4.810133353 0.011179704 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0000702 5.521601615 0.013004463 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0000946 −6.679916322 0.012932185 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002440 −6.148622486 0.012462975 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005194 −11.59318923 0.012266282 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005283 −999999 0.01196375 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015303 −6.786465465 0.011618309 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016884 4.263254847 0.012110062 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015286 3.118330112 0.029569079 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0004654 −5.686961839 0.01362828 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004932 −6.385072062 0.013686265 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005196 −4.895158063 0.013845085 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005480 −999999 0.013572936 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005487 −7.305685364 0.014371155 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005536 −10.36625918 0.014884906 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015296 −4.807415517 0.014773541 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016934 −5.82795032 0.014872206 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0020074 −5.909770084 0.013862312 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004736 −11.15573851 0.015050275 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015285 2.994180948 0.03132633 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0020768 3.020737418 0.031024186 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0000949 −6.148045631 0.016121218 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004575 −5.000131982 0.016035996 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005481 −6.50881642 0.016231452 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014280 −8.568753338 0.016512574 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016883 4.434757969 0.015966667 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0008552 −5.249239545 0.033986576 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0010415 2.926113978 0.034105256 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0008561 2.627883554 0.004901745 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005041 −5.051761505 0.017479222 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0007176 −5.939132476 0.017445852 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0001607 2.898651659 0.035793961 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0020072 −5.660282511 0.018135102 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0017185 2.971517627 0.037354689 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0020071 −4.405926161 0.018601784 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015300 −3.049977067 0.020139906 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015400 −999999 0.020112904 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0020098 −6.615117021 0.021005301 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015301 2.719389261 0.041626036 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0000678 1.63973971 0.008453464 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002690 3.363330411 0.008101346 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002722 −1.564147402 0.007463737 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004468 1.662538324 0.008158739 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006811 −1.609059143 0.007297553 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006812 −1.511080733 0.008535993 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012491 −1.932853101 0.006962235 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012493 −2.202323243 0.006992433 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017163 −1.558131277 0.006353065 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017556 2.143234545 0.006877663 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017567 1.903380276 0.006349022 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018970 −2.058833838 0.008042497 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000949 2.689410764 0.043113151 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0005036 2.767563324 0.044839598 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0011673 2.629457504 0.0446647 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0015289 2.678318188 0.044081469 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0015299 2.654805256 0.044184663 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0000946 2.669358083 0.045946991 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0005695 2.811469716 0.045447643 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:G5E28884) NovelMiR_KnownLoci_ID0004818 −6.196021766 0.022194372 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0007779 2.727244783 0.003788063 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0015544 −4.500632286 0.022646459 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0017528 2.668589403 0.048532059 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0007545 2.59263631 0.049439455 Breast Cancer (adenoid/apocrine/atypical/DCIS/IDC/metaplastic) / Normal Breast Tissue (GEO:GSE28884) NovelMiR_KnownLoci_ID0008359 2.011704424 0.009283711 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004426 1.853026917 0.009686947 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017560 1.737165772 0.009919048 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005014 −9.585535027 0.025171788 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0011540 4.458400468 0.025786267 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004781 −9.395476987 0.026163846 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0013954 −2.099732653 0.010717685 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017161 −1.470665686 0.010772319 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007179 −8.689440872 0.026455013 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0002689 4.09148346 0.011674323 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001154 −5.139644885 0.027907372 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016882 3.773919885 0.027630155 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0020062 −5.199306815 0.027993671 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004432 1.866918358 0.012673655 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020379 1.783544321 0.012664419 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016690 1.303829464 0.002303543 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0001519 3.495084127 0.030168084 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014277 −5.850139788 0.031494141 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015297 −3.902927822 0.032247388 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0020083 −6.648096318 0.031146435 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0020096 −6.001770069 0.031826264 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0005315 −3.795435023 0.033251062 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016688 1.364047233 0.003212126 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002695 3.394433612 0.014345609 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002439 −3.878514025 0.034138099 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0015302 −6.942299677 0.034121148 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0001906 1.908502769 0.014548389 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005204 −3.940659966 0.036129985 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004737 −9.241318909 0.037565137 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004863 −9.935842523 0.037927958 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0006631 4.002038967 0.038357737 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0016693 1.167255074 0.003546619 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0014279 −6.525291936 0.038921497 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0008529 2.067688819 0.01575105 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000306 −1.276829007 0.016965336 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001902 1.748093277 0.016871519 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015204 −1.398700672 0.016586154 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002715 −1.466991859 0.017193956 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003919 1.576953624 0.017712507 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014277 −1.937198131 0.01834988 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020073 −5.205887849 0.041122035 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0006409 2.378137878 0.005587319 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0015755 1.742747985 0.005718571 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0005082 −4.442848618 0.044299988 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0014290 −999999 0.042497344 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0018975 −4.17940066 0.046245562 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0004650 −9.205422795 0.046782419 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0003159 1.953291349 0.019329637 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000681 1.720833577 0.019951538 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005396 −4.84088397 0.049631123 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0006630 4.215954719 0.049646035 MIA PaCa-2 cells / HPNE cells (Pancreas cell lines) NovelMiR_KnownLoci_ID0001932 1.467208476 0.020763228 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0002692 4.508716673 0.020870439 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016963 −1.579827354 0.021314543 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016689 1.150913584 0.004229944 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0017528 1.388855166 0.022816792 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008681 −1.415910329 0.023020018 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007288 −1.162004303 0.023939462 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016883 1.373457132 0.02465819 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017576 1.280836121 0.023989611 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004440 2.466030914 0.026710066 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0001934 1.393928464 0.037974504 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003920 1.469851212 0.033270099 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004472 2.115083278 0.037095492 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0005097 1.448306894 0.036035052 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007176 −2.322515752 0.029182885 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007280 −1.213733056 0.038889348 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008683 −1.163075229 0.037664995 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0008686 −1.222225377 0.038203977 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0010089 −1.468194749 0.037130397 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0012529 1.648332043 0.031908905 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014278 −1.541654148 0.037017883 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015105 1.62973204 0.037223248 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016815 −1.004716381 0.035076862 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016882 1.648854901 0.032305862 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016884 1.324794876 0.031313101 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0017546 1.483552129 0.030812704 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0018551 −1.331114801 0.030201788 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019221 1.749731761 0.030525567 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019416 −1.651587931 0.031310018 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020072 2.664829633 0.038896213 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0020378 1.507625358 0.034265834 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007927 −1.206039215 0.039798641 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016920 2.451481858 0.039738601 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0007283 −1.152071007 0.040272955 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000088 2.220698696 0.010601391 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0000089 2.049970637 0.039988732 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0000224 1.683313144 0.003138308 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0000682 2.109326438 0.031285571 Stage 4 / Stage 3 (Gastric Cancer) NovelMiR_KnownLoci_ID0000698 −2.157963716 0.020841682 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0000737 1.336831131 0.048758326 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0000784 1.3633824 0.036781185 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0000947 1.806852479 0.012925019 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0000948 1.576768281 0.025518181 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0001160 4.854571964 0.041429589 Stage 3 / Stage 2 (Gastric Cancer) NovelMiR_KnownLoci_ID0001165 5.731560691 0.016257999 Stage 3 / Stage 2 (Gastric Cancer) NovelMiR_KnownLoci_ID0001165 −6.453605062 0.036219196 Stage 4 / Stage 3 (Gastric Cancer) NovelMiR_KnownLoci_ID0001327 −1.228387185 0.018252267 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0001566 −1.066033927 0.034946577 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0001570 1.794672439 0.041982753 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0001646 1.419842271 0.026202883 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0001915 0.998975516 0.040626736 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002400 2.287479457 0.005641745 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0002401 1.99835395 0.023361006 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0002692 −1.372538874 0.009774785 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002692 0.762607228 0.04881566 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0002727 2.709903822 0.035504319 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0002758 −1.117083493 0.042992912 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0003376 1.419018058 0.038615939 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0003844 2.414890125 0.007356262 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0003959 1.227885572 0.023325693 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004009 −5.809900285 0.009153553 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004223 1.239236873 0.044800645 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004422 1.765479178 0.043418436 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004438 1.305563882 0.029342735 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004438 3.322260816 0.04485236 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004473 1.37636942 0.049795549 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004474 1.548847529 0.046311928 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0004476 −1.126276568 0.049170806 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004501 −0.893726602 0.018934363 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0004516 −1.113093062 0.011889523 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004517 −1.265688445 0.006687277 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0004574 −1.23698759 0.046926967 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004577 −1.455503013 0.03499536 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0004593 3.27224678 0.049051089 Stage 4 / Stage 3 (Gastric Cancer) NovelMiR_KnownLoci_ID0004596 −0.864062051 0.03841529 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0004597 −0.630520482 0.047858443 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0004721 −1.321658628 0.010904688 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0004809 −0.98996739 0.024062358 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0004818 2.177970749 0.018090344 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0004866 1.627339313 0.0484684 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0005097 1.470792939 0.038892585 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0006226 1.86821704 0.037113475 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0006411 1.743389959 0.022974792 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0006479 1.2232759 0.026039611 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0006560 4.729826759 0.042221497 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0006561 5.211960075 0.024769054 HER2-type Breast Cancer/ Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0006813 −1.138098962 0.045795299 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0006813 1.977903417 0.018333439 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0006814 1.670622645 0.030285572 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0006894 −1.084191179 0.046182118 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0007556 1.873776749 0.029168594 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0007603 −1.956668761 0.041984787 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0007666 −1.923376618 0.028092052 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0007770 3.346151882 0.007675091 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0007773 1.739302008 0.021489457 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0007847 −0.89711351 0.007036571 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007847 1.088213117 0.010644848 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007848 −0.865570163 0.027652257 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0007921 −0.670131896 0.005349009 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008435 2.963276905 0.008255797 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0008464 1.717576882 0.029261999 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0008467 0.963977176 0.045307085 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0008468 1.068682687 0.012714248 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0008485 −0.685820747 0.012549533 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0008547 1.414774817 0.045304595 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0008547 2.518940008 0.018162407 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0008549 1.504805044 0.031601881 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0008553 0.944397695 0.030489258 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008554 0.900934486 0.043221531 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008555 1.167275893 0.018303869 Psoriasis Biopsy / Normal Skin Biopsy NovelMiR_KnownLoci_ID0008556 1.833896322 0.016200819 Psoriasis Biopsy / Normal Skin Biopsy NovelMiR_KnownLoci_ID0008559 0.828984796 0.04245243 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_100008560 0.99198759 0.015119335 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008560 −0.924445904 0.020876496 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008561 −2.931377122 0.012748518 Stage 3 / Stage 2 (Gastric Cancer) NovelMiR_KnownLoci_ID0008563 1.323540598 0.046751873 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_100008566 0.999387659 0.040841497 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008566 −0.881694516 0.032059136 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0008708 −1.027073574 0.015273516 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0008944 0.751405463 0.033035388 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0008946 −0.862788725 0.038658379 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0008958 −1.870420348 0.022232896 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0009656 −1.739443971 0.034211855 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0009679 0.595115288 0.020220076 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0009699 0.641228112 0.039014611 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0009700 0.854564952 0.01874353 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0009828 −1.85215173 0.029340836 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0009829 −1.145057218 0.009240511 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0009832 −2.449877923 0.038294378 Stage 3 / Stage 2 (Gastric Cancer) NovelMiR_KnownLoci_ID0009832 2.571612338 0.004074216 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0009833 2.974707999 0.04483894 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0010025 −1.101362049 0.044469519 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0010073 −1.867234921 0.032964808 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010074 −1.785717327 0.024815947 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010088 −1.77889176 0.047188331 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010090 −2.008438488 0.025649687 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010248 −1.905936049 0.04581867 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010249 −2.182043981 0.04435497 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010253 −1.999496323 0.035818362 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010254 −1.797392481 0.029800152 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010255 −2.054219204 0.02745165 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010257 −1.866289352 0.045009455 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010260 −1.739894387 0.02085559 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010382 1.246253023 0.027412787 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0010389 −1.39579544 0.048335141 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0010397 1.707654703 0.019663764 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0010413 3.068376067 0.015126531 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0010416 1.631607365 0.04709628 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0010417 −1.395227307 0.03783021 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0010742 −1.29229335 0.007165902 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0011287 −2.312120349 0.02059904 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0011539 −2.228691451 0.007392203 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0011541 −2.317923974 0.008490336 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0011626 −1.947263359 0.020009013 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0011627 −2.026699956 0.016540424 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0012493 1.875572367 0.022815238 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012497 2.462583113 0.044717175 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012498 2.081448367 0.040880977 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0012498 3.16875763 0.005854034 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0012562 −0.710169897 0.026014123 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0013156 1.534582087 0.00484704 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013156 −1.070008216 0.030485968 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0013322 −1.347946293 0.044696507 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014063 0.743485673 0.031416042 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0014064 0.966677431 0.003200006 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0014065 0.839251944 0.028796712 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0014423 1.206126894 0.021017621 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0014733 −2.590562831 0.038126349 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0014993 −1.128728015 0.049204401 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0014994 −1.138142176 0.047767547 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0015105 −1.791425838 0.03977389 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0015107 1.896385384 0.008259147 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0015279 0.910704748 0.0225159 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015279 −1.304266004 0.014288165 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0015402 1.61884402 0.010940396 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0015409 0.779206195 0.015354626 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0015411 0.647465866 0.04026841 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0015737 2.842422564 0.024205806 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0015753 1.297156485 0.012687589 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0015758 2.30225198 0.012199665 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0015759 1.724622855 0.007975875 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0016678 −1.265066276 0.049441192 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016678 1.128006491 0.021079613 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016680 1.008731901 0.017186296 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016681 1.049567744 0.009771125 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016682 1.047393175 0.023858444 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016688 −1.899574926 0.01265733 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016689 −1.672530093 0.018368491 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016690 −1.462924949 0.011567979 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016691 1.109140222 0.008040357 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016692 1.134438034 0.016230424 HER2- Breast Cancer / HER2+ Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0016815 2.396041066 0.0198772 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0016861 −2.236398047 0.044484253 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0016886 1.704713716 0.015103114 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0016920 2.630894067 0.026525768 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0017556 −2.596057132 0.002588132 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0017562 −0.867326624 0.040234531 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0017834 −2.050134874 0.045222015 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018651 −2.139228265 0.030309579 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018965 −2.230322649 0.026511325 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018974 −2.307276708 0.021731296 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018975 −1.854048177 0.019114195 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018978 −1.908212986 0.008939353 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0018979 −1.702259229 0.010017986 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019011 −2.198949961 0.018895093 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019021 −2.51084482 0.019670061 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019103 −0.994946976 0.01357584 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019106 −0.641585829 0.0460846 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019193 1.81499641 0.024715179 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019314 1.052082133 0.017089199 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019326 1.679904006 0.046063796 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019334 −1.193003664 0.047626226 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019380 0.748168435 0.003443213 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019381 0.583912589 0.022024621 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019382 0.654162965 0.009789332 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019598 −1.638710921 0.041173281 Gastric Cancer (All Stages) / Normal Gastric Tissue NovelMiR_KnownLoci_ID0019645 −1.72126616 0.036242004 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019678 1.39776551 0.045001464 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019755 1.289004206 0.016157713 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0019795 1.461496566 0.023258829 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019800 1.841394399 0.019540693 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019820 1.510444768 0.009724051 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0019878 −2.256673899 0.022396768 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0020070 −1.036679644 0.035935979 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0020072 2.165354427 0.043723598 Stage 4 / Stage 3 (Gastric Cancer) NovelMiR_KnownLoci_ID0020073 2.415966774 0.016064883 Stage 4 / Stage 3 (Gastric Cancer) NovelMiR_KnownLoci_ID0020074 2.255674941 0.034965722 Stage 4 / Stage 3 (Gastric Cancer) NovelMiR_KnownLoci_ID0020267 −3.760894116 0.005939959 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0020340 −2.818465275 0.012287563 Stage 2 / Stage 1 (Gastric Cancer) NovelMiR_KnownLoci_ID0020505 1.62840462 0.036370203 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0020529 1.913318597 0.002256683 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0020530 0.804475282 0.021573154 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0020532 0.91808085 0.01158306 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0020568 −2.099850561 0.049107554 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0020569 −2.035885526 0.028428266 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0020588 −1.021089956 0.031090753 HER2-type Breast Cancer / Basal-like Breast Cancer (TCGA) NovelMiR_KnownLoci_ID0020617 −1.270619251 0.042133864 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0020669 0.981054114 0.03718236 Prostate Cancer / Normal Prostate NovelMiR_KnownLoci_ID0020711 1.382812489 0.005425765 Hypo-reactive / Hyper-reactive (Platelets) NovelMiR_KnownLoci_ID0020771 1.602996571 0.039724309 PBMC Scleroderma Patients / PBMC Control Individuals NovelMiR_KnownLoci_ID0020776 −0.797841047 0.026112847 Hypo-reactive / Hyper-reactive (Platelets)

Lengthy table referenced here US20230041359A1-20230209-T00002 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20230041359A1-20230209-T00003 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US20230041359A1-20230209-T00004 Please refer to the end of the specification for access instructions.

REFERENCES

-   1.—Lim, I. P., et al., Vertebrate microRNA genes. Science (New York,     N.Y.), 2003, 299(5612): p. 1540-1540. -   2.—Miranda, K. C., et al., A pattern-based method for the     identification of MicroRNA binding sites and their corresponding     heteroduplexes. Cell, 2006. 126(6): p. 1203-1217. -   3.—Rigoutsos, I., et al., Short blocks from the noncoding parts of     the human genome have instances within nearly all known genes and     relate to biological processes. Proceedings of the National Academy     of Sciences of the United States of America, 2006. 103(17): p.     6605-6610. -   4.—Griffiths-Jones, S., miR Base: microRNA sequences, targets and     gene nomenclature. Nucleic Acids Research, 2006. 34(90001): p.     D140-D144. -   5.—Bartel, D. p., MicroRNAs: genomics, biogenesis, mechanism, and     function. Cell, 2004. 116(2): p. 281-97. -   6.—Bartel, D. P., MicroRNAs: target recognition and regulatory     functions. Cell 2009. 136(2) p. 215-33. -   7.—Ambros, V., A hierarchy of regulatory genes controls a     larva-to-adult developmental switch in C. elegans. Cell, 1989,     57(1): p. 49-57. -   8.—Ruvkun, G. and J. Giusto, The Caenorhabditis elegans     heterochronic gene lin-14 encodes a nuclear protein that forms a     temporal developmental switch. Nature, 1989. 338(6213): p. 313-9. -   9.—Reinhart, B. J., et al., The 21-nucleotide. let-7 RNA regulates     developmental timing in Caenorhabditis elegans. Nature, 2000.     403(6772): p. 901-6. -   10.—Chang, S., et al., MicroRNAs act sequentially and asymmetrically     to control chemosensory laterality in the nematode. Nature, 2004.     430(7001): p. 785-9.

11.—Johnston, R. J. and O. Hobert, A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans. Nature, 2003. 426(6968): p. 845-9.

-   12. [193649]—Brennecke, J. and S. M. Cohen, Towards a complete     description of the microRNA complement of animal genomes. Genome     Biol, 2003. 4(9). p. 228. -   13.—Bartel, D. P., MicroRNAs: genornics, biogenesis, mechanism, and     function, Cell, 2004. 116(2): p. 281-297. -   14.—Bartel, D. P., MicroRNAs: target recognition and regulatory     functions. Cell., 2009. 136(2): p. 215-233. -   15.—Rigoutsos, I., New tricks for animal microRNAS: targeting of     amino acid coding regions at conserved and nonconserved sites,     Cancer Research, 2009. 69(8): p. 3245-3248. -   16.—Lee, R. C., R. L. Feinbaum, and V. Ambros. The C. elegans     heterochronic gene lin-4 encodes small RNAs with antisense     complementarity to lin-14. Cell, 1993. 75(5): p. 843-854. -   17.—Wightman, B., I. Ita, and Ruvkun, Posttranscriptional regulation     of the heterochronic gene lin-14 by lin-4 mediates temporal pattern     formation in C. elegans. Cell, 1993. 75(5): p. 855-862. -   18.—Tay, Y., et al., MicroRNAs to Nanog, Oct4 and Sox2 coding     regions modulate embryonic stem cell differentiation. Nature, 2008.     455(7216): p. 1124-1128. -   19.—Brodersen, P. and O. Voinnet, Revisiting the principles of     microRNA target recognition and mode of action. Nat Rev Mol Cell     Biol, 2009. 10(2): p. 141-8. -   20. [2757794]—Lal, A., et al., miR-24 inhibits cell proliferation by     targeting E2F2, MYC, and other cell-cycle genes via binding to     “seedless” 3′UTR microRNA recognition elements. Mol Cell, 2009,     35(5): p. 610-25. -   21.—Rigoutsos, I., and A. Tsirigos, in MicroRNAs in Development and     Cancer Molecular Medicine and Medicinal Chemistry Ch. 10, ed, F. J.     Slack, Vol. Vol. 1. 2010: Imperial College Press. -   22. [3415692]—Xia, Z., et al., Molecular dynaotics simulations of     Ago silencing complexes reveal a large repertoire of admissible     ‘sedd-less’ targets. Sci Rep, 2012, 2: p. 569. -   23.—Ha, I., B. Wightman, and G. Ruvkun, A bulged lin-14/lin-14 RNA     duplex is sufficient for Caenorhabditis elegans lin-14 temporal     gradient formation. Genes Dev, 1996. 10(23): p. 3041-50. -   24. [324419]—Vella, M. C., et al., The C. elegans microRNA let-7     binds to imperfect let-7 complementary sites from the lin-41 3′UTR,     Genes Dev, 2004. 18(2): p. 132-7. -   25.—Farh, K. K., et al., The widespread. impact of mammalian     MicroRNAs on mRNA repression and evolution Science, 2005.     310(5755): p. 1817-21. -   26.—Stark, A., et Aninml MicroRNAs confer robustness to gene     expression and have a significant impact on 3′UTR evolution.     Cell 2005. 123(6) p. 1131-46. -   27.—Didiano, D. and O. Hobert, Perfect seed pairing is not a     generally reliable predictor or miRNA-target interarations. Nat     Struct Mol Biol, 2006. 13(9): p. 849-51. -   28. [1924889]—Easow, G., A. A. Teleman, and S. M. Cohen, Isolation     of microRNA targets by miRNP immunopurification, RNA, 2007.     13(8): p. 1198-204. -   29. [2745094]—Back, D., et al., The impact of microRNAs on protein     output, Nature 2008. 455(7209): p. 64-71. -   30.—Selbach, et al., Widespread changes in protein synthesis induced     by microRNAs, Nature, 2008. 455(7209): p. 58-63. -   31. [2733940]—Chi, S. W., et al., Argonaute HITS-CLIP decodes     microRNA-mRNA interaction maps. Nature, 2009. 460(7254): p 479-86. -   32.—Fabian, M. R., N. Sonenberg, and W. Filipowiez., Regulation of     mRNA translation and stability by microRNAs. Annu Rev Biochem, 2010.     79: p. 351-79. -   33. [2861495]—Hafner, M., et al., Transcriptome-wide identification     of RNA-binding protein and microRNA target sites by PAR-CLIP.     Cell, 2010. 141(1): p. 129-41. -   34.—Thomas, M., J. Lieberman, and A. Lal, Desperately seeking,     microRNA targets. Nat Struct Mol Biol, 2010. 17(10): p. 1169-74. -   35. [2834287]—Zisoulis, D. G. et al,. Comprehensive discovery of     endogenous Argonautic binding sites in Caenorhabditis elegans. Nat     Struct Mol Biol, 2010, 17(2): p. 173-9. -   36. Chi, S. W., G. J. Harmon, and R. B. Darnell, An altenative mode     of micorRNA target recognition. Nat Struct Mol Biol, 2012. 19(3): p.     121-7. -   37. [3266933]—Skalsky, R. L., et al., The viral and cellular     microRNA targetome in lymphoblastoid cell lines. PLoS Pathog, 2012.     8(1): p. e.1002484. -   38.—Calin, G. A., et al., Frequent deletions and down-regulation of     micro-RNA genes. miR15 and miR16 at 13q14 in chronic lymphocytic     leukemia. Proc Natl Acad Sci USA, 2002. 99(24): p. 15524-9. -   39.—Calin, G. A. and C. M. Croce, Chronic lymphocytic leukemia:     interplay between non-coding RNAs and protein-coding genes,     Blood, 2009. 114(23): p 4761-4770. -   40.—Ha. I, B. Wightman, and G. Ruvkun, A bulged lin-4/lin-14 RNA     duplex is sufficient for Caenorhabditis elegans. lin-14 temporal     gradient formation. Genes & Development, 1996. 10(23): p. 3041-3050. -   41.—Ruvkun, G., et al., The 21-nucleotide let -7 RNA regulates     developmental timing in Caenorhabditis elegans. Nature, 2000,     403(6772): p. 901-906. -   42.—Didiano, D. and O. Hobert, Molecular architecture of a     miRNA-regulated 3′ UTR. RNA, 2008. 14(7): p. 1297-1317. -   43.—Small, E. M., R. J. A. Frost, and E. N. Olson, MicroRNAs add a     new dimension to cardiovascular disease. Circulation, 2010.     121(8): p. 1022-1032. -   44.—Small, E. M. and E. N. Olson, Pervasive roles of microRNAs in     cardiovascular biology, Nature, 2011. 469(7330): p. 336-342. -   45.—Taganov, K. D., M. P. Boldin, and D. Baltimore, MicroRNAs and     immunity: tiny players in a big field. Immunity, 2007. 26(2): p.     133-137. -   46.—Perkins, D. O., et. al., microRNA expression in the prefrontal     cortex of individuals with schizophrenia and scbizoaffective     disorder. Genome Biology, 2007. 8(2): p. R27. -   47.—Liu, X. K. Fortin, and Z. Mourelatos, MicroRNAs: biogenesis and     molecular functions. Brain Pathol, 2008. 18(1): p. 113-21. -   48.—Wang, Y., et al., MicroRNA: past present, Front Biosci, 2007,     12: p. 2316-29. -   49.—Wang, W.-X., et al., The expression of microRNA decreases early     in Alzheimer's disease and may accelerate disease progression     through regulation of beta-site amyloid precursor protein-cleaving     enzyme I. Journal of Neuroscience, 2008. 28(5): p. 1213-1223. -   50.—W.-X., et. al., miR-107 regulates gramulin/progranulin with     implications for traumatic brain injury and neurodegenerative     disease. The American journal of pathology, 2010. 177(1): p.     334-345. -   51.—Abelson, J. F., et al., Sequence variants in SLITRK1 are     associated with Tourette's syndrome. Science, 2005. 310(5746) p.     317-320. -   52. [2859437]—Nelson, P. T., W. X. Wang, and B. W. Rajeev,     MicroRNAs. (miRNAs) in neurodegenerative diseases. Brain Pathiol,     2008, 18(1): p. 130-8. -   53.—S. S. and B. Strooper, Alterations of the microRNA network cause     neurodegenerative disease. Trends Neurosci, 2009. 32(4): p. 199-206. -   54. [2705848]—Ibanez-Ventoso, C, and M. MicroRNAs in C. elegans     Aging: Molecular Insurance for Robustness? Curr Genomics, 2009.     10(3): p. 144-53. -   55. [2928499]—Somel, M., et al., MicroRNA, mRNA, and protein     expression link development and aging in human and macaque brain,     Genomic Res. 2010. 20(9): p. 1207-18. -   56.—Mendell, J. T., miRiad roles for the miR-17-92 cluster in     development and disease. Cell, 2008. 133(2): 217-222. -   57.—Vasilescu, C., et al., MicroRNA fingerprints identify miR-150 as     a plasma prognostic marker in patterns with sepsis. PLoS ONE, 2009.     4(10): p. e7405. -   58.—Williams, A. H., et al., MicroRNA-206 delays ALS progression and     promotes regeneration of neuromuscular synapses in mice. Science     (New York, N.Y.), 2009. 326(5959): p 1549-1554. -   59.—Esquela-Kerscher, A. and F. J. Slack, Oncornirs—microRNAs with a     role in cancer. Nature Reviews Cancer, 2006. 6(4): p. 259-269. -   60.—Hammond, S. M., MicroRNAs as tumor suppressors, in Nature     Genetics. 2007, Nature Publishing Group. p. 582-583. -   61.—Poliseno, L., et al., A coding-independent function of gene and     pseudogene mRNAs regulates tumour biology-Supplement. Nature, 2010.     465(7301): p. 1-19. -   62.—Ma, L., J. Ternya-Feldstein, and R. A. Weinberg., Tumour     invasion and metastasis initiated by microRNA-10b in breast cancer,     Nature, 2007. 449(7163): p. 682-688. -   63.—G. A. and C. M. Croce, MicroRNA-cancer connection: the beginning     of a new tale. Cancer Research, 2006. 66(15): p.7390-7394. -   64.—Lu, M., et al., An analysis of human microRNA and disease     associations PLoS ONE, 2008. 3(10): p. e3420. -   65.—Godshalk, S. E., et al., A Variant in a MicroRNA complementary     site in the 3′ UTR of the KIT oncogene increases risk of acral     melanoma Oncogene, 2010. -   66.—Ryan, B. M., A. I. Robles, and C. C. Harris, Genetic variation     in microRNA networks: the implications for cancer research. Nature     Reviews Cancer, 2010. 10(6): p. 389-402. -   67.—Saey, T., Cancer's little helpers: Tiny pieces of RNA may turn     cells to the dark side. Science News, 2010. -   68.—Spizzo, R., et al., Snapshot: MicroRNAs in Cancer. Cell, 2009.     137(3): p. 586-586.e1. -   69.—Ventura, A. and T. Jacks, MicroRNAs and cancer: novel miRNAs go     a long way. Cell, 2009. 136(4): p 586-591. -   70.—Voorhoeve, P. M. and R. Agaroi, Classifying micorRNAs in cancer:     The good, the bad and the ugly. Biochimica et Biophysica Acta     (BBA)-Reviews on Cancer. 2007. 1775(2): p. 274-282.

It is understood that the foregoing detailed description and examples are illustrative only and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiment, which will be apparent to those of skill in the art, may be made without departing from the spirit and scope of the present invention. Further, all patents and other publications identified expressly incorporated herein by reference for the purpose of describing end disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventor is not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20230041359A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

1. A method of determining whether a subject has, or is at risk of developing, or is at a given stage of a condition afflicting a tissue of interest, comprising measuring in a biological sample from the tissue of interest expression level of one or more of the miRNAs, wherein the miRNAs comprise a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 47,972, wherein the alteration of the level of said one or more miRNAs as compared to the level of the same one or more miRNA in a reference sample is indicative of the subject either having, or being at risk of developing, or is at a given stage of the condition.
 2. The method of claim 1, wherein isoforms of the miRNAs are used.
 3. The method of claim 1, wherein the reference sample represents a normal condition of the tissue.
 4. The method of claim 1, wherein the reference sample represents a recognizable stage of an abnormal condition of the tissue.
 5. The method of claim 1, wherein the tissue of interest is breast.
 6. The method of claim 1, wherein the tissue of interest is pancreas.
 7. The method of claim 1, wherein the tissue of interest. is blood.
 8. The method of claim 1, wherein the tissue of interest is prostate.
 9. The method of claim 1, wherein the tissue of interest is colon.
 10. The method of claim 1, wherein the tissue of interest is lung.
 11. The method of claim 1, wherein the tissue of interest is skin.
 12. The method of claim 1, wherein the tissue of interest is brain.
 13. The method of claim 1, wherein the tissue of interest is liver.
 14. The method of claim 1, wherein the tissue of interest is heart.
 15. The method of claim 1, wherein the tissue of interest is muscle.
 16. The method of claim 1, wherein the tissue of interest is ovary.
 17. The method of claim 1, wherein the tissue of interest is testicle.
 18. The method of claim 1, wherein the tissue of interest is bone marrow.
 19. The method of claim 5, wherein the condition of interest is ductal in situ carcinoma (breast carcinoma).
 20. The method of claim 5, wherein the condition of interest is lobular in situ carcinoma.
 21. The method of claim 5, wherein the condition of interest is invasive breast cancer.
 22. The method of claim 6, wherein the condition of interest is early stage cancer of the pancreas.
 23. The method of claim 6, wherein the condition of interest is late stage cancer of the pancreas.
 24. The method of claim 7, wherein the condition of interest is leukemia.
 25. The method of claim 8, wherein the condition of interest is cancer of the prostate.
 26. The method of claim 9, wherein the condition of interest is cancer or the colon.
 27. The method of claim 10, wherein the condition of interest is cancer of the lung.
 28. The method of claim 11, wherein the condition of interest is melanoma.
 29. The method of claim 11, wherein the condition of interest is psoriasis.
 30. The method of claim 12, wherein the condition of interest is Alzheimer's disease.
 31. The method of claim 12, wherein the condition of interest is Parkinson's disease.
 32. The method of claim 12, wherein the condition of interest is cancer of the brain.
 33. The method of claim 13, wherein the condition of interest is cancer of the liver.
 34. The method of claim 14, wherein the condition of interest is cardiomyopathy.
 35. The method of claim 15, wherein the condition of interest is a muscle disorder.
 36. The method of claim 16, wherein the condition of interest is ovarian cancer.
 37. The method of claim 17, wherein the condition of interest is testicular cancer.
 38. The method of claim 18, wherein the condition of interest is myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD). 